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Abstract 
All cells must be able to tailor their energetic resources to different conditions both in 
quiescent and stress contexts. The retinal pigment epithelium (RPE) provides a highly dynamic 
model system to study basic cellular metabolism due to its extremely active mitochondrial 
capacity, which maintains retinal homeostasis and compensates the noxious effects of 
oxidative damage to the tissue. RPE stress, inflammasome activation and metabolic 
alterations with mitochondrial dysfunction have been implicated in retinal diseases. However, 
the causal link between stress, metabolic alterations and retinal degeneration remains 
unclear.  
There are important symbiotic interactions between immune responses and core intracellular 
metabolic pathways. Specific alterations in metabolism couple to immune effector functions, 
most notably resulting in a programmed production of distinct sets of cytokines. To this end, 
immune cells with different functions use several different metabolic pathways to generate 
adequate levels of energy stores to (A) support survival and (B) to facilitate the highly 
expensive production of numerous biosynthetic intermediates. Conversely, evidence 
suggests that intracellular metabolites themselves may modulate immune function.  This 
thesis highlights the interplay between immune responses and cellular metabolism in the RPE 
(a non-haemopoietic innate immune cell responsible for immune privilege in the retina). Key 
components of the RPE innate immune response are responsible for the remodelling of 
metabolic pathways through innate immune receptor signalling and nuclear control over 
protein expression. 
A decline in mitochondrial capacity with age may limit the ability of a cell to divert energy 
sources and maintain optimum retinal health. The data presented suggest that the activity of 
the energy sensor AMP-activated kinase (AMPK) is fundamental to maintaining innate 
immune and metabolic function within the RPE. AMPK acts as a “built-in brake system” to 
limit aerobic glycolysis and anabolic metabolism, whilst simultaneously increasing 
mitochondrial function. During innate immune activation, altering the activation state of 
AMPK allows different Toll-like receptor (TLR) agonists to elicit alternate RPE metabolic 
phenotypes.  
Data presented have identified the “alarmin” interleukin-33 (IL-33) as a key regulatory node 
of RPE metabolism. Activation of the IL-33/ST2 axis is supported metabolically by 
mitochondrial respiration. Through bolstering mitochondrial activity, exogenous IL-33 
administration protects RPE cells against oxidative damage, accompanied by the increased 
expression of PGC-1α and other metabolic regulators. In addition to its extracellular function, 
endogenous IL-33 expression status influences metabolic regulation in RPE cells. IL-33 loss 
constrains oxidative glucose catabolism, as IL-33 was found to regulate pyruvate import into 
the mitochondria through the mitochondrial pyruvate carrier (MPC) complex. In contrast, 
cells overexpressing IL-33 display increased expression of MPC complex components and 
activity of pyruvate dehydrogenase to facilitate increased pyruvate flux into the TCA cycle.  
IL-33 retains its nuclear localisation in vitro under multiple conditions of inflammatory stress 
and interacts with a dynamic network of proteins. Moreover, it is observed that nuclear IL-33 
regulates protein expression of human and murine RPE cells and contributes to the regulation 
of metabolic enzyme splicing. These support the current view of IL-33 as a dual function 
protein with functional roles in the nucleus. As IL-33 and its nuclear interactions are enhanced 
or dampened in response to inflammatory cues, this indicates that intrinsic IL-33 acts as a key 
node to maintain cellular metabolic profiles and likely facilitate innate immune responses 
separate from its extracellular functions.  
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Chapter 1. Introduction   
1.1. Primer 
The retina is referred to as an “immune privileged” tissue, where homeostasis is maintained through 
both hemopoietic immune cells such as microglia and innate immune-competent tissue resident cells 
such as the retinal pigment epithelium (RPE) [1]. RPE are integral in the maintenance of immunity 
within the retina, generating a diverse cytokine and chemokine output that contributes to defence 
against foreign antigens [1, 2]. The RPE is highly differentiated and considered to be a post-mitotic 
single cell layer that performs a host of functions critical to retinal homeostasis, including the 
maintenance of the visual cycle and photoreceptor phagocytosis [3]. RPE cells are highly metabolically 
active whilst providing critical metabolic support through the directional transport of glucose and 
lactate to fuel the outer retina and photoreceptors in particular  [4]. Defects in RPE metabolic and 
mitochondrial function, associated with low grade inflammation or with age-related decline, are 
associated with retinal degenerative diseases including age-related macular degeneration (AMD) [2].  
 
Cellular intrinsic and extrinsic signals regulate the activity of metabolic pathways to couple the growth 
and survival needs of the cell and consequently regulates the generation of key products to fulfil these 
needs. In the context of immunity, metabolic changes directly influence immune cell effector 
functions. The flexibility to switch between multiple biochemical pathways maintains intracellular 
adenosine triphosphate (ATP) levels for energy demanding processes, including cell proliferation, 
growth and immune-modulation via cytokine production [5]. Understanding how immune competent 
tissue-resident cells, like RPE, manage energy consumption to potentially support the maintenance of 
outer retinal function is crucial. Recently, data shows that RPE cells utilise reductive carboxylation [6] 
that supports redox homeostasis. This in turn is re-enforced by the documented disproportionate 
damage to mitochondrial DNA in the RPE of individuals with AMD, corroborating a causal link. 
Therefore, a possible explanation is that photoreceptors, which mainly rely on RPE lactate, starve 
when RPE mitochondria fail and the RPE becomes more dependent on glycolysis, preventing glucose 
from reaching the retina. Furthermore, as the retina ages, RPE become increasingly susceptible to the 
cumulative effects of oxidative stress, as a result of their high metabolic demand [7]. As a result of 
this, adaptive and innate immune functions are disturbed, leading to an imbalanced environment 
unable to control cell death, tissue dysfunction or up-regulate inflammatory responses [1]. 
 
Interleukin-33 (IL-33), a member of the IL-1 family, is a type 2 cytokine that is constitutively expressed 
in the inner retina, RPE and choroid [8] as well as in epithelial cells, endothelial cells, and fibroblasts 
[9]. IL-33 either functions as an “alarmin” molecule released from necrotic barrier cells following 
cellular damage [9] or is retained within the nucleus of cells to control gene expression [10]. However, 
the mechanisms controlling the later remain poorly understood. Extracellular IL-33 binds to its cognate 
receptor, formed of a heterodimeric complex of suppression of tumorigenicity 2 (ST2) and IL-1 
receptor accessory protein (IL-1RAcP), to activate mitogen activated protein kinase (MAPK) and 
nuclear factor kappa B (NF-κB) signalling pathways [11]. The role of IL-33 has been recognized in 
several diseases, such as, chronic gastrointestinal inflammation [12], allergic diseases/ anaphylaxis 
[13], cardiovascular disease [14], choroidal angiogenesis [8] and Alzheimer’s [15]. In experimental 
autoimmune uveitis, IL-33 moderates disease severity [16]. In a phototoxic model of retinal 
degeneration, IL-33 contributed to an upregulated chemokine and cytokine output from Müller Glia, 
leading to the recruitment of mononuclear phagocytes, and ultimately contributing to photoreceptor 
loss and diminished retinal integrity [17]. 
 
It has been previously shown that Toll-like receptors (TLR) ligands (TLR-3, -4) induce up-regulation of 
IL-33 in RPE cells without cell death [8]. Recent exploitation of the cytoplasmic hybrid (cybrid) 
technique for representative mitochondrial DNA (mtDNA) haplotypes of AMD populations, revealed 
alterations in IL-33 expression and altered bioenergetics [18]. This, coupled with novel epigenetic roles 
for IL-33 as shown in the maintenance of mitochondrial function in adipose tissue [19] and the 
observation that a deficiency in the IL-33/ST2 axis reshapes mitochondrial metabolism in 
macrophages, prompts the questions: (1) do aspects of the innate immune system (e.g. endogenous 
vs exogenous IL-33 and TLR signalling) regulate metabolism in the RPE and (2) if so, what are the 




1.2. The eye 
The eye is a highly organized and complex structure, which reflects its specialized function for 
photoreception. Light energy from the environment passes through the ocular media and 
concentrates on the macula (a specialized area of the retina attributed with a dense population of 
photoreceptors for high visual acuity).  Upon reaching the macular, light is transduced by specialized 
nerve cells (rod photoreceptors and cones) into nerve impulses in the form of an action potential. 
These are then relayed to the optic nerve and subsequently to the brain, whereby the neuronal signals 
are appreciated as vision [20]. The retinal anatomy is comprised of several layers: an internal limiting 
membrane, nerve fibre layer, a ganglion cell layer, the inner and outer plexiform layers, the 
photoreceptor layer, the RPE, Bruch’s membrane and the choroidal vasculature (which together form 
the choroid) and the sclera. (Fig. 1.1). Müller glia are observed in the inner nuclear layer as the 
supporting glia cell. Bipolar cells, horizontal cells and amacrine cells also aid neural support to the 
inner nuclear layer. Blood is directed to the neural retina by retinal blood vessels, originating from the 
central retinal artery and supplying the choroidal network. The choroid has a specific VEGF-controlled 
vasculature with caveola and in distinct layers with fibroblasts, mast cells, macrophages and dendritic 
cell populations [21]. Transport across the inner retinal vasculature is mediated by retinal endothelial 
cell tight junctions and by the Bruch’s membrane (BM) which comprise the inner blood-retinal barrier; 
the RPE comprise the outer-blood-retinal barrier. Integrity of the blood-retinal barrier is an important 
physiological barrier which maintains ion, protein, nutrient and water flux between the choroidal 
blood and the retina [20]. Optimal vision is dependent on effective function in the retina, particularly 
that of the macula. Damage to any structure on the visual axis, from the cornea to photoreception in 




Figure 1.1. Schematic of the eye and major anatomical structures of the retina: 
Light enters the eye through the lens and passes through the ocular media before concentrating on the macula. 
Photoreceptors interpret the photons of light as an action potential which is transmitted to the brain via the 
optic nerve. The retinal architecture is comprised of (from anterior to posterior) an internal limiting membrane, 
nerve fibre layer, a ganglion cell layer, the inner and outer plexiform layers, the photoreceptor layer, the retinal 
pigment epithelium (RPE), Bruch’s membrane and the choroidal vasculature (which together form the choroid) 
and the sclera. Damage to the structures along the visual axis likely manifests in visual impairment. This figure 
schematic is reproduced from [22]. 
  
1.3. Retinal pigment epithelium  
Situated between the photoreceptors and the choroidal vasculature is the highly organized monolayer 
of neuroectodermally-derived pigmented cells, termed the RPE (Fig. 1.1) [23]. In terms of its 
orientation, the apical membrane of the RPE faces the photoreceptor outer segments, whereas its 
basolateral membrane faces Bruch’s membrane and separates the RPE from the endothelium of the 
choriocapillaris [3]. On the basolateral membrane of RPE cells, numerous highly convoluted 
invaginations increase the overall surface area for optimal absorption of oxygen and nutrients [24]. 
The apical surface contains numerous microvilli which maximize the surface area of plasma membrane 
surrounding photoreceptor outer segments (POS) in order to maximize transepithelial flux and 
augment phagocytosis [24] (Fig. 1.2). The RPE layer encompasses the optic nerve to the ora serrata 
and subsequently continues as the pigment epithelia of the ciliary body [23]. There are typically 
around three and a half million RPE in a human adult eye and this population remains stable 
throughout young adult life [23]. Studies investigating mitosis and proliferation in RPE cells indicate 
that very low levels of RPE are retained in the cell cycle, with the RPE considered to be a post-mitotic 
terminally differentiated cell [23]. The high abundance of pigment in the RPE monolayer results in the 
absorption of light energy focused onto the macula by the lens [24]. The dark pigment of the RPE is 
attributed to the large distribution of melanin granules within the cells [24]. RPE exhibit a basal nucleus 
and a high level of mitochondria which reflect the high metabolic rate of the cells. Additionally, the 
cells have an abundance of smooth endoplasmic reticulum and lysosomes [24].  
 
The primary role of the RPE is in the preservation and survival of the overlying photoreceptors. The 
RPE facilities the absorption of fluid, ions and nutrients (such as glucose, fatty acids, amino acids and 
retinol) from the choroidal blood flow to supply the photoreceptors. The passage across the RPE 
occurs via lateral plasma membrane barrier junctions and transporters located in the apical and basal 
membranes. Metabolic end products, such as lactate from the highly glycolytic photoreceptors, is 
removed from the sub-retinal space via the lactate/H+ co-transporter monocarboxylate transporter 1 
(MCT1) [4, 25]. The RPE expresses transporters for multiple amino acids including alanine, taurine, 
glutamine and leucine [26]. The high expression of glucose transporter 1 (GLUT1) on both apical and 
basal membranes permits the passive “trans-RPE” flux of glucose from the choroid to the 
photoreceptors [27]. A continuous cycle of retinal exchange occurs between the photoreceptors and 
the RPE [3]. As photoreceptors themselves cannot metabolize trans-retinal (occurring post light 
absorption) into 11-cis-retinal, isomerization occurs in the RPE (via the RPE-specific isomerase retinoid 
isomerohydrolase (RPE65)) and is then transported back to the photoreceptors. This permits the 
preservation of photoreceptor excitability and is a mechanism identified as the “visual cycle of retinal” 
[3]. The RPE plays a key role in the phagocytosis of POS. During a lifetime, it is estimated that each RPE 
cell consumes over 45 outer segments, whereby daily renewal processes result in ~10% of 
photoreceptor volume shed and phagocytosed [28]. Consumed POS are degraded through a 
combination of over 40 different lysosomal protease enzymes, the most prominent of these in the 
RPE is cathepsin D [29]. Daily internalization of POS and rapid proteasomal degradation in RPE cells, 
in conjunction with the observation that in vivo RPE are terminally differentiated and therefore post-
mitotic, indicates that these cells have an enormous proteolytic burden [30]. Indeed, the RPE exhibits 
one of the highest phagocytic capacities of cells in the body [30]. Processed outer segment end-
products are degraded and recycled quickly in young healthy RPE. However, with time, incompletely 
degraded photoreceptor material is accumulated in the form of lipofuscin, lipid-containing residues 
of lysosomal digestion [31]. 
 
The retina is the single neural tissue with constant direct exposure to visible light. This combined with 
the high oxygen consumption and electron transport chain (ETC) activity of RPE cells lead to a high 
production rate of reactive oxygen species (ROS) and photo-oxidized lipids with noxious potential for 
retinal cells [32]. There are various types of ROS, including both superoxide radicals (O-2), hydroxyl ions 
(OH-) and non-radicals, such as hydrogen peroxide (H2O2) [33]. Additionally, phagocytosis of POS 
creates high levels of ROS via the respiratory burst, increasing H2O2 production over nine-fold [34, 35]. 
The RPE plays a critical role in protecting against high levels of oxidative stress and photo-oxidation 
and this is achieved by multiple defence mechanisms. The first line of defence is the presence of the 
multiple pigments (melanin, zeaxanthin and lipofuscin) which act as an optical filter to limit the 
absorption of damaging blue wavelengths before reaching the sensory neurons [35].  Another line of 
defence is comprised of both enzymatic and non-enzymatic antioxidant systems, which facilitate the 
immediate removal of ROS [32]. Antioxidant enzymes, such as superoxide dismutase (SOD)-1 and -2, 
catalase and glutathione peroxidase are expressed at high levels in the RPE [36]. Smaller non-
enzymatic antioxidant, such as carotenoids, vitamin C, vitamin E and ubiquinol are accumulated in the 
RPE and support the enzymes as direct radical scavengers [32, 33].  
 
The RPE have a key role in the secretion of various soluble growth factors, survival factors and 
signalling molecules which are essential for the maintenance of structural integrity of the retina, 
photoreceptors and the choriocapillaris. The importance of secretion direction from the RPE is often 
overlooked, with many proteins exhibiting a preferential secretion by either the apical or basolateral 
membrane to promote either photoreceptors or the choroidal blood flow, respectively [37]. RPE cells 
basolaterally secrete various types of tissue inhibitor of matrix metallo-proteases (TIMPs) to facilitate 
the remodelling and health of the choroidal vasculature via limiting the action of extracellular matrix 
metalloproteinases (MMPs) [3]. Multiple MMPs and TIMPs are apically secreted by the RPE to support 
the turnover and maintenance of the interphotoreceptor matrix [37]. Interestingly, it is proposed that 
RPE secrete certain MMPs and TIMPs in different directions depending on various environmental cues, 
such as cytokine signalling [37]. Moreover, the RPE secretes fibroblast growth factors (FGFs), 
transforming growth factor-β (TGF-β), endothelin 1, cystatin C, vascular endothelial growth factor 
(VEGF) and pigment epithelium-derived factor (PEDF) which regulate optimal circulation and 
stabilization of the endothelium and choriocapillaris on the basolateral side, and avert angiogenesis 
on the apical side [3, 37]. Additionally, PEDF is secreted preferentially on the apical side of RPE, where 
it acts as a neurotropic survival factor for photoreceptors [38]. αB crystallin is a cytoprotective 
molecular chaperone released from the apical side of RPE cells under stress stimuli, which inhibits 
caspase-3-mediated apoptosis in photoreceptors, conferring a survival advantage [39].  
 
Natural regulatory mechanisms are present to regulate inflammation in the ocular microenvironment, 
including the anatomical restriction of lymphatics into the retina through the blood-retinal barrier. As 
previously discussed, RPE constitute part of the blood-retinal barrier preventing movement of cells 
into the eye from the bloodstream [40]. To this end, the eye is referred to as an organ exhibiting 
immune privilege. Innate immune responses in the retina are therefore maintained though tissue-
resident myeloid cells (macrophages/microglia) and innate immune competent - but not 
haematopoietically-derived - cells, such as the RPE [41]. Multiple lines of evidence suggest an 
immunoregulatory function of the RPE which endeavours to maintain tissue homeostasis under stress. 
For example, RPE cells suppress the activation of cluster of differentiation (CD)4+ and CD8+ T-cells 
through TGF-β [42, 43] and elicit the expression of various suppressive anti-inflammatory cytokines 
[44]. The RPE cell expresses innate TLRs, functional NOD-like receptors (NLRs) and complement system 
components, but also exhibits adaptive immune functions, such as major-histocompatibility complex 
(MHC) class I and II antigens expression and contribution as retinal antigen-presenting cell (APC) [44-
48]. Furthermore, the RPE has a vast output of immuno-stimulatory chemokines and cytokines, 
including both anti-inflammatory: TGF-β, interleukin (IL)-11, interleukin-1-receptor agonist (IL-1RA) 
and interferon(IFN)-β, and pro-inflammatory: IL-6, IL-15, tumour necrosis factor (TNFα), IL-1α/β, IL-8, 
IL-18, monocyte chemotactic protein (MCP)-1, granulocyte-macrophage-colony-stimulating factor 
(GM-CSF), C-X-C motif chemokine (CXCL)-10 CXCL-11 and IL-33 [44, 47, 49], which permit 
predominantly immune regulatory signalling networks between RPE cells and other retinal innate 
immune cells. In addition to their rich expression of cytokines, RPE cells also express functional 
cytokine/chemokine receptors to respond to many of the above listed cytokines, but similarly others, 




Figure 1.2. Summary of the retinal pigment epithelium and its functions: 
 The RPE is a monolayer of cells located between the choroid and photoreceptors. RPE cells have a polarized 
morphology with apical microvilli projections extending out between the rods and cones for functional support. 
RPE cells are interconnected by the expression of tight junctions. The RPE has multiple important functions in 
the maintenance of homeostasis and functional support to both the choroid and photoreceptors. These 
functions include: the absorption of photons of light in pigmented granules, metabolic support of the retina, 
secretion of factors which regulate the health of both photoreceptors and the choroidal vasculature, trans-
epithelial movement of nutrients, ions and metabolic waste products, phagocytosis of old rod outer segments, 
re-isomerization of 11-cis-retinal to complete the visual cycle and maintenance of immune privilege through the 
expression of innate-immune receptor complexes/secretion of immune-modulating cytokines and chemokines. 
PEDF, pigment epithelium-derived factor; VEGF, vascular endothelial growth factor; PRR, pattern-recognition 
receptors. Adapted from [3].   
1.4. Age-related macular degeneration 
The leading cause of irreversible blindness within the western world can be attributed to AMD. The 
disease refers to the progressive deterioration of the macula occurring predominantly in the older 
population (post 60 years of age). The annual global economic cost of AMD is estimated to be in excess 
of US$300 billion, with over 30 million individuals worldwide suffering from visual defects by cause of 
AMD [2]. With a progressive increase in the ageing population, it is anticipated that there will be a 
50% increase its prevalence by 2050 [52]. AMD is classified into two distinct subsets: neovascular age-
related macular degeneration (nAMD) (wet) and geographic atrophy (GA) (advanced dry), both of 
which lead to significant visual impairment. nAMD is characterised by abnormal growth of blood 
vessels from the choriocapillaris into the retina. Whilst the fundamental biology remains uncertain, 
molecular therapies which target VEGF (a pro-angiogenic factor) are successful in preventing disease 
progression in a large proportion of patients [53]. Granting current anti-VEGF therapies have 
revolutionized treatment strategies for nAMD, there remains no approved cure for the dry form, 
largely due to a scarcity of suitable molecular targets. The early stages of GA are characterized by 
insoluble extracellular lipid deposits (drusen), which accumulate between the RPE and BM [54]. GA 
develops following the development of drusen, and refers to large confluent areas of RPE detachment 
and cell death, and atrophy of RPE, the overlying photoreceptor and the choriocapillaris [55]. This 
ultimately confers reduced visual function, with GA accounting for around 50% of legal blindness 
associated with AMD [2]. The influence of innate immunity (mainly that of the complement system 
and pattern recognition receptors (PRR)) are widely accepted as central to the progression of dry AMD 
development [2, 56]. Yet, as AMD development is long and insidious, it is likely that altered immune 
responses occur as a result of disparity between protective responses (in place to maintain tissue 
homeostasis) and chronic parainflammatory responses, secondary to a lifetime of oxidative damage 
within the retina, mainly in the RPE [57].  
 
  
1.5. Innate immunity 
1.5.1. Pattern-recognition receptors 
Innate immune responses are evolutionarily perfected; conserved across the animal kingdom, these 
non-clonal inflammatory responses recognize pathogen associated molecular patterns (PAMPs) and 
self-derived danger associated molecular patterns (DAMPs) to produce an immediate output of co-
stimulatory chemokines and cytokines [58]. Innate immune responses differ from adaptive immunity 
in the sense that their recognition of biological material (proteins, lipids, DNA and carbohydrates) is 
not antigen specific and therefore lacks the requirement of anergy and clonal expansion. Whilst 
macrophages and dendritic cells are essential within innate immunity, “non-immunological” cells such 
as fibroblasts, endothelial and epithelial cells contribute through the expression of germline-encoded 
PRR [58]. Once activated by ligand recognition, downstream responses are initiated through complex 
signalling pathways. Cytokines and chemokines produced from PRR signalling promote the activation 
of antigen presenting cells (e.g. dendritic cells), initiating the adaptive immune response through 
constant gene re-arrangement in B and T-lymphocytes [59]. To date, a plethora of PRR and their 
distinct activation pathways have been uncovered, including members of TLR and NLR families. 
 
1.5.1.1. Toll-like receptors 
TLRs are transmembrane proteins capable of PAMP recognition both extracellularly, and within 
endosomes; there are currently 10 TLR observed in humans, and 12 in mice [60]. Each extracellular 
receptor domain recognizes a specific PAMP, so that the TLR family is capable of recognizing a variety 
of bacteria, viral and other pathogens [61]. Expression of TLRs 1-6 and 8-10 gene transcripts, and 
proteins for TLRs 1-6 and 9 have been observed in human RPE [62], with TLRs 2-4, -6 and -9 exhibiting 
functional responses to synthetic ligands [62, 63]. Interestingly, TLR-3 and -4 are noted to have the 
highest expression of any TLR in the RPE [45, 62]. Considering these observations noted within the 
literature - and the fact that I will only examine the effect of TLR-3 and -4 signalling in this body of 
work – I will only address these receptors in this section. However, readers are directed to the 
following reviews for a more comprehensive view on signalling through other TLRs ([60, 64]).  
 
Lipopolysaccharide (LPS), a classically described PAMP, is one of the best studied stimuli of the 
inflammatory response. It is a structural component of the outer membrane of Gram-negative 
bacteria, recognized by TLR-4. TLR-4 signalling is preceded by a cascade of events, starting with the 
interaction of LPS-binding protein with LPS. This facilitates the transfer of LPS to the TLR-4 complex 
through the involvement of the glycoprotein CD14. Upon activation, the TLR-4 complex undergoes 
dimerization; this subsequently activates a pro-inflammatory response through myeloid 
differentiation factor 88 (MyD88) and Toll/IL-1 domain-containing adaptor-inducing IFN-β (TRIF) - 
dependent cytokine production.  
 
Once activated through specific recognition of viral double-stranded RNA (dsRNA), TLR-3 signalling is 
initiated through the activation of TRIF which subsequently leads to the nuclear translocation of NF-
kB and IFN-regulatory factor-3 (IRF-3) promoting the expression of type 1 IFN genes and other 
cytokines/chemokines essential for mediating viral defence [45, 65]. 
 
1.5.1.2. Nod-like receptors and the inflammasome complex 
NLR are cytoplasmic receptors shown to initiate host responses to a wide range of bacterial and viral 
ligands, there are currently 22 identified NLR in humans [60]. The NLR family share a conserved 
structure, with three distinct domains: the nucleotide-binding domain (NOD), an N-terminal protein-
protein interaction domain which initiates downstream signalling and a C-terminal leucine-rich 
repeated (LRR) region responsible for PAMP and DAMP recognition [66]. NLR family members can be 
subcategorized into 4 subfamilies on the basis of their N-terminal domains, these include: acidic 
transactivation, pyrin, caspase-recruitment domain (CARD) and baculoviral inhibitor of apoptosis 
repeat (BIR)-like domain [67]. The most studied and well-known NLR family member is NLRP3, which 
forms a multiprotein immune platform. The inflammasome is an essential part of caspase-1 activation 
through autocatalysis, allowing the post-translational processing and secretion of pro-inflammatory 
cytokines IL-1β, IL-18 and IL-33 [68]. Formation of the inflammasome occurs through 
NLRP1/NLRP3/NLRC4 oligomerization and recruitment of pro-caspase-1 and the apoptosis-associated 
Speck-like protein (ASC). ASC proteins contain a CARD that allows the amplification of caspase-1 
activation [69]. The general mechanism of canonical inflammasome activation by PAMPs and DAMPs 
remains elusive to date. Multiple models have been advocated, including K+ efflux, Ca2+/ cAMP 
signalling, autophagic processing of subcellular material, ROS, altered glycolytic flux, mitochondrial 
dysfunction and release of oxidised mtDNA, cathepsin activity and NLRP3 deubiquitination [70-74]. 
Altogether, the literature implies that the NLRP3 inflammasome acts following energetic stress and 
sub-cellular damage as opposed to an immunological receptor complex. Whilst the NLRP1, NLRP3 and 
NLRC4 are well known as critical inflammasome components along with ASC/CARD domains, it is 
noted that roles for additional components (including NLRP6) are now emerging [75]. In addition to 
this, it is essential to note that whilst caspase-1 inflammasomes have been extensively studied, 
additional initiator caspases have also been identified allowing inflammasome complexes to operate 
in a non-canonical caspase-1-independent manner [76]. 
 
1.5.2. Complement system 
The complement system is a significant component of innate immune responses, providing an initial 
defence response that targets and destroys microbial pathogens. It is comprised of a series of plasma 
proteins which undergo a sequential enzymatic-activation cascade (complement activation pathway), 
ultimately leading to opsonization of extracellular pathogens and their phagocytic removal [77]. 
Activation is divided into four key stages: initiation of complement activity, C3 convertase activation, 
C5 convertase activation and the ultimate formation of a lytic membrane attack complex (MAC). The 
activity of the complement pathway is attenuated through multiple mechanisms, including reduced 
half-lives of activated components and a number of soluble complement regulatory factors (CRegs) 
[78]. Collectively, the complement system is formed of over sixty proteins, of which nine components 
are central to the cascade (C1-C9) (Fig. 1.3). Numerous activation products, inhibitory 
factors/regulators (a key and AMD-relevant example includes complement factor H (CFH)), proteases 
and receptors for effector products (e.g. C5aR) are also included. Complement components are 
produced primarily in hepatocytes; however, recent studies have identified that key complement 
components (regulatory proteins) can be produced by the RPE, suggestive of local regulation in order 
to maintain immune homeostasis [79].  
 
The complement activation process occurs through three dissimilar pathways (alternate (AP), lectin 
(LP) and classical (CP)) initiated by differing stimuli, but ultimately converging at central complement 
protein C3 [80].  The CP is initiated in response to antibodies bound to a pathogen or directly to a 
pathogen surface. The binding of initial component C1q to antibody complexes triggers proteolytic 
cleavage of downstream steps. The lectin pathway is initiated though the activity of mannose-binding 
lectin (MBL) and ficolins which bind PAMPS on pathogen surfaces. Key proteases associated with these 
PRR (e.g. MASP1) trigger the cleavage of C4 and C2. Finally, the alternative pathway is initiated by the 
spontaneous cleavage and activation of C3, permitting the binding of complement factor B (CFB) and 
activation of C3 convertase.  Following the cleavage of C3 (and generation of C3 convertase from each 
pathway), activated proteins C3a, C3b, C5a lead to the formation of the MAC (C5b-9) [77]. 
Interestingly, in the genetic absence of C3, thrombin (coagulation protein) can substitute as a C5-
convertase [81]. Dysregulation of complement is amplified in the pathogenesis of multiple diseases, 
including rheumatoid arthritis, multiple sclerosis and AMD [56, 82]. More information on how 





Figure 1.3. An overview of the systemic complement system: 
The complement system is initiated by three pathways (alternative, classical and lectin) and leads to a sequential 
activation cascade of downstream components. The classical pathway involves the binding of antibody-antigen 
complexes to C1, which itself has three components (C1q, C1r and C1s). The pathway corms a C3 convertase 
C4b2a, which cleaves C3 into two subsequent fragments. C3b attaches to pathogen surfaces to start the 
opsonization process whilst C3a activates mast cells. The C3 convertase C4b2a is similarly formed through the 
lectin pathway: mannose binding lectin binds mannose residues on a pathogen surface, which in turn activate 
associated serine proteases and C4 and C2. The alternative pathway generates the C3 convertase C3bBb. 
Activation is succeeded by an amplification reaction to generate additional C3 convertases and C3b. Subsequent 
C5 convertase formation (C4bC2aC3b for classical and lectin pathways, and C3bBbC3b for the alternative 
pathway) generates the potent inflammatory C5a anaphylatoxin and C5b. C5b initiates the formation of the 
membrane attack complex through the recruitment of C6, C7, C8 and C9 components to the bacterial surface. 
This complex inserts into cell membranes leading to cell lysis through pore formation. Self-tissue is protected 
from the deposition of complement components through extracellular and cell-surface regulators (e.g. 
complement factor 1, CD46 and C1 inhibitor). Convertases are regulated by through decay-accelerating factors 
(e.g. C4b-binding protein and complement factor H) which inhibit their biological activity and thus attenuate 
complement cascade. MASP, mannose lectin activated serine protease; MAC, membrane attack complex; C1-
INH, complement inhibitor. This figure schematic is reproduced from [82].  
  
1.5.3. Para-inflammation  
It is argued that between a true acute inflammatory state and basal homeostasis conferred by the 
immune system, there exists an intermediate stage termed “para-inflammation” [83]. This para-
inflammatory state exists as part of the adaptive immune response, instigated to combat low-level 
cellular stresses and danger signalling. It is generally perceived that an inflammatory response is 
advantageous, bestowing defence against pathogenic infection, only when this response becomes 
dysfunctional and uncontrolled will immune-mediated disorders such as infection and autoimmune 
disorders emancipate. Yet as Medzhitof states, “inflammatory responses are only known in 
pathological settings, and there is no clear understanding of their physiological counterparts” [83]. A 
mass of compelling experimental evidence suggests that inflammation, evolving to restore 
homeostasis may underlie the basis of human diseases such as obesity, gout and degenerative 
disorders [83-85]. RPE are subjected to accumulated oxidative damage from a lifetime of exposure to 
oxidative stress, the build-up of free radicals and oxidized lipoproteins [86]. This combined with RPE 
degeneration, complement activation and alterations to BM structure leave the retina extremely 
susceptible to the development of chronic inflammation [1]. The switch from a “para-inflammatory” 
environment – serving to protect tissue integrity – to that of low grade persistent inflammation within 
the aging retina has been postulated to be a likely mechanism of AMD pathogenesis; it is unknown if 
the RPE continues to adapt and protect the retina prior to this switch, or whether cellular stresses to 
the RPE will lead to an amplification of tissue damage  [41].  
 
1.5.4. Innate inflammation in the pathogenesis of AMD 
An efficient immune response is essential in the maintenance of visual homeostasis and the 
preservation of the retinal environment in response to microbial invasion, but more likely (considering 
the retina is located in a site of immune privilege) tissue destruction and “sterile” inflammation  [2].  
In chronic conditions “sterile” inflammation occurs following uncontrolled activation of PRR via self-
derived ligands. Putative endogenous ligands could be either proteins, polysaccharides, 
phospholipids, nucleic acids, extracellular matrix components and proteoglycans [87]. Degenerating 
RPE-derived drusen components are likely drivers of innate sterile immune responses within the eye 
which manifest as TLR activation [41]. Inflammation is an adaptive response to tissue stress, so when 
tissues are exposed to noxious environmental stressors, cell mediated response pathways (e.g 
inflammasome activation, autophagy or bioenergetic adaptations) are activated to promote survival 
and tissue homeostasis. As previously discussed, failure to maintain low-grade immune responses 
below a certain threshold may upset the balance between tissue homeostasis and overt 
parainflammation, leading to chronic inflammatory dysfunction in degenerative diseases, such as 
AMD. Indeed, recent genome-wide association studies (GWAS) have demonstrated the prominent 
role of the innate immune system during AMD pathogenesis; with genes and single nucleotide 
polymorphisms (SNPs) identified within the complement pathways [88-90], chemokine receptors [91, 
92] and innate endotoxin PRR [93, 94].  
 
In the context of AMD, there is reported cross-talk between the complement system and TLR 
signalling, with drusen component (and complement activation product) C5a reported to induced TLR-
4 upregulation and downstream cytokine expression in an MAPK dependent manner [95]. TLR-4 has 
been suggested to mediate POS phagocytosis through CD36 scavenger receptor clustering in RPE [96]. 
Direct TLR-4 stimulation in Müller glial cells/photoreceptors has been shown to contribute to 
photoreceptor degeneration however, the same study suggested a novel role in regulating 
photoreceptor survival through LPS-mediated pre-conditioning and the suppression of WNT/TNFα 
signalling [97]. Whilst polymorphisms in TLR-4 were previously associated with AMD [94], it is 
interesting to note that follow-up studies have yet to find a genetic association with coding SNPs and 
AMD susceptibility [98, 99]. A pathogenic role for TLR-3 may lie in the accumulation of Alu-repeat 
derived dsRNA observed in GA, a result of reduced processing activity of DICER1 (a microRNA 
processing enzyme) [100]. In addition to this, ultraviolet light has been shown to potently damage self-
non-coding RNA leading to increased TLR-3 activation [101], a phenomenon with direct relevance to 
RPE cell loss in AMD. The implication of TLR-3 polymorphisms in the pathogenesis GA has been met 
with some controversy. The hypomorphic SNP rs3775291 (L412F) was proposed to confer a degree of 
protection to carriers against GA, suggesting deleterious involvement of TLR-3 signalling within 
macular degeneration [93]. However, later genetic association studies failed to identify a significant 
correlation between the TLR-3 variant and a protective phenotype [99, 102]. Recent meta-analyses 
have confirmed the association of L412F with GA through “pooling” the surrounding literature, leading 
on to speculating a protective mechanism for the SNP through decreased affinity for dsRNA [103]. 
L412F however, is proposed as an associative marker in Caucasians but not Asians, with only a small 
influence on disease susceptibility [104]. A recent study has implicated a protective role for TLR-3 
signalling in oxidative stress, mediated by the downstream transcription factor signal transducer and 
activator of transcription (STAT)3; stimulation via commercial TLR-3 agonist Poly (I:C) (dsRNA) rescued 
photoreceptor degeneration and conferred additional protection to cultured RPE [105]. Similarly to 
what is observed in TLR-4 and TLR-9 preconditioning for photoreceptor protection and induced 
tolerance within autoimmune diseases, respectively; it appears that the timing of preconditioning is 
essential for conferring protection [97, 106].  
 
The inflammasome complex is activated during AMD development through a capacity to recognize 
extracellular drusen deposits, leaving to a release of IL-18 and IL-1β [47]. NLRP3 has recently been 
implicated in the pathogenesis of AMD, a result attributed to a range of factors including: drusen 
components, mitochondrial dysfunction and Alu RNA [47, 107-110]. Drusen components isolated from 
AMD eyes were observed to prime the NLRP3 complex leaving to increased IL-18, IL-1β and cleaved 
caspases. Moreover, common drusen-associated components complement component C1Q and 
oxidized carboxyethylpyrrole (CEP)-adducts, prime and activate the NLRP3 inflammasome, 
respectively [47]. In experimental choroidal neovascularisation (CNV) (used as a model of wet AMD) 
disease development was intensified in Nlrp3-/- mice, yet this was not observed in Il1r1 -/- mice. IL-18, 
when processed into its mature form can act as an antiangiogenic factor reducing CNV both alone, 
and in combination with a murine specific anti-VEGF antibody. It was further observed that IL-18 from 
bone marrow derived hematopoietic cells had the potential to protect against CNV [111]. Whilst its 
activation is evident in both GA and neovascular AMD, there remains controversy to whether a 
protective or pathogenic role can be attributed. Theoretically, the initial activation of NLRP3 must be 
protective, to preserve tissue integrity in response to danger-associated signalling. Only when clinical 
disease manifestations lead to an uncontrolled inflammatory response NLRP3 activation may be 
classified as an “immunotherapeutic target”. Drusen, as a hallmark of AMD progression, displays a 
protein-rich composition of complement factors and amyloid beta (Aβ) [112, 113]. When isolated from 
human eyes, and used as an isolated C1Q component alone, both were capable of eliciting NLRP3 
activation and leading to the secretion of IL-1β and IL-18 from LPS-primed macrophages and murine 
bone-marrow-derived-macrophages (BMDM) [47].  Aβ 1-40 was observed in both in vitro and in vivo 
studies to upregulate inflammasome activity through the expression of IL-1β, IL-18, NLRP3 and CASP-
1 within the RPE and choroid [107]. The fluorophore A2E, a major component of lipofuscin (and 
ultimately drusen), was observed to activate the NLRP3 inflammasome and increase the production 
of IL-1β following its endocytosis into RPE cells [114]. In addition to this, A2E can initiate oxidative 
damage and complement activation within RPE [115], with oxidative damage identified as a prominent 
up-regulator of NLRP3 expression [109]. DICER1 deficiency and the accumulation of Alu RNA is well 
noted within GA [100] and has been recently shown to activate the NLRP3 inflammasome 
independently of TLR signalling. Cytotoxicity conferred by the Alu RNA was identified to occur through 
MyD88 and the downstream secretion of IL-18 however, mitochondrial ROS were identified as the 
initial priming event for NLRP3 activation [110]. Although suppression of the NLRP3 inflammasome 
certainly appears to be an attractive therapeutic for the treatment of AMD, as discussed earlier, the 
initial activation is almost certainly in place to preserve tissue health in pre-clinical disease.  
 
A large proportion of the molecular constituents of drusen are complement-activation products, these 
include complement regulators, activators and terminal pathway proteins [116]. This indicates a role 
for complement-mediated local inflammation in the early stages of AMD development. Genetic 
studies have identified significant associations between complement sequence gene polymorphisms 
and AMD risk, including SNPs in complement factor H (CFH), CFB, C3 and C2 [117-119]. CFH is one of 
most widely recognized pre-disposing genetic factor for AMD development [120]. Heterozygotic CFH 
mice develop characteristics of early AMD pathogenesis when fed on a high fat, cholesterol rich diet 
mimicking the environmental pressures of western societies with increased AMD prevalence [121]. 
CFH regulates complement activation at sites of tissue inflammation following injury or during 
degradation [56]. In humans, an amino acid substitution from histidine to tyrosine in the binding 
domain of CFH leads to the expression of an alternative variant (H402) which poorly regulates the AP 
of complement activation [122]. Uncontrolled complement activation is suggested to dysregulate 
immune homeostasis which in turn may manifest into the early stages AMD development [56].  The 
involvement of CFH and other complement pathway genes highlights the role of innate immunity in 
AMD. Despite a mass of both genetic and clinical data pointing to a role of low-grade chronic 
inflammation in the pathogenesis of AMD, the underlying molecular mechanisms are yet to be fully 
elucidated  
 
1.6. The Interleukin-1 cytokine family 
The IL-1 family of cytokines are a group of cytokines with a key role in the regulation of inflammatory 
responses or sterile inflammation. The IL-1 family consists of 11 members that can be separated into 
sub-families based on their pre-processed forms and bioactivities (Fig. 1.3) [123]. They share a highly 
conserved gene arrangement, allowing the formation of a 12-stranded beta-barrel [124]. IL-1 family 
members differ in their signalling pathways and the mechanism whereby they are processed to 
mature bioactive forms. Inflammasome cytokines IL-1β and IL-18 are initially translated as inactive 
pro-peptides (pro- IL-1β -18) that require cleavage by caspases mediated by NLRP3 for both secretion 
and biological activity [125]. In contrast, processing of pro-IL-1α precursor occurs in an inflammasome-
independent manner through a calcium-dependent cysteine protease, calpain [126]. IL-1α and IL-1β 
exert their pro-inflammatory effector functions through the activation of NF-kB, following binding to 
the IL-1 receptor 1 (IL-1R1) and IL-1RAcP complex [127, 128]. IL-18 confers more complexity to its 
signalling, in the sense that it can initiate Th1 and Th2 responses [129]. The IL-18R complex consists of 
two domains - IL-18Rα (ligand binding domain) and IL-18Rβ (co-receptor domain) [130] - which 
following the binding of IL-18 form a heterodimer complex to initiate downstream signalling cascades 
through MAPK and p38 pathways as opposed to NF-kB activation in IL-1R transduction [130].  
 
IL-18 subfamily member IL-37 suppresses innate inflammatory responses through binding to 
interleukin 18 binding protein (IL-18BP), forming a complex that inhibits IL-18 signalling [131]. The 
processed IL-37 acts as a dual function cytokine (like IL-1α and IL-33) displaying intracellular and 
extracellular anti-inflammatory properties initiated through nuclear translocation [131]. 
 
The third IL-36 family subset contains members with the smallest pre-processed peptides [132]. This 
sub-family includes cytokines IL-36α, IL-36β, IL-36γ, IL-36RA and IL-38 that initiate hyper-reactive and 
inflammatory responses through the IL-36R/ IL-RAcP signalling complex [132]. IL-36RA and IL-38 both 
share significant sequence homology with the IL-1RA, allowing them to initiate antagonistic activities 




Figure 1.4. A schematic of ligands and their receptor chains in the IL-1 family: 
The IL-1 family consists of 11 ligands, further separated into their respective sub-families on the basis their pre-
processed form and bioactivities. The IL-1 subfamily contains cytokines with a larger precursor peptide length 
such as IL-1α, IL-1β and IL-33. The IL-18 family have smaller pro-peptides and includes both IL-18 and IL-37. 
Additionally, there is a third IL-36 family subset containing members with the smallest pre-processed peptides. 
There are 7 agonists (IL-1α, IL-1β, IL-18, IL-33, IL-36α, β and γ), three receptor antagonists (IL-1Ra, IL-36Ra and 
IL-38) and one anti-inflammatory member (IL-37). IL-1α, IL-1β and IL-1Ra signal through a receptor complex 
formed of IL-1R1 and a co-receptor IL-1RAcP. IL-33 signals through the ST2 IL-1RAcP complex. IL-18 signals 
through a receptor complex comprised of IL-18Rα, β and the IL-18BP; IL-37 on the other hand, requires only IL-
18Rα.  IL-36α, β and γ signal through the IL-36R/IL-1RAcP-receptor complex.  IL-36RA and IL-38 signal through 
IL-36R without the need for a co-receptor. IL, interleukin; IL-1R, interleukin-1-receptor; IL-1RAcP, interleukin-1-
receptor accessory protein; IL-18R, interleukin-18-receptor; ST2, suppression of tumorigenicity 2; IL-1Rrp2, 
interleukin-1-receptor related protein 2; IL-RA, interleukin receptor agonist. Adapted from [11].  
1.7. Interleukin-33 
IL-33 is a member of the larger IL-1 superfamily of cytokines and is only observed in placental 
mammals [19, 133]. Constitutive nuclear expression of IL-33 is observed at high levels in multiple cell 
types in both human and murine tissues [134]. Prior to its establishment as an IL-1 family member in 
2005 [133], IL-33 was first identified and cloned from canine vasospastic cerebral arteries [135]. It was 
later described as a nuclear factor observed in high endothelial venules, where it was recognized as 
NF-HEV [136]. Expression of IL-33 is observed predominantly in barrier endothelial cells, epithelial cells 
and fibroblasts [14, 133, 136, 137]; additionally, adaptive and innate immunological cells such as 
dendritic cells, monocytes and macrophages have been shown to express IL-33,  [138-140]. IL-33 is 
typically associated with T helper (Th) 2 responses initiated through its IL-1 receptor related protein 
ST2 present on effector cells (mast cells, eosinophils, basophils, natural killer (NK) cells and 
macrophages) [133]. Trans-membrane ST2 is also expressed on a variety of non-immune cells, and 
therefore has been speculated to influence pathogenic inflammatory responses in a number of disease 
models [17, 125, 141, 142], yet on the contrary, protective novel roles for IL-33 have been suggested 
in the attenuation of disease development [8, 14, 15, 143-145]. In addition to this, pro-IL-33 is 
speculated to have a nuclear function in the regulation of gene expression, yet this is currently 




Figure 1.5. Biology of the nuclear alarmin IL-33: 
(A) During homeostasis IL-33 is constitutively expressed at high levels in epithelial barrier cells where it acts (via 
poorly defined mechanisms) to control the epigenome. (B) In apoptotic cell death, IL-33 is released from cells 
and is processed by inflammasome-derived caspases 3 and 7. Processed IL-33 has no biological activity and is 
unable to activate its cognate receptor ST2. (C) Mechanical damage, cellular stress or exposure to allergens or 
viruses leads to the extracellular release of full-length bioactive IL-33. IL-33 alerts the immune system of tissue 
damage by activating multiple ST2-expressing cells such as mast cells, Th2 T-cells and ILC2s. IL, interleukin; ST2, 
suppression of tumorigenicity 2; Th2, T-helper cell type 2; ILC2, type 2 innate lymphoid cell. Adapted from [146].   
1.7.1. The Interleukin-33:ST2 signalling axis 
The IL-33 receptor ST2 is active in the form of a heterodimeric complex comprised of a ligand 
(cytokine) binding chain (IL-1R4) and an accessory chain (IL-1R3) [147]. Both chains contain 
intracellular Toll/IL-1 receptor (TIR) and extracellular immunoglobulin-like (Ig) domains [124]. The Ig 
domains, along with a highly homologous receptor accessory protein (IL-1RAcP) induce the 
dimerization of the two TIR domains following binding of agonist IL-33 [148]. The presence of IL-1RAcP 
is imperative for linking the binding of IL-33 and ST2, acting as a common β-chain for IL-33Rα and three 
other IL-1 receptor family members [149]. The ST2/IL-1RAcP complex allows IL-33 to initiate its 
downstream functions through downstream kinases NF-kB and various MAP kinases (ERK1, ERK2 and 
p38) [133]. The recruitment of TNF receptor-associated factor 6 (TRAF6) is a crucial mediator in the 
initiation of IL-1/TLR signalling and it appears that IL-33 requires the ubiquitin ligase effector function 




Figure 1.6. A schematic of the IL-33/ST2 signalling axis: 
IL-33 binds to its cognate receptor formed as a dimer complex of ST2 and IL-1RAcP.The binding of IL-33 to ST2 
initiates the recruitment of MYD88, IRAK1 and IRAK4 which lead to the activation of NF-κB and MAPK pathways, 
respectively. MAPK activation leads to the activation of P38, JNK and ERK pathways. JNK activation results in 
activation of the transcription factor AP1. The transcription factors AP1 and NF-κB translocate to the nucleus 
whereby they promote the expression of relevant cytokines and chemokines. ST2, suppression of tumorigenicity 
2; IL-1RAcP, interleukin-1-receptor accessory protein; MYD88, myeloid differentiation primary-response protein 
88; IRAK, interleukin-1-receptor associated kinase; NF-κB, nuclear factor kappa B; MAPK, mitogen activated 
protein kinase pathway; AP1, activated protein-1. Adapted from [151].   
1.7.1.1. Interleukin-33 signalling on lymphoid cells 
The alarmin activity of IL-33 potently enhances the lymphoid arm of the immune system. Although 
ST2 was first described on Th2 cells [152, 153], expression is observed on type 2 innate lymphoid cells 
(ICL2) [154], NK cells [155], NK T cells [156], activated Th1 cells [157], cytotoxic CD8 T cells [158], 
regulatory T cells (Tregs) [159], B1 cells [160] and regulatory B cells (Bregs) [161].  
 
Th2 and GATA+ Treg cells constitutively express ST2 at high levels; In cytotoxic lymphocytes (CTL) and 
Th1 cells, ST2 expression is activation-dependent (albeit at lower levels than Th2 subsets) [157, 162, 
163]. IL-33/ST2 signalling in T-cells initiates downstream effector functions through activation of the 
phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signalling pathway 
[164]. IL-33 is essential for promoting the primary differentiation of both CD4 and CD8 subsets, acting 
to extend their cytokine production capacity and effector functions [162]. In Th1 cells, IL-33 signalling 
and activation of STAT4 increases the production of T-bet (a critical factor for Th1 differentiation) 
[157]. In the Th2 subset, IL-33 and IL-2/STAT5 signalling converge on GATA3 to promote Th2 
differentiation [165]; the activation of GATA3 in Treg cells lead to increased FOXP3 expression [159]. 
Whilst IL-33 appears to be a key co-stimulator of various T-cell subsets, additional roles for the 
cytokine have been suggested in both clonal expansion and maturation of functional CTL and Th1 
subsets, increasing expression of pro-survival proteins and proliferation [157, 158]. Indeed, lack of IL-
33/ST2 signalling weakens the capacity of CTL to kill LCMW infected cells and impairs the antiviral 
cytokine output of Th1 cells [158]. Additionally, IL-33 has been observed to initiate antigen-
independent cytokine production from Th2 cells in vitro through solely ST2 activation [166] and with 
a co-stimulatory activation of STAT5 via IL-2 [165].  
 
Unlike T cells, murine NK cell differentiation and development does not appear to involve IL-33/ST2 
signalling, with ST2 deficient cells observed to differentiate into a memory pool [167]. Whilst not 
essential for NK survival, activation and IFN-γ production, IL-33 signalling is critical for the expansion 
of a Ly45H+ subset following in vivo cytomegaloviral infection [167]. IL-33 acts synergistically with IL-
12 to further upregulate IFN-γ production in human NK cells [155]. In both murine NK cells and murine 
invariant NK cells, on the contrary to instigating a Th2 response, IL-33 stimulation upon TCR 
engagement also lead to an increased IFN-γ output in conjunction with IL-12 [156]. Further provoking 
the hypothesis that IL-33 may act as a co-stimulatory factor during adaptive immune responses. 
 
Peripheral B cells can be subdivided into two main classes: the B1 subset, which function as an long-
lived and self-renewing APC and innate immune effector) and the B2 subset (the “classical subset”), 
which responds to antigen stimulation to undergo IgH class switching and affinity development via T-
cell dependent mechanisms [168]. ST2 is expressed exclusively on the B1 subset [160]. IL-33 activates 
murine B1 cells, enhancing proliferation, IgM synthesis and Th2 cytokine output in a IL-5/IL-5R 
dependent mechanism [160]. In addition to their activation by IL-33, B cells purportedly (through an 
unidentified secretory mechanism) release IL-33 following Notch-1 activation to modulate and co-
stimulate T-cell responses [169]. Alike the Treg subset, a Breg can be found in the B lineage. These 
cells have gained increased attention due to their immunoregulatory and suppressive capacity [170]. 
IL-33 elicits the generation of a phenotypically distinct murine Breg subset, of which protects against 
inflammatory bowel disease in an IL-10-dependent manner [161].  
 
ILCs are mucosal effector cells differentiated from common lymphoid progenitors; however, unlike 
adaptive lymphocytes, ILCs do not have the capacity to rapidly rearrange cell-surface receptors to 
recognize non-self-antigens [171]. ILCs express a similar range of transcriptional regulators to their 
adaptive counterparts to control a large cytokine repertoire [171].  
 
GATA3+ ILC2s are highly responsive to IL-33 in vivo and in vitro because of their high ST2 expression 
[172]; indeed, IL-33 is the “hallmark activator” of both peripheral and bone marrow ILC2s [173]. 
Similarly (to Th2 T-cells), IL-33/ST2 signalling engages the activation of the PI3K/mTOR signalling 
pathway [164]. IL-33 is reported to have a critical role in the trafficking of ILC2s from the bone marrow 
into the peripheral tissues, yet not in their differentiation status, proliferative capacity or cytokine 
profile [174]. Interestingly, the IL-33/ICL2 axis appears to play a vital role in acute wound healing 
facilitating re-epithelialization of damaged surfaces [175].  
 
1.7.1.2. Interleukin-33 signalling on myeloid cells 
The ST2 receptor is highly expressed on several myeloid derived immune cells associated with allergy 
(mast cells, eosinophils and basophils). The most well studied of these are eosinophils, of which IL-33 
plays a critical role in both development within the bone marrow and activation. During the early 
stages of cellular differentiation, IL-33 regulates the expansion of an eosinophil precursor [176]. By 
upregulating the expression of the IL-5R and IL-5, IL-33 ensures commitment to the eosinophil lineage 
[176, 177].  IL-33 acts potently on mature eosinophils to increase their cytokine production, CD11b 
and CD69 expression, degranulation capacity, and the expression of several adhesion factors (CXCL8/ 
CCR3) that enhance eosinophil survival [178-181]. Administration of IL-33 drives eosinophilia in vivo 
likely due to augmented eosinophil survival [133, 182].  
 
Not unlike eosinophils, basophils are also cellular targets of IL-33 and once activated, increase their 
cytokine production and expression of several adhesion factors (e.g. CXCL8) that enhance their 
survival [98-100]. IL-33 promotes the secretion of IL-4, IL-13 and IL-8 from human basophils in co-
operation with either IL-3 or Fcε receptor 1 (FcɛRI) [183]. Direct stimulation of human basophils with 
IL-33 is reported to have no observable effect on their degranulation or attraction in vitro [184]. 
Yet in conjunction with immunoglobulin (Ig)E receptor stimulation, IL-33 augments basophil 
degranulation [185]. Independently of FcɛRI, IL-33 regulates the synthesis of leukotrienes via 
alternate mechanisms to IL-3, yet lacks the ability to efficiently prime human basophils for their 
C5a-induced leukotriene generation [183]. Additionally, IL-33 exerts effects on the migratory 
capacity of human basophils by inducing the expression of CD11b in human basophils and 
adhesiveness to nearby endothelial cells [184].  
 
IL-33 acts on ST2 expressing neutrophils to promote migration and recruitment through the 
upregulation of CXCL1, CXCR2 and CXCR3 [186, 187]. In vivo the recruitment of neutrophils appears 
to be dependent on the MC release of TNFα  [188]. On the contrary, IL-33 deficient mice have been 
shown exhibit increased neutrophil migratory capacity, increased production of IL-6 and TNFα, but 
reduced IFN-γ [189]. Direct effects of IL-33 are observed in the activation of neutrophils; IL-33 
polarises neutrophils via C-Jun and NF-kB to a novel IL-33 subpopulation exhibiting a characteristic 
IL-4, IL-13, IL-9 and IL-5 cytokine output [190]. Indirect IL-33-induced IL-5 production in neutrophils 
has previously been observed through the regulation of ILC2-dependent IL-5 production [191]. 
Indirectly action of IL-33 on neutrophils is described via an ILC2-IL-13-STAT6-dependent 
mechanism. This results in the generation of an immunosuppressive neutrophil population 
exhibiting high levels of IL-10 and arginase-1 [192].  
 
Mast cells express the ST2 receptor at high level and represents a murine lineage marker [193]. IL-33 
activation of ST2 can initiate signalling through two independent pathways depending on the 
enzymatic activity of the receptor tyrosine kinase, c-Kit. If c-Kit is enzymatically inactive, IL-33 
signalling occurs through the PI3K/mTOR axis in a similar fashion to TLR activation. However, when c-
Kit is in the active conformation at the ST2/IL1-RAcP complex, STAT3 is activated following IL-33 
stimulation [194]. IL-33 is involved in the mast cell maturation process, and in conjunction with thymic 
stromal lymphopoietin, enhances the maturation of a CD34+ precursor and expression of tryptase (an 
early marker of differentiation status [195]. In addition to this, IL-33 signalling increases mast cell 
survival by upregulating B-cell lymphoma extra-large (BCLXL) expression and attenuating apoptosis 
[196]. IL-33 directly acts on mast cells to increase cytokine production [197, 198] and can augment 
TLR or FcɛRI-dependent cytokine production [199]. The IL-33-induced release of IL-2 from mast 
cells mediates the expansion of both Treg and Th17 populations in a context-dependent manner 
[200, 201]. IL-33 signalling per se activates mast cells without degranulation [199, 202]. The 
consensus is that IL-33 may act in conjunction with IgE to augment the extent of mast cell 
degranulation but not kinetics [203]. Interestingly, it is suggested that the effects of IL-33 on IgE 
production, mast cell degranulation and anaphylaxis, appear to be mediated through downstream 
IL-4 release and signalling [204]. The IL-33/ST2 axis may be critical in the response to tissue 
damage; with the release of IL-33 from necrotic cells activating mast cells to initiate inflammatory 
responses in response to injury [205]. 
 
Macrophages can be broadly classified into two subsets: classically activated (M1), defined by their 
potent type 1 inflammatory responses, TLR expression and inducible NO synthase (iNOS) expression; 
or alternatively activated (M2) macrophages, defined by their roles in type 2 immune responses and 
tissue repair, secretion of high amounts IL-10, and induction by IL-4 and IL-13 [206] (see Fig. 1.7.). IL-
33 was observed to polarize macrophages into an alternatively activated phenotype (expressing IL-4R, 
arginase-1, CCL24 and CCL-17 during airway inflammation via an IL-13-dependent mechanism [101]. 
IL-33 is reported to reduce the expression of IL-1β, IL-12, IFN-γ and TNFα, whilst increasing the 
expression of IL-13, IL-4 and IL-10 from macrophages in vitro [207]. Additionally, IL-33 can augment 
the expression of M2 marker expression when treated in combination with IL-4/IL-13; yet further 
reduces expression when skewed to an M1 phenotype in conjunction with LPS [208].  
  
 
Figure 1.7. Macrophage subsets: “M1”, “M2” and “Mreg”: 
Tissue-resident macrophages can be polarised into three major subsets based on cytokine production and cell 
surface markers. Classically activated “M1” macrophages are polarised by LPS, IFN-γ or IFN-γ in combination 
with TNFα. These cells generate high levels of inducible nitric oxide synthase and MHC II along with a vast output 
of proinflammatory cytokines (TNFα, IL-1, IL-6, IL-23, IL-12 and CCL2) which facilitate their role in pathogen 
clearance and sustaining a Th1 response. Alternatively activated “M2” macrophages are generated through 
stimulation with IL-4 and/or IL-13. These cells are associated with tissue resolving and Th2 responses and express 
high levels of arginase-1 and VEGF. Regulatory “Mreg” macrophages are produced in response to either TLR 
ligation with IL-10 or glucocorticoids. These cells have a cytokine signature defined by high levels of IL-10 
production.  
  
Whilst there is limited research concerning the effects of IL-33 on dendritic cells, it appears to play a 
key role in their generation and activation. In a murine in vitro dendritic cell culture system, IL-33 was 
observed to augment the generation of CD11+ cells via an indirect mechanism involving GM-CSF [209]. 
Dendritic cells expressing ST2 (albeit at low levels) increase their MHC II expression following IL-33 
exposure, leading to T-cell-dependent cytokine production in a co-culture system [102]. IL-33-
stimulated dendritic cells lead to the selective expansion of a Treg population through the indirect 
secretion of IL-2 [210]. Furthermore, the activation of dendritic cells by IL-33 both in vitro and in vivo 
primes naïve T-cells to a Th2 phenotype, with a robust expression of IL-5 and IL-13 [211]. Interestingly, 
the identification of a novel IL-33-ST2-MyD88-STAT1 axis drives dendritic cell activation and 
maturation, ultimately leading to increased anti-tumour immunity in vivo [212].  
 
1.7.1.3. Interleukin-33 signalling in non-haemopoietic cells 
Whilst most literature concerning the IL-33/ST2 axis has focused on hematopoietic immune cells, it is 
essential to note many non-haemopoietic innate immune competent cells also respond to IL-33. ST2 
expression is observed in fibroblasts [8, 150, 213], epithelial cells [8, 214, 215], osteoblasts [216], some 
endothelial cell populations [8, 217-219] , hepatocytes [220], myocytes [14, 221] smooth muscle cells 
[218], and Müller glia [222].  
 
IL-33/ST2 signalling in fibroblasts drives the activation of NF-kB, p38 and JNK through IRAK and TRAF6, 
leading to the secretion of MCP1, MCP3 and IL-6 [150]. IL-33 is observed to affect the migratory 
capacity of choroidal fibroblasts through modulating the expression of migratory factors MMP2, 
MMP9, TIMP1 and TIMP2 [8]. In rheumatoid arthritis-derived synovial fibroblasts, extracellular IL-33 
diminishes MMP1 and IL-6 expression, whilst endogenous IL-33 appears to have a broader role in the 
regulation of TNFα-induced pro-inflammatory, migratory and destructive signalling mediators [223]. 
Additionally, IL-33 promotes the expression of fibronectin and type-1 collagens to facilitate airway 
remodelling [224].  
 
ST2 expression is observed at high levels in epithelial stem cells and progenitor cells; this appears to 
be essential for reprogramming undifferentiated epithelial progenitors into the secretory intestinal 
epithelial lineage through the IL-33-mediated suppression of Notch signalling [225]. Fully 
differentiated epithelial cells respond to IL-33 in vitro, producing IL-6, IL-8 and MCP-1, both 
independently and in conjunction with IL-4 [214]. Endogenous IL-33 appears to regulate the 
expression of the epithelial adhesion molecule E-cadherin, and induction of chemokines and 
surfactants following cryptococcal infection in the lung epithelium [226]. IL-33 enhances epithelial cell 
proliferation and gut mucus production in vivo [133], Ex vivo human epithelial cultures respond to IL-
33 and produce anti-inflammatory mediators IL-1RA, IL-18BPa, IL-1RAcP and sST2 [227].  
 
In quiescent endothelial cells, endogenous IL-33 production is dependent on Notch-1 signalling [228]. 
Nuclear IL-33 expression in human endothelial cells is absent upon cytokine/ pro-angiogenic 
stimulation, with expression only observed at confluence, whereby cells are in a G0/G1 state [229]. 
Furthermore, IL-33 expression correlates with cell-cycle determinants (cyclin-dependent kinase 
inhibitor P27KIP1)  [228], suggesting either cell cycle status may be critical for constitutive IL-33 
expression or, IL-33 may have a regulatory role in endothelial cell cycle progression. Stimulation of 
human endothelial has been found to increase the expression of IL-6, IL-8 and MCP-1, and induce NF-
kB translocation [219]. Endothelial cell activation and upregulation of adhesion molecules (ICAM-1, 
VCAM-1 and E-selectin) which facilitate leukocyte adherence in vitro has also been described [219]. A 
recent study utilising a proteome-based approach to IL-33/ST2 signalling in endothelial cells identified 
a large array of proteins differentially regulated by extracellular IL-33 [230]. IL-33 stimulation primarily 
induces changes in NF-kB signalling, chemokine and cytokine expression, cell adhesion and cell surface 
receptor expression, and antigen processing [230].  
 
1.7.2. Interleukin-33 processing and release 
Similarly, to other IL-1 family cytokines IL-1β and IL-18, IL-33 lacks a signal sequence required for 
secretion through the Golgi apparatus and endoplasmic reticulum [231, 232] and is consequently 
synthesized as a pro-peptide (pro-IL-33). It was initially proposed that IL-33, like IL-1β and IL-18 
required cleavage for release and bioactivity because of a lack of clear signal peptide. IL-33 was later 
found to not require inflammasome activation, with optimum bioactivity occurring at full-length; 
[233]. Whilst pro-IL-33 contains residues denoting a caspase-1 cleavage site, the processed forms of 
the peptide are unable to activate ST2, it is therefore speculated that caspase-1 is involved in the 
attenuation and inactivation of IL-33 signalling [232, 233]. In addition to this, caspase-3 and -7 are 
reported to mediate proteolysis of pro-IL-33 during apoptosis to suppress the pro-inflammatory 
properties of the cytokine [231, 234]. Neutrophil-derived proteases (elastase, cathepsin G) initiate N-
terminal cleaving of IL-33 (at sites between residues 109-95) yielding forms with an increased potency 
for ST2 activation [235]. Endogenous calpains and exogenous extracellular allergy proteases in airway 
epithelial cells are reported to process IL-33 to increase its alarmin activity, yet systematic analysis of 
the both proteolysis sites and the structure of the processed forms remain unknown [236, 237]. These 
results suggest that IL-33 is bioactive in its unprocessed form; endogenous and exogenous proteases 
may be utilized to enhance/dampen the IL-33/ST2 signalling axis depending on certain micro-
environmental cues. 
 
Because of its constitutive expression and lack of signal peptide, it is proposed that IL-33 functions as 
an alarmin molecule, released into the extracellular space (via poorly defined mechanisms) following 
cellular necrosis or mechanical damage [146]. Release of endogenous IL-33 has been observed both 
in vitro (following mechanical disruption [233], induction of oxidative stress by hydrogen peroxide 
[234], viral infection [238] and formation of cellular pores by streptolysin O [234]) and in vivo 
(following viral infection of both human primary bronchial epithelial cells [238] and in nasal fluid of 
asthmatic subjects following rhinovirus infection [239].  
 
A fungal allergen is reported to elicit the release of IL-33 in the absence of cell death through 
extracellular ATP release, ROS generation and changes in intracellular calcium concentrations both in 
vitro and in vivo [240, 241]. It has been suggested that extracellular ATP exposure or pharmacological 
modulation of intracellular calcium may lead to the release of IL-33; however, the capacity of these 
agents to prompt nuclear-cytoplasmic translocation has not been confirmed in other studies [242]. 
Additionally, many studies have not confirmed specificity of IL-33 detection in an IL-33 deficient 
system or considered cellular necrosis/cell death which may account for the release [243].  
 
 
1.7.3. Regulation of Interleukin-33 
As one of the most biologically potent families of cytokines, control over the IL-1 family members is 
exerted through a variety of mechanisms including: signal peptide processing (in a caspase-dependent 
or independent manner as noted in the previous sections), extracellular signalling inhibitors, soluble 
decoy receptors and natural receptor agonists to block or diminish the affinities of receptor complexes 
for their intended ligands [123, 132]. IL-33 is not an exception to this phenomenon, with many 
counter-regulatory strategies exhibited to control its downstream signalling. 
 
Before the discovery of IL-33, the soluble form of ST2 (sST2), was observed to inhibit LPS-induced 
production of pro-inflammatory cytokines from macrophages, in addition to halting the toxicity 
conferred by the administration of LPS [244]. Whilst it was already known that alternative splicing of 
the ST2 receptor generated a soluble form [213, 245], it was not until the identification of IL-33 as the 
natural ligand for ST2, that sST2 was classified as a decoy receptor for IL-33-dependent signalling [133]. 
sST2 is extracellularly identical to its membrane bound counterpart except for nice amino acids at the 
C-terminus [246]. Lacking the transmembrane and intracellular TIR receptor domains, the 
upregulation of sST2 expression allows sequestration of IL-33, decreasing its ST2L/IL-1RAcP binding 
probability [247]. A protective role for sST2 was originally suggested in the context of attenuating the 
severity inflammatory and auto-inflammatory conditions, based on its anti-inflammatory properties 
[244, 248]. 
 
IL-1RAcP facilitates the binding between IL-33 and ST2, acting as a common β-chain for IL-33Rα and 
three other IL-1 receptor family members [149]. Alternative splicing leads to the generation of two IL-
1RAcP variants, one membrane bound and the other soluble. The soluble form ((s)IL-1RAcP) 
contributes to counter-regulation through increasing the affinity of IL-1 cytokines to the IL-1R2 decoy 
receptor [249]. In the negative-regulation of IL-33 signalling, sIL-1RAcP forms a complex with sST2, 
and together bind IL-33 [11]. SIGIRR (single immunoglobulin IL-1R-related molecule)/TIR8 (Toll IL-1R8). 
SIGIRR/TIR8 has been identified as a negative regulator of TLR-4, TLR-9 and IL-1R signalling [250, 251]. 
SIGIRR/TIR8 inhibits IL-33 signalling through an interaction with the ST2 receptor complex and 
subsequent interaction between respective extracellular Ig domains and intracellular TIR domains 
[250]. In addition to this, negative-regulation of IL-33 signalling can be exerted through the 
posttranslational modification of ST2L; the over-expression of E3 ubiquitin ligase (FBXL19) lead to the 
poly-ubiquitination of ST2L and proteasome-dependent degradation, lessening lung inflammation and 
severity of lung injury in a murine model [252]. 
 
Whilst little is known about the biological half-life and natural degradation of IL-33 when released 
from cells, a recent study has identified cysteine oxidation as a mechanism to inactivate IL-33. Free 
cysteine residues in the c-terminal are rapidly oxidized into two disulphide which disrupt the 
conformation of IL-33 and lead to disruption of the ST2 interaction [236]. It is interesting to note that 
other IL-1 family members (IL-1α, IL-1β, IL-18 and IL-36) exhibit free cysteine residues in their c-
terminal domain [236, 253] , suggesting a biologically conserved mechanism to control their potent 
activity.  
 
1.7.4. Nuclear interleukin-33 
IL-33 shares many features with IL-1 superfamily member IL-1α, including potent biological immune 
activity and nuclear localization, leading to its classification as a “dual-function cytokine” [133, 254]. 
Whilst IL-1α is targeted to the nuclei via a classical nuclear localization sequence [255], IL-33 contains 
a helix-loop-helix bipartite DNA-binding homeodomain within residues (1-56) [254]. It was originally 
suggested that IL-33 may influence transcriptional repression through an association with 
heterochromatin [254, 256]. However, the nuclear functions of IL-33 remain diverse and incompletely 
understood to date.  
 
A formation of an IL-33:SUV39H1 histone methyltransferase complex reportedly allows IL-33 to bind 
multiple homeobox binding motifs in the promoter regions of IL1RL1, IL6 and CCL5 repressing their 
transcription in human atrial endothelium [254, 257]. IL-33 has been reported to directly bind a 
conserved non-coding sequence before the translation initiation site in the IL13 gene in HEK293T cells 
to directly activate its transcription [258]. Additionally, IL-33 is suggested to repress the transcriptional 
activity of NF-kB by sequestering the p65 subunit in endothelium [10] and fibroblast-like synoviocytes 
[259]. Yet in contrast, IL-33 is reported to bind to the NF-kB promoter region to enhance its 
transcription [260]. A recent study has identified a large IL-33 nuclear interactome in squamous cell 
carcinoma cells, with a large array of transcriptional regulators and chromatin remodelling factors 
which converge on the modulation of NF-kB activity and downstream gene targets [261]. The 
identification of co-localization of IL-33 within both membrane-bound cytoplasmic vesicles/ nuclear 
euchromatin [262] question the original theory of IL-33 acting as a transcriptional repressor and may 
support the role of IL-33 in enhancing gene expression.  
 
Despite the broad range of transcriptional associations, nuclear roles for IL-33 remain unknown in 
certain cell types [230]. In a recent study, IL-33 was transduced in an oesophageal epithelial cell line 
lacking constitutive expression of the protein. Following RNA sequencing, no global gene changes in 
the transcriptional profile of the cells was observed. Moreover, utilizing fluorescence recovery after 
photobleaching it was observed that IL-33 exhibited a reduced intranuclear mobility compared to 
other transcriptional factors such as IL-1α and high mobility group box protein 1 (HMBG1) [263]. 
Additionally, another study utilizing a global proteomics approach following IL-33 knockdown by siRNA 
observed no observable changes to the endothelial proteome [230]. These two studies advocate a 
lack of nuclear function for the cytokine and speculate nuclear localization is an evolutionary 
adaptation whereby cells can sequester the cytokine in order to suppress its potent extracellular 
activities.  
 
The consensus still remains that IL-33 functions as an epigenetic regulator or a chromatin “insulator” 
protein [262]. These factors play a role in the modification of higher-order chromatin structure and 
the regulation of gene expression, with common molecular mechanisms found in modulating 
chromatin accessibility, long-range interactions with distant elements or compartmentalization of 
interphasic chromatin with nuclear pore complexes or additional nuclear structures [264]. There 
remains however, a desperate requirement for the utilization of a MeDIP/ChIP-seq/microarray-based 
sequencing approach to determine the magnitude of IL-33 regulation at an epigenetic level.  
 
1.7.5. Role of interleukin-33 in disease 
Studies have started to uncover the potential of IL-33 signalling, with elevated antagonistic sST2 levels 
correlating with disease severity in a wide range of disorders including diabetes, systemic lupus 
erythematosus, sepsis, preeclampsia, cardiovascular disease and obesity [14, 265-269]. In the case of 
cardiovascular disease, sST2 levels are increased following myocardial infarctions and negatively 
correlate with patient outcome, suggesting the potential of sST2 as a diagnostic marker. Recombinant 
IL-33 administration following transverse aortic constriction attenuated hypertrophy and fibrosis, 
indicating a protective role for IL-33 in regulating myocardial mechanical strain [14]. Interestingly, 
common genetic variation in IL-33/ST2 signalling has been identified, with multiple SNPs identified in 
the locus of ST2. Five of these missense variants were mapped to the intracellular region of ST2 and 
conferred a phenotype of increased sST2 production [270]. As increased sST2 may be precarious in 
multiple disease settings, screening for SNPs in this gene may be an attractive avenue for predicting 
clinical outcomes, especially in cardiovascular disease and degenerative disorders.  
 
IL-33 plays a fundamental role in the defence against helminth infection. Administration of 
recombinant IL-33 to mice infected with Truchris muris conferred increased protection against disease 
severity through a Th2 mediated response [271]. Mice lacking IL-33 exhibited an incompetence for 
removal of Strongyloides venezuelenis and Nippostrongylus brasiliensis [272, 273]. As a Th2 response 
is essential for removal of parasites, this further supports the crucial role of IL-33 in the activation of 
mast cells and ICL2 which mediate helminth removal [172, 274]. In the context of protozoa infection, 
a Th1 response is protective whereas Th2 initiation exacerbates; IL-33 as a potent activator of Th2 
immunity worsens disease severity. Indeed, patients with leishmania show high serum concentrations 
of IL-33 [275]. In a murine model of fungal infection with Canadia albicans recombinant IL-33 
administration instigates increased fungicidal activity on neutrophils which contribute to removal of 
fungal aggregations [276]. A similar phenomenon was observed in Canadia neoformans infection in 
vivo, where mice deficient in ST2 had amplified fungal development within their lungs [277]. In 
bacterial infections the IL-33/ST2 axis is critical in host defence, through enhancing the antimicrobial 
capacity of macrophages and neutrophils [278, 279]. It appears that following sepsis recovery, high 
serum levels of IL-33 may contribute to prolonged immune suppression through enhanced numbers 
of IL-10-producing Tregs [134].  
 
A plethora of literature has described the roles of IL-33 within allergic diseases. Genetic 
polymorphisms in IL33 and IL1RL1 are supposed drivers of allergic susceptibility [134]. Indeed, in the 
serum samples of asthma patients increased IL-33 protein is observed and correlates robustly with 
severity [280]. Treatment of mice with recombinant IL-33 leads to the development of acute 
eosinophil/IL-13-mediated allergic inflammatory responses and airway inflammation dependent on 
ILC2 [133, 281]. Atopic dermatitis is associated with ST2 polymorphisms which drives increased IL-33 
specificity and IL-33/ST2 signalling [282, 283]. Additionally, IL-33 expression is increased in dermatitis 
patients [282] and intradermal administration of IL-33 drives an atopic dermatitis-like inflammatory 
phenotype with neutrophil and eosinophil accretion [187]. Increased IL-33 is observed in rhinitis and 
conjunctivitis and augments the release of histamine/chemoattractants, which drive eosinophil and 
basophil accumulation and inflammation at early stages in the disease [284]. Interestingly, the 
exposure of IL-33 to allergen proteases leads to cleavage of a central IL-33 domain with increased 
potency for initiating Th2 responses [285]. This has been shown to be prevented by the generation of 
a novel antibody to the IL-33 protease “sensor” domain which blocks allergen-associated 
inflammation [285].  
 
1.7.6. Interleukin-33 and implications for AMD 
IL-33 and ST2 are constitutively expressed across the retina and choroid by a range of cells, including, 
Müller cells, RPE, retinal and choroidal endothelial cells [8, 17]. RPE are critical to the maintenance of 
immune homeostasis within the retina, stimulation with agonists for TLR-4 and TLR-3 have been 
shown to up-regulate the expression of IL-33 and ST2L [8, 286]. IL-33 subsequently acts on multiple 
cells within the retina to propagate immune responses and initiate cellular signalling processes, many 
of which have yet to be uncovered. Whilst literature surrounding the influence of this “novel” cytokine 
in the development of AMD is limited, it appears from other discoveries of context-dependent 
functions of IL-33, particularly in the CNS [145, 287], that many pleiotropic alarmins with functions in 
attenuating tissue injury should not be overlooked prior to adequate investigation. 
 
IL-33 has recently been implicated in the development of AMD. In a phototoxic model of retinal 
degeneration, stress to the retina - in the form of constant bright light – was shown to increase the 
release of IL-33 from Müller cells. Once activated in an autocrine-dependent manner, IL-33 
contributed to an upregulated chemokine and cytokine output, leading to the recruitment of 
mononuclear phagocytes, and ultimately contributing to photoreceptor loss and diminished retinal 
integrity. This phenomenon was attenuated by the knockdown of ST2 and led to reduced expression 
of CCL2, IL-6 and IL-1β. An increased expression of IL-33 and IL-33+ Müller cells was found in the macula 
and central retina of AMD cases [17]. A later study observed the TLR-dependent up-regulation of IL-
33 by RPE without any influence on cell viability; intravitreal administration of IL-33 was shown not to 
affect the retinal integrity or thickness. Moreover, in stark contrast, IL-33 did not lead to the 
accumulation of Iba+ macrophage or CD45+/CD11b+/Ly6C+ monocyte within the retina (even when 
administered 500-times greater than the therapeutic dose) [8]. As IL-33 is released from RPE and 
Müller cells without cell death, it is likely that this is an adaptive response to maintain homeostasis. 
The release of IL-33 following exposure to light may have evolved to combat the recurrent minor cell 
damage and tissue injury faced by the retina. 
 
It is proposed that dry AMD may be classified as a precursor state to wet AMD, with significant overlap 
in the underlying biological mechanisms and clinical manifestations [2]. However, as anti-VEGF 
treatments have proved successful in preventing disease progression of wet AMD, there remain no 
viable therapeutic options for those unresponsive to anti-VEGF. Additionally, it is suggested that long 
term anti-VEGF treatment leads to inner retina degeneration, as well as increased choroidal fibrosis. 
 
 A novel role for IL-33 has been observed, reducing the manifestations of nAMD. IL-33 was shown to 
attenuate angiogenesis with exogeneous administration of recombinant human (rh)IL-33 protecting 
against CNV; interestingly, it was observed that a lower dose was more effective at suppressing CNV 
[8], suggesting greater doses of IL-33 may elicit negative-regulatory mechanisms to balance excessive 
inflammation.  
 
The retina has a massive metabolic throughput, entailing more oxidative damage than any other 
tissue; the effects of prolonged oxidative stress, through the high production of ROS over a lifetime 
are sorely felt as the retina ages. Whilst para-inflammation has evolved to combat noxious damage, a 
dysregulated para-inflammatory environment can contribute to macular degeneration [57]. IL-33 may 
exert potential anti-oxidative roles through the direct upregulation of SOD activity in the context of 
chronic heart failure [288]. In addition to this, the IL-33/ST2 axis has been proposed to affect the 
cellular concentrations of magnesium and reduced glutathione, both key mediators of cellular anti-
oxidative capacities [289].  
 
The predominant clinical hallmark of AMD progression is the deposition of drusen between the RPE 
and Bruch’s membrane/choroid [113]. Recent studies identified common characteristics between the 
progression of AMD and Alzheimer’s, with the presence of Aβ observed within both drusen and senile 
neuronal plaques [290]. The RPE and retinal ganglion cells contribute to Aβ production and 
accumulation in the posterior eye [290]. Elevated levels are observed in the aging retina and correlate 
strongly with the development of AMD. As the retina can be viewed as an extension of the neuronal 
environment, many findings and therapeutic strategies for targeting neurodegeneration may have 
direct applicability to AMD treatment. IL-33 has recently shown to reduce the accumulation of both 
soluble Aβ and Aβ plaques through the recruitment of phagocytic microglia [15].  
 
Microglia activated through ST2/p38 were shown to increase the expression of CD68 scavenger 
receptor, promoting phagolysomal activity to clear Aβ deposits, even at later stages of disease 
progression [15]. In addition to this, through polarization of microglia to an M2 phenotype and the 
induction of Treg proliferation, IL-33 reduces the expression of pro-inflammatory cytokines [15, 145]. 
Polymorphisms of IL-33 may confer a reduced risk of AD development with increased sST2 correlated 
with mild cognitive decline in humans [291]. It is plausible that in an ocular setting, impaired IL-33 
signalling may contribute to the aggregation of Aβ, implicating IL-33 as an attractive therapeutic 




Cells extract energy and reducing power from their environment, this energy is necessary for the 
synthesis of higher order macromolecules such as proteins and DNA. Energy-generating processes are 
comprised of a highly integrated network of chemical reactions, which collectively are known as a 
cell’s metabolic pathways. Intrinsic and extrinsic signals regulate the activity (and/or expression) of 
enzymes and therefore flux through these metabolic pathways to accommodate the growth and 
survival requirements under quiescent or stress contexts. The free energy donor in all energy-
requiring processes is ATP. Energy is liberated in its hydrolysis to form ADP and Pi. Whereas an input 
of free energy is required for the reverse reaction. Electron donors such as nicotinamide adenine 
dinucleotide (NAD)+ and flavin adenine dinucleotide (FAD)+ provide the reductive power to facilitate 
ATP production. The basic strategy of metabolism is to form reduced ATP, NADH and other “building 
blocks” for biosynthesis. ATP synthesis is the end point extraction from the breakdown of foodstuffs 
(such as saccharides, amino acids and lipids) into smaller molecules which in the context of aerobic 
metabolism, converge on the citric acid (TCA) (commonly known as Krebs) cycle and oxidative 
phosphorylation (OXPHOS). The interconnected nature of various metabolic pathways (through 
shared metabolites, fuel inputs and endpoints) indicates the complex metabolic interplay which 
occurs in cells. Six key pathways: glycolysis, the TCA cycle, fatty acid synthesis, fatty acid oxidation, the 
pentose phosphate pathway and amino acid degradation have an important role in energy 
metabolism, the generation of products which influence cell survival responses to stress and forming 




Figure 1.8. A schematic of core metabolic pathways:  
Glucose enters a cell via a glucose transporter and is metabolised though the glycolysis pathway to yield 
pyruvate. Pyruvate can either be converted to lactate and secreted from a cell or can enter the TCA cycle where 
reduced NADH and FADH2 are generated for utilisation in the ETC. Glycolytic carbon can also be diverted into 
the pentose phosphate pathway to generate ribonucleotides, amino acids and the electron carrier NADH. Amino 
acids are taken up through their respective solute carriers and feed into the mitochondrial TCA cycle either 
through pyruvate or glutamine. Citrate is withdrawn from the TCA cycle and is used in the synthesis of fatty 
acids. Fatty acid oxidation generates reduced NADH and FADH2, which again drive mitochondrial ATP production 
in the ETC. The TCA cycle, fatty acid oxidation and the ETC are all oxygen-dependent pathways. Glycolysis, amino 
acid metabolism, fatty acid synthesis and the PPP are oxygen-independent pathways. PPP, pentose phosphate 
pathway; FAD, flavin adenine dinucleotide; NAD, nicotinamide adenine dinucleotide. Blue squares represent 
metabolic pathways, light green squares represent transporters and orange squares represent metabolites. 
Adapted from [5].  
1.8.1. Glycolysis 
Glycolysis is a universal pathway in biological systems and refers to the collective sequence of 
reactions involved in the conversion of glucose into pyruvate. In aerobic organisms, glycolysis is a 
preface to the TCA cycle and the ETC, which maximises the potential free energy available from a 
single glucose molecule. In mammalian cells, glycolysis begins with the intracellular uptake of glucose 
across the plasma membrane via the activity of several glucose transporters (GLUT1-5) [292]. The 
subsequent intracellular processing reactions occur within the cytosol and are divided into two 
sections (Fig. 1.9.). The bioenergetically expensive first stage sees the consumption of two molecules 
of ATP, as glucose is converted into fructose-1,6-bisphosphate. In the first step, glucose is rapidly 
phosphorylated by the action of hexokinase which catalyses the transfer of a phosphate from ATP to 
glucose, consuming one ATP molecule but preventing the exit of glucose from the cell. The next step 
involves the isomerisation of glucose-6-phosphate into fructose-6-phosphate by phosphoglucose 
isomerase. Fructose-6-phosphate is phosphorylated into fructose-1,6-bisphosphate by 
phosphofructokinase (PFK). This is the rate limiting step in the glycolytic pathway and is critically 
dependent on the level of activity of phosphofructokinase, which is allosterically regulated by changes 
to the ATP/AMP ratio. In this reaction another molecule of ATP is consumed as a phosphate is 
transferred to fructose-6-phosphate. The second stage of glycolysis consists of four reactions which 
collectively generate four molecules of ATP per glucose molecule. The second stage starts with the 
hydrolysis of fructose-1,6-bisphosphate into glyceraldehyde-3-phosphate and dihydroxyacetone 
phosphate by aldolase. These two molecules are isomers (glyceraldehyde-3-phosphate is an aldose 
whereas dihydroxyacetone phosphate is a ketose sugar) so a supplementary reaction is required to 
convert dihydroxyacetone phosphate into glyceraldehyde-3-phosphate. This isomerisation is 
catalysed by triose phosphate isomerase and allows the biproduct of this reaction to enter the main 
glycolytic pipeline rather than requiring a complete set of reactions to yield pyruvate. Accordingly, two 
molecules of glyceraldehyde-3-phosphate are formed from fructose-1,6-bisphosphate from this 
section of glycolysis. Up to this point, no energy has been extracted from the metabolism of glucose, 
but energy has been exploited in the form of two ATP molecules. The preceding steps permit ATP 
production via the generation of “high potential phosphorylated molecules”. Glyceraldehyde-3-
phosphate is first converted into 1,3-bisphosphoglycerate through the activity of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The product of this reaction (1,3-bisphosphoglycerate) exhibits 
a high phosphoryl transfer potential due to an acyl phosphate group (a mixed anhydride of phosphoric 
and carboxylic acid). The next step sees the high phosphoryl transfer potential of 1,3-
bisphosphoglycerate used to phosphorylate ADP and concurrently reduce NAD+ to NADH. This 
reaction is catalysed by phosphoglycerate kinase and leads to the generation of the next glycolytic 
metabolite, 3-phosphoglycerate. As there are two molecules of glyceraldehyde-3-phosphate formed 
from glucose, two molecules of ATP are formed in this step. The next reaction involves the 
intramolecular rearrangement of 3-phosphoglycerate into 2-phosphoglycerate via phosphoglycerate 
mutase. 2-phosphoglycerate is subsequently dehydrated yielding phosphoenolpyruvate and a 
molecule of H2O. The dehydration of 2-phosphoglycerate by enolase and the formation of an enol 
phosphate increases the phosphate group transfer potential present on phosphoenolpyruvate. In the 
final reaction of glycolysis, the high potential phosphoryl group of this group is transferred to ADP, 
forming the final molecules of ATP. This reaction is catalysed by pyruvate kinase and forms a molecule 
of pyruvate. Once again, as two molecules of phosphoenolpyruvate are formed from a single molecule 
of glucose, a total of two molecules of ATP are formed in this stage [292].  
 
Glycolytic metabolism is relatively inefficient in terms of the ATP generation compared to the TCA 
cycle and ETC, yielding only two molecules of ATP per glucose unit. Whilst inefficient in terms of net 
ATP yield, glycolysis provides advantages to cells as it permits the reduction of NAD+ to NADH, used 
by many enzymes as a co-factor. To maintain flux through the glycolytic pathway, cells frequently 
reduce pyruvate to lactate through lactate dehydrogenase A (LDHA). This is coupled to the oxidation 
of NADH to maintain constitutive NAD+ levels. Glycolysis has key survival advantages for cells requiring 
a rapid generation of ATP for growth and proliferation. Glycolysis generates ATP at a rate over 10-
times faster than the complete mitochondrial oxidation to CO2 and ATP [293]. In addition to this, 
glycolytic metabolism provides the biosynthetic precursors for the synthesis of ribose for nucleotides 
(via the pentose-phosphate pathway) and the amino acid serine (via the serine biosynthesis pathway 
which diverts from 3-phosphoglycerate). Consequently, highly glycolytic metabolism is associated 
with the phenotype of rapidly proliferating cells.  
 
1.8.2. The pentose phosphate pathway  
The pentose phosphate pathway branches off the main glycolytic pathway at glucose-6-phosphate. 
This pathway permits a “metabolic diversion” of intermediates from glycolysis towards the synthesis 
of ribose-5-phosphate and NADPH. The production of nucleotides and amino acids require the 
synthesis of ribose. This is termed the non-oxidative branch of the pentose phosphate pathway and is 
critical for both cell growth and proliferation. This pathway is much more active when more ribose-5-
phosphate than NADPH is required. A different function of the pathway is active when cells require 
more NADPH than ribose-5-phosphate: the oxidative branch. NADPH has a key role in the 
maintenance of redox homeostasis within a cell and is also required for fatty acid synthesis [5, 292]. 
The oxidative branch generates 12 NADPH molecules per molecule of glucose. The interplay between 
glycolysis and the pentose phosphate pathway allows cells to continuously meet their demands of 
NADPH, ATP, pyruvate and ribose.  
  
 
Figure 1.9. The glycolytic pathway: 
Glycolysis refers to the catabolism of a glucose molecule to yield two molecules of pyruvate, two molecules of 
ATP, reduced NADH and a molecule of H2O. Glucose is first phosphorylated into glucose-6-phosphate by 
hexokinase, this step consumes one molecule of ATP. Glucose-6-phosphate is then isomerized into fructose-6-
phosphate by phosphoglucose isomerase. Phosphofructokinase is responsible for the addition of another 
phosphate group to fructose-6-phosphate, yielding fructose-1,6-bisphosphate. Fructose-1,6-bisphosphate is 
split into a molecule of dihydroxyacetone phosphate and a molecule of glyceraldehyde-3-phosphate by aldolase. 
Dihydroxyacetone phosphate is isomerized into a second molecule of glyceraldehyde-3-phosphate by triose 
phosphate isomerase. Glyceraldehyde-3-phosphate is converted to 1,3-bisphosphoglycerate by glyceraldehyde-
3-phosphate dehydrogenase, yielding NADH. 1,3-Bisphosphoglycerate is dephosphorylated into 3-
phosphoglycerate by phosphoglycerate kinase, this step yields one molecule of ATP. 3-Phosphoglycerate is 
isomerized into 2-phosphoglycerate by phosphoglycerate mutase. Enolase catalyses an aldol condensation 
reaction which produces phosphoenolpyruvate and a molecule of H2O. The final step of glycolysis sees the 
dephosphorylation of phosphoenolpyruvate into pyruvate. This step is catalysed by pyruvate kinase and yields 
one molecule of ATP. ATP, adenine triphosphate; NADH, nicotinamide adenine dinucleotide. Red writing 
corresponds to consumption and green writing corresponds to production. Adapted from [292]. 
  
1.8.3. The TCA cycle  
The preceding section considered the glycolytic pathway, whereby glucose is catabolised into pyruvate 
yielding a small amount of ATP. Under aerobic conditions, the TCA cycle is the subsequent pathway in 
the generation of additional ATP from a single molecule of glucose (see Fig. 1.10). The TCA cycle acts 
as a common pathway for the oxidation of all fuel molecules (amino acids, fatty acids and 
carbohydrates). Most of these molecules enter the cycle in the form of acetyl CoA, however other TCA 
metabolites serve as additional entry points. Unlike the reactions of the glycolysis pathway, the TCA 
cycle occurs within the mitochondria of cells [292].  
 
The first entry point of the TCA cycle is the formation of acetyl coenzyme A (CoA) from pyruvate. This 
step bridges glycolysis and the TCA cycle, permitting the full oxidation of glucose. In order to first enter 
the TCA cycle, pyruvate must first be imported into the mitochondria through the mitochondrial 
pyruvate carrier complex (MPC) consisting of components MPC1/2 [294]. Once inside the 
mitochondrial matrix, the pyruvate dehydrogenase complex catalyses the oxidative decarboxylation 
of pyruvate to form acetyl CoA and CO2. This reaction is the first to generate a molecule of reduced 
NADH for later utilisation in the ETC. The cycle starts with the condensation of a two-carbon acetyl 
CoA molecule with a four-carbon molecule (oxaloacetate) to yield citrate and CoA. This step is 
catalysed by the enzyme citrate synthase. Citrate requires isomerization into isocitrate prior to 
undergoing oxidative carboxylation in the forthcoming step. The isomerisation is catalysed by 
aconitase which utilises inorganic Fe-S clusters to facilitate dehydration and the successive 
rehydration of citrate. In the next step, isocitrate undergoes an oxidative carboxylation reaction to 
produce α-ketoglutarate and a molecule of CO2.  This reaction is catalysed by isocitrate dehydrogenase 
and is the second reaction to generate a molecule of reduced NADH. The next step of the cycle is 
another oxidation decarboxylation reaction, forming succinyl CoA from α-ketoglutarate. The reaction 
is catalysed by the α-ketoglutarate dehydrogenase complex and in a similar manner provides a 
molecule of reduced NADH and a molecule of CO2. A high energy thioester bond is formed in the 
formation of succinyl CoA. The cleavage of this bond is coupled to the phosphorylation of GDP in the 
following step of the cycle. Succinyl CoA synthetase catalyses this reaction and leads to the formation 
of a four-carbon succinate molecule, GTP and CoA. GTP can be used for cellular signal transduction or 
can be readily converted into a molecule of ATP via the activity of nucleoside diphosphokinase. 
Succinate is oxidised to fumarate by the enzyme succinate dehydrogenase. The oxidation of this 
reaction is coupled to the reduction of acceptor FAD+ into FADH2, which is later utilised in the ETC. 
Fumarate produced in this reaction is utilised in the next step of the cycle. Fumarase catalyses the 
stereospecific trans hydration of fumarate to produce malate. The final step of the TCA cycle involves 
the oxidation of malate to form oxaloacetate. This reaction is catalysed by malate dehydrogenase and 
is the final NADH-producing reaction in the cycle, using NAD+ as a hydrogen acceptor. The 
oxaloacetate produced in this reaction condensates with an acetyl unit, and another turn of the cycle 
will occur. The TCA cycle collectively yields four molecules of NADH (three from the cycle and one from 
the formation of acetyl CoA), one molecule of reduced FADH2 and one molecule of GTP from a single 
molecule of pyruvate. Additionally, the three carbons of pyruvate are lost as three molecules of CO2 
during one turn of the cycle [292].  
 
Whilst the discussion of the TCA cycle so far has concentrated on the TCA cycle as a major catabolic 
pathway in the generation of ATP, it is important to highlight that the TCA cycle is a key provider of 
intermediates for biosynthetic pathways. For example, many amino acids are derivatives of either 
oxaloacetate or α-ketoglutarate, citrate provides acetyl groups for fatty acid synthesis and moreover, 
succinyl CoA provides the carbon skeleton required for the synthesis of porphyrins. Considering the 
observations that biosynthetic pathways feed of the TCA cycle, how is it that cycling continues and 
metabolite pools are replenished, when the starting point is via the entry of acetyl CoA? 
Hypothetically, if all the oxaloacetate was utilised in the generation of amino acids, one would assume 
that the TCA cycle would terminate unless new anaplerotic oxaloacetate was formed. In order to 
replenish oxaloacetate levels to a basal level, pyruvate is carboxylated into oxaloacetate through the 
pyruvate carboxylase complex, which serves as an additional entry point of pyruvate into the TCA cycle 
[295]. Additionally, as briefly highlighted, and discussed in the forthcoming section, glutamine 




Figure 1.10. The TCA cycle: 
Prior to entry into the TCA cycle, a three-carbon pyruvate molecule undergoes an oxidative decarboxylation into 
acetyl CoA by pyruvate dehydrogenase. This step generates one molecule of CO2 and a molecule of NADH. In 
the first step of the TCA cycle, a four-carbon oxaloacetate condenses with a two-carbon acetyl unit to produce 
the six-carbon citrate. This step is catalysed by citrate synthase. Citrate is isomerized into isocitrate by aconitase. 
Isocitrate undergoes oxidative decarboxylation to produce a five-carbon α-ketoglutarate, CO2 and a molecule of 
NADH. This step is catalysed by the enzyme isocitrate dehydrogenase. α-Ketoglutarate is immediately oxidatively 
carboxylated to yield a four-carbon compound (succinyl CoA), CO2 and a molecule of NADH. This step is catalysed 
by the enzyme α-ketoglutarate dehydrogenase. In the next step, succinyl CoA synthetase catalyses the hydrolysis 
of succinyl CoA to succinate, which provides one molecule of GTP. Succinate is oxidised into fumarate by the 
enzyme succinate dehydrogenase. This reaction provides reduced equivalents in the form of FADH2. In the next 
step, fumarase catalyses the hydration of fumarate into malate. Malate is subsequently oxidised by malate 
dehydrogenase to provide another molecule of NADH and the original four-carbon starting molecule, 
oxaloacetate. Pyruvate may enter the TCA cycle as oxaloacetate through a reaction catalysed by pyruvate 
carboxylase and requiring ATP and bicarbonate. ATP, adenosine triphosphate; NADH, nicotinamide adenine 
dinucleotide; GTP, guanosine triphosphate; FADH2, flavin adenine dinucleotide; HCO3, bicarbonate. Red writing 
corresponds to consumption and green writing corresponds to production. Adapted from [292]. 
  
1.8.4. Amino acid metabolism 
In contrast to fatty acids, amino acids are unable to be stored or excreted, therefore when produced 
in excess amino acids provide key metabolite precursors within cells. In each case, the amino group is 
removed as urea and the residual core carbon molecules are converted into metabolic intermediates. 
Ultimately, the strategy of amino acid metabolism is to convert amino acids into a major metabolite 
which can either be converted to glucose or fatty acids or provide energy in the form of ATP via the 
TCA cycle. There is a degree of biochemical efficiency in the carbon skeleton which allows a diverse 
set of over 20 core amino acids to be catabolised into seven molecules (Fig. 1.11.). Amino acids which 
are metabolised into either acetyl CoA or acetoacetyl CoA are referred to as ketogenetic as they lead 
to the conversion of ketone bodies. On the other hand, amino acids that enter core metabolic 
pathways via pyruvate, α-ketoglutarate, succinyl CoA, fumarate or oxaloacetate are termed 
glucogenic, as glucose synthesis from their TCA cycle intermediates is permitted through conversion 
to phosphoenolpyruvate. Amino acids are split into families based on number of carbons (e.g C3, C4 
and C5) present in their core skeleton and this underlies their respective degradation pathways. The 
C3 family, consisting of alanine, serine, cysteine, threonine, glycine and tryptophan, use the three-
carbon molecule pyruvate. The C4 family, consisting of aspartate and asparagine, are transaminated 
for entry at the four-carbon TCA metabolite oxaloacetate. Aspartate can additionally be converted 
into fumarate via the coupling of the TCA and urea cycles. The C5 family sees the entry of several 
amino acids into the TCA cycle, first through conversion to glutamate and then through oxidative 
deamination to C. This pathway has significance as it involves the metabolism of glutamine, the most 
abundant amino acid present in the body with key roles in cell proliferation [296]. Glutamine 
undergoes catabolism to α-ketoglutarate via glutamine anaplerosis, a process comprising of two 
deamination reactions [297] . The first of these generates glutamate from glutamine through the 
enzyme glutaminase. α-Ketoglutarate is formed via the action of either glutamate dehydrogenase or 
transaminases. Non-polar amino acids such as methionine, isoleucine and valine require succinyl CoA 




Figure 1.11. Fates of amino acid carbon skeletons: 
Bold metabolites represent the entry points for the fundamental amino acids. Glucogenic amino acids are 
shaded in blue, whereas ketogenic amino acids are shaded orange. Alanine, cysteine, glycine, serine, threonine 
and tryptophan enter at pyruvate; isoleucine, leucine and tryptophan enter at acetoacetyl CoA; lysine, leucine, 
tryptophan, tyrosine and phenylalanine enter at acetyl CoA; arginine, glutamate, glutamine, histidine and 
proline enter at α-ketoglutarate; isoleucine, methionine, threonine and valine enter at succinyl CoA; 
phenylalanine, tyrosine and aspartate enter at fumarate; asparagine and aspartate enter at oxaloacetate. CoA, 
coenzyme A. Adapted from [292]. 
  
1.8.5. Fatty acid oxidation 
Fatty acids are a class of biomolecules with  a long hydrocarbon chain and a terminal carboxyl group 
[292]. Whilst fatty acids play key biological roles in the synthesis of phospholipids, glycolipids and 
cholesterol, and act as intracellular signalling intermediates, they provide key fuel molecules for 
oxidation within the mitochondria, via a process termed either β-oxidation or fatty acid oxidation. 
Prior to oxidisation, fatty acids must be first attached through a thioester linkage reaction to a 
molecule of CoA. This reaction is catalysed by acyl CoA synthetase and occurs on the outer 
mitochondrial membrane. Once activated, long-chain acyl CoA fatty acids are transported across the 
inner mitochondrial membrane into the mitochondrial matrix for further processing. Carnitine 
palmitoyl transferase I (CPT1) is the translocase enzyme responsible for the movement of long chain 
acyl units across the inner mitochondrial matrix [292]. This step constitutes the rate limiting step in 
the process of long chain β-oxidation [298]. Fatty acid molecules having six or fewer carbon atoms in 
their aliphatic tail diffuse passively across the mitochondrial membrane without the need of a 
transporter. Once in the mitochondrial matrix, the saturated acyl CoA chain is degraded (two carbons 
at a time) through the β-oxidation pathway to produce FADH2, NADH and Acetyl CoA. In the first step, 
acyl CoA is oxidised to enoyl CoA by acyl CoA dehydrogenase. This step uses FAD+ as an electron 
acceptor and is subsequently reduced to FADH2. In the next step, enoyl CoA hydratase catalyses the 
hydration of enoyl CoA to form 3-hydroxyacyl CoA. A second oxidation step then takes place as 3-
hydroxyacyl CoA is converted to 3-ketoacyl CoA. This step is catalysed by 3-hydroxyacyl CoA 
dehydrogenase and generates NADH, which acts as an electron acceptor from the oxidised 3-
hydroxyacyl CoA. In the final step, β-ketothiolase catalyses a thiolysis reaction, cleaving an acetyl CoA 
group from the end of the fatty acid chain. The reduced electron carriers FADH2 and NADH are 
imminently utilised to generate ATP in the ETC. The oxidation of fatty acids generates a high energy 
yield in terms of net ATP production. Indeed, the complete oxidation of a molecule of palmitate (a 
sixteen-carbon fatty acid chain) yields a total of 106 ATP molecules [292]. This accounts to almost 
three-times the amount of ATP generated in glycolysis, thus is a robust pathway to generate ATP [299].   
  
1.8.6. The electron transport chain 
To this point, only a small amount of ATP has been generated in glycolysis; the TCA cycle and fatty acid 
oxidation pathways do not generate ATP themselves, but rather produce energy-rich molecules NADH 
and FADH2. The process of mitochondrial OXPHOS couples the transfer of electrons from NADH and 
FADH2 via a series of electron carriers located in the inner mitochondrial membrane, to the final 
electron acceptor O2. This process generates large quantities of ATP, with 32 of the 36 molecules 
formed from the complete oxidation of glucose generated in this pathway [292].  
 
The electrons from NADH enter the ETC at complex I (also known as NADH-Q-reductase) and are 
immediately transferred a series of iron-sulphur (Fe-S) clusters. From here, electrons are transferred 
to the electron carrier ubiquinone. The flow of electrons from complex I to ubiquinone is accompanied 
by the pumping of four protons (H+) from the matrix across the inner mitochondrial membrane. 
Complex II (succinate-Q-reductase) catalyses the transfer of electrons from FADH2 to its Fe-S clusters 
and then on to ubiquninone. Unlike the oxidation of NADH, the transfer of electrons from FADH2 does 
not lead to the pumping of H+ across the inner mitochondrial membrane. So subsequently, less ATP is 
produced per FADH2 molecule than that of NADH. The reduced ubiquinone molecule passes its 
electrons into the second of the three proton pumps present in the ETC (complex III; cytochrome 
reductase), which facilitates the transfer of two H+ across from the matrix. Complex IV (cytochrome 
oxidase) catalyses the final transfer of electrons from complex III to the final acceptor molecular 
oxygen, forming two molecules of H2O. This reaction leads to the concomitant pumping of H+ into the 
intermembrane space. As the electrons have passed through the ETC complexes I to IV, an 
electrochemical H+ gradient is formed across the inner mitochondrial membrane (Fig. 1.12). The 
electrochemical gradient provides a proton-motive force which drives the conversion of ATP from ADP 
in the ATP synthase complex. The complex is formed of an F0 subunit which permits H+ passage 
through the membrane, and an F1 subunit which sequentially releases tightly bound ATP molecules 
from three binding sites. The flow of electrons from a molecule of NADH to molecular oxygen 
generates a proton gradient adequate to produce 2.5 ATP molecules. FADH2 on the other hand, only 
generates a proton gradient enough for the synthesis of 1.5 ATP [292]. Under normal conditions, 
electron flux through the ETC is tightly coupled to the synthesis of ATP. This respiratory coupling can 
be disrupted, and maximal respiration is stimulated by chemical uncouplers such as p-
trifluoromethoxyphenylhydrazone (FCCP), or thermogenic uncoupling proteins such as uncoupling 
protein-1 (UCP1) [300, 301].  
 
Under aerobic conditions, quiescent cells typically favour the utilization of oxygen dependent OXPHOS 
in order to maximize the yield of ATP production. Anaerobic conditions lead to an increased output of 
lactate as the cell derives its energy production solely from glycolysis. Yet, even in the absence of 
oxygen deprivation or mitochondrial dysfunction, cells may preferentially undertake glycolytic 
metabolism [302]. The switch from OXPHOS to glycolysis under these conditions is characteristic of 
the “Warburg effect”, where cancer cells are reprogrammed to increase glycolytic flux under aerobic 
conditions to meet their energetic requirements within minutes [302]. Whilst glycolysis may be 
inefficient in terms of ATP generation (2 ATP generated per glucose molecule compared to 36 in 
OXPHOS), it can utilize glucose 12 times faster [303, 304]. Energetically, this makes perfect sense, 
increased glycolysis allows a rapid proliferation and the production of bio-effectors to be achieved 




Figure 1.12. The electron transport chain: 
The main pathway of ATP generation in cells occurs through mitochondrial OXPHOS. This involves the transfer 
of electrons from reduced equivalents (FADH2 and NADH), through the multi-subunit ETC complexes (I to IV) to 
the final electron acceptor, molecular oxygen (O2). NADH transfers its electrons to complex I, whereas FADH2 
transfers its electrons to complex II. Upon receiving electrons, complexes I, III and IV are responsible for pumping 
protons (H+) from the mitochondrial matrix to the intermembrane space. This generates an electrochemical 
gradient across the inner mitochondrial membrane. The ATP synthase complex exploits this proton gradient to 
facilitate ATP production as protons flow back to the matrix. ATP, adenosine triphosphate; NADH, nicotinamide 
adenine dinucleotide; FADH2, flavin adenine dinucleotide.   
1.8.7. Fatty acid synthesis 
The synthesis of fatty acids allows cells to produce lipids which are physiologically relevant for 
components of phospholipids, lipophilic modifiers of proteins, glycolipids, hormones and intracellular 
messengers. Fatty acids are synthesised in the cytosol and utilises products derived from multiple 
metabolic pathways, namely glycolysis, the TCA cycle and the pentose phosphate pathway. The malate 
pyruvate shuttle is used to transfer acetyl groups from the mitochondria to the cytosol in the form of 
TCA-derived citrate.  Once in the cytosol, the enzyme ATP-citrate lyase is responsible for the 
conversion of citrate into oxaloacetate and acetyl CoA. Synthesis starts with the rate limiting 
carboxylation of acetyl CoA to malonyl CoA by acetyl CoA carboxylase (ACC). Then, the fatty acid 
synthase complex catalyses the NADPH-dependent elongation of the fatty acid chain to yield products 
such as palmitate. Fatty acid synthesis and β-oxidation are both reciprocally regulated through the 
ACC complex to ensure that both pathways are not occurring simultaneously [5, 292].  
 
1.8.8. Regulation of cellular metabolism 
Cells must be able to rapidly adapt to changes in their environment and respond to perturbations in 
energy status. Metabolism is constantly reprogrammed in cells to maintain metabolic homeostasis 
and provide enough ATP for cellular functions. In order to bolster flux through a given pathway, cells 
can either increase the amount of a rate limiting enzyme, for example: phosphofructokinase in 
glycolysis or CPT1 in the oxidation of long chain acyl fatty acids or use activators to convert an enzyme 
into its active formation, such as AMPK, which will be discussed later. Conversely, the same principles 
apply if a cell intends to stop given pathway, by reducing the expression of key enzymes and/or 
altering their active state, flux through the pathway will be reduced. Feedback inhibition permits the 
fine-tuning of metabolic pathways in response to concentrations of intermediate metabolites. For 
example, the first enzyme of glycolysis (hexokinase) is inhibited by its product glucose-6-phosphate. 
 
  
1.8.5.1. Transcriptional regulation  
The genes encoding metabolic pathway enzymes are frequently assumed to be regulated solely at the 
post-transcriptional level and therefore similarly expressed under diverse conditions and cell 
populations. This has led to many metabolic genes (such as GAPDH) used frequently experimentally 
as “housekeeping” controls. Whilst activity of metabolic enzymes is indeed regulated by “in pathway” 
mechanisms (such as feedback inhibition), it is becoming increasingly more appreciated that metabolic 
gene programs are regulated at the transcriptional level to control proliferation, differentiation and 
adaptive responses to cellular signalling. Many of the transcription factors which facilitate metabolic 
programming are well-characterised due to their roles in cancer metabolism and other programs (such 
as T-cell activation) which support dynamic proliferation. Oncogenic signalling is frequently associated 
with the reprogramming of pathways to facilitate enhanced nutrient attainment and integration of 
carbon into macromolecules to support cell growth (Fig. 1.13). This is associated with rapidly increased 
rates of both glycolysis and (in many cases) glutaminolysis [305].  
 
The MYC oncogene is a transcription factor responsible for the modulation of global gene expression 
through transcriptional regulation [306]. MYC is located downstream of multiple signal transduction 
pathways receptive to extracellular stimuli, such as growth factors, cytokines, nutrient availability and 
extracellular matrix [306]. MYC directly binds DNA at proximal promotor regions, relieving pausing of 
the RNA polymerase complex, subsequently activating transcription. MYC is associated with the 
activation of transcriptional programs which favour aberrant cellular growth and proliferation in many 
biological systems [306, 307]. MYC induces the expression of numerous genes involved in the 
glycolysis and glutaminolysis pathways due to the presence of conserved MYC consensus binding sites 
in the promoter regions. In addition to this, MYC has been shown to induce the expression of genes 
involved in both nucleotide biosynthesis and the shuttling of citrate out of the TCA cycle to be used in 
lipid synthesis [306]. To support the increased metabolic demand MYC activation places on a cell, 
mitochondrial biogenesis is additionally upregulated to support biosynthetic pathways involving the 
TCA cycle [306].  
 
Hypoxia inducible factor 1 alpha (HIF-1α) is another transcription factor involved in the cellular 
response to environmental changes. The HIF-1 complex consists of an O2-regulated HIF-1α subunit 
and a constitutively expressed HIF-1β subunit [308]. Under conditions of low oxygen, degradation of 
the HIF-1α subunit is attenuated. The increased active HIF-1α binds HIF-1β to form a heterodimer (HIF-
1) with transcriptional properties. The HIF-1 complex binds to the promoter regions of (hypoxia-
inducible) genes exhibiting a specific binding site and subsequently elicits broad transcriptional 
changes [309]. HIF-1 therefore translates information regarding oxygen state into specific gene 
expression programs which allow a cell to adapt to its environment. HIF-1 has a key role in the 
reprogramming of cells towards a pro-glycolytic phenotype by activating the transcription of glucose 
transporters and glycolytic enzymes [308]. Furthermore, the increased expression of pyruvate 
dehydrogenase kinase 1 (PDK1) by HIF-1 leads to the phosphorylation and inactivation of the pyruvate 
dehydrogenase (PDH) complex. As a result, pyruvate is shunted away from oxidation in the 
mitochondrial TCA cycle and is converted into lactate by LDHA [308]. Genetic or pharmacological 
inhibition of HIF-1 or PDK1 increases the oxygen consumption in cancer cells [310, 311].  
 
The p53 tumour suppressor gene has long been characterised as a metabolic regulator with functions 
in promoting OXPHOS and suppression of aerobic glycolysis. P53 binds to and regulates the expression 
of over 500 genes, among these are key regulators of and genes within glycolysis, TCA cycle, lipid 
metabolism, amino acid metabolism, OXPHOS and ROS generation pathways [312]. In terms of 
glycolysis, the role of p53 be both inhibitory and promotive. For example, p53 promotes the 
expression TP53-induced glycolysis and apoptosis regulator (TIGAR) but decreases the expression of 
(GLUT1 and 4) and phosphoglycerate mutase. TIGAR lowers the intracellular concentrations of 
fructose-2,6-bisphosphate and therefore decreases glycolytic flux. As glycolysis is downregulated, 
more glucose can pass into the pentose phosphate pathway for the generation of NADPH [313]. P53 
promotes OXPHOS by the induction of cytochrome c oxidase expression. In addition to this, p53 
increases the transcription of genes involved in the metabolism of glutamine, subsequently increasing 
α-ketoglutarate levels and mitochondrial respiration [313]. 
 
Members of the peroxisome proliferator-activated receptor (PPAR)γ coactivator-1 (PGC-1) family of 
transcriptional coactivators (PGC-1α and PGC-1β) activate a cellular metabolic program of increased 
mitochondrial biogenesis, oxidative metabolism and fatty acid β-oxidation [314]. PGC-1α lacks 
histone-modifying enzymatic activities but directly binds DNA and interacts with a variety of chromatin 
remodelling complexes and transcriptional co-activators. These include the nuclear respiratory factors 
(NRF), PPARα and estrogen-related orphan nuclear receptor (ERR). PGC-1α promotes the expression 
of genes involved glutamine and β-oxidation metabolic pathways through interactions with ERRα and 
sirtuin (SIRT)-1, respectively [315, 316]. NRF-1 acts directly on the transcription of genes involved in 
the respiratory transport chain and therefore promotes increased biogenesis [316]. In addition to this, 
PGC-1s have an important role in the defence against ROS (produced by bolstered mitochondrial 
activity) through the ability to directly induce the transcription of multiple antioxidant enzymes, such 
as SOD, catalase and glutathione peroxidases [317].  
 
Enzymes involved in the modification of chromatin require cofactors or substrates that can be found 
in core metabolic pathways. These metabolites provide a mechanism to synchronize epigenetic 
regulation with the metabolic status of a cell. Such examples are the use of acetyl-CoA by histone 
acetyltransferases to acetylate and increase the accessibility of chromatin, and the use of NAD+ as a 
substrate for SIRTs (class III HDACs) to deacetylate and repress gene transcription [318]. SIRT1, 3 and 
6 inhibit the proinflammatory transcription NF-kB, AP-1, and HIF-1a, and enhances oxidative 
metabolism [319]. Histone methylation is controlled by histone methyltransferases which use S-
adenosylmethionine (SAM) as methyl donor. SAM is derived from the folate-mediated one carbon 
metabolism of amino acids serine and glycine [320]. Therefore, dietary amino acid availability directly 
affects the methylation status of chromatin [318].  
 
In addition to the influence of metabolites of gene expression, many metabolic enzymes have been 
shown to “moonlight” and directly influence chromatin regulation, transcription and post-
transcriptional control [318]. An example of this is in the nuclear interaction between fructose-1,6-
bisphosphatase and HIF-1α. Fructose-1,6-bisphosphatase acts as a transcriptional corepressor of HIF-
1α, binding to its inhibitory domain to facilitate silencing of hypoxia response DNA elements [321]. 
Other enzymes such as phosphofructokinase and pyruvate kinase isoform 2 (PKM2) lack DNA-binding 
domains but interact with other transcription factors, such as HIF-1α/MYC to regulate transcription 
[322]. Key metabolic enzymes such as GAPDH and enolase directly function as transcription factors 
through DNA-binding domains [322]. GAPDH localizes to the nucleus following phosphorylation by 
AMPK, whereby it activates SIRT1 to reprogram gene transcription in energy metabolism pathways 
[323]. In addition, GAPDH interacts with the p53 tumour suppressor complex  to promote the 
expression of genes involved in oxidative metabolism [324]. Enolase directly binds to the MYC 
promotor to positively regulate its transcription and ultimately MYC-activated glycolysis [322]. LDHA 
orchestrates global histone deacetylation status through controlling NAD+ availability and interacting 
with SIRT1 [325]. Nuclear regulation of metabolic gene transcription is not just a phenomenon 
reserved to enzymes of the glycolytic pathway; malate dehydrogenase translocates to the nucleus of 
cells where it binds to p53-responsive elements, including promoter regions of TCA cycle enzymes and 
OXPHOS genes [326].   
 
 
Figure 1.13. Transcriptional reprogramming of cell metabolism: 
Metabolic reprogramming in cells is regulated by key transcription factors.  P53 inhibits the expression of GLUT1 
and glycolytic enzyme PGM. P53 also inhibits the efflux of metabolites into pathways which feed of glycolysis. 
By inhibiting the transcription of G6PDH and PHGDH, p53 regulates the ox-PPP and serine biosynthesis, 
respectively. P53 promotes mitochondrial OXPHOS by inhibiting the expression of PDK1 and promoting the 
expression of COX1. Moreover, p53 promotes the expression of genes involved in glutaminolysis (SLC1A5 and 
GS) and FAO (CPT1), whilst inhibiting enzymes of the FAS pathway (SREBP and FASN). HIF-1α promotes a 
metabolic phenotype of aerobic glycolysis through increasing the expression of pro-glycolytic genes (GLUT1, 
ENO1, PKM2, LDHA and PDK1). PKM2 directly interacts with HIF-1α, activating the hypoxia response element 
required for HIF-1α binding to target genes. The MYC transcription factor alters the expression of key genes 
involved in glucose (GLUT1, ENO1, PKM2, LDHA) and glutamine metabolism (SLC1A5 and GS), serine biosynthesis 
(PHGDH) and FAS (FASN and ACACA). PGC-1α increases the expression of genes involved FAO (CPT1), 
glutaminolysis (SLC1A5 and GS) and the ETC (COXIV and CYC). HIF-1α, hypoxia inducible factor-1α; PGC-1α, 
peroxisome proliferator-activated receptor gamma coactivator 1α;  oxPPP, oxidative pentose phosphate 
pathway; G6PDH, Glucose-6-phosphate dehydrogenase; PGM, Phosphoglycerate mutase; ENO1, enolase; PKM2, 
pyruvate kinase isoform 2; LDHA, lactate dehydrogenase A; PDK1, pyruvate dehydrogenase kinase; GLS, 
glutamine synthetase, SLC1A5, Solute Carrier Family 1 Member 5; NADH, nicotinamide adenine dinucleotide; 
FADH2, flavin adenine dinucleotide; CYC, cytochrome C; COXI, cytochrome C oxidase I; COXIV, cytochrome C 
oxidase IV. Metabolites are noted in black text and genes of metabolic enzymes are noted by dark blue italic 
text. Green arrows represent positive regulation of a target gene by transcription factor(s). Red arrows represent 
negative regulation of a target gene by transcription factor(s).  Adapted from [305].  
1.8.5.2. Alternative splicing of the PKM gene 
Pyruvate kinase is a rate-limiting enzyme in the glycolysis pathway, responsible for the irreversible 
catalysation of phosphoenolpyruvate into pyruvate [327]. This final reaction commits pyruvate to 
either oxidation in the TCA cycle or aerobic lactate production [328]. In mammals, four pyruvate kinase 
isoforms are observed, encoded by two different genes [329]. The PKLR gene encodes PKL and PKR 
which are expressed in the liver and erythrocytes, respectively. The PKM gene encodes the muscle 
isoforms PKM1 and PKM2 [330]. The expression of pyruvate kinase is tissue specific and is regulated 
by various mechanisms, including alternative splicing and the activity of upstream promotors. As PKL 
and PKR isoforms are restricted to the liver, kidneys, intestines and red blood cells (the later exclusively 
expressing PKR), PKM isoforms are expressed in the remaining terminally differentiated tissues. PKM1 
and PKM2 are produced through the alternative splicing of mutually exclusive exons, identical in 
length but encode a 56-amino acid region that varies at 22 residues (Fig. 1.14) [330]. PKM1 contains 
exon 9, whereas PKM2 exclusively contains exon 10. Although both isoforms have equal catalytic 
functions in the glycolysis pathway, the extra 22 amino acids present in the PKM2 isoform lead to the 
addition of a fructose-1,6-bisphosphate binding pocket. The presence of this binding site renders the 
active PKM2 tetramer sensitive to the allosteric binding of fructose-1,6-bisphosphate [330]. The non-
allosteric isoform PKM1 is constitutively expressed in tissues requiring a large demand of ATP, 
including both the muscle and brain [328]. PKM1 is thought to generate a bioenergetic profile in favour 
of oxidative phosphorylation and the entrance of pyruvate into the TCA cycle. In cancer cells, PKM2 is 
overexpressed at the expense of PKM1, regulated by the activity of MYC [331]. MYC promotes the 
transcription of heterogeneous nuclear ribonucleoproteins (hnRNPs) A1 and A2 and the 
polypyrimidine tract binding protein (PTB), which bind repressively to sequences flanking exon 9, 
resulting in exon 10 inclusion [331]. This leads to the inhibition of PKM1 and mRNA splicing and 
promotes PKM2 isoform expression. The serine/arginine-rich splicing factor 3 (SRSF3) has a key role 
in the splicing of PKM2 and binds to an exonic splicing enhancer found on PKM exon 10 [332]. How 
mRNA splicing controls the inclusion of PKM1 is not as well understood, in a large part because PKM1 
is generally expressed at much lower levels within cells. In the A172 cell line, commonly used to study 
PKM1 expression, PKM1 expression is observed at 5% of total transcript levels [333].  
Both PKM isomers are tetrameric proteins consisting of four identical subunits. Due to the splicing of 
different exons into in their mRNA transcripts, PKM1 and PKM2 exhibit differences in the encoded C 
domain of the monomer subunit, ultimately conferring altered stability to the tetramer. 
Physiologically, PKM1 protein constitutively arranges as a tetramer whereas PKM2 exists in either 
dimer or tetramer. The differences between dimer or tetramer conformation depend on the allosteric 
regulation fructose-1,6-bisphosphate [334]. This intermediate directly binds PKM2 and increases its 
affinity for phosphoenolpyruvate, which in turn increases flux through the glycolysis pathway [335]. 
PKM1 on the other hand, is not significantly affected by fructose-1,6-bisphosphate [335]. The dimer 
conformation of PKM2 exhibits an activity of less than 10% of the tetramer [336]. Using this 
mechanism, reversible activation of PKM2 allows for dynamic regulation of enzymatic activity and an 
additional control point in the glycolysis pathway.  
 
Inactivation of PKM2 allows for a build-up of phosphorylated glycolytic intermediates, which feed into 
the biosynthesis pathways of serine and nucleotides. Altering PKM expression status into the forced 
expression of PKM1 leads to an inability of cells to produce deoxynucleotides [337]. Typically, PKM2 
expression is thought to be associated with rapidly proliferating cancer cells favouring anabolic 
metabolism. Phosphorylation and inactivation of PKM2 via tyrosine kinase signalling is critical for the 
entry of glucose-derived carbon into the pentose phosphate pathway to generate sufficient reducing 
potential to aid redox balance [338]. 
 
A multitude of recent work has identified multiple non-canonical functions for PKM2 in gene 
regulation, cell signalling and the cell cycle. For example, the PKM2 dimer is observed to interact with 
multiple tyrosine kinases including A-Raf and fibroblast growth factor receptor 1 [339]. PKM2 also 
functions as the cytosolic receptor for thyroid hormone [340].  Additionally, PKM2 translocates into 
the nucleus where it acts as a transcriptional co-activator and protein kinase involved in modulation 
of histone phosphorylation status [341]. PKM2 has been shown to interact with β-catenin, STAT3, NF-
κB and OCT4 [334]. Nuclear PKM2 directly interacts with HIF-1α to promote the expression of target 
genes. This is achieved by enhancing the binding of HIF-1α to hypoxia response elements, ultimately 
conferring augmented transcription of glycolytic genes [342].  
 





Figure 1.14. Splicing and “moonlighting” of pyruvate kinase M2: 
(A) Several transcription factors regulate the activity of the PKM promoter including: SP1, SP3, HIF-1α and PPARγ. 
PKM2 expression is regulated at the level of transcribed PKM mRNA via splicing. The splicing factors hnRNPA1, 
hnRNPA2, PTB and SRF3 bind to the mRNA transcript to favour the exclusion of exon 9 (PKM1) and inclusion of 
exon 10 (PKM2). HnRNPA1, hnRNPA2 and PTB are upregulated by the transcription factor MYC. (B) Pyruvate 
kinase catalyses the final rate-limiting step in the glycolysis pathway by catalysing a phosphoryl transfer reaction 
from phosphoenolpyruvate to ADP, to yield pyruvate and ATP. Allosteric control of PKM2 tetramerization 
regulates its enzymatic activity, with the PKM2 dimer exhibiting low catalytic activity compared to the tetramer. 
The PKM1 isoform lacks an allosteric control site and is therefore always present as a tetramer. (C) PKM2 has 
been found to translocate into the nucleus upon mitogenic stimuli. Once in the nucleus, PKM2 functions as a 
transcriptional activator by phosphorylating histones, indicating a crucial role in the epigenetic control of the 
Warburg effect through a MYC-dependent feedback loop. PKM2 directly interacts with HIF-1α to promote 
binding to hypoxia response DNA elements. HIF-1α, hypoxia inducible factor-1α; mTOR, mammalian target of 
rapamycin; SP1, specificity protein 1; SP3, specificity protein 3; PPARγ, peroxisome proliferator-activated 
receptor; PKM; pyruvate kinase muscle isoform; SRSF3, serine/arginine-rich splicing factor 3; PTB, 
polypyrimidine tract binding protein; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; hnRNPA2, 
heterogeneous nuclear ribonucleoprotein A2; PKM1, pyruvate kinase muscle isoform 1, PKM2; pyruvate kinase 
muscle isoform 2; PEP, phosphoenoylpyruvic acid. Adapted from [341]. 
1.8.5.3. AMP-activated kinase and mammalian target of rapamycin 
The maintenance of cellular energy homeostasis is dependent on a number of regulatory strategies, 
including the trafficking and uptake of hexose sugars through various transporters, ATP production by 
glycolysis, Kreb’s cycle and other catabolic pathways, OXPHOS, and the overall control of metabolic 
pathway flux by the governing activities of AMPK and mTOR [343-345]. The fundamental regulator of 
cellular metabolic homeostasis is AMPK. This evolutionarily conserved protein-kinase is observed in 
principally all eukaryotic cells where it exists as a heterodimeric complex comprised of catalytic α-
subunits and regulatory β- and γ-subunits. The catalytic subunits contain a conserved 
Serine/Threonine (Ser/Thr) kinase at the amino terminus. Kinase activity of the AMPK complex 
increases 100-fold following the phosphorylation of Thr172 in the activation loop by the upstream 
kinase liver kinase B1 (LKB1). A high level of basal Thr172 phosphorylation is conferred by LKB1, with 
modulation initiated by the binding of AMP to the γ-subunit. AMP (or ADP) binding to the γ-subunit is 
indicative of bioenergetic stress; allosteric activation induces conformational changes to Thr172, 
leading to constitutive phosphorylation by LKB1. Allosteric binding of ATP to the γ-subunit promotes 
net dephosphorylation; this mechanism modulates kinase activity to the degree of energy impairment 
[344, 346]. Once activated, AMPK endeavours to restore energy balance by switching on catabolic 
pathways that generate ATP (e.g. glycolysis, fatty acid oxidation, glucose transporter trafficking to the 
plasma membrane, and mitochondrial biogenesis), whilst simultaneously inhibiting anabolic, ATP 
consuming pathways such as protein/sterol/fatty acid synthesis, which contribute to cell-cycle 
progression [344] (Fig. 1.15). This implicates AMPK activation with the phenotype of quiescent anti-
inflammatory cells, preferentially favouring OXPHOS, rather than proliferative inflammatory cells 
undergoing glycolytic metabolism [345]. The result of AMPK activation is to conserve cellular energy 
prior to a bioenergetic crisis leading to cell death.  
 
AMPK directly regulates the activity of ACC to control lipid biosynthesis. ACC mediates the conversion 
of acetyl CoA to malonyl CoA, which is directed to a carbon pool for lipid biosynthesis. Increased 
malonyl CoA levels simultaneously inhibits CPT1 and therefore lipid oxidation. Phosphorylation of Ser-
79 by AMPK inhibits ACC, indirectly relieving the inhibition of CPT1 and directly inhibiting fatty acid 
synthesis. In addition to this, AMPK has been shown to promote glycolytic flux by phosphorylation of 
phosphofructokinase [347].  
Another key metabolic pathway controlled by the activity of AMPK is autophagy, a natural mechanism 
of cell “self-devouring” which mediates the disassembly and recycling of intracellular components to 
promote cell survival. AMPK positively regulates autophagy through a direct interaction with the 
autophagy initiating kinases ULK1 and ULK2 [348]. AMPK phosphorylates both kinases on multiple 
regulatory sites to promote autophagy in response to nutrient depletion and energetic stress [349]. 
Furthermore, AMPK may promote autophagy under energetic stress through inhibition of the mTOR 
complex 1 [350]. 
 
AMPK activation can be modulated by various compounds, including AICA-riboside, 2DG, metformin 
and dorsomorphin, which act either directly (influencing the phosphorylation of Thr172) or indirectly 
(via the ratio of intercellular AMP/ATP) [351]. 
 
mTOR is an evolutionarily conserved serine-threonine protein kinase belonging to the phospho-
inositide 3-kinase (PI3K) family. mTOR integrates numerous biological signals to regulate an array of 
cellular functions including cell growth, apoptosis, protein synthesis, cytoskeletal reorganization and 
metabolism. mTOR forms the catalytic subunit of two distinct multi-protein complexes: mTOR 
Complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is described by its three core proteins: mTOR, 
regulatory protein associated of mTOR (Raptor), and GβL. mTORC2 on the other hand, is comprised of 
mTOR, rapamycin-insensitive companion of mTOR (Rictor), mammalian stress-activated protein 
kinase interacting protein, protein observed with Rictor-1; mLST8; and Deptor [352, 353]. 
 
mTORC1 is the most well studied of the mTOR complexes and has many of its upstream and 
downstream signals well defined. mTORC1 incorporates key signals in the form of growth factors, 
energy status, oxygen tensions and amino acid abundances. Intracellular messengers such as insulin-
like growth factors (IGF), interleukins, IFNs and chemokines have been shown to activate mTORC1 
through AKT and PI3K pathways [343]. Additionally, TNFα activates IkB kinase-β which physically 
interacts with TSC1, leading to mTORC1 activation [354]. AMPK conveys information on bioenergetic 
status to mTORC1 through multiple pathways. The first of which sees phosphorylation of TSC2 by 
AMPK, this ultimately reduces mTORC1 activation through a lack of activity of TSC2 for Rheb [355]. In 
addition to this, AMPK phosphorylates Raptor on conserved Ser residues, leading to the inhibition of 
mTORC1 [356]. mTORC1 activity is influenced by intracellular amino acid concentrations via the 
nutrient sensing Rag GTPases [357]. Aerobic glycolysis in cells is positively regulated by mTORC1 
through the transcriptional activation of multiple core glycolytic and pentose phosphate pathway 
enzymes [358]. Rapamycin treated cells have impaired upregulation of glucose transporters, glucose 
uptake and expression of glycolytic enzymes [359, 360]. mTORC1 interacts with core metabolic 
transcription factors including HIF-1α and MYC to promote glycolytic metabolism [361]. mTORC1 
increases the expression of HIF-1α mRNA, this in turn promotes a hypoxia-response pro-glycolytic 
gene program in cells [362]. mTORC1 is reported to regulate the expression of MYC via post-
transcriptional modifications [363]. MYC is a key mTORC1 effector, leading to the splicing of PKM2 and 
an increased glycolytic flux [358]. In addition to its role in promoting glycolysis, mTORC1 is a key 
regulator of mitochondrial biogenesis and TCA cycle activity. Inhibiting mTORC1 through rapamycin 
drastically lowers mitochondrial oxygen consumption, cellular ATP levels, and is associated with a 
complete shift in the mitochondrial phosphoproteome [364]. Evidence suggests that dysregulated 
overexpression of glycolysis and OXPHOS genes are observed in T-cells with hyperactive mTOR activity 
[365]. 
 
Compared to mTORC1, relatively little is known about the biology of mTORC2. Due to an embryonic 
lethality caused by the deletion of mTORC2 components in mice and (up until very recently) a lack of 
specific inhibitors, knowledge of this complex has remained elusive [366]. Despite this, many 
important discoveries have highlighted a role for mTORC2 in the regulation of many core cellular 
processes, including cell survival and metabolic reprogramming. mTORC2 activates AKT on one of its 
key sites (Ser 473) to activate forkhead box protein O1 (FOXO1) and FOXO3a transcription factors, key 
transcriptional nodes in the regulation of genes involved in stress response and metabolism [367]. 
Interestingly, a lack of mTORC2 in T-cells appears to increase their metabolic capacity, both in terms 
of glycolysis and OXPHOS. This mechanism has yet to be elucidated, yet it is suggested to occur 
through stabilization of FOXO1 [368].  
 
  
Figure 1.15. Regulation of AMP-activated kinase and its downstream pathways: 
AMPK is activated by phosphorylation by LKB1. Binding of AMP/ADP (which increase in response to metformin) 
or ZMP (which increases in response to the modulation of purine biosynthesis by AICAR) to allosteric binding 
sites promote phosphorylation. Compound C inhibits AMPK activation. Once activated, AMPK activates catabolic 
pathways (left side) and inhibits anabolic pathways (right side). AMPK promotes both mitochondrial biogenesis 
and fatty acid oxidation, whilst down-regulating aerobic glycolysis through the inhibition of the mTORC1 
complex (mTOR-raptor) and HIF-1α. HIF-1α, hypoxia inducible factor-1α; mTOR, mammalian target of 
rapamycin; NAD+, nicotinamide adenine dinucleotide; SIRT1, sirtuin 1; AICAR, 5-Aminoimidazole-4-carboxamide 
ribonucleotide; ZMP, 5-Aminoimidazole-4-carboxamide ribonucleotide; AMP, adenine monophosphate; ATP, 
adenine triphosphate; ACC2, acetyl-coenzyme A carboxylase-2, PGC-1α, peroxisome proliferator-activated 
receptor gamma coactivator 1α; CPT1, carnitine palmitoyl transferase 1; PFKFB3, fructose-2,6-biphosphatase 3; 
F26BP, fructose-2,6-biphosphate; PFK1, phosphofructokinase 1; ACC1, acetyl-coenzyme A carboxylase-1; 
SREBP1, sterol regulatory element binding transcription factor 1; FAS, fatty acid synthase; HMGR, 3-hydroxy-3-
methylglutaryl-coenzyme A reductase; LKB1, liver kinase B1. Adapted from [345].  
1.8.6. Metabolism of the retina and RPE 
In humans, 14 plasma membrane transporters have been identified for the transport of 
monosaccharides and polyol sugars, and are encoded by the SCL2 gene family [369]. The RPE 
are reported to express a range of GLUT transporters during early development however, 
their sugar uptake post-maturation is restricted to the expression of GLUT1, GLUT11 and 
SGLT1 [370]. The predominant transporter in RPE is GLUT1 which facilitates the trans-
epithelial uptake of substrates: glucose, galactose and mannose [369]; roles for transporters 
GLUT2-5 remain ambiguous, this could potentially be attributed to low basal expression [371, 
372]. The presence of additional transporters has yet to be functionally documented in RPE.  
 
The retina is dependent on glucose and other fuel sources from the choroidal blood flow. 
Before these nutrients can reach cells within the retina, they must first pass through the RPE 
monolayer. Glucose passes through the basolateral surface of the RPE and exits into the retina 
on the apical surface. Recent work in the laboratories of Hurley and Philp have led to the 
emergence of a concept of “metabolic coupling” between the RPE and the retina which 
provides an explanation to why RPE metabolic dysfunction has a global effect on retinal 
function [373, 374]. In a series of elegant experiments, Kanow et al., show that the retina and 
RPE function as part of a “metabolic ecosystem”, whereby symbiotic metabolic relationships 
between each cell type are required for cell survival [4]. In this model, most of the glucose 
passes through the RPE to the photoreceptors and for the most part, is not required to 
support their metabolism. Photoreceptors use glucose as a major fuel source, exporting 
lactate as a product of glycolysis. Lactate is then used to fuel OXPHOS is neighbouring Müller 
glia and the RPE. It is of interest to note that the retina (along with tumours) were two tissues 
first identified by Otto Warburg in the 1920’s to rely predominantly on aerobic glycolysis 
[375]. Accumulating evidence suggests that photoreceptors are the site of retinal aerobic 
glycolysis.  
 
Metabolism in RPE cells is supported predominantly by their mitochondria. Studies show that 
mitochondria are abundant within RPE cells [376] and in culture, RPE cells exhibit high levels 
of oxygen consumption [377]. Lactate is suggested to be the most prominent RPE fuel source 
in vivo [4]. Indeed, lack of monocarboxylate lactate transporters can cause retinal dysfunction 
and degradation [378]. In addition to lactate, photoreceptors also supply the RPE with lipids 
through phagocytosis of outer segments. These lipids serve as key substrates for beta-
oxidation, producing acetyl-coA which feeds into the TCA cycle. Glutamine is another key fuel 
source used by the RPE, with studies indicating that the RPE has a high capacity for reductive 
carboxylation of a-ketoglutarate to isocitrate through isocitrate dehydrogenase 2 [6]. 
Reductive carboxylation appears to be a key pathway in the RPE to support mitochondrial 
metabolism and redox homeostasis. In the absence of reductive carboxylation, RPE function 
is impaired and oxidative damage to the RPE is augmented. Proline and taurine are key 
nutrients consumed by the RPE. Interestingly, studies have indicated that proline is the 
preferred fuel source of the RPE [379, 380]. Proline is taken up basolateral by RPE cells at 
levels ~7-fold greater than that of glucose. When inside the RPE, proline is utilised to generate 
TCA intermediates through both mitochondrial oxidative and reductive pathways. Proline-
derived metabolites are exported preferentially to the apical side where they are used as a 
retinal fuel source. In addition to the metabolites discussed above, the RPE has been 
suggested to function based on glucose uptake and storage as glycogen, followed by glycogen 
utilisation [371]. Collectively, the metabolic program adopted by RPE cells in vivo appears to 
be that of mitochondrial OXPHOS, utilising multiple substrates to feed into the TCA cycle 
rather than the utilisation of glycolysis. Cultured RPE cells, however, are adept at utilising 
glycolysis, and produce high levels of lactate in vitro [381]. Despite their high capacity for 
glycolysis, it is unlikely to be used as a fuel source in vivo. Studies show that the RPE is unable 
to support the retina when forced to rely on glycolytic rather than mitochondrial metabolism 
[382]. Interestingly, activation of mTORC1 or the normoxic stabilisation of HIF-1α in RPE cells 
in vivo causes degeneration in the surrounding photoreceptors [383]. Activating AMPK or 
PGC-1α in RPE cells on the other hand, has been shown to improve mitochondrial function 
and in the case of AMPK activation, protect against photoreceptor damage [36, 384]. 
 
 
Figure 1.16. Metabolism of the RPE in vivo: 
In a heathy retina, retinal pigment epithelium (RPE) cells take up glucose through GLUT1 transporters yet is not 
used as a metabolic substrate. Instead, glucose from the choroidal blood flow is shuttled to the photoreceptors 
for use in aerobic glycolysis. Lactate produced in the photoreceptors is taken up by RPE monocarboxylate 
transporters and enters the mitochondrial TCA cycle as pyruvate. Photoreceptors also supply the RPE with lipids 
from the degradation of photoreceptor outer segments. These lipids are used to generate ATP in mitochondrial 
β-oxidation. Glutamine enters the RPE through the SLC1A5 transporter and enters the TCA cycle as α-
ketoglutarate. RPE cells use reductive carboxylation of α-ketoglutarate to support cellular functions. Proline 
imported into RPE cells can be catabolized into glutamate for mitochondrial intermediates. RPE cells export TCA 
intermediates to the retina as additional fuel sources. Adapted from [4].  
 
   
1.8.7. Bioenergetic dysfunction in AMD 
With progressing age, the observation that bioenergetic function declines is well documented 
[385]. Aging models of rats and mice have shown complexes I and IV of the ETC display 
reduced kinetic activity, whilst complexes II, III, and the F1-ATP-synthase complex remain 
largely unaffected [386, 387]. The impaired enzymatic functions of complexes I and IV 
compromise energy transduction through the ETC, and therefore decrease the ATP output of 
mitochondrial OXPHOS [385]. Additionally, aging results in increased ROS production, the 
accumulation of mtDNA mutations, and a decline in the function of CPT1 [86, 388, 389]. RPE 
are susceptible to reductions in bioenergetic fluxes because of their high metabolic capacity; 
there is now increasing evidence that mitochondrial health decline plays a prominent role in 
the pathogenesis of AMD [390, 391].  
In addition to their role in energy production, mitochondria function as a signalling platform 
for retrograde/anterograde communication with the nucleus [392]. Under normal conditions, 
ROS act as an important signalling molecule in these processes. Communication between the 
two organelles is important for adjustments in nuclear and mitochondrial-encoded genes to 
accommodate cellular bioenergetic demands. Excessive ROS production, however, can 
damage mtDNA and mitochondrial proteins and lipids. Damage to the mitochondrial genome 
leads to defects in the expression of essential ETC components. Damage to the mitochondrial 
membrane can elicit the formation of mitochondrial permeability pores, reducing 
mitochondrial membrane potential and leading to the release of mitochondria-derived 
biomolecules such as mtDNA, apoptosis-inducing factor and cytochrome C [393]. Release of 
these molecules initiates apoptotic and inflammasome cascades, leading to cell death via 
pyroptosis [71].  
 
Outcomes of ROS-mediated DNA damage include double and single strand breaks, in addition to the 
formation of DNA adducts. These DNA lesions can affect the interpretation and transmission of 
mitochondrial genetic material [394]. One repercussion of double-strand break repair is the 4977bp 
deletion of mtDNA, a common deletion zone observed in various post-mitotic tissues with a high-
energy demand [395]. Age-dependent increases in 4977bp deletions have been observed in RPE from 
healthy and AMD donors [395]. Analysis of multiple AMD cohorts has shown that the degree of mtDNA 
damage is correlated to AMD severity [376]. Upon further investigation, it was found that sites of 
increased mitochondrial genome damage were localised to regions encoding 16S and 12S ribosomal 
RNA [396], suggesting that the translation of various mitochondrial-encoded genes could be adversely 
affected. In addition to this, other significantly damaged regions in the AMD cohorts included genes 
encoding ETC subunits, potentially suggesting reduced ATP production. Recent studies have built on 
this, and shown using extracellular flux analysis, that RPE from AMD donors have significantly reduced 
mitochondrial OXPHOS [397, 398]. In both experimental systems used in these studies, there appears 
to be differences in how glycolytic metabolism is affected in AMD donor RPE cells. Further studies will 
be required to explore if other metabolic pathways support ATP synthesis with mitochondrial 
dysfunction.  
 
In the context of the metabolic ecosystem discussed in the previous section [399], it is plausible that 
AMD-mediated dysfunction in RPE mitochondria would disrupt the energy balance, not just in RPE 
themselves, but in other cells in the retina which rely on the RPE for metabolic support. RPE cells rely 
predominantly on β-oxidation and oxidative metabolism of lactate and amino acids, such as proline 
and glutamine [6, 374, 379]. As mitochondria are the site of these key pathways, damage would likely 
cause defects in ATP production. It is suggested that defects in OXPHOS would force the RPE to rely 
on glycolytic metabolism to support cellular bioenergetics. As discussed previously, RPE cells are 
capable of utilising glycolysis and have a robust expression of key glycolytic enzymes [400]. In vivo, 
glycolysis is seldom used, with glucose shuttled through the RPE to fuel photoreceptors [4]. An 
increased RPE glycolytic program would have adverse effects for photoreceptors, which rely solely on 
glycolysis. A reduction in photoreceptor lactate production would reduce the available retina lactate 
pool for RPE cells to use as a fuel source, increasing their reliance on glycolysis, starving 
photoreceptors further and ultimately leading to degeneration and cell death. It is well known that 
AMD patients exhibit the degeneration of rods, which precedes the death of cones [401]. Interestingly, 
rods secrete thioredoxins to promote glucose uptake and augment cone glycolytic flux [402]. If one 
assumes the theory of a retinal metabolic ecosystem is true, and that metabolic reprogramming to 
glycolysis occurs following AMD-induced mitochondrial damage, a reduced flow of glucose to the 
photoreceptors could accelerate rod loss. With a higher density of cones to rods, fewer rods would 
thus be able to support cone metabolism, contributing to the loss of macular photoreceptors.  
 
1.9. Immunometabolism 
Cells of both the innate and adaptive immune system require the ability to rapidly respond to 
pathogenic insults, initiating responses such as antigen presentation, phagocytosis and the production 
of inflammatory/effector cytokines. Immunometabolism refers to the concept that metabolic 
plasticity governs the ability of immune cells to quickly proliferate and initiate immunological 
responses, following exposure to pathogenic or noxious stimuli [5]. Lymphocytes (T-cells, B-cells and 
NK cells), macrophages and DC have all reported to undergo the Warburg effect when activated, 
facilitating the rapid output of cytokines and chemokines [403-407]. Indeed, the small molecule 
inhibitor of hexokinase (the enzyme responsible for catalysing the first step in glycolysis), 2-
deoxyglucose (2DG), has been reported to inhibit inflammation in many contexts [408-411]. Recent 
studies have confirmed integration between metabolic reprogramming and immune function, with 
various immune cells exhibiting a “metabolic plasticity” [412]. This flexibility between ATP-generating 
pathways allows the functional demands of cells to be met, even under nutrient deprivation and 
hypoxic conditions [413]. Inflammation itself is a bioenergetically expensive process and in certain 
contexts elicits a switch from OXPHOS to aerobic glycolysis. This “Warburg-like” switch provides a 
rapid generation of ATP for cytokine production [414]. Metabolic reprogramming is observed in 
response to PRR stimulation of innate immune cells and Th1/Th17 proliferation [403-405]; a metabolic 
shift away from OXPHOS and Kreb’s cycle, into glycolysis, supports an immediate ATP output that fuels 
the immune response. Cells involved in the attenuation of a pro-inflammatory environment, such as 
M2 macrophages, Tregs and CD8+ memory cells, and exhibit reduced glycolytic rates, favouring 
production of ATP through the utilization of Kreb’s cycle and the ETC [404, 415]. The maintenance of 
cellular energy homeostasis within mammalian cells is controlled by the enzymatic activity of AMPK 
and mTOR [343, 344]. Studies have identified, that similar to the regulation of cancer cell proliferation, 
immune cells require a similar regulation of bioenergetic sourcing, controlled through AMPK and 
extracellular signal-transduction [345]. 
 
1.9.1. Metabolism of innate immune cells 
Resting dendritic cells and macrophages rely predominantly on OXPHOS to generate ATP, yet upon 
activation of TLRs they undergo a switch in metabolic state towards a program of highly glycolytic 
metabolism [403, 416]. Activated cells display increased expression of various metabolic enzymes, 
increased lactate output and a decrease in mitochondrial OXPHOS. LPS activation of cells is a classic 
example of PAMP/TLR interaction inducing amplified cellular glycolytic flux in a HIF-1α/PI3K/AKT-
dependent manner [417]. The increased output of lactate from glycolysis may contribute to 
immunological defence through its reported antimicrobial properties [418]. LPS-activated 
macrophages and dendritic cells increase the expression of glucose transporter GLUT1, facilitating 
enhanced glucose uptake [416]. Interestingly, TLR-9 stimulation of DC induce the expression of type-
1 IFNs which modulate metabolism away from aerobic glycolysis, and towards OXPHOS of fatty acids 
and mitochondrial pyruvate [419]. Macrophages are differentially activated into the M1 (pro-
inflammatory) and M2 (anti-inflammatory) isoforms. These vary in their metabolic profile, with M1 
macrophages relying heavily on Warburg metabolism as oppose to their OXPHOS-utilizing M2 
counterparts [412]. This can be attributed to a number of mechanisms including, expression of highly 
active glycolytic enzyme ubiquitous phosphofructokinase (uPFK) in M1 macrophages compared to the 
less-active PFKFB1 in M2 and the induction of PKM2 which alters the expression of HIF1-α-dependent 
genes, including glycolytic enzymes and IL-1β [416]. M1 macrophages exhibit a “broken” TCA cycle 
which prevents coupling to OXPHOS. The broken cycle leads to an accumulation of citrate - a result of 
decreased isocitrate lyase expression – which facilitates fatty acid synthesis, antimicrobial itaconate 
synthesis and nitric oxide (NO) production [416]. NO is essential for prolonging the longevity of 
dendritic cells and M1 macrophages through inhibition of the terminal ETC electron acceptor, 
cytochrome c oxidase [420]. Without inhibition of cytochrome c oxidase, a rapid drop in mitochondrial 
membrane potential would occur, leading to the recruitment of (BCL-2-associated X protein) BAX to 
the mitochondria and the subsequent initiation of apoptosis cascades [165]. IL-10 limits the switch to 
aerobic glycolysis and blocks TLR activation of dendritic cells, implicating mitochondrial metabolism 
with an anti-inflammatory phenotype [403]. IL-4 activation of macrophages promotes the expression 
of PPARγ-coactivator-1β (PGC-1β) via STAT6; this ultimately leads to increased transcription of genes 
involved within fatty acid oxidation and mitochondrial biogenesis [421]. Phagocytic functions of 
immune-cells are mediated by Phox/NADPH oxidase (NOX)-dependent respiratory bursts, which 
generate mitochondrial ROS through complexes 1 and 2 of the ETC [422]. The upregulation of the 
pentose-phosphate pathway in M1 macrophages serves as an essential counter-regulatory 
mechanism of preventing tissue damage in response to rapid ROS generation through the generation 
of antioxidants and glutathione; this is modulated by the expression of carbohydrate kinase-like 
protein [423]. Mitochondrial stress and increased ROS production form a prominent danger signal in 
the activation of the NLRP3 inflammasome [69].  
 
Studies of TLR-mediated changes in bioenergetic sourcing have primarily focused on immunological 
cells of the adaptive and innate immune system (T-cells, dendritic cells, macrophages). Whilst not 
strictly an immunological cell, RPE plays a pivotal role in the maintenance of ocular immune privilege; 
with an output of immuno-stimulatory chemokines and cytokines, APC functions, and a rich 
expression of TLR, RPE initiate cellular responses stretching beyond innate-frontline defence [45, 46]. 
Recent studies have shown that integrated immunological and metabolic pathways are observed in 
the RPE, indicating a translational aspect to much of the current research in immunometabolism. RPE 
are reported to undergo the Warburg effect following TLR activation via TLR-3 and TLR-4 agonists Poly 
(I:C) and LPS, respectively [286, 424]. This switch from OXPHOS into glycolytic metabolism was 
accompanied by an increased expression of GLUT1, increased glucose consumption and lactate 
production. 
 
1.9.2. AMPK activation in immune cells 
AMPK activation elicits cell-cycle arrest and prevents metabolic adaptations occurring in proliferating 
cells, leading to the consensus that AMPK functions as a suppressor of tumorigenesis and 
inflammation [345]. The role of AMPK appears to be in the suppression of the “Warburg effect” upon 
immune cell activation and the continued usage of mitochondrial respiration, through creating a state 
of “pseudo-starvation” that mimics nutrient deprovision [345]. Indeed, glycolysis and the expression 
of glycolytic enzymes are elevated in T-cells from AMPK deficient mice [425]. Activation or inhibition 
of AMPK through small molecules have been reported to attenuate inflammatory responses in several 
settings. These include, inhibition of LPS-induced ROS-NF-kB signalling in macrophages; a reduced LPS-
induced cytokine output of IL-1β IL-6 and IL-8 in the bovine endometrium; a suppression of IFN-γ 
production by CD8+ T effector cells; attenuation of disease severity in experimental autoimmune 
encephalomyelitis through the reduction of Th1 cytokines IFN-γ and TNF-α, whilst upregulating Th2 
cytokines IL-4 and IL-10; prevention of LPS-induced inhibition of neutrophil chemotaxis and 
inflammatory responses, yet interestingly, AMPK activation facilitated enhanced phagocytic and 
bactericidal activity [426-430]. AMPK activation may facilitate a “pro-Warburg” phenotype in LPS-
induced monocytes expressing inducible 6-phosphofructo-2-kinase variant PFKFB3 [431]. When 
phosphorylated by AMPK, its kinase activity is increased, resulting in amplified fructose-2,6-
bisphosphate; this allosterically activates PFK1, leading to increased glycolytic metabolism under 
hypoxia [431]. It is argued that small molecule activators of AMPK may induce a state of pseudo-
starvation conferring an anti-inflammatory phenotype [345]. As AMPK inhibitors confer a similar anti-
inflammatory shift, it gives the impression that, the integration of energy metabolism and innate 
immunity depends on the activity of AMPK and the maintenance of cellular energy homeostasis. 
Disruption via inhibition or activation of AMPK may negatively impact the innate immune response. 
In addition to its roles in inflammation, AMPK has been shown to control several cellular processes in 
RPE, including phagocytosis of photoreceptors, permeability, and survival under oxidative stress [432, 
433]. 
 
The mTOR complex unsurprisingly (given its central role in the regulation of cellular function), plays a 
key role in the development of immune cells. mTORC1 mediates metabolic activation networks in 
response to TLR signalling [434] and promotes glycolytic metabolism in innate immune cells through 
the induction of HIF-1α and MYC which, in turn facilitate the upregulation of genes involved in 
glycolytic metabolism [306]. Additionally, mTORC1 promotes fatty acid and cholesterol synthesis for 
utilization in ER and Golgi synthesis, which promote secretion of pro-inflammatory mediators [434]. 
Initial studies focused on the immunosuppressive actions of rapamycin on the proliferation of T-cells 
and IL-2 production [435]. In innate immune cells, rapamycin promotes pro-inflammatory cytokine 
production and limits IL-10 production. mTORC1 limits the activation NF-kB whilst promoting the 
activity of STAT3 [436]. As mTORC1 signalling is reported to increase with RPE cell senescence [437], 
this gives an indication of how aging may negatively influence immune responses. The effects of 
rapamycin on immune cell metabolism were shown to be pivotal in the promotion of fatty acid 
oxidation [438]. Activation of macrophages by IL-4 is associated with enhanced fatty acid oxidation 
and increased glucose oxidative catabolism; recent studies have shown that mTORC2 is a key node in 
this metabolic reprogramming [439]. As previously discussed, a lack of mTORC1 regulation in T-cells 
leads to enhanced glycolytic metabolism and the failure of memory T-cell (T-mem) development [365].  
Inhibition via the dual inhibitor Torrin1, but not rapamycin, has been reported to limit endometrial 
inflammatory responses [427]. The glycolytic enzyme hexokinase-1 has been observed to up regulate 
macrophage NLRP3 activation in a raptor/mTORC1-dependent manner [437].  
 
1.9.3. Interleukin-33 and the control of cellular metabolic profiles 
The previous sections have discussed how the metabolism of immune cells is modulated through 
external environmental cues (e.g. TLR, T-cell receptor or cytokine receptor-mediated signalling) and 
the roles of metabolic regulators (such as AMPK and mTOR) in initial immune cell metabolic 
adaptations and ultimately the regulation of immune responses. In this section I will focus entirely on 
the immunometabolic interactions of IL-33. 
 
A recent study exploited the cytoplasmic hybrid (cybrid) technique [440] to generate RPE cell lines 
containing representative mtDNA haplotypes. These haplogroups were associated with protective (H 
haplogroup) or high risk (J haplogroup) AMD populations. The J haplogroup was found to exhibit 
reduced expression of seven mitochondrial genes involved in OXPHOS, including essential proteins of 
complexes I, IV, and F1-ATP-synthase [18]. It was additionally observed that the J haplogroup exhibited 
a reduced oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)/OCR ratio, yet 
ATP turnover, and spare respiratory capacity remained constant when compared to the H haplogroup. 
Interestingly, it was observed that the J haplogroup revealed an >2-fold reduction in the expression of 
IL-33, yet in response to oxidative stress, its expression was greater in the H haplogroup [18]. Although 
this study observed a correlation in the RPE metabolic phenotype and expression of IL-33, this finding 
was timely to another study suggesting a novel role for IL-33 in the regulation of thermogenesis and 
uncoupled mitochondrial respiration [19]. IL-33 was observed to be critical for the splicing of 
uncoupling protein 1 (Ucp1) mRNA in adipocytes, and the expression of functional UCP1. In addition 
to this, mitochondria from Il33-/- mice exhibited profound respiratory defects, including reduced 
OXPHOS, and enzymatic activity of ETC complexes II and IV. Further RNA-seq experiments identified 
an increased expression of genes involved in the catabolism of fatty acids, glucose and amino acids in 
Il33-/- mice [19]; this suggests a compensatory mechanism for defects in uncoupled respiration, 
upregulating flux through catabolic pathways to generate ATP.  
 
Murine mast cells activated with exogenous IL-33 are reported to increase glycolysis, the expression 
of key glycolytic enzymes and OXPHOS [441]. Endogenous and exogenous IL-33 have been shown to 
up-regulate HIF-1α in synovial fibroblasts [442] and increase glycolysis in cancer cell lines [443]. 
Furthermore, IL-33 is proposed to be a key regulator of macrophage metabolism in response to LPS 
stimulation; cells with ST2 deficiency were associated with increased mitochondrial metabolism and 
IL-33 overexpressing cells displayed an augmented shift to aerobic glycolysis in response to LPS [444]. 
Although these studies support a role in the regulation of central carbon metabolism, the biology of 
IL-33 is clearly multifaceted, especially when we consider the influence of endogenous and exogenous 
forms. As IL-33 is not normally released from cells [9], it is of interest to understand how a lack of ST2 
alters metabolic phenotypes [19, 444].  
 
1.10. Thesis objectives 
Experimental observations have demonstrated that inflammation plays a prominent role in the 
pathogenesis of AMD. The integration of immune responses and metabolic pathways has been 
demonstrated in immune cells, yet evidence of this is only just emerging within the retina. 
Bioenergetic dysfunction, para-inflammation and oxidative stress are linked with the exacerbation of 
age-related disorders. Whilst inflammation has the potential to mediate bioenergetic sourcing, 
mitochondria themselves appear to drive and regulate inflammatory signalling, suggesting a cyclic 
relationship between the two co-dependent processes. One consequence of a bioenergetic switch in 
the RPE is the concurrent production of IL-33. IL-33 is an immunomodulatory alarmin of the innate 
immune system, which targets a diverse array of cell types, and exhibits complex functions as both an 
extracellular cytokine and as a nuclear regulator. Novel and protective roles for this cytokine are 
beginning to emerge in the context of degenerative disorders; it appears that IL-33 is essential for the 
prevention of ocular angiogenesis, Aβ clearance in the brain, and may attenuate the noxious effects 
of oxidative stress in the tissue. Whilst IL-33 appears to be an attractive therapeutic adjuvant, it should 
be noted that a vast proportion of its underlying biology remains undetermined to date. Little is known 
about the processing of IL-33, and mechanisms of its regulation through various endogenous peptides 
and decoy receptors. Additionally, the role of IL-33 within the nucleus and its influence on cellular 
metabolism remain ambiguous. 
 
In summary the hypotheses, on which this thesis was based, were designed to focus on the integration 
between aspects of the innate immune response and cellular metabolism in the RPE: 
 
1. Under conditions of tissue damage and parainflammatory stress, innate immune-derived signals 
elicit metabolic reprogramming in the RPE which impair its ability to provide functional support to the 
retina. 
2. IL-33 is released following tissue damage and stress to maintain cellular and metabolic homeostasis 
in the RPE. 
3. IL-33 functions as a key node in the metabolic regulation of the RPE, acting through both canonical 
(ST2-dependent) and non-canonical (ST2-independent) pathways. 
 
To test these hypotheses, this thesis aimed to: 
 
1. Investigate the metabolism of RPE in normal aged mice and examine if metabolic differentiation 
exists in the RPE after stress of immune system (Chapter 3 and 4). 
2. Examine how IL-33 maintains RPE health under conditions of cellular stress (Chapter 4). 
3. Explore the links between IL-33 and metabolic function in the RPE (Chapter 4 and 5). 


















Chapter 2. Materials and methods  
2.1. Experimental models 
2.1.1. Cell lines 
Immortalized human retinal pigment epithelium (ARPE-19), a spontaneously formed mouse RPE cell 
line (B6-RPE07) [445],  human colorectal adenocarcinoma (SW1463) [446] and human Müller glial 
Moorfields/Institute of Ophthalmology- Müller 1 (MIO-M1) cell lines were cultured in DMEM 
(4.5mg/L) supplemented with 10% heat-inactivated foetal bovine serum (FBS), 2mM L-glutamine, 
1mM sodium-pyruvate, 0.5µM 2-mercaptoethanol, 100U/ml penicillin, and 100µg/ml streptomycin. 
Cells were passaged with a split ratio of 1:4 using trypsin EDTA and allowed to recover for 2 days in 
complete medium prior to experiments. All cell lines were maintained at 37°C and were routinely 
screened for mycoplasma contamination. ARPE-19 cells were received as a kind gift from Dr. Gabi 
Braun (University of Bristol, UK). B6-RPE07 cells were received as a kind gift from Prof. Heping Xu 
(Queens University Belfast, UK). The human SW1463 was received as a kind gift from Prof. Ann 
Williams (University of Bristol, UK). The human MIO-M1 was obtained from the UCL Institute of 
Ophthalmology, London, UK. MIO-M1 express markers of mature Müller cells, including cellular 
retinaldehyde binding protein [CRALBP], glutamine synthetase, vimentin and epidermal growth factor 
receptor-[EGF-R] [447]. B6-RPE07, MIO-M1 and SW1463 cells are female, and ARPE-19 are male.  
 
2.1.2. Primary cells 
C57BL/6J mice were purchased from Charles River Laboratories, Margate, UK. All mice were 
maintained in the animal house facilities of the University of Bristol, according to Home Office 
Regulations. Animal husbandry and procedures complied with the ARVO (Association for Research in 
Vision and Ophthalmology) statement for the use of animals in ophthalmic and vision research. IL-33 
knockout mice (Il33-/-) were generated as described [448] at the animal house facilities of Trinity 
College Dublin and sent to the animal house facilities of the University of Bristol when required. ST2 
knockout mice (Il1rl1-/-) were generated as described [8] at the animal house facilities of the University 
of Bristol.  
  
2.1.2.1. Primary RPE 
Primary murine RPE cells were obtained as described [449]. Briefly, eyes were enucleated and cleaned 
using angles scissors to ensure than no connective tissue remained attached to the sclera.  A large 
incision was made in the centre of the cornea so that the lens could be removed. Once removed, the 
eyes were incubated at 37°C in hyaluronidase for 45min, and in Hank’s balanced salt solution (HBSS) 
with calcium, magnesium and 10mM HEPES for a further 30min. An incision was made beneath the 
ora serrata to remove the iris epithelium and cornea. The neural retina and the attachment to the 
optic nerve were removed. Eyecups were incubated at 37°C in trypsin EDTA for 45min. Eyecups were 
then transferred into HBSS with 20% FBS and shaken gently to allow the RPE to detach. The RPE sheets 
were incubated at 37°C in 1ml trypsin EDTA for 1min, 9ml primary RPE media was then added, 
centrifuged, and supernatant removed. The resulting RPE cells were resuspended in 200µL primary 
RPE media and homogenously mixed using a p200 pipette. Cells were used within 10 days of 
extraction. Cells were cultured in alpha-MEM, containing 1% N1 supplement, 1% glutamine-1% 
penicillin-streptomycin, 1% non-essential amino acid solution, 5% heat-inactivated foetal bovine 
serum (FBS), 20µg/L Hydrocortisone, 250mg/L Taurine and 13ng/L triiodo-thyronin. Purity was 
assessed by immunoblotting for RPE specific protein RPE65 and rhodopsin contamination from the 




Figure 2.1. Isolation of primary RPE: 
(A) Immunoblot of primary RPE purity with RPE65 and rhodopsin protein expression. Western blot analysis 
represents two individual mice. 
  
2.1.2.2. Bone marrow derived mast cells 
Bone marrow derived mast cells (BMMCs) were generated from C57BL/6 as described [194]. Briefly, 
legs were taken from mice and stripped of muscle. Under sterile conditions the bones were placed 
into a petri dish and cut at the end using angles scissors to expose the red marrow. Using a syringe 
and a 23-gauge needle DMEM was flushed through the bone until marrow was not visible. DMEM 
containing the cell suspension was spun at 14,000g for 5min in a centrifuge cooled to 4°C. The resulting 
cell pellet was resuspended in 15ml of DMEM containing IL-3 and dispensed into a cell culture flask. 
The cell suspension was left for 5 weeks (with bi-weekly passages) to allow the generation of a mast 
cell population. Prior to functional assays, mast cells were sorted into a viable population using a MACS 
dead cell removal kit and the purity was assessed by FACS based on CD117 (c-Kit) and CD45 (BD 
Bioscience, UK) cell surface marker expression.  
 
2.2. Method details 
2.2.1. Cell culture 
Cells were seeded at a density of 100,000 per well of a 24 well plate and were exposed to different 
inflammatory stimuli; Poly (I:C) (high and low molecular weight), LPS, IL-33, peptidoglycan (PGN), CpG 
oligodeoxynucleotide (CpG), IL-1β, IL-4, IL-6 IL-10, IL-17A, IL-22, TNFα and IFN-γ. Poly (I:C) from 
Invivogen was used as a result of its highly referenced usage as a potent TLR-3 ligand within the 
literature [65, 450]. Ultrapure LPS (from E. coli O111:B4) from Invivogen was used as a result of its 
highly referenced usage as a potent TLR-4 ligand within the literature [451, 452]. Ultrapure LPS was 
used as opposed to the standard LPS-EB. Unlike the LPS-EB, Ultrapure LPS was further purified to 
remove other bacterial components such as lipopeptides which may activate TLR-2, ensuring TLR-4 
specificity. Recombinant IL-33 was purchased from Enzo Life Science; this specific IL-33 was used so 
that the work from this thesis was in keeping with other published research [8]. Oxidative stress was 
induced by the addition of hydrogen peroxide (1mM). AMPK activity was modulated by activator 
AICAR (1mM), and inhibitor Compound C (40µM). Unstimulated controls and vehicle controls (DMSO) 
were always included. Further information regarding these agonists can be found in Table 2.4.1; page 
109. 
  
2.2.2. Protein isolation  
2.2.2.1. Protein isolation from cell lines 
Following treatment, total protein extraction was performed using Cell-Lytic-M (Thermo Fischer, UK) 
with the addition of Protease/Phosphatase Inhibitor Cocktail (Cell Signalling, UK). The resulting cell 
suspension was centrifuged for 15min at 14,000g in a centrifuge cooled to 4°C. A commercial nuclear 
extraction kit (Active Motif, Belgium) was used for the preparation of nuclear and cytoplasmic extracts 
as per the manufacturer’s instructions. Briefly, cells were washed twice with 1ml of ice-cold 
PBS/phosphatase inhibitors and 0.3ml of ice-cold PBS/phosphatase inhibitors was added. Cells were 
removed from the cell culture plate by gentle scraping. Samples were pooled from 2 wells of a 24 well 
plate. The resulting cell suspension was centrifuged for 5min at 200g in a centrifuge cooled to 4°C. The 
supernatant was removed, and the pellet kept on ice prior to resuspension in 100μl hypotonic buffer 
containing 5% (vol/vol) detergent. The resulting cell suspension was centrifuged for 30s at 14,000g in 
a centrifuge cooled to 4°C. The supernatant was removed as the cytoplasmic fraction. The remaining 
pellet was resuspended in 25µL of complete lysis buffer and incubated for 30min on ice on a rocking 
platform. The resulting cell suspension was centrifuged for 10min at 14,000g in a centrifuge cooled to 
4°C. The supernatant was removed as the nuclear fraction.  
 
2.2.2.2. Isolation of RPE protein 
RPE cell protein was isolated from mouse tissue as previously described [453]. In brief, eyes were 
enucleated and cleaned using angles scissors to ensure than no connective tissue remained attached 
to the sclera.  A large incision was made in the centre of the cornea so that the lens could be removed. 
Once removed, four small slits were made into the RPE/choroid to flatten the tissue. The tissue was 
then transferred into a 1.5μL eppendorf containing 200μL of RIPA buffer with the addition of 
protease/phosphatase Inhibitor Cocktail for 30min on ice. After incubation, the tube was tapped 
gently fifty times to allow the RPE to be released into the lysis buffer. The choroid/sclera was then 
removed and the RPE was left on ice for a further 30min. Proteins were then extracted from the RIPA 
lysis buffer by first subjecting the lysate to one round of sonication for 20s and centrifuging for 15min 
at 14,000g and 4°C. The supernatant was removed and placed in a fresh pre-chilled eppendorf.  
2.2.3. Western blot 
Protein concentration was assessed using a bicinchonic acid (BCA) assay kit (Thermo Fischer, UK). 15µg 
of protein (to a total volume of 28µL), 2µL of β-mercaptoethanol (Sigma, UK) and 10µL of NuPage SDS 
buffer (Thermo Fischer, UK) were heated for 5min at 90°C. The denatured proteins were then added 
to each well of a precast NuPage tris-glycine mini gel (Thermo Fischer, UK) with at least one well empty 
for the addition of protein standards. 500mL of 1X NuPage tris-glycine (Thermo Fischer, UK) was added 
to the mini-Tank (Thermo Fischer, UK) and SDS-page electrophoresis was performed for 45min at 
200V/160mA. Following electrophoresis, the gel was submerged in 10% methanol for 10min. The 
precast gel coating was then cracked open and the gel removed. Dry blotting of proteins from mini 
gels was performed using an iBlot-2 dry blotting system (Thermo Fischer, UK). The iBlot-2 transfer 
stacks (Thermo Fischer, UK) and the pre-run gel were inserted into the iBlot-2 machine as per the 
manufacturer’s instructions. A pre-designed method (20V for 2min, 23V for 3min and 25V for 2min) 
for a total of 7min was used to transfer proteins between 30-150kDa. Reducing the run time to 5-
6mins was required for proteins <30kDa and an increase to 8-10min was required for proteins 
>150kDa. After transfer, the stacks were removed and the PVDF membrane was cut as required. The 
membrane was blocked in 5% milk/TBS for 2h at room temperature (R.T.). Immunoblotting was 
performed by the addition of a primary antibody to protein of interest overnight at 4°C (antibody 
concentrations detailed in Table 2.4.2; page 110). The membrane was then washed in TBS/Tween-20 
for 5min three consecutive times. The membrane was then incubated at R.T. for 1h with a polyclonal 
HRP-conjugated secondary antibody. The membrane was then washed in TBS/Tween-20 for 5min 
three consecutive times. An electrochemiluminescence (ECL) was used to detect protein abundance 
in the membrane as per the manufacturer’s instructions. In brief, membranes were incubated in 0.5mL 
of both ECL detection agent A and B (G.E. Healthcare, UK) for 1min at R.T. Protein expression was 
visualized using chemiluminescent film (G.E. Healthcare, UK) at increasing exposure time. Relative 
protein expression was calculated by normalization to beta actin, beta tubulin or histone 3.  
  
2.2.4. RNA and DNA analysis  
2.2.4.1. RNA isolation 
RNA was isolated from cells using the RNeasy extraction kit (QIAGEN, UK). In brief, 100,000 cells were 
lysed directly in a 24-well plate with 350µL of RLT plus buffer, containing 3.5µL β-mercaptoethanol. 
The lysate was transferred into a fresh pre-chilled eppendorf and vortexed for 30s. The lysate was 
transferred to a gDNA eliminator spin column placed in a 2ml collection tube and centrifuged for 30s 
at 10,000g. The column was discarded and 350µL of 70% ethanol was added to the flow-through and 
mixed well by pipetting. 700µL of the sample was placed in a RNeasy spin column in a 2ml collection 
tube and centrifuged for 30s at 10,000g. The flow-through was discarded and 700µL of RW1 buffer 
was added to the RNAeasy spin column. This was centrifuged for 30s at 10,000g and the flow-through 
was discarded. 500µL of RPE buffer was added to the RNAeasy spin column and centrifuged for 30s at 
10,000g. The flow-through was discarded and 500µL of RPE buffer was added to the RNAeasy spin 
column. This was centrifuged for 2min at 10,000g. The RNAeasy spin column was removed and placed 
into a new 2ml collection tube before centrifugation at full speed for 1min to further dry the 
membrane. The RNAeasy spin column was then placed into a new eppendorf. 30µL of RNase-free 
water was added directly to the spin column membrane and centrifuged for 1min at 10,000g to elute 
the RNA.  
 
2.2.4.2. cDNA conversion 
Purity and RNA concentration was assessed using a nanodrop 3000 spectrophotometer (Thermo 
Fischer, UK) and 1μg RNA was reverse-transcribed into cDNA using a SuperScript III First Strand 
Synthesis system (Thermo Fischer, UK). In brief, RNA, 1μl of 50μM oligo(dT), 1μl of 10mM dNTP mix 
and RNase-free water (up to 10μL) were added to a 0.2mL tube and incubated for 5min at 65°C and 
5min on ice. A cDNA synthesis mix was prepared by adding the following components: 2μL of 10X RT 
buffer, 4μL of 25mM MgCl2, 2μL of 0.1M DTT and 1μL reverse-transcriptase. The cDNA synthesis mix 
was added to the RNA/primer mixture, vortexed gently and collected by brief centrifugation. The 





Resulting cDNA was diluted 1:20 and 2.5μL was added to a micro-amp optical 96-well reaction plate. 
0.25μL of 100μM forward and reverse primers were also added to the cDNA, along with 2.5μL DNA-
free water and 5μL SYBR-green reagent (Thermo Fischer, UK). cDNA was amplified in a StepOne Plus 
detection system (Thermo Fischer, UK). Cycling conditions: Heat ramp 95°C for 10min, extension (95°C 
for 15s, 60°C for 1min) for 45 cycles, melt curve 95°C for 15s, 60°C for 1min, 95°C for 15s. Relative 
gene expression was calculated by normalization to βActin. Primer sequences used are detailed in 
Table 2.4.3; page 111.   
 
2.2.4.4. Mitochondrial DNA content  
The content of mtDNA was examined as previously described using RT-PCR [397]. In brief, three sets 
of mitochondrial primers were used in the RT-PCR analysis. Total mtDNA copies were generated by 
amplifying two regions of the mitochondrial genome: cytochrome b and 16 S rRNA. An average of 
these were taken and normalised to cell number using the nuclear-encoded β-globulin gene. 
 
2.2.5. Enzyme-linked immunosorbent assay (ELISA) 
IL-33, IL-6 and ST2 release from supernatants, and IL-1β and malonyl CoA abundance in cell lysates 
were measured using commercially available ELISA kits (DuoSet, R&D Systems, UK; CUSABIO, UK). In 
brief, 50μL of capture antibody in PBS was added to Nunc “immuno” plates (VWR, UK) for overnight 
incubation at RT. Concentrations of all antibodies used for ELISA are detailed in Table 2.4.4, page 114. 
Antibody pre-coated plates were incubated with 1% bovine serum albumin (BSA; Sigma-Aldrich, UK) 
in PBS (PBSA) for 1h at RT to prevent antibody non-specificity. The plates were washed three times 
with 0.5% Tween-20 (Sigma-Aldrich, UK) in PBS; to remove excess liquid, plates were dabbed on tissue 
paper several times. Cell supernatants and recombinant protein standards were added for 2h at RT 
and washed prior to the addition of the detection antibody in PBSA for 2h at RT. After the next wash, 
100ul of Extra-Avidin-Peroxidase (1:1000) was added for 20min at RT followed by three further 
washes. TMB substrate (BD Biosciences, UK) was added to permit the development of the peroxidase-
linked chromogen, 2N H2SO4 was used to stop the reaction. The optical density was read at 450nm 
with a background absorbance read at 540nm. Concentrations in the supernatants were calculated by 
reference to the standard curve.  
2.2.6. Immunoprecipitation 
Immunoprecipitation was performed on both cell line protein lysates and primary lysates isolated 
from mice.  Pre-clearing of the lysate was performed by adding 10µl of 50% Protein A agarose bead 
slurry (Cell Signalling, UK) to 200µl cell lysate at 1 mg/ml. The lysate was incubated with rotation at 
4°C for 30min and centrifuged for 15min at 4°C. Immunoprecipitation was performed by adding an 
anti-IL-33 antibody (Nessy-1) at a 1:100 dilution and incubated with rotation at 4°C overnight. Protein 
A agarose (10µl of 50% bead slurry) was added and incubated with rotation for 3hr at 4°C. The lysate 
was centrifuged for 30s at 4°C and washed five times with 500µl of cell lysate buffer to yield the 
immunoprecipitate.    
 
2.2.7. Proteomics 
2.2.7.1. Tandem mass-tagging of pull-down 
2.2.7.1.1. TMT labelling   
Samples were digested with trypsin (2.5µg trypsin; 37°C, overnight), labelled with Tandem Mass Tag 
(TMT) six plex reagents according to the manufacturer’s protocol (Thermo Fisher Scientific, UK) and 
the labelled samples pooled. The pooled sample was then evaporated to dryness, resuspended in 5% 
formic acid and then desalted using SepPak cartridges according to the manufacturer’s instructions 
(Waters, USA)).  Eluate from the SepPak cartridge was again evaporated to dryness and resuspended 
in 1% formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Tribrid Mass 
Spectrometer (Thermo Scientific, UK).    
 
2.2.7.1.2. Nano-LC mass spectrometry  
The pooled TMT-labelled sample was fractionated using an Ultimate 3000 nano-LC system in line with 
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific, UK).  In brief, peptides in 1% (vol/vol) 
formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific, UK). 
After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were resolved on a 
250mm × 75μm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific, UK) over a 
150 min organic gradient, using 6  gradient segments (5-9% solvent B over 2min, 9-25% B over 94min, 
25-60%B over 23min, 60-90%B over 5min, held at 90%B for 5min and then reduced to 1%B over 2min) 
with a flow rate of 300nl min−1.  Solvent A was 0.1% formic acid and Solvent B was aqueous 80% 
acetonitrile in 0.1% formic acid.  Peptides were ionized by nano-electrospray ionization at 2.0kV using 
a stainless-steel emitter with an internal diameter of 30μm (Thermo Scientific, UK) and a capillary 
temperature of 275°C.   
 
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 
2.0 software (Thermo Scientific, UK) and operated in data-dependent acquisition mode using an SPS-
MS3 workflow.  FTMS1 spectra were collected at a resolution of 120 000, with an automatic gain 
control (AGC) target of 400,000 and a max injection time of 100ms. Precursors were filtered with an 
intensity range from 5000 to 1E20, according to charge state (to include charge states 2-6) and with 
monoisotopic precursor selection. Previously interrogated precursors were excluded using a dynamic 
window (60s +/-10ppm). The MS2 precursors were isolated with a quadrupole mass filter set to a 
width of 1.2m/z. ITMS2 spectra were collected with an AGC target of 10,000, max injection time of 
70ms and CID collision energy of 35%.  
 
For FTMS3 analysis, the Orbitrap was operated at 30,000 resolution with an AGC target of 50,000 and 
a max injection time of 105ms.  Precursors were fragmented by high energy collision dissociation 
(HCD) at a normalised collision energy of 55% to ensure maximal TMT reporter ion yield.  Synchronous 
Precursor Selection (SPS) was enabled to include up to 5 MS2 fragment ions in the FTMS3 scan.  
 
2.2.7.1.3. Data analysis  
The raw data files were processed and quantified using Proteome Discoverer software v2.1 (Thermo 
Scientific, UK) and searched against the UniProt Human or murine databases (downloaded 13/09/18: 
152927 entries) using the SEQUEST algorithm.  Peptide precursor mass tolerance was set at 10ppm, 
and MS/MS tolerance was set at 0.6Da.  Search criteria included oxidation of methionine (+15.9949) 
as a variable modification and carbamidomethylation of cysteine (+57.0214) and the addition of the 
TMT mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. Searches were 
performed with full tryptic digestion and a maximum of 2 missed cleavage events was allowed.  The 
reverse database search option was enabled, and the data was filtered to satisfy a false discovery rate 
(FDR) of 5%.   
 
2.2.7.2. Whole proteome analysis 
2.2.7.2.1. TMT labelling and high pH reversed-phase chromatography 
Aliquots of 100µg of six samples per experiment were digested with trypsin (2.5µg trypsin per 100µg 
protein; 37°C, overnight), labelled with TMT six plex reagents according to the manufacturer’s 
protocol (Thermo Fisher Scientific, UK) and the labelled samples pooled. 
 
An aliquot of the pooled sample was evaporated to dryness, resuspended in 5% formic acid and then 
desalted using a SepPak cartridge according to the manufacturer’s instructions (Waters, USA).  Eluate 
from the SepPak cartridge was again evaporated to dryness and resuspended in buffer A (20 mM 
ammonium hydroxide, pH 10) prior to fractionation by high pH reversed-phase chromatography using 
an Ultimate 3000 liquid chromatography system (Thermo Fisher Scientific, UK).  In brief, the sample 
was loaded onto an XBridge BEH C18 Column (130Å, 3.5µm, 2.1mm X 150mm, Waters, UK) in buffer 
A and peptides eluted with an increasing gradient of buffer B (20mM Ammonium Hydroxide in 
acetonitrile, pH 10) from 0-95% over 60min.  The resulting fractions were evaporated to dryness and 
resuspended in 1% formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Tribrid 
mass spectrometer (Thermo Scientific, UK). Nano-LC MSMS protocol is previously detailed (see section 
2.2.7.1.2.). 
 
2.2.7.2.2. Data analysis 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 (Thermo 
Scientific, UK) and searched against the UniProt Human database (downloaded September 2018: 
152927 entries) or the Uniprot Mouse database (downloaded November 2018: 81925 entries) using 
the SEQUEST algorithm.  Peptide precursor mass tolerance was set at 10ppm, and MS/MS tolerance 
was set at 0.6Da.  Search criteria included oxidation of methionine (+15.9949) as a variable 
modification and carbamidomethylation of cysteine (+57.0214) and the addition of the TMT mass tag 
(+229.163) to peptide N-termini and lysine as fixed modifications. Searches were performed with full 
tryptic digestion and a maximum of 1 missed cleavage was allowed.  The reverse database search 
option was enabled, and all peptide data was filtered to satisfy FDR of 5%.     
 
2.2.8. Cell viability assays 
Cell proliferation was assessed using the colorimetric MTT assay (Sigma Aldrich, UK) as per the 
manufacturer’s instructions. Briefly, 10µL of the 12 mM MTT stock solution in 100µL of culture 
medium was added to cells and incubated at 37°C for 2h. After labelling the cells with MTT, all but 
25µL of medium was from the wells. 50µL of DMSO was added and incubated 37°C for 30min; the 
resulting solution was transferred into a 96well plate. Absorbances were read at 540nm and expressed 
as a percentage of an untreated control. Cellular cytotoxicity was quantified using an LDH detection 
kit (Sigma Aldrich, UK) as per the manufacturer’s instructions. Briefly, 50µL of cell culture supernatant 
was transferred to a 96well plate with 50µL of the reaction mixture and incubated 37°C for 30min. 
Absorbances were read at 450nm and expressed as relative to an untreated control. 
 
2.2.9 In vitro genetic modulation 
2.2.9.1. Small interfering RNA (siRNA) 
Knock-down of IL-33 from ARPE-19 cells was achieved using the fast-forward transfection technique. 
Cells were seeded at a concentration of 55,000 per well of a 24 well plate in 0.5ml of culture medium 
with 1% FBS and no antibiotics. Cells were incubated for 1h at 37°C prior to transfection. The FlexiTube 
GeneSolution (QIAGEN, UK), as a specific mixture of four preselected siRNA duplexes was used to 
target different sequences of the human IL33 gene. Each siRNA was diluted in 100µl of culture medium 
without serum and antibiotics (final concentration 20nM each siRNA). 6µl HiPerfect transfection 
reagent (QIAGEN, UK) was added to the siRNA, vortexed and left for 5min. 100µl of transfection 
complex was added to the cells and left for 48h at 37°C.  
 
2.2.9.2. Clustered regularly interspaced short palindromic repeats (CRISPR)-cas9 
For IL-33 overexpression in ARPE-19 cells, a CRISPR-cas9 activation plasmid was used to up-regulate 
the expression of the human IL33 gene. A commercially available IL-33 activation plasmid was 
purchased from Santa Cruz Biotechnology. Cells were seeded at a concentration of 40,000 per well of 
a 24 well plate in 0.5ml of culture medium with 10% FBS and no antibiotics. Cells were incubated 
overnight at 37°C prior to transfection. Media was replaced just before transfection. For each 
transfection, 0.16µg of Plasmid DNA was diluted into 25µl plasmid transfection medium. Separately, 
0.833µl of transfection reagent was diluted in 25µl plasmid transfection medium. Both solutions were 
left for 5min before combined, mixed and left for a further 30min. 50ul of transfection complex was 
added to the cells and left for 48h at 37°C.  
 
2.2.10. Enzyme-based metabolic assays 
2.2.10.1. Glucose consumption 
Glucose consumption was assessed using a glucose coulometric assay kit (Thermo Fischer, UK) as per 
the manufacturer’s instructions. Briefly, 15µL of cell culture supernatant was transferred to a 96well 
plate with 85µL of diluted assay buffer. 100µL of enzyme buffer was then added and incubated at 37°C 
for 10min. Absorbances were read at 520nm. Glucose consumption was calculated by subtracting the 
glucose concentration of samples from the glucose concentration of unconditioned media and 
expressed as relative to an untreated control. 
 
2.2.10.2. Lactate assay 
Extracellular lactate production was measured using a L-lactate fluorometric assay kit (Abcam, UK) as 
per the manufacturer’s instructions. In brief, 20µL of cell culture supernatant was transferred to a 
96well plate with 100µL diluted assay buffer, 20µL of cofactor mixture, 40µL of enzyme mixture and 
20µL of fluorometric substrate. The plate was incubated for 20min at RT and read using an excitation 
wavelength at 530nm and an emission wavelength of 590nm. Lactate production was calculated by 
subtracting the lactate concentration of samples from the lactate concentration of unconditioned 
media and expressed as relative to an untreated control. 
 
2.2.10.3. ATP and ADP assay 
ATP and ADP measurements were quantified using an ATP/ADP fluorometric assay kit (Abcam, UK). In 
brief, cell supernatants were removed and 500µL of nucleotide releasing buffer was added to cells. 
90µL of this buffer was transferred to a 96well plate and background ATP fluorescence was measured. 
10µL of ATP-monitoring enzyme was added and left for 2min at RT. ATP fluorescence levels were then 
measured. The fluorescence levels were subsequently measured again to give background ADP 
fluorescence. 10µL of ADP converting enzyme was then added and left for 2min at RT. ADP 
fluorescence levels were then measured. ATP and ADP levels were calculated and expressed as the 
ratio ATP/ADP. Data is expressed as relative to an untreated control. 
 
2.2.11. Extracellular flux (XF) analysis 
Cell metabolism was assessed using a Seahorse XFp Extracellular Flux Analyzer (Agilent, UK). ARPE-19 
and M1-MO were seeded at a density of 30,000 cells per well, 24h prior to analysis, with further 
treatments detailed in results. Cell tack was used to attach primary RPE and BMMC at a density of 
50,000 to the XFp. Real time measurements of oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) (see Fig. 2.2.) were normalized to total protein content using a BCA assay. 
Pre-optimised injections specific for each assay were used. Cell Mito Stress kit injections: oligomycin 
(1µM) and antimycin A/rotenone (1µM). Glycolysis stress injections: glucose (10mM), oligomycin 
(1µM) and 2DG (1µM). Glycolysis rate injections: antimycin A/rotenone (1µM) and 2DG (1µM). 
UK5099 (5µM) was used to inhibit the mitochondrial pyruvate transporter MCP1. Etomoxir (10µM) 
was used to inhibit CPT1. Potassium dichloroacetate (20mM) was used to inhibit PDK1. XF medium 
included 25mM glucose, 1mM pyruvate, 2mM glutamine and 10% FBS in minimal DMEM at pH 7.4. 
Metabolic parameters were calculated using the formulae detailed in Table 2.4.5; page 115.  
 
Different cell types vary in their metabolic profile and it was necessary to first characterise specific cell 
types with respect to basal and maximal OCR. In order to effectively assess the maximal respiratory 
function, the concentration of FCCP (required to uncouple the ETC) was determined empirically for 
both ARPE-19 and primary murine RPE. A XFp cartridge and cell culture plate were divided into two 
groups: a “low” concentration range (0.125, 0.25 and 0.5µM) and a “high” concentration range (0.5, 
1 and 2µM) of FCCP. Each group was treated with 1µM oligomycin followed by three serial injections 
of FCCP at the different concentrations. The data was transformed into a dose curve of OCR vs [FCCP]. 
0.5µM was chosen as the optimum dose for both cell types, as under these conditions it was the dose 
which elicited the maximal OCR response (Fig. 2.3A-B). 
 
 
Figure 2.2. Using extracellular flux: 
(A) Typical mitochondrial stress bioenergetic profile revealing numerous parameters such as maximal, basal and 
spare respiration rates. (B) Mitochondrial oxygen consumption. (C) Glycolytic stress profile showing basal 
glycolysis rate along with the capacity and reserve. (D) The glycolysis end-point metabolite lactate is released 








































































































Figure 2.3. Optimisation of FCCP concentration:  
A FCCP dose response was used to assess maximal mitochondrial respiration (OCR) on the XFp platform. (A) 
Maximal FCCP OCR data transformed into a dose response curve: OCR vs. [FCCP] for isolated primary murine 
RPE. (B) Maximal FCCP OCR data transformed into a dose response curve: OCR vs. [FCCP] for ARPE-19 cells. 
  
2.2.12. Metabolomics  
For stable isotope tracing (SITA) experiments, ARPE-19 cells were seeded at a concentration of 
1,000,000 per well of a 6-well plate in 3ml of normal culture medium with 10% FCS and antibiotics and 
left for 24h to reach sub-confluency before treatment. Cells were washed twice with PBS before 
pulsing with [U-13C]-glucose medium (Cambridge Isotopes, UK) for 2h. SITA media contained 10mM 
[U-13C]-glucose, 2mM glutamine and 10% dialysed FBS. Cells were washed twice with saline and 
overlaid with 0.8ml of ice-cold methanol. The cells were subjected to three rounds of sonication and 
freeze-dried using a speed-vacuum centrifuge. Gas chromatography coupled to mass spectrometry 
(GCMS) was performed on the samples using previously detailed methods [311]. In brief, dried 
samples were re-suspended in 30μL anhydrous pyridine and added to GC-MS autoinjector ports 
holding 70μL N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide derivatization reagent. The 
samples were first heated to 70°C for 1hr, 1μL aliquots were taken and injected for analysis. GC-MS 
data were collected on an Agilent 5975C series GC/MSD system (Agilent, Canada) functioning in 
election ionization mode (70 eV) with selective ion monitoring. Mass isotopomer distributions (MID) 
were derived using an algorithm developed at McGill University  [454]. Relative metabolite levels were 
normalised to protein content (µg) using a BCA assay. This was performed in the Core Metabolomics 
Facility (McGill University, Canada) with the technical and scientific assistance of Dr. Emma Vincent 
(University of Bristol, UK) and Mr. Luc Choinière (McGill University, Canada). 
 
2.2.13. Electron microscopy  
2.2.13.1. Ex vivo electron microscopy 
WT and Il33-/- mice eyes were enucleated with the anterior chamber removed and fixed in 2.5% 
glutaraldehyde in 0.1m phosphate buffer. Eyes were washed in buffer post fixation in Osmium 
tetroxide for 1 hour and enbloc stained with uranyl acetate prior to being dehydrated with ethanol 
and embedded in Epon-resin (TAAB, UK). After polymerisation the embedded eyes were trimmed to 
remove excess material revealing the retina and choroid layers these were sectioned transversely at 
0.5µm for light microscopy. Suitable areas were selected for transmission electron microscopy and 
these were sectioned (80nm thick) and sectioned stained with uranyl acetate and lead citrate prior to 
observation in a Tecnai 12 microscope. This was performed in the Electron Microscopy unit of the 
Wolfson Bioimaging Facility (University of Bristol, UK) and assisted by Dr. Chris Neal as technical 
support.   
 
2.2.13.2. In vitro electron microscopy 
Cells were grown on 24-well plates. Cells were washed in buffer and fixed in phosphate buffered 
glutaraldehyde and post fixed using osmium tetroxide in the same buffer. Cells were stained with 
uranyl acetate and then after ethanol dehydration were infiltrated with Epon resin mix (TAAB, UK) and 
polymerised at 60°C for 2 days. Sections were cut at 70-80nm thickness using an Ultracut S 
ultramicrotome and stained with Reynolds' lead citrate and uranyl acetate. Sections were viewed and 
images recorded on a Tecnai T12 microscope (FEI). 
 
2.2.14. Confocal microscopy  
To prepare RPE/choroid sections, enucleated eyes were initially fixed in 4% formaldehyde overnight, 
cryosectioned and mounted onto poly-lysine coated slides. Mito Green™ (Thermo Fischer, UK) staining 
was used on fixed cells to visualise mitochondria. Slides were incubated for 1h in 20nM Mito Green™ 
and washed twice in PBS before imaging with a Leica TCS-SP2-AOBS confocal laser scanning 
microscope on a 488 nm argon laser line. Image analysis: Mitochondria density in confocal images 
were assessed using the Volocity® Image Analysis Software 6.3 (Perkin Elmer, UK).  
 
2.2.15. Chromatin immunoprecipitation (ChIP) with parallel DNA sequencing  
2.2.15.1. Interleukin-33 ChIP  
ChIP assays were performed by Active Motif Epigenetic Services.  In brief, ARPE-19 cells were fixed 
with 1% formaldehyde for 15min and quenched with 0.125M glycine. Chromatin was isolated by 
adding chromatin lysis buffer, followed by disruption with a Dounce homogenizer. Lysates were 
sonicated to shear the DNA to an average length of 300–500 bp. Genomic DNA (Input) was purified 
from an aliquot of chromatin and quantified on a Nanodrop spectrophotometer. Extrapolation to the 
original chromatin volume permitted quantitation of the total chromatin yield.  
 
An aliquot of chromatin was precleared with protein G agarose beads. IL-33-bound genomic DNA 
regions were isolated using a Nessy-1 (mouse derived polyclonal anti-IL-33). After overnight 
incubation at 4°C, protein G agarose beads (Cell Signalling, UK) enabled isolation of IL-33-chromatin 
complexes. These were subsequently washed, eluted from the beads with SDS buffer, and subjected 
to RNase and proteinase K treatment. Crosslinks were removed by incubation overnight at 65°C, and 
immunoprecipitated DNA was purified by phenol-chloroform extraction and ethanol precipitation.  
 
RT-PCR were performed in triplicate on specific genomic regions using SYBR green reagents (Thermo 
Fischer, UK). Data were normalized for primer efficiency by carrying out RT-PCR on input DNA with 
each primer pair. 
 
2.2.15.2. DNA sequencing  
ChIP and input DNAs were prepared for amplification by converting overhangs into phosphorylated 
blunt ends and adding an adenine to the 3' ends. Illumina adaptors were added, and the library was 
size-selected (175-225 bp) with an agarose gel. The adaptor-ligated libraries were amplified for 18 
cycles. The resulting DNA libraries were purified, quantified by RT-PCR at the same specific genomic 
regions as the original ChIP DNA to assess amplification efficiency. Subsequently, DNA libraries were 
sequenced on the Illumina Genome Analyzer II (Illumina, UK). Reads were filtered to keep only those 
with > 70% of bases having Phred quality score of >20. These filtered reads were mapped to the human 
genome by GSNAP, allowing maximum of two mismatches. Mean fragment length was estimated 
using a correlation method applied in the ‘chipseq’ package from Bioconductor. Reads were then 
extended according to the estimated fragment length, and per base coverage was calculated through 
the extended reads. ChIP-seq enrichment regions for anti-IL-33 ChIP were identified using MACS 1.4. 
with a p-value threshold of 1x10-9 and enrichment threshold of 5. Mapping enrichment regions to 
different regions of the genome was performed with Genentech in-house software tools using 
R/Bioconductor.  
 
2.3. Quantification and Statistical Analysis 
2.3.1. ImageJ 
Mitochondrial morphology was manually assessed using ImageJ software (NIH, USA). A scale was set 
by normalising the pixel distance to the scale provided (in nm) on each image. Area measurements 
were calculated by freehand selection around every whole mitochondrion observed in each image 
(Fig. 2.4A). Three separate measurements were taken the mean value was used as the area. Diameter 
measurements were calculated by freehand lines at the largest part of every whole mitochondrion 
observed in each image (Fig. 2.4B). Mitochondrial numbers were manually counted in each image 
which corresponded to a 4.95µm2 (ex vivo) or 37µm2 (in vitro) area of the RPE; only whole 
mitochondria were counted (Fig. 2.4C). Mitochondria were manually characterized into either (Fig. 





Figure 2.4. Quantification of mitochondria using Image J:  
(A) Area measurements were calculated by freehand selection around every whole mitochondrion observed. (B) 
Diameter measurements were calculated by freehand lines at the largest part of every whole mitochondrion 
observed in each image. (C) Mitochondrial numbers were manually counted in each image. Mitochondria were 
manually classed into either (D) “fragmented”, (E) “short tubular” or (F) “long tubular“.  
2.3.2. Heatmap generation and hierarchal clustering 
Proteomics datasets were expressed as a heatmap using Morpheus matrix visualisation and analysis 
software (https://software.broadinstitute.org/morpheus/). In brief, the mean value from a complete 
dataset was subtracted from each value, the dataset was imported into the online software package 
and minimal/maximal points were adjusted based on the variance either side of zero. Hierarchal 
clustering was performed using an algorithm found on Morpheus matrix visualisation and analysis 
software. In brief, columns and rows were clustered using an average linkage method and a metric of 
one minus Pearson correlation.  
 
2.3.3.  STRING functional protein associations 
The IL-33 “interactome” was assessed using the STRING database of known and predicted protein 
interactions (https://string-db.org/). The interactions include direct (physical) and indirect (functional) 
associations. In brief, gene-names were extracted from a proteomics dataset and copied into the 
online software package. The data was then assigned to either human or murine origin and expressed 
as a network. The PPI enrichment value (an indication that the given dataset has more interactions 
among themselves than what would be expected for a random set of proteins of similar size, drawn 
from the genome) above P < 0.01 was considered significant. Functional enrichments were assessed 
within the network based on biological processes (GO terms). Enrichments were expressed as a ranked 
analysis on both gene counts and false discovery rate.  
 
2.3.4. Gene annotation enrichment analysis 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 
(https://david.ncifcrf.gov) was used for gene annotation enrichment analysis, functional annotation 
clustering and BioCarta/KEGG pathway mapping. This identified enriched biological themes, 
particularly GO terms within a dataset. A Benjamini-Hockberg corrected P <0.01 was used as a 
significance threshold to adjust for false discovery rates. 
 
2.3.5. Statistics 
Data are presented as mean ± SD for technical replicates or mean ± SEM for biological replicates. 
Statistical analysis was performed using GraphPad Prism version 7.04.  An unpaired two-tailed 
Student’s t test or a parametric ANOVA was used as specified for multiple comparisons between 
groups. P < 0.05 was considered significant.  
  
2.4. Tables 
2.4.1. Summary of agonists and recombinant proteins  
Reagent Company Catalog number 
LPS (0.5-1μg/ml ; Ultrapure from E-coli 0111:B4) Invivogen Cat tlrl-eblps 
Poly (I:C) HMW (1-25μg/ml)  Invivogen Cat tlrl-pic-5 
Poly (I:C) LMW (10μg/ml)  Invivogen Cat tlrl-picw 
PGN-EB (10μg/ml)  Invivogen Cat tlrl-pgneb 
GPN ODN 2006 (10μg/ml)  Invivogen Cat tlrl-2006 








Recombinant murine IL-3 (10ng/ml) Preprotech Cat 213-13 
Recombinant human IL-1β (50ng/ml) Invivogen Cat rcyec-hil1b 
Recombinant human IL-4 (10ng/ml) R&D systems  Cat 204-IL-010 
Recombinant human IL-6 (10ng/ml) R&D systems Cat 206-IL-010 
Recombinant human IL-10 (10ng/ml) Biolegend  Cat 571002 
Recombinant human IL-17A (100ng/ml) Preprotech  Cat 200-17 
Recombinant human IL-22 (100ng/ml) R&D systems Cat 782-IL-010 
Recombinant human TNFα (100ng/ml) R&D systems Cat 210-TA-005 
Recombinant human IFN-γ (100U/ml) Preprotech Cat 300-02 
Hydrogen peroxide (0.2-1mM) Sigma Aldrich Cat H1009 
AICAR (1mM) Tocris Cat 2840 
Compound C (40μM) Millipore Cat 171260 
 
  
2.4.2. Western blotting antibodies  
Antibody Cell Signaling Ca    
 
Company Catalog number 
Rabbit monclonal anti-beta actin (1:2000) Cell Signaling Ca    
 
Cell Signaling Cat #4970  
Rabbit monoclonal anti-beta tubulin (1:2000) Cell Signaling Cat #2146 
Rabbit monoclonal anti-AMPKa (1:1000) Cell Signaling Cat #5831 
Rabbit monoclonal anti-phospho AMPK (T172) 
(1:400) 
Cell Signaling Cat #2535 
Rabbit monoclonal anti-ACC (1:1000) Cell Signaling Cat #3676 
Rabbit monoclonal anti-phospho ACC (S79) (1:1000) Cell Signaling 
 
Cat #11818 
Rabbit monoclonal anti-mTOR (1:800) Cell Signaling Cat #2983 


















Rabbit monoclonal anti-raptor (1:1000) Cell Signaling Cat #2280 
Rabbit monoclonal anti-PI3 kinase p110a (1:500) Cell Signaling Cat #4255 
 
Rabbit monoclonal anti-MPC2 (1:800) Cell Signaling Cat #46141 
Rabbit monoclonal anti-MPC1 (1:1000) Cell Signaling Cat #14462 
Rabbit monoclonal anti-catalase (1:1000) Cell Signaling Cat #12980 
Mouse monoclonal anti-SOD1 (1:1000) Cell Signaling Cat #4266 
Rabbit monoclonal anti-SOD2 (1:1000) Cell Signaling Cat #4266 
Rabbit monoclonal anti-BCL2 (1:1000) Abcam Cat ab692 
Rabbit monoclonal anti-survivin (1:1000) Abcam Cat ab76424 
Goat polyclonal anti-IL-33 (1:1000) R&D Systems Cat AF3625 
Mouse polyclonal Nessy-1 (anti IL-33) (1:1000) ENZO Life Science ALX-804-840-C100 
Rabbit polyclonal anti-ST2 (1:1000) Abcam Cat ab25877 
Rabbit Anti-Pyruvate Dehydrogenase E1-alpha 











Mouse monoclonal anti-RPE65 (1:1000) Santa Cruz Cat sc-390787 
Mouse monoclonal anti-rhodopsin (1:1000) Santa Cruz Cat sc-57432 





Rabbit monoclonal anti-PKM2 (1:1000) Cell signaling  Cat D78A4 
Rabbit monoclonal anti-PKM1 (1:1000) Cell signaling Cat 7067S 
Rabbit monoclonal anti-GLUT1 (1:2000) Abcam Cat ab115730 
Total OXPHOS Human WB Antibody Cocktail (1:300) Abcam Cat ab110411 
Rabbit polyclonal anti-SRSF3 (1:1000) Abcam Cat ab125124 
Rabbit polyclonal anti-hnRNPA2B1 (1:1000) Abcam  Cat ab31645 
Rabbit polyclonal anti-hnRNPA1 (1:1000) Abcam  Cat ab137780 
Anti-rabbit IgG, HRP-linked Antibody (1:1500) Cell Signaling Cat #7074 
Anti-mouse IgG, HRP-linked Antibody (1:1500) Cell Signaling Cat #7076 
Donkey anti-goat IgG-HRP (1:2500) Santa Cruz Cat sc-2020 
 
2.4.3. Primer sequences  
Primers for RT-PCR Sequence (5'-) 
βACTIN forward AGAGCTACGAGCTGCCTGAC 
βACTIN reverse  AGCACTGTGTTGGCGTACAG 
GLUT1 forward  TCACTGTGCTCCTGGTTTTCTG 
GLUT1 reverse CCTGTGCCTCCTGAGAGATCC 
HK2 forward TGATCGCCTGCTTATTCACGG 
HK2 reverse  AACCGCCTAGAAATCTCCAGA 
LDHA forward TGGAGTGGAATGAATGTTGC 
LDHA reverse ATAGCCCAGGATGTGTAGCC 
PFKP forward  ACCACAGTCCGGGCATGTAA 
PFKP reverse TGTCTCCAGCCCTAAGTCCA 
GAPDH forward ACCACAGTCCATGCCATCAC 
GAPDH reverse TCCACCACCCTGTTGCTGTA 
PKM1 forward ACCGCAAGCTGTTTGAAGAA 
PKM1 reverse TCCATGAGGTCTGTGGAGTG 
PKM2 forward GAGGCCTCCTTCAAGTGCT 
PKM2 reverse CCGACTTGGTGAGAGACGAT 
ENO1 forward GAATAAGAAGGCCTGGAGC 
ENO1 reverse TAGACACCACTGGGTAGTCC 
SHDH forward ATGGCGGTTCTCTGGAGGCTG 
SHDH reverse GAGCTTCCACAGCATGGCAAC 
IL33 forward CACCCCTCAAATGAATCAGG 
IL33 reverse GGAGCTCCACAGAGTGTTCC 
PC forward CCTTTGGGAATGGGGCGCTGTTTGT 
PC reverse ACAGAGTCGCTGGTGAGCCGAGTC 
MPC1 forward  TGACCTTTGCTTTGTGTTGC 
MPC1 reverse CACCTTGGATCAATTGTGCT 
MPC2 forward  CGATATGGCTAGACCAGCAG 
MPC2 reverse ACAGCGAACAAAGACCAATTT 
PDK1 forward CGGATCAGAACCGACACA 
PDK1 reverse ACTGAACCATTCTGGCTGGTGA 
CS forward GATTGTGCCCAATGTCCTCT 
CS reverse TTCATCTCCGTCATGCCATA 
IDH1 forward GGCGAGCAGCACAGAGAC 
IDH1 reverse TCACCCCAGATACCATCAGA 
FH1 forward CTACCCAAGCTCCCTCAGC 
FH1 reverse CAGGCAGGAGGGCTGAAG 
HIF1α forward TATGAGCCAGAAGAACTTTTAGGC 
HIF1α reverse CACCTCTTTTGGCAAGCATCCTG 
PGC1α forward GTCACCACCCAAATCCTTAT 
PGC1α reverse ATCTACTGCTGGAGACCTT 
MYC forward AGCGACTCTGAGGAGGAACAAGAA 
MYC reverse CGTAGTTGTGCTGATGTGTGGAGA 
SIRT1 forward TCGCAAAGGAACATAGACA 
SIRT1 reverse CTGTTGCAAAGGAACCATGACA 
SIRT4 forward CAGCAAGTCCTCCTCTGGAC 
SIRT4 reverse CCAGCCTACGAAGTTCTCG 
CYTB forward CCCCACAAACCCCATTACTAAACCCA 
CYTB reverse  TTTCATCATGCGGAGATGTTGGATGG 
16 S rRNA forward GAGTGAAATTGACCTGCCCGTGAA 
16 S rRNA reverse  TCTTAGCATGTACTGCTCGGAGGT 
BGLOB forward CTTGGGTTTCTGATAGGCAC 
BGLOB reverse CTTAGGGTTGCCCATAACAG 
MFN1 forward ATGGCAGAACCTGTTTCTCCACT 
MFN1 reverse GGAAGCAATTGGTTGGTTATATGGCCA 
MFN2 forward AATCTGAGGCGACTGGTGA 
MFN2 reverse CTCCTCCTGTTCGACAGTCA 
OPA1 forward GAAAGGGTCTGCTTGGTGAG 
OPA1 reverse CGCTTCTGTTGGGCATAG 
PINK1 forward TACCGTGCACCAGGAGAAG 
PINK1 reverse GCTTGGGACCTCTCTTGGAT 
DRP1 forward TGAAGGATGTCATGTCGGACC 
DRP1 reverse GTTGAGGACGTTGACTTGGCT 
Il33 forward CCTCCCCTGAGTACATCAATGACC 
Il33 reverse GTAGTAGCACCTGGTCTTGCTCTT 
βActin forward GCCCACTACTAAATCATTCGCA 
βActin reverse TAGACACTTGCTTACTGGCCAC 
 
  
2.4.4. ELISA antibodies 
Antibody Company Catalog number 
Human IL-1β capture (1/60) R&D Systems DY201 
Human IL-1β detection (1/60) R&D Systems DY201 
Human IL-6 capture (1/40) R&D Systems DY206-05 
Human IL-6 detection (1/60) R&D Systems DY206-05 
Human IL-33 capture (1/60) R&D Systems DY3625B 
Human IL-33 detection (1/60) R&D Systems DY3625B 
Human ST2 capture (1/60) R&D Systems DY523B-05 
Human ST2 detection (1/60) R&D Systems DY523B-05 




 2.4.5. Seahorse parameters  
Metabolic parameter Equation  Definition 
OCR/ECAR 
(First OCR measurement)/(first 
ECAR measurement) 
The ratio of mitochondrial 
OXPHOS to glycolytic lactate 
production. 
Proton leak 
(Difference between OCR after 
oligomycin and non-
mitochondrial respiration) 
Basal respiration not coupled 
to ATP-production. Can 
indicate mitochondrial damage 
or a mechanism to regulate 
ATP-production. 
Non-mitochondrial respiration 
(OCR measurement after 
antimycin-A/ rotenone) 
Continued oxygen 
consumption as a result of a 
subset of cellular enzyme 
which consume oxygen after 
rotenone or antimycin A. 
Basal respiration 
(Difference between OCR before 
oligomycin and non-
mitochondrial respiration) 
Oxygen consumption under 
baseline conditions which 
results from both ATP-
production and proton leak. 
ATP production 
(Difference between basal 
respiration and proton leak) 
The decrease in OCR after ATP-
synthase inhibitor oligomycin 
injection, signifies the amount 
of basal respiration utilized to 
drive ATP synthesis. 
Maximal respiration 
(Difference between maximum 
OCR post FCCP injection and non-
mitochondrial respiration) 
The maximal OCR reached 
through the injection of 
uncoupler FCCP mimics a 
physiological energy demand. 
This stimulates the ETC to 
operate at full capacity, leading 
to the rapid oxidation of TCA 
cycle substrates (amino acids, 
glucose and fatty acids). 
Spare respiratory capacity 
((Maximal respiration) / (basal 
respiration) x 100) 
This measurement indicates 
both the ability of a cell to 
respond to a metabolic 
demand and how closely a cell 
is respiring to its theoretical 
maximum. An ability of a cell to 
respond to demand can 
indicate cell fitness and 
flexibility between metabolic 
pathways. 
Glycolysis 
(Difference between maximum 
ECAR rate before oligomycin and 
non-glycolytic acidification) 
This measurement indicates 
the ability of cells to 
metabolise glucose to lactate 
under basal conditions. 
Glycolytic capacity 
(Difference between maximum 
ECAR rate after oligomycin and 
non-glycolytic acidification) 
Oligomycin inhibits the ATP-
synthase complex which shifts 
the energy production to 
glycolysis. The subsequent 
increase in ECAR indicates the 
theoretical maximal glycolytic 
capacity of a cell. 
Glycolytic reserve 
(Difference between glycolytic 
capacity and glycolysis) 
This measurement indicates 
both the ability of a cell to 
respond to metabolic stress 
and how closely a cell is 
undergoing glycolytic 
metabolism compared to its 
theoretical glycolytic 
maximum. This can indicate 
flexibility between metabolic 
pathways. 
Non-glycolytic acidification 
(Last ECAR measurement before 
glucose injection) 
ECAR in glucose-starved cells, 
prior to glucose injection. This 
is a result of other acidifying 
processes within a cell other 
than glycolysis.  
Basal glycolysis (glycoPER) 
(Last glycoPER measurement 
before rotenone/antimycin-A) 
Proton efflux rate derived from 
glycolysis, discounting CO2-





Glycolytic rate in cells 
following the inhibition of 
oxidative phosphorylation and 
driving compensatory 
glycolytic adaptations to meet 
metabolic demand. 
MitoOCR/glycoPER 
([(Last OCR before 
rotenone/antimycin-A)-
(minimum OCR after 
rotenone/antmycin-A)] / basal 
glycolysis) 
A more refined ratio of 
mitochondrial OXPHOS to 
glycolytic lactate production, 
compared to OCR/ECAR. 
Percentage PER from glycolysis 
Glycolysis ((basal glycolysis/basal 
PER) x 100) 
Percentage of ECAR which 
equates to lactate 
acidification. 
CPT1-dependent respiration  
(Difference between OCR before 
and after etomoxir) 
The contribution of fatty acid 
oxidation through CPT-1 to 
maximal OCR. 
MPC-dependent respiration 
(Difference between OCR before 
and after UK5099) 
The contribution of pyruvate 


















Chapter 3. AMP-activated kinase links metabolism 
and innate immunity in the retinal pigment 
epithelium 
  
3.1. Introduction  
The retina is referred to as an “immune privileged” tissue. The blood retinal barrier is a key structure 
in maintaining immune privilege; it describes a series of adaptations by the vascular endothelium and 
the RPE [455], whereby tight junction and adherens complexes are aptly formed in both cells. The BRB 
excludes circulating molecular toxins and microorganisms along with patrolling pro-inflammatory 
leukocytes [456]. With the absence of efferent lymphatics to the eye, immune homeostasis is 
maintained through hemopoietic immune cells such as microglia and resident macrophages/mast 
cells, as well as innate immune-competent tissue resident cells [457]. 
 
The RPE functions as a non-haematopoietic immune cell which responds to PAMPs and DAMPs 
through PRRs (e.g. TLR/NLR) [457]. Immune-mediated activation has been observed to have profound 
effect on aerobic glycolysis, the  “Warburg effect”, and leads to metabolic reprogramming in cells of 
both the innate and adaptive immune system (see section 1.9.) [5]. Metabolic alterations in RPE 
including the “Warburg effect” may contribute to inflammatory processes [286]. With progressing age, 
increased ROS production, the accumulation of mtDNA mutations and a decline in the function of CPT 
all contribute to a decline in bioenergetic function [86, 388, 389]. There is now increasing evidence 
that diminished mitochondrial health in RPE is suggested to play a prominent role in the pathogenesis 
of AMD [390, 391]. Indeed, a decline in bioenergetic health and the induction of the Warburg effect 
in RPE may impair its metabolic stability and ability to support the retina. This chapter investigates the 
role of the RPE as an innate immune competent cell and how its response to “immune stress” in the 
form of TLR activation (via synthetic ligands) impacts its metabolism. It is currently unknown to what 
extent the RPE can rapidly switch between metabolic pathways during quiescence and activation, and 
how this may be regulated (e.g. are there conserved mechanisms which occur in other activated innate 
immune cells). 
 
The aims of this chapter are (1) to address the metabolic changes that occur with age; (2) define how 
immunological “stress” can define bioenergetic status in the RPE; (3) investigate the role of the 
metabolic regulator AMPK during innate immune activation.  
 
3.2. Long-term in vitro cultivation of ARPE-19 induces changes in glycolytic metabolism and 
mitochondrial respiration 
RPE cells require a massive metabolic output to provide functional support to the retina [6]. 
Whilst the mechanisms of AMD have yet to be elucidated, there is increasing evidence that 
mitochondrial deterioration, antioxidant defense, and mitophagy are likely drivers of 
pathogenesis. To understand how bioenergetic dysfunction may contribute to AMD, analysis 
of bioenergetic flux was used to examine metabolic status in RPE. Long-term in vitro 
cultivation of ARPE-19 lead to differences in their metabolic profile particularly the increase 
in basal oxidative phosphorylation (Fig. 3.1A and B) and decline in glycolytic function (Fig. 3.1C 
and D). I noted the decline in spare respiratory capacity (Fig. 3.1B) and increased proton leak 
(Fig. 3.1B), which may reflect a strain on mitochondrial function. Supporting the decline in 
glycolytic function, a reduction in GLUT1 and GAPDH mRNA transcripts were observed (Fig. 
3.1F).  
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Figure 3.1. Long-term in vitro cultivation of ARPE-19 induces changes in glycolytic metabolism and 
mitochondrial respiration: 
(A) Representative mitochondrial stress test measured with sequential injections of oligomycin, FCCP and 
rotenone/antimycin A. (B) mitochondrial parameters (BR- basal respiration; MR- maximal respiration; SRC- spare 
respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from data shown in (A). (C) Representative 
glycolysis stress test measured with sequential injections of glucose, oligomycin and 2DG. (D) Glycolytic 
parameters (G- glycolysis; GC- glycolytic capacity; GR- glycolytic reserve; NGA- non-glycolytic acidification) 
calculated from data shown in (C). (E) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR. (F) 
Gene expression analysis of GLUT1, LDHA, GAPDH and SDHD mRNA transcripts, normalised to β-ACTIN as an 
internal control. Data are presented as means ± SD from three independent experiments performed in 
triplicates. Unpaired Student’s T-test; *p<0.05, **p<0.01, ***p<0.005, ****p<0.001.  
  
3.3. Isolation and bioenergetic analysis of primary murine RPE 
Extended cultivation of a cell line cannot replicate the complexities of an in vivo environment, 
including a lifetime of oxidative insults to the retina. For this reason, I isolated and cultured primary 
RPE from C57BL/6 mice. The isolated RPE purity was assessed by immunoblotting for RPE specific 
protein RPE65 and rhodopsin contamination from the neurosensory retina as previously described 
[453] (See materials and methods - Fig. 2.1.). After establishing a specific ex vivo RPE population, young 
(<10 weeks) and older (>18 months) primary RPE were isolated and subjected to bioenergetic analysis. 
The mitochondrial stress assay gave a characteristic profile in both groups (Fig. 3.2A), but there were 
significant changes in both maximal respiration (Fig. 3.2B) and glycolytic capacity (Fig. 3.2D).  
Parameters such as coupling efficiency and proton leak were found to be significantly altered in aged 
mice compared to their younger counterparts, in a fashion such that older RPE can be described as 
relatively impaired (Fig. 3.2C). Because of reduced ECAR observed in the aged population (Fig. 3.2E), 
there was a significant change in the basal OCR/ECAR (Fig. 3.2F).  
 
Compared to the data obtained from long term in vitro cultivation of the ARPE-19 cell line, similar 
results were observed in terms of the reduced glycolytic function. In contrast to the “aged” ARPE-19 
cell line, older primary RPE were not observed to display an increased basal OCR. Both groups 
exhibited reduced mitochondrial function. 
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Figure 3.2. Isolation and bioenergetics analysis of primary murine RPE: 
(A) Representative mitochondrial stress test measured with sequential injections of oligomycin, FCCP and 
rotenone/antimycin A. (B) Mitochondrial parameters (BR- basal respiration; MR- maximal respiration; SRC- spare 
respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from data shown in (B). (C) ECAR data 
from (A). (D) Glycolytic capacity calculated from ECAR values of data shown in (C). (E) Basal ECAR measurements. 
(F) OCR and ECAR measurements expressed as the ratio OCR/ECAR. Data presented as means ± SD from three 
independent experiments performed in triplicate. Unpaired Student’s T-test; *p<0.05, **p<0.01, ***p<0.005, 
****p<0.001.  
  
3.4. Metabolic adaptations in ARPE-19 to TLR stimulation  
Having established that ageing, both in vitro (with cell lines) or directly ex vivo, led to significant 
bioenergetic changes which were chronic and persistent, I then investigated whether RPE cells 
underwent bioenergetic modulation over short timescales, as might be expected in the event of 
inflammatory stimuli. To test this, I used PRR activation by PAMP/DAMP ligands. 
 
TLRs are vital components for innate immunity; the RPE has a robust expression of TLRs 1-7,9 and 10 
which that facilitate host defence against microbes [45]. In TLR-activated macrophages and DC, a 
switch to aerobic glycolysis has previously been reported [403, 416]. The impact of PAMP stimulus on 
RPE bioenergetics was investigated to identify if a similar metabolic shift occurs in the RPE. I chose to 
utilise agonists for TLR-3 due to a possible association with AMD [458] and TLR-4 because of its 
extensive study in the field of immunometabolism [416].  
 
There was first a necessity to identify the effect of TLR agonists on ARPE-19 cell viability. Both LPS and 
Poly (I:C) treatment (based around doses found commonly in the literature [45, 427]) had no 
significant effect on LDH release after 24h (Fig. 3.3A-B). Using the doses of 1μg/ml for LPS and 10μg/ml 
for Poly (I:C), it was investigated to what extent RPE metabolism may be modulated over a time course 
of treatment. Cells were stimulated with agonists and OCR/ECAR measurements were taken at 30min, 
1h, 2h, 6h, 12h, 24h and 48h. It was observed that Poly (I:C) treatment significantly increased the 
OCR/ECAR ratio between 12-24h, with the greatest significance observed at 24h of treatment (Fig. 
3.3C). LPS treatment significantly decreased the OCR/ECAR ratio between 30min-6h of treatment. 
Having established the differential effects of each TLR agonist on RPE metabolism, I decided to test 
whether these occurred in a dose-response manner, at time points where each agonist exerted the 
most significant effect (24h for Poly (I:C) and 30min for LPS). Cells were treated with three doses of 
Poly (I:C) (5, 10 and 25 μg/ml) for 24h, it was found that the intermediate dose of Poly (I:C) (10μg/ml) 
elicited the greatest response in the OCR/ECAR ratio (Fig. 3.3E). Cells were treated for 30min with two 
doses of LPS (0.5 and 1 μg/ml) with a dose response observed (Fig. 3.3F). 
 
The results of this section indicate the tolerability of the ARPE-19 cell line to both agonists in terms of 
LDH release. Both agonists exhibit differential effects on ARPE-19 metabolism accompanied by 
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Figure 3.3. Metabolic adaptations in ARPE-19 following TLR-stimulation: 
(A) ARPE-19 cells were treated for 24h with varying doses of Poly (I:C) (5, 10 and 25µg/ml). Supernatants were 
taken and LDH levels were assessed using a commercial kit. LDH release was expressed as a (%) of an untreated 
control. (B) ARPE-19 cells were treated for 24h with varying doses of LPS (0.5 and 1µg/ml). Supernatants were 
taken and LDH levels were assessed using a commercial kit. LDH release was expressed as a (%) of an untreated 
control. (C) ARPE-19 cells were treated with Poly (I:C) (10µg/ml), basal OCR and ECAR measurements were taken 
at the indicated time points (0, 30min, 1h, 2h, 6h, 12h, 24h and 48h). (D) ARPE-19 cells were treated with LPS 
(1µg/ml), basal OCR and ECAR measurements were taken at the indicated time points (0, 30min, 1h, 2h, 6h, 12h, 
24h and 48h). (E) ARPE-19 cells were treated with varying doses of Poly (I:C) (5, 10 and 25µg/ml), OCR and ECAR 
measurements were taken at 24h. (F) ARPE-19 cells were treated with varying doses of LPS (0.5 and 1µg/ml), 
OCR and ECAR measurements were taken at 30min. Data presented as means ± SD from (C-F) two and (A-B) 
three independent experiments performed in duplicate.   
3.5. Toll-like receptor-3 and -4 agonists differentially modulate glycolysis and mitochondrial 
respiration in ARPE-19 
The results from the previous section indicated that TLR-3 and TLR-4 agonists (Poly (I:C) and LPS, 
respectively) induced differential effects on RPE metabolism in terms of the “OXPHOS to glycolysis 
ratio”. These results suggest varying kinetics of the response between the two agonists. Poly (I:C) 
stimulation has no immediate effect on metabolism until 12h onwards, where increased OXPHOS is 
observed and sustained until 48h. LPS stimulation on the other hand, elicits an immediate drop in the 
ratio of OXPHOS to glycolysis which returns to baseline after 12h. Considering these findings and 
having optimised doses and time points of interest for each agonist, it was necessary to further 
interrogate the metabolic responses that occur in the RPE.  
 
Results from Figs 3.3C-D in the previous section showed that by 30min of LPS stimulation there was 
contemporaneous drop in OCR and increase in ECAR which was maintained until 6h. Poly (I:C) had 
little effect on ECAR or OCR in these time points, but it was plausible that a metabolic change could 
have occurred before 30min and not sustained. A similar experiment was conducted over a shorter 
timeframe to identify the kinetics of the metabolic response over minutes to hours. Real-time 
measurements indicated a rapid increase in ECAR accompanied by a drop in OCR in LPS-stimulated 
ARPE-19. The metabolic “switch” was observed by the first measurement (+3min post-injection). LPS 
promoted a 1.5-fold relative increase in the ECAR levels relative to resting controls, this was sustained 
until the end of the assay at (+2h post-injection). OCR measurements returned to the basal levels 
towards the end of the assay with values only significantly reduced within the first 90min (Fig. 3.4A-
B). Poly (I:C) stimulation of cells was found to have no significant effect on either OCR or ECAR during 
the timeframe of this experiment (Fig. 3.4A-B). 
 
Consequently, bioenergetic analysis was performed following stimulation of cells with either Poly (I:C) 
or LPS for 30min or 24h, respectively. Using a glycolysis stress test, the data showed that LPS 
stimulation increased glycolysis, but reduced glycolytic reserve, whereas Poly (I:C) stimulation 
increased both glycolytic capacity and reserve (Fig. 3.4C-D). Increased glycolytic capacity (and 
therefore glycolytic reserve) post-oligomycin is indicative of increased glycolytic flux for oxidative 
pyruvate catabolism (see materials and methods). A mitochondrial stress test identified reduced 
mitochondrial activity following LPS stimulation, in terms basal and maximal respiration (Fig. 3.4E-F). 
Poly (I:C) increased basal respiration yet had no significant effect on maximal respiration (Fig. 3.4E-F).  
 
As Poly (I:C) is reported to display differential TLR-3 activation efficacy depending on which synthetic 
mimic is used [459], a Low molecular weight (LMW) Poly (I:C) was used to confirm the effects observed 
with the high molecular weight agonist. The use of two different synthetic agonists support the 
hypothesis that the effects observed are indeed specific to TLR-3 activation (see appendices section 
10.3).  
 
Collectively, this data shows that RPE cells undergo metabolic changes during a short timescale in 
response to inflammatory stimuli. These results suggest that activation of different TLRs in the RPE 
lead to distinct bioenergetic adaptations. In the context of TLR-4 activation, there is a rapid switch to 
“aerobic glycolysis” within minutes. Aerobic glycolysis (Warburg effect) is observed frequently in many 
cancer cells and activated immune cells and refers to the generation of ATP from glycolytic lactate 
production as opposed to mitochondrial metabolism (see section 1.9.1). LPS-stimulated ARPE-19 cells 
exhibit increased glycolysis at the expense of impaired mitochondrial function, suggesting the 
initiation of the Warburg effect in these cells. Poly (I:C)-stimulation increases mitochondrial function 
and oxidative glycolysis in ARPE-19 cells, yet this occurs much later after treatment.  
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Figure 3.4. Toll-like receptor-3 and -4 agonists differentially modulate glycolysis and mitochondrial respiration 
in ARPE-19: 
(A) Real-time changes in ECAR following injection of LPS (1µg/ml) or Poly (I:C) (10µg/ml). (B) Real-time changes 
in OCR following injection of LPS (1µg/ml) or Poly (I:C) (10µg/ml). (C) Representative glycolysis stress test 
measured with sequential injections of glucose, oligomycin and 2DG, following stimulation with LPS (30mins; 
1µg/ml) or Poly (I:C) (24h; 10µg/ml). (D) Glycolysis parameters (G- glycolysis; GC- glycolytic capacity; GR- 
glycolytic reserve; NGA- non-glycolytic acidification) calculated from data shown in (C). (E) Representative 
mitochondrial stress test measured with sequential injections of Oligomycin, FCCP and rotenone/antimycin A, 
following stimulation with LPS (30mins; 1µg/ml) or Poly (I:C) (24h; 10µg/ml). (F) Mitochondrial parameters (BR- 
basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-
production) calculated from data shown in (E). Data presented as means ± SD, from two to three independent 
experiments performed in duplicate. (D and F) One-way ANOVA with Dunnet’s multiple comparisons test, (G-H) 
Unpaired Student’s T-test; *p<0.05, **p<0.01, ***p<0.005. 
  
3.6. Glycolysis rate assay analysis of TLR-stimulated ARPE-19 
A glycolysis rate assay was used to quantify the contribution of TCA cycle acidification to total ECAR. 
By subtracting the mitochondrial acidification from the total proton efflux rate (PER), a glycolytic PER 
(glycoPER) can be calculated to provide a more accurate quantification of lactate production by cells 
(see materials and methods). Following treatment of ARPE-19 with TLR agonists, it was observed that 
LPS stimulation lead to an increased glycoPER at basal levels, whilst both agonists increased glycoPER 
at compensatory levels (Fig. 3.5A-B). The mitoOCR/glycoPER ratio gives an indication of TCA activity 
within a cell, here it was identified that Poly (I:C)-stimulated ARPE-19 cells increased TCA activity (Fig. 
3.5C). Furthermore, using both PER and glycoPER values, a percentage contribution of glycolysis and 
TCA acidification can be quantified. It was shown that LPS stimulated ARPE-19 had a greater 
percentage of PER from lactate production compared to a control, whereas Poly (I:C) treatment 
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Figure 3.5. Glycolysis rate assay analysis of TLR-stimulated ARPE-19: 
(A) Representative glycolysis rate assay measured with sequential injections of rotenone/antimycin A and 2DG, 
following stimulation with LPS (30min; 1µg/ml) or Poly (I:C) (24h; 10µg/ml). (B) Glycolysis rate parameters (BG- 
basal glycolysis; CG- compensatory glycolysis) calculated from (A). (C) Basal OCR and glycoPER measurements 
expressed as the ratio mitoOCR/glycoPER, following stimulation with LPS (30min; 1µg/ml) or Poly (I:C) (24h; 
10µg/ml). Percentage contribution of glycolytic PER and non-glycolytic PER to total PER, following stimulation 
with LPS (30mins; 1µg/ml) or Poly (I:C) (24h; 10µg/ml). Data are expressed as means ± SD from two independent 
experiments performed in duplicate. One-way ANOVA with Dunnet’s multiple comparisons test; *p<0.05, 
*p<0.01. 
  
3.7. Effect of TLR agonists on primary murine RPE bioenergetics 
To examine if the results obtained in ARPE-19 cells were truly indicative of the metabolic response of 
RPE to LPS and Poly (I:C), bioenergetic analysis was performed on primary cultured RPE. Basal OCR 
and ECAR measurements were taken pre and post injection of LPS and Poly (I:C) (Fig. 3.6A-B). It was 
observed that LPS treatment lead to a similar metabolic response to ARPE-19 cells, with a rapid 
increase of ECAR post-injection (Fig. 3.6A). This peaked at around 20min post injection of LPS and 
continued to fall until the end of the assay. LPS had no significant effect on the OCR post injection (Fig. 
3.6B). Poly (I:C) stimulation had no significant effect on either OCR or ECAR measurements in the 
timeframe assessed (Fig. 3.6A-B). A mitochondrial stress test was used to further assess RPE OXPHOS 
parameters under stimulation of TLRs. Primary RPE cells were stimulated for 30min and 24h for LPS 
and Poly (I:C), respectively, based on time course data obtained using ARPE-19 in the previous chapter. 
It was observed that Poly (I:C) treatment had no significant effect on any parameters of mitochondrial 
respiration (Fig. 3.6C-D). LPS stimulation on the other hand, lead to a significant decrease in maximal 
respiration (post-injection of FCCP) and decreased spare respiratory capacity (Fig. 3.6C-D). The 
corresponding ECAR data of the mitochondrial stress test identified an increased glycolytic capacity of 
the RPE cells when stimulated with Poly (I:C) (Fig. 3.6E-F). LPS stimulation had no significant effect on 
glycolytic capacity (Fig. 3.6E-F). Primary RPE stimulated with Poly (I:C) for 24h had no significant 
changes in either OCR or ECAR measurements (Fig. 3.6C). RPE stimulated for 30min with LPS had a 
significantly reduced OCR/ECAR ratio. 
 
Collectively, the data in this section indicates that primary murine RPE display a similar metabolic 
response to the human ARPE-19 cell line. LPS stimulation lead to increased glycolytic metabolism at 
the expense of mitochondrial capacity, suggesting a similar switch to aerobic glycolysis in these cells. 
LPS increased glycolysis for a shorter time period in primary murine RPE than ARPE-19 which may 
reflect fundamental differences in either metabolism or LPS sensitivity between the cells. Like ARPE-
19 cells, Poly (I:C) stimulation of primary RPE was not accompanied by a switch to aerobic glycolysis. 
In contrast, no significant changes were observed to mitochondrial metabolism in Poly (I:C)-stimulated 
RPE compared to ARPE-19. There was however increased glycolytic capacity observed in both cell 
types. LMW Poly (I:C) stimulation of primary RPE was not assessed.  
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Figure 3.6. Effect of TLR agonists on primary murine RPE bioenergetics: 
(A) Real-time changes in ECAR following injection of LPS (1µg/ml) or Poly (I:C) (10µg/ml). (B) Real-time changes 
in OCR following injection of LPS (1µg/ml) or Poly (I:C) (10µg/ml). (C) Representative mitochondrial stress test 
measured with sequential injections of Oligomycin, FCCP and rotenone/antimycin A, following stimulation with 
Poly (I:C) (24h; 10µg/ml) or LPS (30min; 1 µg/ml). (D) Mitochondrial parameters (BR- basal respiration; MR- 
maximal respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from data 
shown in (C). (E) ECAR data from (C). (F) Glycolytic capacity calculated from (E). Basal OCR and ECAR 
measurements expressed as the ratio OCR/ECAR, (G) following 24h Poly (I:C) treatment (10µg/ml) or (H) 30mins 
LPS (1µg/ml). Data are expressed as means ± SD. (A-F) represents data from two independent experiments 
performed in duplicate. (G-H) represents data from two independent experiments performed in triplicate. 
Unpaired Student’s T-test; ***p<0.001. 
  
3.8. Poly (I:C) stimulation of ARPE-19 under hypoxia increases glycolysis 
The photoreceptors are the most energy demanding cell within the retina, requiring full metabolic 
support from the RPE which receives 100% of the oxygen and nutrients from the choriocapillaris [382]. 
Glucose from the choroid fuels the whole retina, but must first cross the RPE for utilisation in 
photoreceptors [4]. Hypoxia is defined as a loss of oxygen supply from tissues. Initiation of hypoxia-
induced metabolic stress in RPE is enough for the atrophy of photoreceptors, as glucose is utilised as 
an RPE fuel source rather than transported to the photoreceptors [382]. Inflammation and hypoxia 
exhibit a mutual dependence, with hypoxia-prompted inflammation, or inflammation during hypoxic 
conditions implicated in a range of human inflammatory diseases [460]. Contributors to tissue hypoxia 
during inflammation comprise of an increase in the metabolic demands of cells and increased cellular 
presence which therefore leads to a reduction in metabolic substrate abundance [461]. Additionally, 
replication of bacterium and multiplication of intracellular host pathogens can withdraw oxygen from 
infected cells [461]. Considering this, it is plausible that the initiation of inflammation in the retina 
would likely lead to a hypoxic retinal environment, with the RPE forced to utilize glycolytic 
consumption of glucose as opposed to mitochondrial OXPHOS. It therefore was of interest to see if 
the metabolic response to TLR-3 activation in the absence of oxygen would require increased aerobic 
lactate production instead of “coupling” glucose catabolism to the TCA cycle (as suggested from 
results in the previous sections).  
 
ARPE-19 cells were cultured under hypoxic conditions for 24h. Hypoxia conditions in these 
experiments were 1% O2, 94% N2, and 5% CO2 (as detailed in materials and methods). In order to first 
confirm hypoxia-induced metabolic stress, AMPK activation state was assessed in cell lysates. AMPK 
is an evolutionarily conserved energy sensor which responds to energetic stress through changes in 
AMP concentration (see section 1.8.5.3). During oxygen scarcity, restrictions in mitochondrial 
respiration lead to a decrease in the ATP/AMP ratio, which subsequently induce AMPK activation 
[462]. Western botting confirmed AMPK activation from control and treatment under hypoxia (Fig. 
3.7A). In response to AMPK activation, cells up-regulate ATP generating pathways such β-oxidation, 
glycolysis and glucose uptake [344]. Hypoxia treatment significantly increased glycolytic metabolism 
in ARPE-19 cells (Fig. 3.7B-C). Both glycolysis and glycolytic capacity were significantly increased in 
response to hypoxia (Fig. 3.7B-C). Glycolytic reserve was significantly reduced (Fig. 3.7B-C), indicating 
cells had reduced oxidative glucose catabolism in the TCA.  
 
ARPE-19 cells were stimulated with Poly (I:C) under hypoxia for 24h. It was found that AMPK (and its 
downstream activation target ACC) continued to retain their phosphorylation under stimulation of 
TLR-3 (Fig. 3.7A). The increased ECAR and lactate output following treatment indicates Poly (I:C)-
stimulated cells metabolize pyruvate through LDHA in absence of oxygen (Fig. 3.7D-E). Interestingly, 
hypoxia treatment alone was unable to up-regulate basal ECAR or lactate output in ARPE-19 (Fig. 3.7D-
E). 
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Figure 3.7. Poly (I:C) stimulation of ARPE-19 under hypoxia increases glycolysis: 
(A) ARPE-19 were treated with Poly (I:C) (10µg/ml) for 24h under 1% O2; western blot analysis was used to 
determine the phosphorylation of AMPK and ACC following treatment. (B) Representative glycolysis stress test 
measured with sequential injections of glucose, oligomycin and 2DG following treatment of ARPE-19 for 24h 
under 1% O2. (C)   Glycolysis parameters (G- glycolysis; GC- glycolytic capacity; GR- glycolytic reserve; NGA- non-
glycolytic acidification) calculated from data shown in (B). ARPE-19 were treated with Poly (I:C) (10µg/ml) for 
24h under 1% O2. (D) Basal ECAR measurements. (E) Extracellular lactate measurements were taken in the media 
and expressed as a percentage of the control. Data are expressed as means ± SD from two independent 
experiments performed in duplicates. (B) One-way ANOVA with Dunnet’s multiple comparisons test, (C) One-




3.9. Metabolic response of Müller glia and mast cells to TLR stimulation 
To determine if the TLR-induced metabolic changes in RPE were cell specific, BMMCs and MIO-M1 
Müller glial cells were used as comparators. Mast cells are key effector innate immune cells well 
known for their roles in allergic inflammation, but additionally play a key role in innate immune 
defence against pathogens; mast cells have a robust expression of functional TLRs observed [463]. 
Müller glia cells are the principle glial cell within the retina and contribute to innate immune defence 
via an expression of TLRs 2-6 [464]. These cells were used to compare the immediate metabolic 
responses of TLR activation in the RPE. The use of both an innate immune cell and a tissue-resident 
innate immune competent cell (like the RPE) provided excellent systems for studying the responses. 
 
In a similar fashion to the RPE, MIO-M1 Müller glial cells displayed increased ECAR post-injection of 
LPS, but not Poly (I:C) (Fig. 3.8A). No significant changes to the OCR was observed with either agonist 
(Fig. 3.8B). BMMC increased ECAR with the injection of LPS and Poly (I:C) (Fig. 3.8C), OCR was also 
found to be increased with LPS, but not Poly (I:C) (Fig. 3.8D). 
 
These results indicate the varied metabolic responses of cells to innate immune stimulation. Like the 
RPE, Müller glial cells display a similar immediate response to TLR-4 activation. TLR-3 activation was 
not accompanied by any metabolic changes. Longer-term Poly (I:C) treatment was observed to 
increase OXPHOS in the RPE, yet I did not investigate this response in Müller glia. Mast cells displayed 
an immediate metabolic response contrasting both the RPE and Müller glia. This may reflect core 
differences in the requirement of innate immune cells (such as mast cells) to respond rapidly to 
pathogens. 
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Figure 3.8. Metabolic response of Müller glia and BMMC to TLR stimulation:  
Real-time ECAR (A) and OCR (B) measurements following injection of LPS (1µg/ml) or Poly (I:C) (10µg/ml) to MIO-
M1. Real-time ECAR (C) and OCR (D) measurements following injection of LPS (1µg/ml) or Poly (I:C) (10µg/ml) to 
BMMC. Data are expressed as means ± SD from two independent experiments performed in duplicates.  
  
3.10. Glycolysis is essential for TLR-mediated cytokine production 
The data presented to this point has indicated that glycolytic metabolism is enhanced following 
stimulation of RPE cells with TLR-agonists. As suggested in previous studies, enhancing glycolysis 
rapidly provides ATP for cytokine production and cell effector functions. It was therefore of interest 
to determine whether glycolysis was necessary for inflammatory responses in the RPE and if 
impairment or forcing RPE cells to utilize other carbon sources would impair their cytokine production.  
 
ARPE-19 cells were cultured in either (A) media without glucose, (B) without glucose but 
supplemented with lactate (a suppressor of glycolysis [465]) or (C) control media containing the 
hexokinase inhibitor 2DG. Cells were stimulated with either Poly (I:C) or LPS and innate immune 
responses were quantified through the output of inflammatory cytokines IL-1β and IL-6. As expected, 
treatment with Poly (I:C) and LPS elicited a robust expression of IL-1β and IL-6 (Fig. 9). Blocking 
glycolysis via any of the three described strategies significantly impaired the production of IL-1β and 
IL-6 (Fig. 9). 
 
Taken together, this data indicates the requirement of glycolysis for efficient innate immune 
responses. Blocking the pathway with 2DG and depriving cells of glucose significantly reduces 
inflammatory responses. In addition to this, replacement of glucose with lactate (a metabolite readily 
converted to pyruvate) was unable to fully restore cytokine levels to that of stimulated cells in glucose-
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Figure 3.9. Glycolysis is essential for TLR-mediated cytokine production 
ARPE-19 cells were treated for 24h with Poly (I:C) (10µg/ml) in either control media (25mM glucose), glucose-
free media, glucose-free media with 25mM lactate or control media with 2DG (2.5mM). Cell culture 
supernatants were assessed for IL-6 release (A) and cell lysates were assessed for IL-1β (C). ARPE-19 cells were 
treated for 24h with LPS (1µg/ml) in either control media (25mM glucose), glucose-free media, glucose-free 
media with 25mM lactate or control media with 2DG (2.5mM). Cell culture supernatants were assessed for IL-6 
release (B) and cell lysates were assessed for IL-1β (D). One-way ANOVA with Tukey’s multiple comparisons test, 





3.11. TLR stimulation alters glucose consumption, transcriptional programs and the ATP/ADP ratio 
Having established that TLR-stimulation enhances glycolysis (and is required for cytokine production), 
it was essential to confirm these results using a variety of additional in vitro assays and assessing the 
effects on the ARPE-19 transcriptome.  
 
Glucose consumption was measured in the media of ARPE-19 and was observed to increase following 
TLR-stimulation (Fig. 3.10A). Considering the rapid switch to aerobic glycolysis with LPS treatment 
(observed using extracellular flux in the previous sections), it was logical to investigate the expression 
status of HIF-1α. HIF-1α is a master regulator of oxygen homeostasis, switching glucose metabolism 
from OXPHOS to glycolysis under low oxygen tensions. Normally HIF-1α is activated in response to 
hypoxia but can be induced by TLR stimulation in innate immune cells to reprogram their metabolism 
[466]. In response to LPS treatment, but not Poly (I:C), HIF-1α expression was observed to increase 
(Fig. 3.10B-C). Hypoxia treatment alone was used as a positive control (Fig. 3.10B-C). QPCR analysis 
identified increased glycolytic enzyme and GLUT1 expression in TLR-stimulated ARPE-19, however 
only Poly (I:C) increased the expression of TCA enzymes (Fig. 3.10D). Additionally, transcripts of 
metabolic regulators HIF1α, PGC1a and MYC were assessed. It was observed that Poly (I:C) treatment 
on the gene expression of any of these targets (Fig. 3.10D). LPS treatment significantly reduced the 
expression of PGC1α transcripts and increased the expression of MYC (Fig. 3.10D). This appears to fit 
with the hypothesis that LPS treatment increases glycolysis at the expense of OXPHOS, with PGC-1α 
promoting oxidative metabolism and mitochondrial biogenesis in cells [36], and MYC promoting the 
Warburg effect in cancer cells [467]. To confirm changes in transcription preceded translation of these 
key enzymes, western blotting was used to confirm the expression of three key targets, GLUT1, 
pyruvate carboxylase and PKM2. Comparable results were found, with Poly (I:C) treatment increasing 
GLUT1 and pyruvate carboxylase expression (Fig. 3.10E). LPS increased PKM2 at the protein level, 
supporting transcriptional changes (Fig. 3.10E). LPS additionally increased GLUT1 expression, 
suggesting that an increase of GLUT1 mRNA may have been observed prior to the 24h time point 
assessed. Previously published results in macrophages showed that LPS treatment lead to a decreased 
ATP/ADP ratio, as there is a switch away from mitochondrial ATP production to glycolytic ATP 
production [468]. Consistent with these results, LPS treatment decreased the ATP/ADP ratio in ARPE-
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Figure 3.10. TLR-stimulation alters glucose consumption, transcriptional programs and the ATP/ADP ratio: 
ARPE-19 cells were treated for 24h with Poly (I:C) (10µg/ml) or LPS (1µg/ml). (A) Supernatants were assessed for 
relative glucose consumption. (B) HIF-1α protein expression was assessed using western blotting. (C) Relative 
densitometry of (B). (D) Quantitative RT-PCR of glycolytic pathway enzymes (HK, LDHA, PFKp, GAPDH, PKM1, 
PKM2 and ENO1), GLUT1, PDK1, MPC1, MPC2 TCA cycle enzymes (PC, IDH, FH, SDHD and CS), PGC1α, HIF1α, 
MYC, SIRT1 and SIRT4 mRNA transcripts. (E) PKM2, pyruvate carboxylase and GLUT1 expression were assessed 
using western blotting. (F) Densitometry analysis of (E). (G) ATP and ADP levels were quantified following cell 
lysis and expressed as the ratio ATP/ADP. Data are expressed as means ± SD from (B-C) two and (A and D-G) 
three independent experiments performed in duplicate. One-way ANOVA with Dunnet’s multiple comparisons 
test; *p<0.05, **p<0.01, ***p<0.005, ***p<0.001. 
 
  
3.12. The immediate glycolytic switch following LPS stimulation is dependent on PDK1-mediated 
PDH inactivation 
I next investigated the mechanisms involved in mediating the pronounced metabolic response to LPS 
stimulation in RPE cells. The PDH complex is responsible for the oxidative metabolism of pyruvate to 
acetyl-CoA for entry into the TCA cycle; PDH is inactivated via PDH-kinase-1 (PKD1) which 
phosphorylates of a highly conserved serine residue (Ser293) on the E1 subunit [469]. It was 
hypothesised that LPS treatment may lead to the phosphorylation (and therefore inactivation) of PDH, 
thus preventing mitochondrial pyruvate oxidation. As expected, LPS treatment increased the 
phosphorylation of PDH (Fig. 3.11A-B). To investigate whether PDK1 was required for the glycolytic 
response, in RPE cells, the inhibitor potassium dichloroacetate was used to inhibit PDK1 activity prior 
to TLR-4 activation. Potassium dichloroacetate incubation inhibited the increase in ECAR following LPS 
stimulation in RPE cells (Fig. 3.11C-D). Interestingly, potassium dichloroacetate treatment lead to a 
compensatory increase in OCR following LPS treatment (Fig. 3.11E-F), suggesting that mitochondrial 
pyruvate oxidation occurs in the absence of PDH inhibition. Collectively, these results support the 
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Figure 3.11. The immediate glycolytic switch following LPS stimulation is dependent on PDK1-mediated PDH 
inactivation: 
(A) ARPE-19 cells were treated for 2h with LPS (1µg/ml). Western blot analysis was used to determine the 
phosphorylation of pyruvate dehydrogenase. Black line indicates that samples were run on the same gel but 
were discontinuous. (B) Reprehensive densitometry from (A). (C) Real-time changes in ECAR following injection 
of DCA (PDKi; 20mM) and following injection of LPS (1µg/ml) to ARPE-19 cells. (D) Fold-ECAR change calculated 
from (C). (E) Real-time changes in OCR following injection of DCA (PDKi; 20mM) and following injection of LPS 
(1µg/ml) to ARPE-19 cells. (F) Fold-OCR change calculated from (E). Data are expressed as means ± SD from three 
independent experiments performed in duplicate. (A-C) One-way ANOVA with Dunnet’s multiple comparisons 




3.13. Mass spectroscopy-based metabolomics in TLR stimulated ARPE-19 
To further confirm the differential bioenergetic adaptations to the RPE to TLR stimulation, I used a GC-
MS approach to quantify total intracellular metabolites. This was carried out in collaboration with Dr. 
Emma Vincent (University of Bristol, UK) and the Metabolomics Core Facility (McGill University, 
Canada) to generate Fig 3.13.  
 
SITA with [U-13C]-glucose was used to assess the uptake of isotopically labelled glucose into metabolite 
pools following treatment with both TLR agonists. This approach allowed the quantification of C13 
labelling into metabolite pools as cells approach steady-state equilibrium (schematic in Fig. 3.12.) 
 
Cells were treated for with both Poly (I:C) and LPS for 24h and 2h respectively (as these were pre-
optimised time points, at which significant effects on RPE metabolism were observed on the XF 
platform), followed by 2h of culture in [U-13C]-glucose. Relative concentrations of C13-labelled 
glyceraldehyde-3-phosphate, 3-phosphoglycerate, pyruvate and lactate were increased following LPS 
and Poly (I:C) treatment, suggesting increased glycolytic flux (Fig. 3.13A-D). LPS and Poly (I:C) 
treatment significantly increased the incorporation of glucose-derived carbon into TCA metabolites, 
including citrate (Fig. 3.13E), glutamate (Fig. 3.13G), succinate (Fig. 3.13H), fumarate (Fig. 3.13I), 
malate (Fig. 3.13J), oxaloacetate (Fig. 3.13K), and aspartate (Fig. 3.13L). No significant C13 enrichment 
was observed in α-ketoglutarate, regardless of treatment (Fig. 3.13F).  
 
Collectively, these data indicate that TLR-stimulated cells increase the flux of glucose through the 
glycolytic pathway, indicated by increased C13 labelling in glycolytic intermediates. Furthermore, the 
relative abundance of unlabelled C12 intermediates of fumarate, succinate, aspartate and glutamate 
substantially increased with Poly (I:C) treatment, suggesting other fuels may contribute to these 





Figure 3.12. Schematic of glucose metabolism in the first turn of the TCA cycle  
Glucose is taken up by cells and converted to pyruvate via a series of reactions termed glycolysis. Pyruvate is a 
key intersection in the network of metabolic pathways and has many fates including: transamination to form 
the amino acid alanine, cytosolic oxidation into lactate and mitochondrial oxidation into acetyl-coA via a loss of 
one carbon molecule as CO2. The mitochondrial citric acid cycle utilizes the oxidation of pyruvate in the form of 
"bond energy” in the formation of NADH and FADH2 which is used to make ATP in the ETC. Acetyl-coA combines 
with a four-carbon acceptor molecule oxaloacetate to form the six-carbon citrate. Citrate is converted to its 
isomer isocitrate and is then oxidized to yield CO2 and a five-carbon metabolite α-ketoglutarate. α-ketoglutarate 
is then oxidized, releasing CO2 and yielding the four-carbon succinate. In the fifth step, succinate is oxidized to 
form fumarate (a step yielding reduced FAD). Fumarate is then converted into malate via the nucleophilic 
addition of H2O. In the final step of the citric acid cycle, oxaloacetate (the primary starting molecule) is 
regenerated via the oxidation of malate and reduction of NAD. An aminotransferase reaction takes place to 
convert oxaloacetate into aspartate for use in the malate-aspartate shuttle.  
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Figure 3.13. Glucose tracing in TLR-stimulated ARPE-19: 
Cells were treated with Poly (I:C) (10µg/ml; 24h) or LPS (1µg/ml; 2h). Cells were incubated for 2h with media 
containing isotopically labelled glucose and GC-MS was used to quantify relative C13 (black) or C12 (white) 
incorporation into glyceraldehyde-3-phosphate (A), 3-phosphoglycerate (B), pyruvate (C), lactate (D), citrate (E), 
α-ketoglutarate (F), glutamate (G), succinate (H), fumarate (I), malate (J), oxaloacetate (K) and aspartate (L) 
metabolite pools.  Represents data from three independent experiments. 
  
3.14. Mitochondrial changes in TLR stimulated ARPE-19 
Results from the previous sections indicate that TLR stimulation of RPE cells initiate metabolic 
reprogramming. LPS stimulation initiates aerobic glycolysis, whereas Poly (I:C) stimulation increases 
mitochondrial OXPHOS. Considering these observations, I further interrogated the changes to 
mitochondria which occur under innate immune activation. Mitochondria are hubs of metabolic 
activity, antiviral responses and cell death cascades which continually remodel their structure via 
nuclear GTPases to facilitate cell processes [470]. Dynamic changes in mitochondrial remodelling are 
acutely responsive to changes in cell metabolism [471] yet the impact of morphological changes on 
metabolic pathway utilisation have not been studied in great depth [472]. Generally, a deletion of any 
of the fission/fusion machinery impacts OXPHOS and glycolysis under basal conditions [473]. To 
investigate whether metabolic changes following TLR stimulation were accompanied with alterations 
to the RPE mitochondrial structure, samples were studied by transmission electron microscopy. This 
was carried out in collaboration with Dr. Chris Neal (University of Bristol, UK) who provided data 
shown in Figures 3.14A-E.  
 
ARPE-19 cells were treated for the indicated time points with LPS or Poly (I:C), followed by fixation 
and imaging. It was observed that stimulation with Poly (I:C) increased mitochondrial size relative to 
an unstimulated control (Figs 3.14A and D). Similarly, LPS treatment increased RPE mitochondrial size 
(Fig. 3.14C-D). After treatment with both agonists, it was evident there were changes in the 
mitochondrial morphologies. Unstimulated cells showed mostly fragmented mitochondria (~77.5%) 
and short tubular mitochondria (~20%), long tubular mitochondria were observed at a low frequency 
(~2.5%) (Fig. 3.14E). When cells were stimulated with either Poly (I:C) or LPS there was shift in the 
morphologies, with decreased fragmented mitochondria, and an increase in long and short tubular 
mitochondria observed (Fig. 3.14E). The increased mitochondrial size and elongation suggested that 
mitochondrial fission and fusion processes were affected by TLR stimulation. Mitochondrial fission 
generates individual fragmented mitochondria which facilitate mitophagy [474], autophagy [475] and 
boost cell proliferative capacity [476]. “Fissed” mitochondria typically favour increased ROS 
production [477]. Mitochondrial fission is typically mediated by dynamin-related protein 1 (DRP1) 
which upon activation, scissions mitochondria at the outer membrane [472]. Mitochondrial fusion, 
and elongation into tubular networks, increases interactions between mitochondria and the 
endoplasmic reticulum to provide intercommunication during Ca2+ signalling [478]. Mitochondria 
elongation is initiated in response to nutrient stress to increase ATP synthase dimerization and 
activation under starvation [479]. Generally, oxidative metabolism stimulates elongation of 
mitochondria to facilitate the assembly of quaternary respiratory chain super-complexes which 
maximize ETC activity [471, 472, 480]. Modulation of cristae remodelling dramatically  affects RCS 
activity and respiratory-dependent growth [481]. Outer mitochondrial membrane (OMM) fusion is 
mediated by mitofusin-1 and -2 (MFN1/2), whereas inner mitochondrial membrane fusion is mediated 
by OPA1. PTEN-induced kinase 1 (PINK-1) has a key role in the regulation of mitophagy, whereby 
damaged and dysfunctional mitochondria are removed [482]. The transcription of nuclear-encoded 
mitochondrial fission/fusion enzymes was assessed by RT-PCR in LPS and Poly (I:C)-stimulated cells. 
Poly (I:C) treatment led to an increased expression of pro-fusion MFN1, MFN2, OPA1 mRNA transcripts 
(Fig. 3.14F). A decrease in the transcription of pro-fission DRP1 was also observed (Fig. 3.14F). LPS 
treatment increased the expression of MFN1 and MFN2, yet there was no change to OPA1 or DRP1 
expression (Fig. 3.14F). In addition, PINK1 gene expression was increased with LPS treatment, yet 
remained unaffected by Poly (I:C) (Fig. 3.14F). Collectively, these data indicate that the changes in 
mitochondrial morphology are contemporaneous to transcriptional changes in fission and fusion 
genes, suggesting that TLR stimulation affects mitochondrial remodelling through canonical pathways. 
 
The cellular content of mitochondria  can influence oxidative capacity in the RPE [397]. The electron 
microscopy analysis showed, structural alterations that affected the mitochondria. This was followed 
up by an assessment of total mitochondrial number was affected. RT-PCR was used to estimate 
mitochondrial content through the amplification of two segments of the mitochondrial genome (the 
gene encoding cytochrome B and 16 S rRNA). These two sites were chosen due to both their stability 
and location in different regions of the genome [397]. Expression of both genes was normalized to the 
expression of the nuclear encoded β-globulin gene. No significant changes to mtDNA copy number 
was observed following treatment of cells with both TLR agonists (Fig. 3.14G). Whilst there were no 
changes observed to the mtDNA, it was of interest to identify whether the changes in metabolism 
were associated with alterations in the abundance of mitochondrial ETC complexes. To answer this 
question, I quantified the expression of mitochondrial ETC components using immunoblotting. 
Treatment with either agonist had little effect on the expression of ETC complexes, apart from 
complex III which was found to be significantly upregulated by Poly (I:C) treatment (Fig. 3.15A-B). Very-
long chain specific acyl-coA dehydrogenase (ACAVDL) sits in the inner mitochondrial membrane and 
catalyses the first set in the β-oxidation of long chain fatty acids [483]. There was no significant change 
to the expression of this mitochondrial enzyme following stimulation of ARPE-19 with Poly (I:C) or LPS 
(Fig. 3.15A-B). 
 
The results from this section show that the metabolic changes observed in TLR-stimulated ARPE-19 
cells are accompanied by changes in mitochondrial morphologies. These are likely a result of 
transcriptional changes in fission/fusion genes which mediate mitochondrial remodelling. The changes 
to mitochondrial structure are not attributed to an increase in mitochondrial number or mitochondrial 
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Figure 3.14. Mitochondrial changes of TLR-stimulated ARPE-19: 
Representative transmission electron microscopy of ARPE-19 mitochondria either untreated (A), stimulated with 
Poly (I:C) (10µg/ml) (B) or LPS (1µg/ml) for 24h (C). Magnification 9300x. (D) Mitochondrial area was calculated 
using ImageJ. (E) Quantification of mitochondrial morphology into either fragmented, short tubular or long 
tubular phenotypes. (F) Quantitative RT-PCR was performed to assess the mitochondrial fission and fusion 
enzymes MFN1, MFN2, OPA1, PINK1 and DRP1 mRNA transcripts. (G) Quantitative RT-PCR was performed to 
assess mitochondrial content; this was estimated from the amplification of CTYB and 16S rRNA relative to BGLOB 
mRNA transcripts. Data expressed as relative mean from three independent experiments.  One-way ANOVA with 
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Figure 3.15. Expression of ETC components in TLR-stimulated ARPE-19: 
ARPE-19 were stimulated with either Poly (I:C) (10µg/ml) (B) or LPS (1µg/ml) for 24h. (A) Western blot analysis 
was used to determine the expression of ETC complexes (ATP synthase V, Cox2 IV, UQCRC2 III, SHDB II and 
NDUFB8 I) and ACAVDL. (B) Relative densitometry was calculated from (H) using ImageJ. Bands were normalised 
to a loading control (Beta Actin). Represents two independent blots.  
3.15. Effect of TLR-agonists on AMP-activated kinase activation status in ARPE-19. 
Having demonstrated that different TLR stimulation initiates divergent metabolic reprogramming and 
morphological adaptations in RPE mitochondria, there remained a question of how this may be 
mechanistically regulated in the RPE. The data presented heretofore demonstrates that LPS 
stimulation of RPE drives a rapid switch to aerobic glycolysis. Poly (I:C) stimulation on the other hand 
increases oxidative glucose metabolism and TCA activity. Considering observations made in dendritic 
cells whereby LPS-stimulation was accompanied by a rapid in-activation of the AMP-activated kinase 
AMPK to facilitate a shift to aerobic glycolysis [403], it was hypothesised that different TLR-induced 
metabolic responses may be governed by the AMPK activation status in the RPE.  
 
AMPK is a key regulator of cellular metabolism, that plays a central role in maintaining  energy 
homeostasis by switching on catabolic pathways that generate ATP, whilst simultaneously inhibiting 
anabolic, ATP consuming pathways such as protein/sterol/fatty acid synthesis, which contribute to 
cell-cycle progression (see section 1.8.5.3.) [344]. AMPK is a well described negative regulator of the 
Warburg effect, with a loss of AMPK-dependent signalling in cancer cells enough to stabilize normoxic 
HIF-1α, promoting aerobic glycolysis and biomass accumulation via lipid synthesis [311]. The overall 
effects activation of AMPK are compatible with the view of AMPK as a tumour suppressor promoting 
oxidative metabolism characteristic of quiescent anti-inflammatory cells [345]. Indeed, anti-
inflammatory cytokines promote AMPK activation and the generation of M2 macrophages [484]. 
 
In view of previous experiments performed using seahorse analysis - whereby LPS stimulation initiated 
rapid metabolic changes within minutes – it was of interest to observe how TLR-4 activation affected 
AMPK activation status over a short-term period. ARPE-19 cells were stimulated with LPS for either 0, 
20, 40 or 60min and western blotting was used to determine the activation of AMPK via its immediate 
downstream target (and surrogate for activation) Acetyl Co-A carboxylase (ACC). Alike previously 
published work [403, 484], AMPK activation was observed to diminish rapidly after exposure to LPS 
(Fig. 3.16A-B). Having observed that the inactivation of AMPK (and subsequent activation of ACC) 
occurs within the early time points of LPS stimulation, 30min was chosen as a time point to measure 
the phosphorylation of AMPK on Thr172 in its activation loop. Stimulation with LPS for 30 min reduced 
the phosphorylation (and activation) of AMPK and ACC (Fig. 3.16C-E). 
 
The rapid suppression of AMPK during RPE activation (via TLR-4) led to the hypothesis that AMPK may 
function to antagonise the switch to aerobic glycolysis, and therefore is rapidly inactivated upon LPS 
stimulation. As Poly (I:C)-stimulation RPE was not accompanied by a similar metabolic switch, it was 
of interest to investigate AMPK activation status following the activation of TLR-3. ARPE-19 cells were 
cultured in the presence or absence of Poly (I:C) for 24h. It was observed that treatment of cells 
increased the phosphorylation of AMPK Thr172 and its downstream target ACC on Ser79 (Fig. 3.16F-
H) suggesting increased activity of AMPK and subsequent inactivation of ACC.  
 
To examine whether the metabolic phenotypes associated with AMPK activation or inactivation were 
observed with LPS or Poly (I:C) treatment, I subsequently investigated the fatty acid oxidation and 
synthesis pathways. As previously discussed, AMPK activation opposes anabolic pathways such as 
fatty acid synthesis whilst promoting catabolic fatty acid oxidation. Confirming the varying effects on 
AMP activation status, I observed that LPS and Poly (I:C) treatment of RPE cells differentially affected 
these two pathways. With Poly (I:C) treatment, there was a significant increase in fatty acid oxidation 
(as quantified through a mitochondrial stress test, including the third injection of CPT1 inhibitor 
etomoxir) (Fig. 3.17A-B). LPS on the other hand, significantly reduced fatty acid oxidation (Fig. 3.17A-
B). Fatty acid synthesis was assessed by quantification of malonyl CoA, a core metabolite in this 
pathway. Malonyl coA is formed in the reaction catalysed by ACC and is transferred to the terminal 
thiol group of acyl carrier protein [292]. Moreover, malonyl CoA inhibits the rate limiting step of β-
oxidation through an association with CPT1. Treatment with LPS increased malonyl coA (as previously 
described in macrophages [485]), whereas Poly (I:C) treated cells exhibited reduced malonyl coA (Fig. 
3.17C). 
 
Collectively, the data from this section indicate a potential mechanism whereby the two TLR agonists 
exert differential effects on RPE metabolism. Suppression of AMPK and subsequent activation of ACC 
is enough to permit the Warburg effect and fatty acid synthesis in LPS-stimulated cells. In the context 
of Poly (I:C) treatment, the sustained activation of AMPK opposes this metabolic shift, allowing cells 
to continue utilising mitochondrial OXPHOS as opposed to metabolic reprogramming into an 






















































































































































































































Figure 3.16. Effect of TLR agonists on AMP-activated kinase activation status in ARPE-19: 
(A) Cells were treated with 1µg/ml LPS for 0, 20, 40 and 60min. Western blot analysis was used to determine 
AMPK activation via its downstream surrogate ACC. (B) Densitometry analysis of P-ACC/ACC over the indicated 
time points of LPS treatment. (C) Cells were treated with LPS (1µg/ml) for 30min. Western blot analysis was used 
to determine the activation of P-AMPK/AMPK and P-ACC/ACC following treatment. (D) Densitometry analysis of 
P-AMPK/AMPK. (E) Densitometry analysis of P-ACC/ACC. (F) Cells were treated with Poly (I:C) (10µg/ml) for 24h. 
Western blot analysis was used to determine the phosphorylation of AMPK and ACC following treatment. (G) 
Densitometry analysis of P-AMPK/AMPK. (H) Densitometry analysis of P-ACC/ACC. Data are expressed as means 
± SD from (A-B) two or (C-H) three independent blots. Unpaired Student’s T-test; *p<0.05, ***p<0.001. 
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Figure 3.17. Effect of TLR-agonists on fatty acid metabolism: 
(A) ARPE-19 were treated for 24h with Poly (I:C) (10µg/ml) or 30min with LPS (1µg/ml); a mitochondrial stress 
test with a third injection of etomoxir (10µg/ml) was used to assess fatty acid oxidation. (B) Analysis of data 
shown in (A). (C) ARPE-19 were treated for 24h with either Poly (I:C) (10µg/ml) or LPS (1µg/ml); relative malonyl 
coA levels were assessed in cell lysates.  Data expressed as relative mean from three independent experiments.  
One-way ANOVA with Dunnet’s multiple comparisons test; *p<0.05, **p<0.01, ***p<0.005, ***p<0.001.   
3.16. Effect of TLR agonists on mammalian target of rapamycin signalling in ARPE-19. 
Due to the opposing effects of Poly (I:C) and LPS on AMPK activation, the downstream mTOR signalling 
pathway was examined. mTOR is modulated by a variety of cellular signals, including insulin, cytokines, 
TLRs and amino acids (see section 1.8.5.3.) [434]. Considering the modulation of AMPK activation 
status via differential TLR stimuli, it was of interest to investigate the downstream mTORC1 and PI3K 
signalling pathways.  
 
ARPE-19 cells were cultured for 24h with Poly (I:C) and western blotting of mTOR/PI3K components 
was performed. Poly (I:C)-stimulation was observed to increase mTOR phosphorylation (and therefore 
activation) at the catalytic subunit (Ser 2448) (Fig. 3.18A-B). Downstream of mTOR is the mitogen 
activated Ser/Thr protein kinase p-70 S6 kinase, a key player in cell growth and proliferation through 
the regulation of translation [486]. p-70 S6 kinase is commonly used as a surrogate of mTOR activation. 
Poly (I:C)-stimulation increased the expression of p-70 S6 kinase (Fig. 3.18A and C). Interestingly, Poly 
(I:C) reduced the expression of mTORC1 subunit Raptor (Fig. 3.21A and C). Cells stimulated for 24h 
with Poly (I:C) showed no significant change in the expression of catalytic PI3K subunit p110 (Fig. 3.18A 
and C). This suggests PI3K activation as an early event in the signalling cascade and may explain why 
there is no change in the phosphorylation status when stimulated with Poly (I:C) for 24h.  
 
Stimulation with LPS for 30min upregulated the expression of catalytic PI3K subunit p110 (Fig. 3.18D 
and F). Downstream of PI3K, LPS treatment lead to increased activation of mTOR at the catalytic Ser 
2448 subunit (this was notably larger than the Poly (I:C)-induced expression) and immediate 
downstream mTORC1 target p-70 S6 kinase (Fig. 3.18D-F). LPS had no effect on the expression of 
Raptor (Fig. 3.18D and F). The phosphorylation status of Raptor or the expression of GβL was not 
assessed for either LPS or Poly (I:C) treatment.  
 
These data indicate that both TLR agonists activate the mTORC1 pathway despite the observed 
differences in AMPK activation status. As previously mentioned, the mTOR system incorporates a 
variety of environmental cues (including that of AMPK and PI3K activation). This suggests that even 
with prominent AMPK activation under a Poly (I:C) stimuli, mTORC1 signalling is still significantly 
enhanced. Notably, the LPS-induced mTORC1 response was greater than that of Poly (I:C), which may 
encompass the negative regulation conferred by active AMPK. However, the kinetics of LPS and Poly 
(I:C) treatments are completely dissimilar (as a result of different time points of stimulation) so it is 
difficult to make comparisons between the two groups. Poly (I:C) may activate mTOR/PI3K at earlier 
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Figure 3.18. Effect of TLR-agonists on mammalian target of rapamycin signalling in ARPE-19: 
(A) Cells were treated with Poly (I:C) (10µg/ml) for 6h. Western blot analysis was used to determine the 
activation of the PI3K/mTOR pathway following treatment. (B) Densitometry analysis of P-mTOR/mTOR. (C) 
Densitometry analysis of Raptor, p-70 S6 kinase and PI3K. (D) Cells were treated with LPS (1µg/ml) for 30min. 
Western blot analysis was used to determine the activation of the PI3K/mTOR pathway following treatment. (E) 
Densitometry analysis of P-mTOR/mTOR. (F) Densitometry analysis of p-70 S6 kinase and PI3K. Data are 
expressed as means ± SD from three independent blots. Unpaired Student’s T-test; *p<0.05, **p<0.01. 
  
3.17. AMP-activated kinase agonists differentially affect ARPE-19 metabolism. 
The data presented in the previous sections indicate a potential mechanism for the differential effects 
of TLR-3 and -4 activation on RPE metabolism. LPS inactivates AMPK by dephosphorylation of Thr172 
enabling engagement anabolic processes and a “Warburg-like” switch away from oxidative pyruvate 
metabolism. Poly (I:C) on the other hand, activates AMPK to induce a state of pseudo-starvation, 
which may prevent aerobic glycolysis in the RPE. To further explore how AMPK may regulate 
metabolism in the RPE, a pharmacological activator (AICAR) and inhibitor (compound C) of AMPK were 
utilised.  
 
Due to the reported toxicity of both compounds [487, 488], an initial time-course experiment was 
conducted to investigate the tolerability of both compounds to the RPE at doses used commonly in 
experiments on other cell lines [426, 427, 489]. It was observed that 24h of treatment with either 
compound led to significant LDH release (Fig. 3.19A). Cell viability was significantly decreased from as 
early as 2h following compound C treatment (Fig. 3.19B). The effect of AICAR treatment on cell viability 
was only detected at 24h (Fig. 3.19B). Based on these results, a 1h treatment of both compounds was 
used to carry out the following experiments to minimise cell death.  It was confirmed by western blot 
that AICAR and compound C increased/decreased AMPK Thr172 phosphorylation, respectively (Fig 
3.19C). Pharmacological activation and inhibition of AMPK had opposing effects on the OCR/ECAR 
ratio (Fig. 3.19D).  The ATP/ADP ratio showed that compound C treatment significantly reduced the 
cellular production of ATP, whereas AICAR had minimal effect (Fig. 3.19E). A mitochondrial stress test 
identified significant increases in maximal respiration and spare respiratory capacity following AICAR 
treatment (Fig. 3.19F and G). Compound C treatment decreased the maximal respiration yet had no 
significant effect on the spare respiratory capacity, basal metabolism or ATP-production (Fig. 3.19F 
and G). This supports previous work which showed that pharmacological AMPK activation boosted 
spare respiratory capacity [489]. AICAR was additionally observed to decrease glucose consumption 
and lactate output in keeping with previous studies [489]; compound C had no significant effect on 
the consumption of glucose or lactate production (Fig. 3.19H-I). Collectively, these data are consistent 
with the hypothesis that AMPK is promoting oxidative phosphorylation rather than aerobic glycolysis 
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Figure 3.19. AMP-activated kinase agonists differentially affect ARPE-19 metabolism: 
Cells were treated with AICAR (1mM) or Compound C (40µM) for the indicated time points. (A) LDH release was 
quantified in supernatants and expressed as a percentage of an untreated control. (B) Cell viability was 
quantified using an MTT assay and expressed as a percentage of the untreated control. Cells were pre-treated 
for 1h prior to XF assays. (D) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR. (E) Cellular 
ATP and ADP levels were quantified in lysed cells after 2h of treatment. (F) Representative mitochondrial stress 
test measured with sequential injections of Oligomycin, FCCP and rotenone/antimycin A. (G) Mitochondrial 
parameters (BR- basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- proton leak; 
ATP- ATP-production) calculated from data shown in (F). Cell supernatants were collected after 24h. (H) Lactate 
release was quantified in supernatants and expressed relative to an untreated control. (I) Glucose consumption 
assessed and expressed as a percentage of the mean untreated control. Both (H-I) were normalised to cell 
viability calculated from (B). Data are expressed as means ± SD. (A-B) and (H-I) represent three independent 
experiments performed in duplicate. (D-F) represent two independent experiments performed in duplicates. (C) 
Represents three independent blots. One-way ANOVA with Dunnet’s multiple comparisons test; *p<0.05, 
**p<0.01, ***p<0.005, ***p<0.001. 
   
3.18. Activation of AMP-activated kinase attenuates aerobic glycolysis in ARPE-19. 
The results from the previous sections indicate that in the RPE, AMPK is a negative regulator of aerobic 
glycolysis. This applies to RPE both under quiescent/unstimulated conditions and under “stress” 
conditions such as TLR stimulation. Boosting AMPK activity via the small molecule activator AICAR 
drastically inhibits glycolytic metabolism and lactate output in RPE cells, whereas inhibition attenuates 
mitochondrial function and sustains glycolysis. In the context of TLR stimulation, LPS treatment rapidly 
inactivates AMPK which likely augments the switch to aerobic glycolysis. Poly (I:C) on the other hand, 
activates AMPK which likely prevents a similar metabolic reprogramming to LPS.  
 
Considering these findings, and to further examine the role of AMPK on innate inflammatory 
responses, the effect of AMPK activation on the LPS-induced immediate metabolic switch was 
assessed. ARPE-19 cells were pre-treated in the presence or absence of AICAR for 1h prior to XF 
analysis. Basal OCR and ECAR measurements were taken before and after an injection of LPS. Due to 
the previously presented effects of AICAR on basal metabolism (see section 3.17.), OCR and ECAR data 
was normalised as “relative ECAR/OCR”, prior to LPS injection to assess the relative changes in both 
parameters. LPS-induced increases in ECAR were attenuated by the pre-treatment of cells with AICAR 
(Fig. 3.20A-B). AMPK activation blunted the initial decrease in OCR following LPS stimulation (Fig. 
3.20C-D). The decreased OCR post injection of LPS was observed to return to basal levels more rapidly 
with the pre-treatment of AICAR (Fig. 3.20C). As AMPK was already activated with Poly (I:C) 
stimulation, the effect of AICAR pre-treatment on the initial metabolic changes following Poly (I:C) 
injection was not investigated.  
 
Collectively, the data from this section strengthen the hypothesis of AMPK as a negative regulator of 
aerobic glycolysis in the RPE. AMPK activation was enough to completely dampen the LPS-induced 
metabolic switch.  
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Figure 3.20. Activation of AMPK attenuates aerobic glycolysis in ARPE-19: 
Cells were pre-treated with AICAR (1mM) for 1h prior to real-time measurements of ECAR (A) or OCR (C) 
following injection of LPS (1µg/ml). Changes in ECAR (B) or OCR (D) post injection of LPS. Data are expressed as 
means ± SD from (A-D) two experiments with two technical repeats. 
 
  
3.19. Activation of AMP-activated kinase attenuates translation of IL33 in ARPE-19. 
RPE cells have been previously shown to respond to TLR agonists, inducing the expression of IL-33 
which contributes to the regulation of tissue homeostasis [8]. For this reason, the effect of AMPK on 
IL-33 expression was investigated. Modulation of the activity of AMPK by pharmacological activation 
had no effect on the transcription of IL33 mRNA (Fig. 3.21A) yet there was reduced expression of IL-
33 protein (Fig. 3.21B), suggesting that AICAR affected constitutive IL-33 translation. mRNA stability 
and decay rates are another mechanism whereby gene expression is influenced in mammalian cells 
[490], however this was not assessed in this body of work. Pre-treatment with both compounds 
reduced the LPS and Poly (I:C)-induced translation of IL33 mRNA into IL-33 protein (Fig. 3.21C-F).  
 
The mTORC1 complex is a central regulator of protein translation, when activated it phosphorylates 
and inactivates 4EB-P1 (an e1F4F sequestering protein). Free e1F4F is a platform protein for eukaryotic 
initiation factor 4E and G (eIF4E/G) which together bind to the 7-methyl-GTP cap present at the 5’ of 
each mRNA to initiate mRNA translation [486]. Because of the effect of AICAR on IL33 translation, it 
was necessary to investigate the activity of the mTORC1 complex. Both AMPK modulation decreased 
the expression of mTORC1 complex component Raptor and downstream signalling components p-70 
S6 kinase and P 4EB-P1 (Fig. 3.21G-H) indicating a mechanism whereby IL33 mRNA translation is 
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Figure 3.21. Activation of AMPK attenuates translation of IL33 in ARPE-19: 
Cells were treated for 24h with AICAR (1mM) and IL-33 expression was assessed at both the RNA level (A) or at 
the protein level (B). Cells were pre-treated with AICAR (1mM) for 1h prior to treatment with Poly (I:C) (10µg/ml) 
for 24h. IL-33 expression was assessed at both the RNA level (C) or at the protein level (D). Cells were pre-treated 
with AICAR (1mM) for 1h prior to treatment with LPS (1ug/ml). IL-33 expression was assessed at both the RNA 
level (E) or at the protein level (F). (G-H) Cells were treated for 24h with AICAR (1mM), mTORC1 activation was 
assessed western blotting analysis of RAPTOR, p70 S6 kinase and P-4EBP1. Data are expressed as means ± SD. 
(A, C and E) represent three independent experiments performed with duplicates. (B, D, F and G) represent two 
and (H) represents three independent blots.  (H) One-way ANOVA with Dunnet’s multiple comparisons test, (C 
and E) One-way ANOVA with Tukey’s multiple comparisons test; *p<0.05, **p<0.01. 
  
3.20. Discussion. 
It remains unresolved how RPE cell metabolism is regulated following immune activation to maintain 
retinal homeostasis and retinal function. As mitochondrial dysfunction and inflammatory processes 
are likely underlying mechanisms driving early AMD disease progression, it is probable that defects in 
the ability of RPE to respond to tissue stress signals exacerbate homeostatic regulatory immune 
responses to altered dysregulated inflammatory state. The rationale behind this chapter is that under 
stress, RPE cells adapt their metabolic profile to provide ATP for bioenergetically expensive processes. 
As cells or organisms age, a decline in mitochondrial health [491] may limit the ability of a cell to divert 
bioenergetic sources for a rapid generation of ATP.  
 
Results obtained in this chapter suggest that the energy sensor AMPK is a critical node linking innate 
immune and metabolic function within the RPE. I have shown that AMPK functions to limit aerobic 
glycolysis and anabolic metabolism, whilst simultaneously increasing mitochondrial function. In the 
context of innate immune activation, altering the activation state of AMPK allows different TLR 
activation to elicit alternate RPE metabolic phenotypes. In the case of TLR-4 signalling, AMPK is rapidly 
inactivated, permitting an immediate switch to aerobic glycolysis and the augmentation of anabolic 
amino-acid/ fatty acid biosynthesis pathways (Fig. 3.22). Conversely, TLR-3 signalling activates AMPK, 
providing a key metabolic checkpoint which antagonises pro-anabolic metabolism and the “Warburg 
effect” to permit functional mitochondrial OXPHOS.  
 
Age, leading to progressive biological changes over time, remains one of the most obvious 
predisposing factors for the development of AMD [492]. Any cell with replicative potential may 
undergo cellular senescence (often allied with aging), where a non-dividing state is reached in 
otherwise mitotically competent cells [493]. RPE cells have been shown to reach a senescent state 
both in vitro culture and in situ [492]. To examine how aging and senescence may contribute to 
bioenergetic dysfunction in RPE, Seahorse analysis was carried out on RPE aged both in vitro and in 
vivo. Long-term in vitro cultivation leads to the development of RPE with reduced glycolytic and 
mitochondrial function, yet an increased metabolic demand in terms of a significantly increased OCR. 
Interestingly, the increased mitochondrial activity exhibited in these cells may be indicative of a switch 
to a senescence-associated secretory phenotype, where increased fatty acid oxidation fuels the 
release of secretory proteins that may contribute to increased sterile inflammation within the tissue 
[494, 495]. RPE from aged mice are more representative of the multifaceted in vivo environment faced 
during a lifespan. Parameters associated with impaired mitochondrial health were found to be more 
prominent in aged RPE, such as proton leak and coupling efficiency. The observation that aged murine 
RPE have an reduced capacity to utilize mitochondrial respiration and glycolysis compared with 
younger cells supports results from aged human RPE, where both glycolysis and mitochondrial reserve 
capacity were diminished [496]. 
 
Inflammation and metabolism are intertwined, with cells rapidly modulating their metabolic pathways 
to generate effective responses against pathogen invasion followed by the restoration of tissue 
homeostasis.  Microbial products such as LPS and Poly (I:C) activate TLR which leads to the output of 
cell-type specific pro-inflammatory cytokines [45]. RPE display responsiveness to Poly (I:C) and LPS, 
which is in keeping with previous studies [45, 286]. LPS stimulation is a well-known inducer of aerobic 
glycolysis within immune and non-immune cells [5]. TLR-4 stimulation decreases AMPK activation in 
macrophages [497] and AMPK has been shown to agonise LPS-induced glucose consumption in 
dendritic cells [403]. A recent study demonstrated a role for AMPK in LPS-challenged monocytes, 
whereby under glucose deprovision, AMPK activation drives oxidative metabolism of fatty acids and a 




Figure 3.22. Signalling events in LPS-stimulated RPE which promote aerobic glycolysis: 
LPS signals through TLR-4 in the RPE leading to immediate changes in RPE metabolism. AMPK is inactivated via 
dephosphorylation of Thr172 on the catalytic subunit. AMPK promotes catabolism and opposes anabolism, 
therefore in its activation, FAS and amino-acid biosynthesis from glucose occurs. AMPK opposes the metabolic 
switch to aerobic glycolysis via inhibition of the mTORC1-HIF-1α axis. LPS inhibits AMPK allowing increased 
normoxic stabilisation of HIF-1α to occur and subsequently a metabolic switch to aerobic glycolysis. LPS activates 
anabolic mTOR signalling through PI3K.   
It was anticipated that Poly (I:C) activated cells would undergo a similar switch to aerobic glycolysis as 
observed in other cell types [499, 500]. Yet interestingly, Poly (I:C) stimulation led to the activation of 
AMPK and an increase in OXPHOS. This increase in mitochondrial activity was attributed to both the 
increased flux of glucose-derived carbon into the TCA cycle and the activation of a fatty acid oxidation 
metabolic program. These results confirm observations made in bone marrow-derived dendritic cells, 
whereby Poly (I:C) and TLR-9 agonist CpG have been shown to promote both fatty acid oxidation and 
mitochondrial pyruvate oxidation [419].  
 
Fatty acid synthesis and cholesterol biosynthesis pathways are upregulated in virus-infected cells in 
order to support the generation of progeny. Viruses typically inactivate AMPK to promote these 
anabolic pathways, whilst inhibiting catabolic fatty acid oxidation [501]. Pharmacological inhibition of 
fatty acid oxidation has previously been shown to impact the ability of cells to control viral replication 
[502]. AMPK activation has been shown to limit a broad array of viral infections, including Rift Valley 
Fever virus, through inhibiting the rate limiting step (ACC) of the fatty acid synthesis pathway [503]. 
This suggests a potential mechanism for AMPK in ocular viral defence; via inhibiting ACC, fatty acid 
synthesis repression diverts free fatty acids that could otherwise be used in viral replication. 
Additionally, the effects of AMPK extend beyond metabolic reprogramming during infection, with 
antiviral defence mediated through the modulation of stimulator of IFN genes (STING) [504].  
 
AMPK, when activated endeavours to maintain energetic homeostasis by increasing ATP production 
and limiting energetic expenditure [344]. In the RPE, both strategies are engaged, and bioenergetically 
expensive processes (such as cytokine expression) are halted. A similar effect is observed in nutrient 
starved murine T-cells, whereby AMPK activation reduces the translation of Ifng mRNA [428]. The 
results obtained suggest a critical role for AMPK in the translation of IL33 mRNA and limitation of the 
“Warburg effect”. It is essential to note the potential off-target effects through pharmacological 
manipulation of AMPK using small molecule activators/inhibitors; data obtained should be interpreted 
with care [505, 506]. 
 
Hypoxia is an activator of AMPK; through alterations in the AMP:ATP ratio, AMPK strives to restore 
energy homeostasis through the promotion of catabolic processes [344]. Poly (I:C) was capable of 
sustaining AMPK activation under hypoxia to further up-regulate glycolysis. Considering, the 
observation that HIF1α transcripts were reduced with Poly (I:C) treatment, it is interesting that RPE 
cells are still able to function under hypoxic conditions and upregulate glycolytic metabolism. 
Unsurprisingly, hypoxia treatment alone was enough to increase glycolysis in the RPE.  Mouse models 
using the genetic induction RPE hypoxia, impact its ability to support nutrient availability within the 
retina [507].  
 
The mTOR network is more of a general regulator of metabolism compared to AMPK, and therefore 
must integrate multiple environmental cues to augment the inflammatory response [434]. Both TLR 
agonists activated the mTOR pathway, despite the alternate effects on AMPK phosphorylation status. 
This suggests that whilst AMPK is activated by Poly (I:C), the inhibitory effects on mTOR are overcome 
by PI3K activation. Interestingly, Poly (I:C) was found to decrease the expression of Raptor. Raptor 
interacts with HIF-1α via an mTOR signalling motif in HIF-1α, thereby promoting HIF-1α activity [361]. 
As GβL is reported to stimulate the kinase activity of mTORC1 independently of Raptor [508], this may 
permit mTOR signalling to continue, whilst restricting the ability of the cell to undergo a HIF-1α-
dependent switch to aerobic glycolysis (Fig. 3.23). Interestingly, silencing of Raptor diminishes the 
expression HIF1α mRNA transcripts [311], indicating a mechanism independent of AMPK whereby Poly 




Figure 3.23. Signalling events in Poly (I:C)-stimulated RPE which limit aerobic glycolysis: 
The synthetic analogy of dsRNA, Poly (I:C) is recognised by TLR-3. TLR-3 activation leads to the downstream 
activation of AMPK which promotes mitochondrial metabolism. Activation of mTORC1 is possibly mediated by 
PI3K in RPE cells as an early signalling event in response to Poly (I:C). The mTORC1 complex remains active, 
despite the downregulation of regulatory subunit Raptor, to maintain effector responses (such as gene 
transcription of antiviral genes). The absence of Raptor limits HIF1α gene transcription therefore antagonising 
aerobic glycolysis.  
The concept of a metabolic ‘retinal ecosystem’ that was recently introduced by Hurley et al, suggests 
that energy homeostasis in retina and RPE relies on a complex and specialized metabolic interplay 
between metabolically distinct cells in the retina and RPE and has implications for retinal diseases [4]. 
That study suggests that dysfunctional mitochondrial activity with age restricts the concentration of 
glucose able to reach the photoreceptors and consequently reduces the lactate available to the RPE 
as a fuel source. This increased reliance on glycolysis may upset the “metabolic ecosystem” and lead 
to photoreceptor death. Indeed, as previously mentioned, hypoxia-induced metabolic stress and the 
induction of glycolysis in RPE cells leads to photoreceptor atrophy [382]. The results in this chapter – 
when applied to the context of a “metabolic ecosystem” – suggest that increased RPE glycolysis 
observed following TLR “stimulation” may have an adverse effect on the photoreceptor metabolism 
and subsequently, health.  
 
PRR activation and the subsequent effects on RPE metabolism were assessed via the use of 
commercially available TLR agonists in this study. Typically, innate inflammatory responses occur as a 
result of microbial stimulation. However, as the eye exhibits a degree of immune-privilege [1], 
frequent TLR “stimulation” via bacterial and viral-derived PAMP ligands is improbable. In chronic 
conditions a form of “sterile” inflammation can occur in response to uncontrolled activation of PRR 
via self-derived ligands. TLRs bind and are activated by putative endogenous ligands (e.g. proteins, 
polysaccharides, phospholipids, nucleic acids and proteoglycans). There is now increasing evidence 
that endogenous ligand-TLR signalling occurs during pathological conditions such as tissue damage 
and repair under sterile inflammation [87]. Degenerating RPE-derived drusen components are likely 
drivers of innate sterile immune responses within the eye which manifest as TLR activation [41].  
 
In summary, the results presented in this chapter identify variances in metabolic profiles in TLR-
stimulated, and aging RPE both in vitro and ex vivo. The AMPK activation state restricts the “Warburg 
effect” in RPE following innate immune activation and limits the translation of IL33 during disruption 

















Chapter 4. Extracellular interleukin-33 modulates 
retinal pigment epithelium bioenergetics   
4.1. Introduction 
Interleukin-33 (IL-33) is a newly discovered member of the IL-1 superfamily of cytokines [509]. IL-33 
initiates signalling through a heterodimeric receptor complex comprised of its cognate receptor ST2 
and IL-1RAcP [132]. Alternative splicing of ST2 generates a soluble extracellular form which acts as a 
decoy receptor for IL-33-dependent signalling [245]. It was initially proposed that IL-33, like IL-1β and 
IL-18 required cleavage for release and bioactivity because the protein lacked a clear signal peptide. 
IL-33 release was later found to not require inflammasome activation, with optimum bioactivity 
occurring at full-length; and rather, caspase-mediated cleavage inactivated IL-33 [233]. Full length pro-
IL-33 is released from barrier cells following cellular damage and PRR activation and acts as an 
endogenous danger signal (“alarmin”) to alert the immune system to tissue injury [9]. Typically, IL-33 
is associated with Th2 responses as ST2 is expressed at high levels on mast cells and Th2 lymphocytes 
[9].  
 
IL-33 plays an important role in several diseases, such as, chronic gastrointestinal inflammation [12], 
allergic diseases/ anaphylaxis [13], cardiovascular disease [14], choroidal angiogenesis [8] and 
Alzheimer’s [15]. In experimental autoimmune uveitis, IL-33 moderates disease severity [16]. In a 
phototoxic model of retinal degeneration, IL-33 contributed to an upregulated chemokine and 
cytokine output from Müller Glia, leading to the recruitment of mononuclear phagocytes, and 
ultimately contributing to photoreceptor loss and diminished retinal integrity [17]. IL-33 was released 
as a 19-kD cleavage product from activated Müller Glia in the absence of cell death, implicating 
inflammasome mediated cleavage and inactivation of IL-33 [233]. As TLR-dependent up-regulation of 
IL-33 by RPE does not influence cell viability [8], it is likely that this is an adaptive response to maintain 
homeostasis. 
 
How IL-33 exerts effects on ST2 expressing cells are not fully established. Evidence suggests IL-33 binds 
to its heterodimeric receptor complex and recruits the adaptor proteins MyD88 (also used by other 
TLRs [60]) and interleukin-1 receptor-associated kinase (IRAK), this leads to the activation of MAPK 
and NF-KB through the activity of TRAF6 [133]. ST2 activation is known to drive phosphorylation of 
ERK1/2, JNK1/2 and AKT pathways to facilitate the production and release of cytokines and 
chemokines [133]. IL-33 signalling has been shown to lead to broad transcriptional changes in cells 
modulating hundreds of genes depending on cell type. A detailed macrophage phosphoproteome 
analysis identified changes in over 600 proteins with IL-33 stimulation [510]. Microarray analysis of 
human epithelium identified close to 1400 gene transcripts differentially regulated by IL-33 [511].  
There is currently no uniform picture of the extent of intracellular gene induction regulated by IL-
33/ST2 signalling. Therefore, between cell types it is unknown to what degree IL-33 influences 
transcriptional adaptations in innate immune response genes. 
 
Recent exploitation of the cytoplasmic hybrid technique for representative mtDNA haplotypes of AMD 
populations, revealed alterations in IL-33 expression and altered bioenergetics [18]. IL-33 likely drives 
changes in transcription and intracellular signalling pathways to permit innate immune defence. As 
detailed in the previous chapter, innate immune signalling has been shown to be accompanied by 
metabolic reprogramming to bioenergetically support the demand of an innate immune response by 
an RPE cell. Collectively this led the investigation into the role of IL-33 in the regulation of RPE 
metabolism with a focus on the extracellular signalling activities.   
 
  
4.2. Effect of recombinant human IL-33 on ARPE-19 basal metabolism and viability 
Expression of the IL-33 cognate receptor ST2 has been previously demonstrated on RPE cells [8]. It 
was hypothesised that activation of RPE through the IL-33/ST2 signalling axis may be accompanied by 
metabolic changes like that of TLR activation considering their convergence on multiple conserved 
signalling pathways.  
 
Although previously published work indicated the safety and tolerability of RPE cells to recombinant 
IL-33 [8], I first confirmed these results by assessing cell viability (MTT) and LDH release (indicative of 
cell cytotoxicity) in ARPE-19 cells stimulated for 24h with varying doses of rhIL-33 (Fig. 4.1A-B). Having 
established that IL-33 had no significant effect of the health of ARPE-19 cells, I investigated the initial 
metabolic responses to IL-33/ST2 signalling using seahorse XF. As IL-33/ST2 signalling is a rapid process 
in epithelial cells, leading to ERK activation and NF-kB nuclear translocation within minutes [512], it 
was of interest to see if there were metabolic change which accompanied immediate signalling 
cascades following ST2 activation; similarly to that of LPS activation of TLR-4 (see chapter 3). I utilised 
a similar experimental set-up as with TLR agonists (see section 3.4.), taking basal OCR and ECAR 
measurements every 7min over a 2h time frame, post injection of rhIL-33.   No metabolic changes 
were observed in either ECAR or OCR measurements post injection of rhIL-33 (Fig. 4.1C-D). To 
investigate whether metabolic changes would occur later post stimulation, ARPE-19 cells were 
subsequently treated with varying doses of rhIL-33 (100-1ng/ml) for 12h. However, no significant 
effect was observed in terms of basal OCR or ECAR (Fig. 4.1E). ARPE-19 cells treated for an additional 
12h (total 24h) with rhIL-33 showed a dose dependent increase in the basal OCR/ECAR ratio (Fig. 4.1E).  
 
Collectively, these data suggest that RPE cells undergo metabolic changes in response to IL-33 
stimulation for 24h. The increase in the OCR/ECAR ratio is indicative of an increase in OXPHOS over 
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Figure 4.1. Effect of recombinant human IL-33 on ARPE-19 basal metabolism and viability: 
Cells were treated for 24h with rhIL-33. (A) LDH release was quantified in supernatants and expressed relative 
to an untreated control, (B) Cell viability was quantified using an MTT assay and expressed as a percentage of 
the untreated control. (C) Real-time ECAR measurements post injection of 100ng/ml rhIL-33. (D) Real-time OCR 
measurements post injection of 100ng/ml rhIL-33. Basal OCR/ECAR ratio 12h (E) and 24h (F) after treatment 
with rhIL-33. Data are expressed as means ± SD. (A-B) Represent data from four independent experiments 
performed with four technical repeats. (C-D) Represents data from two independent experiments performed in 
triplicate. (E-F) Represent data from three independent experiments performed with no technical repeats. One-
way ANOVA with Dunnet’s multiple comparisons test; *p<0.05, **p<0.01. 
  
4.3. Effect of recombinant human IL-33 on ARPE-19 glycolytic and mitochondrial metabolism 
To further investigate the effects of IL-33 on ARPE-19 metabolism, additional experiments were 
performed using pre-optimised “metabolic tests” on the XF platform (as shown in chapter 3). A 
glycolysis stress test was used to examine glycolytic parameters following treatment of rhIL-33. No 
significant changes were observed in glycolysis (post glucose injection), yet there was an increase in 
glycolytic capacity (post oligomycin) and glycolytic reserve (Fig. 4.2A-B). This suggested that there was 
an increased ability of IL-33 treated cells to accommodate increased ATP demand by increasing 
glycolytic flux. I subsequently utilised a mitochondrial stress test to evaluate mitochondrial respiration 
in IL-33-stimulated RPE. This test identified increases in oxidative metabolism following treatment, 
particularly increases in basal, maximal and spare capacity (Fig. 4.2C-D). Collectively these results 
indicate that IL-33 stimulation of ARPE-19 leads to increased glycolytic and mitochondrial metabolism.  
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Figure. 4.2. Effect of recombinant human IL-33 on ARPE-19 glycolytic and mitochondrial metabolism: 
(A) Representative glycolysis stress test measured with sequential injections of glucose, oligomycin and 2DG, 
following stimulation with rhIL-33 (100ng/ml) for 24h. (B) Glycolysis parameters (G- glycolysis; GC- glycolytic 
capacity; GR- glycolytic reserve; NGA- non-glycolytic acidification) calculated from data shown in (A). (C) 
Representative mitochondrial stress test measured with sequential injections of Oligomycin, FCCP and 
rotenone/antimycin A, following stimulation with rhIL-33 (100ug/ml) for 24h. (D) Mitochondrial parameters (BR- 
basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-
production) calculated from data shown in (C). Data are expressed as means ± SD from three independent 
experiments performed in triplicates. Unpaired Student’s T-test; *p<0.05, **p<0.01. 
  
4.4. Effect of recombinant murine IL-33 on primary murine RPE bioenergetics 
To investigate whether the metabolic changes observed with IL-33 treatment were not limited to this 
immortalised cell line but represented an ability of RPE to adapt its metabolism under stress, primary 
murine RPE were also used. Like the ARPE-19 cell-line, rmIL-33 was observed to have no effect on 
immediate metabolic responses post-injection (Fig. 4.3A-B). Primary RPE were stimulated for 24h with 
rmIL-33 and a mitochondrial stress analysis was used to identify changes to mitochondrial respiration. 
It was observed that IL-33 treatment increased oxidative metabolism; with basal and maximal 
respiration increased post treatment (Fig. 4.3C-D). No significant changes were observed to spare 
respiratory capacity (Fig. 4.3C-D). rmIL-33 increased the OCR/ECAR ratio of the primary RPE (Fig. 4.3E). 
 
IL-33 signals through its cognate receptor comprised of ST2 and IL-1RAcP [133]. To determine if the 
effects of IL-33 were due to IL-33/ST2 signalling, primary murine RPE were isolated from mice lacking 
the ST2 receptor gene (Il1rl1-/-). Both WT and Il1rl1-/- RPE were stimulated for 24h with rmIL-33 and 
the OCR/ECAR ratio was measured. This showed that the effect of rmIL-33 on the primary isolated RPE 
was dependent on ST2 expression (Fig. 4.3F).  
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Figure 4.3. Effect of recombinant murine IL-33 on primary murine RPE bioenergetics: 
(A) Real-time changes in ECAR following injection of rmIL-33 (100ng/ml). (B) Real-time changes in OCR following 
injection of rmIL-33 (100ng/ml). (C) Representative mitochondrial stress test measured with sequential 
injections of oligomycin, FCCP and rotenone/antimycin A. (D) mitochondrial parameters (BR- basal respiration; 
MR- maximal respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from 
data shown in (C). (E) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR, following 24h rmIL-
33 treatment (100ng/ml). (F) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR, following 
24h rmIL-33 treatment (100ng/ml) to either WT or Il1rl1 KO mice. Data are expressed as means ± SD from either 
(A, B, E and F) two independent experiments performed in triplicates or (C-D) three independent experiments 
performed in triplicates. (C-E) Unpaired Student’s T-test; *p<0.05, **p<0.01. (F) One-way ANOVA with Dunnet’s 
multiple comparisons test; *p<0.05. 
 
  
4.5. Metabolic response of mast cells and Müller glia to recombinant IL-33 
The results from the previous sections indicate that IL-33 stimulation of RPE cells elicits metabolic 
reprogramming and an increase in mitochondrial metabolism. To identify whether these effects were 
specific to the RPE, or ubiquitous within other ST2 expressing cells, two additional cell types were 
utilised: mast cells and Müller glia.  
 
Mast cells express high levels of ST2 and are potently activated by IL-33 [513]. Considering this, the 
mast cell was an excellent candidate to determine whether the metabolic effects observed with IL-33 
treatment were specific to the RPE. To determine whether IL-33 elicited any metabolic changes in 
mast cells, real-time measurements of ECAR and OCR were taken post-injection of IL-33. rmIL-33 had 
no effect on the basal OCR or ECAR measurements (Fig. 4.4A-B). A mitochondrial stress test was 
coupled to this assay (2h post injection) to determine the effect of rmIL-33 on mitochondrial 
metabolism. There was no significant effect of treatment on mast cell OXPHOS parameters (Fig. 4.4B-
C). Using the corresponding ECAR data generated from this assay, it was observed that there were no 
significant changes to the glycolytic capacity post-injection of oligomycin (Fig, 4.4D). Treatment of 
mast cells for 24h with rmIL-33 had no significant effect on OXPHOS parameters (Fig, 4.4E-F), glycolytic 
capacity (Fig, 4.4G) or basal OCR/ECAR ratio in mast cells (Fig. 4.4H). As a positive control for mast cell 
activation and degranulation, the degranulating agent calcimycin [514] was also used as a positive 
control. It was observed that calcimycin treatment induced a rapid increase in mast cell glycolytic 
metabolism post injection (Fig. 4.4A-B).  
 
GFAP+ Müller glia have been observed to highly express transmembrane ST2 after light exposure to 
the retina [17]. IL-33 was observed to elicit a robust expression of cytokine and chemokine expression 
from Müller glia cells in an autocrine manner [17]. To further investigate the role of IL-33 signalling on 
cellular metabolism, the response of Müller glia to rhIL-33 was additionally investigated. Real-time 
measurements of ECAR and OCR were taken post-injection of rhIL-33, however there were no 
significant changes observed (Fig. 4.5A-B). Treatment of Müller glia for 24h with rhIL-33 had no 
significant effect on the mitochondrial function of Müller glia (Fig. 4.5C-D), glycolytic capacity (Fig. 
4.5E), or the OCR/ECAR ratio (Fig. 4.5F). 
Taken together, the results from this section indicate that the effects of IL-33 on cellular metabolism 
in the retina may be specific to the RPE. Other ST2 expressing cells such as human Müller glia and 
murine mast cells displayed no significant metabolic alterations when treated with the cytokine.  
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Figure 4.4. Metabolic response of BMMC to recombinant IL-33:  
(A) Real-time changes in ECAR following injection of rmIL-33 (100ng/ml) or Calcimycin (50nM) to BMMC (B) Real-
time changes in OCR following injection of rmIL-33 (100ng/ml) or Calcimycin (50nM) to BMMC. Sequential 
mitochondrial stress test measured with sequential injections of oligomycin, FCCP and rotenone/antimycin A. 
(C) mitochondrial parameters (BR- basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; 
PL- proton leak; ATP- ATP-production) calculated from data shown in (B). (D) glycolytic capacity calculated from 
data shown in (A). (E) Mitochondrial stress test analysis following rmIL-33 treatment (100ng/ml) of BMMC. (F) 
mitochondrial parameters (BR- basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- 
proton leak; ATP- ATP-production) calculated from data shown in (E). (G) Glycolytic capacity calculated from the 
corresponding ECAR data to (E). (H) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR, 
following 24h rmIL-33 treatment (100ng/ml) of BMMC. Data are expressed as means ± SD. A-C represents data 
from two experiments performed in duplicate. E-H represents data from two experiments performed in 
triplicates.  
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Figure 4.5. Metabolic response of Müller glia to recombinant IL-33:  
(A) Real-time changes in ECAR following injection of rmIL-33 (100ng/ml) to Müller glia. (B) Real-time changes in 
OCR following injection of rmIL-33 (100ng/ml) to Müller glia. (C) Mitochondrial stress test analysis following 24h 
rmIL-33 treatment (100ng/ml) of Müller glia. (D) mitochondrial parameters (BR- basal respiration; MR- maximal 
respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from data shown 
in (C). (E) Glycolytic capacity calculated from the corresponding ECAR data from (C). (F) Basal OCR and ECAR 
measurements expressed as the ratio OCR/ECAR, following 24h rmIL-33 treatment (100ng/ml) of Müller glia. 
Data are expressed as means ± SD. (A-B) represents data from two experiments performed in duplicate. (B-H) 
represents data from two experiments performed in triplicates.  
 
  
4.6. Glucose consumption, lactate production and metabolic gene transcription in IL-33-stimulated 
ARPE-19 
To confirm the results in the previous sections using the XF platform, I utilized several alternative 
assays to measure RPE metabolism. Glucose consumption was first measured in the media of ARPE-
19 cells treated with rhIL-33 for 24h. This showed no statistically significant change between the 
unstimulated and rhIL-33 groups (p=0.067) (Fig. 4.6A).  
 
RT-PCR analysis of metabolic genes (encoding glycolytic and TCA cycle enzymes and nuclear 
transcription factors) was performed. This indicated that in the glycolysis pathway there was 
significantly increased expression of GLUT1 (responsible for glucose import) and PKM2 transcripts 
with rhIL-33 treatment compared to an untreated control (Fig. 4.6B). An increase in GLUT1, but not 
PKM2 expression was observed at the protein level (Fig. 4.6C-D). In terms of the TCA cycle, increased 
expression of IDH1, FH, CS and SDHD transcripts were observed in the rhIL-33 treatment group (Fig. 
4.6B). rhIL-33 treatment additionally increased the transcription of “master metabolic regulators” 
MYC and SIRT1 (Fig. 4.6B).  
 
Lactate output was measured in the media as a direct quantification of glycolytic activity, and there 
was no statistically significant change observed (p=0.057) (Fig. 4.6E). The ATP/ADP ratio was assessed 
to identify if a metabolic shift with rhIL-33 treatment was accompanied by augmented ATP production. 
It was observed that ARPE-19 treated with rhIL-33 displayed an increased ATP/ADP ratio (Fig. 4.6F), 
suggesting increased mitochondrial activity and ATP production.  
 
The PDH complex catalyses the irreversible decarboxylation of pyruvate into Acetyl-CoA, which feeds 
into the TCA cycle for oxidative metabolism via NADH production [469]. PDH is therefore critical in 
connecting the glycolysis pathway to the TCA cycle. PDH is regulated by PDK1 which phosphorylates 
and inactivates PDH on a highly conserved serine residue [469]. It was observed that rhIL-33 increased 
the expression (but not activation status) of PDH relative to an unstimulated control (Fig. 4.6G-H). This 
indicates that increased PDH expression likely results in increased oxidative pyruvate catabolism in 
the mitochondria. Collectively these results confirm previously observed results that IL-33 treatment 
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Figure 4.6. Glucose consumption, lactate production and glycolysis gene transcription in IL-33-stimulated 
ARPE-19:  
ARPE-19 cells were stimulated for 24h with rhIL-33 (100ng/ml). (A) Supernatants were assessed for relative 
glucose consumption. (B) Quantitative RT-PCR of glycolytic pathway enzymes (HK, LDHA, PFKP, GAPDH, PKM1, 
PKM2 and ENO1), GLUT1, PDK1, MPC1, MPC2, TCA cycle enzymes (PC, IDH1, FH, SDHD and CS), PGC1α, HIF1α, 
MYC, SIRT1 and SIRT4 mRNA transcripts. (C) Extracellular lactate measurements were taken in the media and 
expressed as a percentage of the mean untreated control. (D) ATP and ADP levels were quantified following cell 
lysis and expressed as the ratio ATP/ADP. (E) Western blot analysis was used to determine the phosphorylation 
of pyruvate dehydrogenase. (F) Reprehensive densitometry from (E). Data are expressed as means ± SD. (A and 
C) Represents data from three independent experiments performed in triplicate. (B and D) Represents data from 
three independent experiments performed in duplicate. (F and G) Represent two independent blots. Unpaired 
Student’s T-test; *p<0.05, **p<0.01.  
 
  
4.7. Mass spectroscopy-based metabolomics in IL-33-stimulated ARPE-19 
The data shown in the previous sections indicate that IL-33 stimulated RPE cells (but not other ST2 
expressing cells) specifically undergo metabolic reprogramming accompanied by increased TCA 
activity and glycolytic metabolism. To further investigate the metabolic changes which occur, a mass-
spectroscopy-based approach was used to quantify total intracellular metabolites following treatment 
of ARPE-19 with rhIL-33.  
 
SITA with [U-13C]-glucose was used to assess the uptake of isotopically labelled glucose into metabolite 
pools following treatment with rhIL-33. This approach allowed the quantification of C13 labelling into 
metabolite pools as cells approach steady-state equilibrium (see schematic in Fig. 3.12). Cells were 
treated for the indicated time points with rhIL-33, followed by 2h of culture in [U-13C]-glucose. Relative 
concentrations of C13-labelled labelled glyceraldehyde-3-phosphate, 3-phosphoglycerate, pyruvate 
and lactate were increased in the rhIL-33 treatment group, suggesting increased glycolytic flux (Fig. 
4.7A-D). Significantly enriched C13 labelling was also observed in TCA metabolites citrate (Fig. 4.7E), 
succinate (Fig. 4.7H), fumarate (Fig. 4.7I), malate (Fig. 4.7J) and oxaloacetate (Fig. 4.7K) in the IL-33 
treatment group. No C13 labelling was observed in α-ketoglutarate, yet there was a significant 
reduction of the unlabelled metabolite pool with IL-33 treatment (Fig. 4.7F). No significant changes 
were observed in glutamate (Fig. 4.7G) or aspartate (Fig. 4.7L) between treatment groups.  
 
These data indicate that glycolytic metabolism is increased in cells stimulated with IL-33, as observed 
by the increased C13 flux into glycolytic intermediates. Moreover, increased labelling in TCA cycle 
metabolites confirms the increased pyruvate oxidation and mitochondrial activity observed in 
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Figure 4.7. Glucose tracing in IL-33-stimulated ARPE-19: 
Cells were treated with IL-33 (100ng/ml; 24h). Cells were incubated for 2h with media containing isotopically 
labelled glucose and GC-MS was used to quantify relative C13 (black) or C12 (white) incorporation into 
glyceraldehyde-3-phosphate (A), 3-phosphoglycerate (B), pyruvate (C), lactate (D), citrate (E), α-ketoglutarate 
(F), glutamate (G), succinate (H), fumarate (I), malate (J), oxaloacetate (K) and aspartate (L) metabolite pools.  
Represents data from three independent experiments. 
 
  
4.8. Mitochondrial morphology of IL-33-treated ARPE-19 
Results from the previous sections indicate that IL-33/ST2 signalling in RPE cells initiates metabolic 
reprogramming, increasing both glycolysis and mitochondrial OXPHOS. Considering these 
observations, I further interrogated the changes to mitochondria which occur in innate immunity via 
cytokine/cytokine receptor signalling. As previously mentioned (see section 3.14.), mitochondrial 
dynamics is essential to the maintenance of organelle quality control and adaptation to bioenergetic 
parameters (e.g. nutrient supply, energy demand and pathway efficiency) [473]. Opposing 
mitochondrial morphologies (mediated by fission or fusion) are linked with different bioenergetic 
programs, with increased mitochondrial fragmentation in anabolic cells associated with increased 
proton leak. Mitochondrial fragmentation and leak permit increased TCA flux for anabolism in a 
situation of aerobic glycolytic metabolism [515]. Inhibition of mitochondrial fission machinery 
prompts mitochondrial elongation, accompanied bioenergetically by increased OXPHOS [472]. To 
investigate whether metabolic changes following exposure of RPE cells to IL-33 were accompanied 
with alterations to mitochondrial structure, samples were studied by transmission electron 
microscopy. 
 
ARPE-19 cells were treated for 24h with rhIL-33, followed by fixation and imaging. Stimulation with 
rhIL-33 had little effect on the size of mitochondria compared to an unstimulated control (Fig. 4.8A-
C). rhIL-33 elicited changes to RPE mitochondrial morphologies. Unstimulated cells showed mostly 
fragmented mitochondria (77.5%) and short tubular mitochondria. Long tubular mitochondria were 
observed at a low frequency (2.5%). With treatment of rhIL-33, there was a 10-fold increase in the 
frequency of long tubular mitochondria (27.4%) at the expense of fragmented mitochondria which 
dropped to around 50% of total mitochondria (Fig. 4.8D). The increased frequency of elongated 
mitochondria suggested that mitochondrial fission/fusion enzymes were affected by IL-33 treatment. 
Considering this, the transcription of nuclear-encoded mitochondrial fission/fusion enzymes was 
assessed by RT-PCR in ARPE-19 cells exposed to IL-33. IL-33 treatment lead to increased expression of 
the OMM-localized, pro-fusion, OPA1 gene transcripts (Fig. 4.8E). Conversely, IL-33 treatment was also 
accompanied by an upregulation of DRP1, which is involved in mitochondrial fission (Fig. 4.8E). DRP1 
is inactivated by phosphorylation on a conserved subunit, however the protein expression of DRP1 
and its phosphorylation status was not investigated in this body of work. No significant changes were 
found in the transcription of pro-fusion MFN1 or MFN2, or mitophagy regulator PINK1 (Fig. 4.8E). The 
data presented so far indicates that IL-33 treatment drives elongation of RPE mitochondria. This shift 
in the mitochondrial morphologies was not as profound as that of TLR stimulation (see chapter 3), 
likely due to reduced transcriptional changes in fission/fusion genes. RT-PCR was used to estimate 
mitochondrial content through the amplification of two segments of the mitochondrial genome (the 
gene encoding cytochrome B and 16 S rRNA). Expression of both genes was normalized to the 
expression of the nuclear encoded β-globulin gene. No significant changes to mtDNA copy number 
was observed following treatment of cells with IL-33.  
 
To further explore mitochondrial structure during the metabolic changes associated with IL-33 
signalling, the expression of ETC components were assessed using western blotting. ARPE-19 cells 
were stimulated for 24h with rhIL-33, total protein was isolated and a commercially available 
preoptimized OXPHOS antibody cocktail was used to assess protein expression. IL-33 treatment was 
observed to significantly up-regulate the protein expression of Cox2 (complex IV), UQCRC2 (complex 
III), SHDB (complex II) and NDUFB8 (complex I) (Fig. 4.9A-B). No significant changes were observed in 
the expression of the ATP synthase complex (Fig. 4.9A-B).  
 
The data presented in this section show that structural changes in mitochondria are observed in 
response to IL-33 signalling. IL-33 has little effect on mitochondrial biogenesis but affects both 
mitochondrial remodelling and the expression of ETC components. This suggests that the changes 
observed to metabolic function in the previous sections are likely to be attributed to the increased 
capacity of mitochondria to undergo OXPHOS (through increased ETC components) rather than 
increased mitochondrial numbers. By altering the functionality of mitochondria rather than their 
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Figure 4.8. Mitochondrial morphologies in IL-33-stimulated ARPE-19: 
Representative transmission electron microscopy of ARPE-19 mitochondria either untreated (A) stimulated with 
rhIL-33 for 24h (B). Magnification 9300x. (C) Mitochondrial area was calculated using ImageJ. (D) Quantification 
of mitochondrial morphology into either fragmented, short tubular or long tubular phenotypes. (E) Quantitative 
RT-PCR was performed to assess the mitochondrial fission and fusion enzymes MFN1, MFN2, OPA1, PINK1 and 
DRP1 mRNA transcripts. (F) Quantitative RT-PCR was performed to assess mitochondrial content; this was 
estimated from the amplification of CTYB and 16S rRNA relative to BGLOB mRNA transcripts. One-way ANOVA 
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Figure 4.9. Expression of ETC components in IL-33-stimulated ARPE-19: 
ARPE-19 were stimulated with rhIL-33 (100ng/ml) for 24h. (A) Western blot analysis was used to determine the 
expression of ETC complexes (ATP synthase V, Cox2 IV, UQCRC2 III, SHDB II and NDUFB8 I). (B) Relative 
densitometry was calculated from (H) using ImageJ. Represents two independent blots. 
 
  
4.9. Effect of IL-33 on AMP-activated kinase activation status in ARPE-19 
The data presented in the previous sections has shown that IL-33/ST2 signalling drives metabolic 
changes in the RPE towards oxidative mitochondrial metabolism. Glycolysis is also increased but it 
appears that IL-33 does not elicit an immediate “Warburg-like” metabolic switch to aerobic glycolysis 
(like LPS stimulated RPE (see chapter 3), but rather utilises the mitochondrial TCA cycle. The metabolic 
changes in IL-33 stimulated cells were accompanied by structural alterations to mitochondria and 
increased expression of OXPHOS components. Whilst there was a clear increase in mitochondrial 
metabolism with IL-33 treatment, the underlying mechanisms whereby TCA cycle/ETC activity was 
boosted remained elusive.  
 
Data from the previous chapter indicated that mitochondrial OXPHOS was regulated by the activation 
status of AMPK in the RPE. AMPK signalling was observed to limit the Warburg effect in RPE cells in 
response to TLR-3 and -4 stimulation. Comparable to TLR-3 activated RPE, bioenergetic adaptations 
which followed IL-33/ST2 signalling in the RPE, were increased OXPHOS and a restriction of aerobic 
glycolysis, occurring at a later time-point of 24h post-stimulation. It is well known that AMPK activation 
limits the Warburg effect and drives increased mitochondrial metabolism in cells [311, 344]. It was 
therefore of interest to determine whether IL-33/ST2 signalling in the RPE elicits bioenergetic 
adaptations through the activation of AMPK.  
 
ARPE-19 cells were stimulated with rhIL-33 for 24h and the activation of AMPK was assessed by 
western blot analysis. IL-33 was observed to increase the phosphorylation (and activation) of AMPK 
(Fig. 4.10A-B). Downstream of AMPK, there was a non-significant increase of the phosphorylation of 
ACC (p=0.054) (Fig. 4.10A and C). Collectively this supports the hypothesis that IL-33 signalling is not 
accompanied by a shift to aerobic glycolysis but rather maintains the activity of mitochondrial 
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Figure 4.10. Effect of IL-33 on AMP-activated kinase activation status in ARPE-19: 
(A) Cells were treated with rhIL-33 (100ug/ml) for 24h. Western blot analysis was used to determine the 
phosphorylation of AMPK and ACC following treatment. (B) Densitometry analysis of P-AMPK/AMPK. (C) 
Densitometry analysis of P-ACC/ACC. Data are expressed as means ± SD from two independent blots. Unpaired 
Student’s T-test; *p<0.05. 
  
4.10. Effect of IL-33 pre-treatment on hydrogen peroxide-mediated oxidative stress 
Given the functional significance of IL-33/ST2 signalling on both AMPK activation and mitochondrial 
capacity, it was hypothesised this could be exploited to protect against oxidative damage to the RPE.  
As AMD progresses, there is an increase in chronic photo-oxidative stress. This results in the 
production of reactive oxygen intermediates which initiate RPE dysfunction and death [516]. The RPE 
is susceptible to the noxious effects of oxidative stress as a result of its high levels of metabolic activity, 
high oxygenation and exposure to photosensitizers such as lipofuscin [3]. As a comparator for RPE 
oxidative stress and cytotoxicity, H2O2 was used as an in vitro platform of inducing reactive oxygen 
species within the RPE [517]. Increased oxidative stress (via H2O2) in RPE cells manifest in ATP 
depletion, receptor-interacting serine/threonine-protein kinase 3 (RIPK3) aggregation, membrane 
breakdown and HMGB1 release (all key features of necrosis) [517]. Oxidative stress-mediated cell 
death in RPE cells has been shown to occur through necrosis rather than apoptosis, autophagy or 
pyroptosis [517]. The use of H2O2 in this body of work enabled the formation of a platform of RPE 
degeneration secondary to oxidative stress. As anticipated dose and time-dependent relationships 
were observed between H2O2 concentrations and cell viability (Fig. 4.11A). Cell viability was measured 
using the MTT assay to provide a direct readout of the cytotoxicity of treatments. I used the two doses 
of H2O2 (0.2mM and 1mM) at 24h of treatment as this was the time point which elicited significant 
variation between the two doses, which was not observed at 12h, and preserved a level of cell viability 
which was lost at 48h (Fig. 4.11A).  
 
To test the hypothesis that IL-33 may confer a protective effect against oxidative stress in RPE cells, 
ARPE-19 cells were co-treated with both H2O2 and rhIL-33 for 24h. It was found that co-treatment of 
rhIL-33 and H2O2 had no protective effect on cell viability at either dose (Fig. 4.11B). Considering the 
observation that IL-33 undergoes oxidation-induced conformational changes, responsible for 
terminating biological activity upon ST2 binding [236], I hypothesised that the co-treatment with 
hydrogen peroxide may terminate its biological activity. In order to overcome this problem and to 
assess if IL-33 was protective against oxidative stress, ARPE-19 cells were pre-treated with different 
doses of rhIL-33 for 12h prior to exposure to H2O2 for 24h. It was observed that IL-33 pre-treatment 
(at any of the doses investigated) had no significant effect on cell viability following treatment of 
0.2mM H2O2 (Fig. 4.11C). At the higher dose of H2O2 (1mM), IL-33 pre-treatment was observed to 
increase cell viability (Fig. 4.11C). To confirm the effects of IL-33 in promoting RPE survival during 
oxidative stress using cell viability (MTT) as a read-out, cell cytotoxicity was also measured using LDH 
release into cell culture supernatants. LDH release is indicative of loss of cell membrane integrity and 
cell necrosis which can be attributed to treatment cytotoxicity. H2O2 treatment at the greater dose of 
1mM significantly increased the LDH release into ARPE-19 supernatants (Fig. 4.11D). Pre-treatment of 
ARPE-19 cells with low concentrations of IL-33 (1-10ng/ml) were protective against the 1mM H2O2-
induced cytotoxicity (Fig. 4.11D). 
 
These data indicate an ability of IL-33 to protect against H2O2-mediated oxidative damage to the RPE. 
Interestingly, IL-33 was ineffective in protecting against cytotoxicity when treated in combination with 
H2O2. This was likely a result of impaired bioactivity, although it was not investigated in this body of 
work whether H2O2 conferred structural changes to the IL-33 polypeptide, rendering its signalling 
ineffective. Pre-treatment of cells with IL-33 positively influenced RPE survival in high levels of 
oxidative damage. However, as this was only assessed after 12h of pre-treatment and 24h of H2O2 
treatment, there is little indication on how long the protective effect of IL-33 remains in RPE cells 
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Figure 4.11. Effect of IL-33 pre-treatment on hydrogen peroxide-mediated oxidative stress: 
(A) ARPE-19 were exposed to hydrogen peroxide (0.2 and 1mM), cell viability was quantified using an MTT assay 
and expressed as a percentage of the untreated control. (B) Cell viability was quantified following co-treatment 
with either hydrogen peroxide (0.2 and 1mM) or hydrogen peroxide (0.2 and 1mM) and rhIL-33 (100ng/ml) for 
24h. Cells were pre-treated with rhIL-33 (1-100ng/ml) for 12h before exposure to hydrogen peroxide (0.2 and 
1mM) for 24h. (C) Cell viability was quantified using an MTT assay and expressed as a percentage of the 
untreated control. (D) LDH release was quantified in supernatants and expressed relative to an untreated 
control. Data are expressed as means ± SD. Represents data from three independent experiments performed 
with four technical repeats. (A and B) One-way ANOVA with Dunnet’s multiple comparisons test, (C and D) One-
way ANOVA with Tukey’s multiple comparisons test; *p<0.05, **p<0.01, ***p<0.005. 
  
4.11. Effect of IL-33 on ST2 expression   
The results obtained in the previous section indicated that IL-33 augmented RPE survival over short 
periods of oxidative stress. Interestingly, the lower doses of IL-33 (1 and 10ng/ml) were observed to 
confer a greater degree of protection in terms of both cell viability (MTT) and H2O2-mediated 
cytotoxicity (LDH release). It was hypothesised that “dose-response” kinetics of IL-33 may be 
attenuated by the release of decoy receptor sST2 into the cell culture supernatants. sST2 lacks the 
transmembrane and extracellular components required for signalling and is found in the extracellular 
space whereby it binds and sequesters IL-33 to neutralise IL-33/ (membrane bound) ST2 signalling. 
Previous reports have shown that exogenous recombinant IL-33 administration increases the 
secretion of sST2 from cells [227]. To confirm that in ARPE-19 cells, rhIL-33 dose-dependently 
increases the secretion of sST2, a commercial ELISA was used to determine the secreted sST2 into the 
supernatants. rhIL-33 treatment for 24h lead to a dose-dependent increase in the secretion of sST2 
into the supernatants (Fig. 4.12A). Increased sST2 expression was also confirmed intracellularly at the 
protein level using western blot analysis (Fig. 4.12B-C). No changes were observed in the expression 
of the membrane-bound ST2 receptor following treatment with rhIL-33 (Fig. 4.12B). Collectively these 
data indicate that IL-33 promotes the expression and secretion of sST2 from RPE cells. As IL-33 is a 
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Figure 4.12. Effect of IL-33 on ST2 expression:   
ARPE-19 cells were treated with varying does of rhIL-33 (100-1ng/ml) for 24h. (A) ST2 expression was quantified 
in supernatants using a commercial ELISA kit. (B) Western blot analysis was utilised to confirm the expression of 
ST2. (C) Densitometry analysis of ST2 expression. Data are expressed as means ± SD. (A) Represents data from 
three independent experiments performed with four technical repeats. (B and C) Represents data from two 
independent experiments performed with two technical repeats. One-way ANOVA with Tukey’s multiple 
comparisons test; *p<0.05, **p<0.01, ***p<0.005, ***p<0.001.  
  
4.12. Protection against mitochondrial dysfunction by IL-33 
Corroborating the above data that demonstrate a protective effect of IL-33 against hydrogen-
peroxide-induced stress, it was of interest to further refine the findings in the context of RPE metabolic 
health. With oxidative stress and mitochondrial damage, there is impaired mitochondrial and 
glycolytic activity in RPE cells [397, 518]. Indeed, as AMD disease severity progresses, there is 
increased mitochondrial damage observed in the RPE [396] To validate the in vitro platform of 
oxidative stress, extracellular flux analysis was used to determine the metabolism of ARPE-19 cells 
following treatment with H2O2. Treatment with H2O2 (1mM) for 24h resulted in altered mitochondrial 
function as established by decreased basal respiration, maximal respiration, spare respiratory capacity 
and ATP-production (Fig. 4.13A-B). H2O2 treatment lead to reduced basal ECAR and glycolytic capacity 
(Fig. 4.13C-D) signifying reduced glycolytic energy metabolism.  
 
Subsequent to confirming extracellular flux as a read-out of mitochondrial damage, I investigated how 
pre-treatment with IL-33 would affect metabolic health. ARPE-19 were first pre-treated with rhIL-33 
(100ng/ml) for 12h (as this was observed to protect against H2O2 in the LDH and MTT assays). Basal 
respiratory measurements were taken, and hydrogen peroxide was then injected. rhIL-33 treatment 
increased the OCR measurements post hydrogen peroxide (Fig. 4.13E). No significant “protection” was 
observed in ECAR post injection (Fig. 4.13F). To understand how the mitochondrial capacity may be 
altered with oxidative stress, a mitochondrial stress was utilised with an acute primary injection of 
H2O2 (Fig. 4.13G). It was observed that H2O2 reduced the maximal mitochondrial respiration and spare 
respiratory capacity (Fig. 4.13H). rhIL-33 pre-treatment of the cells for 24h prior to treatment 
significantly increased the maximal respiration and the spare respiratory capacity of the cells post H2O2 
treatment (Fig. 4.13G-H). The top dose of 100ng/ml rhIL-33 was observed to elicit the greatest 
protection to the cells in this assay (Fig. 4.13G-H).  
 
Combined, this data supports the observations from the preceding sections whereby IL-33 pre-
treatment of cells was protective against H2O2-induced cytotoxicity. In this section I have shown that 
H2O2 treatment impairs mitochondrial function and glycolytic capacity. Pre-treating RPE cells with IL-
33 protected against acute mitochondrial dysfunction, yet this was investigated on different time 
scales (1h vs 24h of H2O2 treatment) to the previous section so it is unknown to what extent 
mitochondrial function is sustained in IL-33 treated cells. 
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4.13. Protection against mitochondrial dysfunction by IL-33: 
ARPE-19 were treated with hydrogen peroxide (1mM) for 24h. (A) Mitochondrial stress test analysis (B) 
Mitochondrial parameters (BR- basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- 
proton leak; ATP- ATP-production) calculated from data shown in (A). (C) Corresponding ECAR data from (A). (D) 
Glycolytic capacity was calculated from (C). ARPE-19 were pre-treated with rhIL-33 (100ng/ml) for 12h. (E) Real-
time OCR readings post-injection of hydrogen peroxide (1mM) (F) Real-time ECAR readings post-injection of 
hydrogen peroxide (1mM). (G) Representative modified mitochondrial stress test measured with sequential 
injections of hydrogen peroxide, Oligomycin, FCCP and rotenone/antimycin A, following stimulation with rhIL-
33 (100ng/ml) for 24h. (H) Mitochondrial stress parameters (PI- ΔOCR post H2O2; MR- maximal respiration; SRC- 
spare respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from data shown in (G). Data are 
expressed as means ± SD except for (H) which is expressed as means ± SEM. (A-D) Represents data from two 
experiment performed with three technical repeats. (E-F) Represents data from three experiment performed 
with three technical repeats. (G-H) Represents data from three independent experiments performed with no 
technical repeats. One-way ANOVA with Tukey’s multiple comparisons test; *p<0.05, **p<0.01.  
 
  
4.13. Effect of IL-33 on expression of antioxidant enzymes, survival proteins and transcription 
factors  
To investigate the potential mechanistic basis for the ability of IL-33 treatment to protect against 
oxidative damage, the expression of antioxidant enzymes was assessed in ARPE-19 following rhIL-33 
stimulation.  The cellular antioxidant capacity has a significant impact on how the cell responds to an 
oxidative challenge. Antioxidant enzymes and redox sensitive genes are essential to the maintenance 
of a healthy environment post oxidative insult. The major enzymes involved in the removal of ROS are 
SOD1 and SOD2 enzymes (responsible for the conversion of superoxide radicals to H2O2) and catalase 
and glutathione peroxidase (enzymes responsible for the later conversion of H2O2 into H2O) [519, 520].  
It was found that the treatment of ARPE-19 cells with rhIL-33 had no significant effect on the 
expression of catalase, SOD1 or SOD2 (Fig. 4.14A). 
 
Since AMPK has been implicated in upregulating BCL-2/survivin expression [521], I examined the 
possibility that in addition to the metabolic effects described in the previous section, IL-33/AMPK 
promoted cell survival by upregulating anti-apoptotic factors such as survivin and BCL-2. It was 
observed that rhIL-33 had no significant effect on the expression of either anti-apoptotic protein (Fig. 
4.14B). 
 
The transcriptional coactivator, PGC-1α is a well-studied mediator of mitochondrial function. Previous 
work has shown that PGC-1α increases mitochondrial function and protects against oxidative damage 
in the RPE [36]. It is also known that AMPK activation increases PGC1α expression and activates PGC-
1α by direct phosphorylation [522]. SIRT-1 has a major role in cellular metabolism, epigenetic 
regulation and directly associates with a variety of transcriptional co-factors (including PGC-1α) which 
confer protection against oxidative damage [523]. I examined the possibility IL-33/ST2 signalling 
influenced PGC-1α expression in the RPE, which could serve as a possible mechanism to protect 
against oxidative stress. It was observed that IL-33 treatment increased the expression of PGC1α and 
PGC-1α protein.  No significant changes were observed in the gene expression of SIRT1 following 
treatment with rhIL-33 (Fig. 4.14C). 
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Figure 4.14. Effect of IL-33 on expression of antioxidant enzymes, survival proteins and transcription factors: 
ARPE-19 were treated with rhIL-33 (100ug/ml) for 24h. (A) Western blot analysis of antioxidant enzymes: 
catalase, superoxide dismutase-1 and superoxide dismutase-2. (B) Western blot analysis of antiapoptotic 
enzymes: survivin and B-cell lymphoma 2. (C) Quantitative RT-PCR of PGC1α, SIRT1 and SIRT4. Data are 
expressed as means ± SD. (A-B) Represents data from two independent blots, (C) represents data from three 




Key changes in innate immune cell metabolic regulatory events are initiated in response to both 
nutrient and oxygen deprivation, but additionally in response to DAMPS and other cell derived 
signalling events. One example of this is the polarisation of macrophages to an M2 phenotype by IL-4 
or IL-13; under these conditions M2 macrophage activation is maintained by increased fatty acid 
oxidation and OXPHOS [524].  In this chapter I have presented data that IL-33 initiates metabolic 
reprogramming in the innate immune-competent RPE cell with increased metabolic flux through the 
glycolysis pathway and into the TCA cycle. IL-33 bolsters mitochondrial activity and protects against 
oxidative damage, likely through the increased expression of PGC-1α and other metabolic regulators. 
These data indicate that activation of the IL-33/ST2 axis is supported metabolically by mitochondrial 
respiration. This likely permits a generation of ATP for bioenergetically expensive innate immune 
responses. Moreover, the increased mitochondrial activity and antioxidant response conferred by IL-
33 may have implications for the oxidative damage response in RPE degeneration.  
 
IL-33 functions extracellularly as an “alarmin” molecule; when released extracellularly following 
cellular damage/stress, exposure to allergens or infection with viruses, it potently activates immune 
(and non-immune) cells expressing its receptor ST2 [146]. The metabolic adaptations of the RPE to IL-
33 signalling may reflect the need to reprogram its metabolism to support the bioenergetic demands 
of cytokine and chemokine production. However, mast cell activation by IL-33 also elicits a robust 
output of inflammatory cytokines and chemokines [13], yet a metabolic change was not observed. 
Future work should aim to address whether the IL-33/ST2 signalling axis is specific to the RPE or 
whether other ST2 expressing cells undergo metabolic changes when activated. 
 
The basis of investigating the role of IL-33 on RPE metabolism was centred around a study investigating 
mtDNA haplotypes in AMD [18]. mtDNA can mediate cellular bioenergetics and expression levels of 
nuclear genes related to complement, inflammation and apoptosis [18]. This study - using cybrid RPE 
cells with representative mtDNA haplotypes - demonstrated that different mtDNA variants exhibit a 
difference in ATP levels, lactate production and metabolic (glycolytic) enzyme expression, which 
further dictates altered expression of nuclear encoded genes in complement, innate immunity, 
apoptosis and pro-inflammatory signalling pathways [18, 390]. One component of the innate immune 
signalling pathways found to alter significantly in RPE according to mtDNA content was IL-33 [18]. 
These “high-risk” AMD RPE cybrids exhibit both reduced mitochondrial metabolism and expression of 
IL-33 [18]. Therefore, there are contemporaneous changes in RPE metabolism and expression of IL-33 
when mtDNA change is observed. The notion is that IL-33 acts as a signal in the RPE to adapt or 
maintain its mitochondrial metabolism.  
 
Consistent with prior reports within cancer cells [443] and fibroblasts [442] IL-33/ST2 signalling was 
identified to be accompanied with increased metabolic activity (particularly in the glycolysis pathway). 
My findings here indicate that IL-33 increases glucose uptake (through the increased expression of 
GLUT1) and flux through glycolysis supported by both increased expression of glycolytic enzymes and 
carbon tracing data. C13 glucose SITA indicated that for the major part, increased glycolytic 
consumption was accompanied by flux into the TCA cycle which along with increased expression of 
key TCA cycle enzymes may account for the upregulated mitochondrial capacity in IL-33 stimulated 
RPE. This suggests that future work should aim to identify the contribution of glycolysis and 
mitochondrial pyruvate entry to the augmented oxygen consumption under an IL-33 stimulus. It is 
probable (as a Th2 cytokine capable of eliciting M2 macrophage polarisation [278]) that IL-33 may 
induce metabolic reprogramming in the RPE through comparable pathways to IL-4 and IL-13 activated 
macrophages. In these conditions IL-4/IL-13 signal via the mTORC2/IRF4/STAT6 axis to promote 
oxidative glucose metabolism and support fatty acid metabolism [439]. It would also be of interest to 
identify if this effect on the RPE is indeed specific to IL-33 “alarmin” signalling, or whether other Th2 
cytokines (such as IL-4/IL-13) facilitate a similar metabolic signature.  
 
The data presented in this chapter suggests that IL-33 promotes RPE oxidative pyruvate metabolism, 
yet the effects on mitochondrial capacity is unlikely to be solely attributed to increased glycolytic flux 
into the TCA cycle. Future experiments employing alterative isotopically labelled analytes will permit 
a greater understanding of additional metabolic pathways modulated by IL-33. Activation of AMPK 
and expression of mitochondrial fusion genes (e.g. OPA-1) may additionally drive fatty acid oxidation 
under an IL-33 stimulus. Indeed, increased mitochondrial fusion in T-cells generates increased 
oxidative potential, largely dependent on fatty acid oxidation [472].  
 
Activation of AMPK appears to be associated with the counter regulation of inflammatory pathways 
in innate immune cells [345]. Stimulation of macrophages with anti-inflammatory cytokines 
(specifically IL-10, TGF-β and IL-4) drive the activation of AMPK, which in turn suppresses pro-
inflammatory responses [497] and promotes OXPHOS through the inhibition of mTORC1 [525]. The 
activation of AMPK may contribute to the regulation of mTORC1 in the RPE in order to suppress high 
rates of aerobic glycolysis and loss of mitochondrial integrity [525], whilst simultaneously supporting 
mitochondrial oxidative metabolism and biogenesis [345]. Future work should aim to interrogate not 
only canonical ST2 signalling pathways in the RPE (i.e. MyD88/NF-kB) but the input of mTORC1/2 
signalling in response to IL-33. AMPK activation via IL-33/ST2 signalling may be of great significance in 
vivo, whereby AMPK stimulation prevents loss of the photoreceptors and RPE in three models of 
retinal degeneration [384]. Whilst in this study metformin was utilised to mediate protection via the 
induction of oxidative damage response and mitochondrial biogenesis transcriptional changes [384], 
there are emerging studies which question the effectiveness of metformin as an AMPK activator [505].   
 
The data indicated that IL-33 signalling protected RPE cells against the noxious effects of oxidative 
stress. IL-33 release is regulated by oxidative stress and antioxidants within airway epithelium [240], 
reported to reduce ROS production in fibroblasts [14]  and directly enhance the activity of SOD in 
cardiomyocytes [288]. However, the data here identified no change to antioxidant enzyme expression 
but rather an increase in metabolic flux and mitochondrial activity. Whilst not examined entirely here, 
future work should aim to identify if IL-33 pre-treatment enables the RPE to have an increased 
protective response (rather than increased basal expression) under oxidative stress in terms of 
antioxidant enzymes and mitochondrial biogenesis. TFAM, and NRF1 are both key mediators of 
mitochondrial biogenesis and mtDNA maintenance [384]. Although these were not examined 
following IL-33 stimulation, future work should aim to assess their involvement to the IL-33-induced 
RPE stress response. The protection against oxidative damage may likely be attributed to increased 
expression of PGC-1α following treatment of RPE with IL-33. ARPE-19 and human foetal RPE cells 
overexpressing PGC-1α have previously been shown to increase mitochondrial mass, mitochondrial 
respiration and strongly induce the expression of antioxidant genes which protect the RPE from 
oxidant-mediated cell death [36]. Increased function of PGC-1α could improve the increased oxidative 
stress and reduced metabolism observed in AMD without affecting RPE survival or function [36]. It is 
worth noting however, that cultured RPE cells from AMD patients have been shown to exhibit 
increased PGC-1α expression compared to non-AMD controls [397]. In the context of the “metabolic 
ecosystem” hypothesis [4], bolstering both glycolysis and OXPHOS in the RPE may have adverse effects 
on photoreceptor health. If IL-33 signalling increases the glucose consumption and flux through 
glycolysis and the TCA cycle, less glucose would (in theory) be able to traverse to the photoreceptors 
to support their program of highly glycolytic metabolism [4].  Future studies are warranted to test 
whether the regulation of mitochondrial function could have beneficial effects for RPE survival in in 
vivo models of oxidative stress and retinal degeneration. 
 
It was of interest to note that even the lower doses of IL-33 (1ng/ml) could still influence RPE responses 
and viability, consistent with reports that low levels of circulating cytokines can modulate human brain 
function [526]. While high extracellular levels (100ng/ml) of IL-33 are physiologically unlikely within 
the retinal microenvironment of patients (with or without AMD) [527], one cannot eliminate a local 
high concentration of IL-33 which may occur at a site of tissue damage [528]. 
 
In summary, the results presented in this chapter identify IL-33/ST2 signalling in the RPE to be 
accompanied by a metabolic adaptation of increased mitochondrial activity, likely to support the 
effector functions of the RPE in “stress” conditions. Activation of AMPK by IL-33 to reduce oxidative 
stress and expand mitochondrial capacity provide evidence for an attractive immunotherapeutic-















Chapter 5. Nuclear interleukin-33 regulates cellular 
metabolism in the retinal pigment epithelium 
  
5.1. Introduction  
IL-33 is constitutively expressed in the inner retina, RPE and choroid [529], as well as in epithelial cells, 
endothelial cells, and fibroblasts [217]. IL-33 is expressed in the nucleus of these cells during 
homeostasis at a high level [217]. During inflammation the expression of this protein can be further 
upregulated, whilst still retaining the nuclear localization [530]. In the RPE, IL-33 is upregulated by 
exposure to TLR-3 and TLR-4 ligands LPS and Poly (I:C), respectively (see chapter 3). Full-length 
unprocessed IL-33 is released from the nucleus after necrotic cellular damage and displays potent 
biological activity [233]. IL-33 cytokine activity is therefore constrained by its subcellular localization 
and regulated through proteolytic cleavage [233, 531]. Full length IL-33 is bioactive [233]. Cleavage by 
caspases in the IL-1 cytokine domain process IL-33 into inactive forms during apoptosis [233]. 
Processing by neutrophil-derived or environmental allergen proteases can generate processed forms 
of IL-33 with augmented cytokine activity [235, 285]. Nuclear localization of full-length IL-33 appears 
to be a property that is observed universally across all IL-33-producing cells of both human and murine 
origin. Nuclear IL-33 exhibits a chromatin-binding motif which permits an association with the histone 
heterodimer H2A-H2B [256]. The chromatin-binding motif (contained within the nuclear domain) is 
evolutionarily conserved in all IL-33 sequences, implicating a role in chromatin association [254].  
 
A largely unanswered question concerning the biology of IL-33 is the significance of its nuclear 
localisation. Other nuclear alarmins (e.g. HMGB1 and IL-1α) are considered to display dual 
functionality, “moonlighting” as transcription factors through their ability to bind DNA [532, 533]. 
Roles for nuclear IL-33 have previously been described in the transcriptional repression of NF-kB [10, 
254], leading to the proposed theory that it also has  dual functionality, acting both extracellularly and 
as a nuclear factor regulating gene transcription. Despite multiple studies describing a role for IL-33 in 
transcriptional regulation [257, 258, 534], recent reports which provide evidence that endogenous 
nuclear IL-33 is not a dominant regulator of gene expression raise questions over this conclusion [230, 
263].  
 
A recent study suggested a novel epigenetic role for IL-33 as shown in the maintenance of uncoupled 
metabolism in adipose tissue [19]. This combined with results detailed in the previous chapter  
(whereby activation of the IL-33/ST2 axis in the RPE drives metabolic changes), and the altered IL-33 
expression observed in AMD hybrids [18], lead to the hypothesis that IL-33 may act an intranuclear 
regulator of RPE metabolic pathways as well as at the extracellular level. Therefore, the primary 
objective of this chapter was to test if genetic modulation of the expression status of intracellular 
nuclear IL-33 could have any effect on the control of RPE metabolism. 
 
5.2. Establishing knockdown and overexpression of IL-33 in ARPE-19 using siRNA and CRISPR cas9 
In order to answer the hypothesis of this chapter “does intracellular IL-33 expression status influence 
RPE metabolism?”, there remained a need to first achieve stable knockdown (KD) and overexpression 
of full-length nuclear IL-33 in the RPE. Continuing with the use of ARPE-19 as an RPE model system, I 
first optimised genetic modulation of IL-33 in this cell line. To KD IL-33 in ARPE-19 cells, four 
preselected siRNA duplexes each targeting different sequences of the human IL33 gene were utilized. 
The effectiveness of siRNA KD was confirmed both at the protein and gene level (Fig. 5.1A-C). 
Additionally, ARPE-19 cells were genetically engineered to constitutively overexpress IL-33 using a 
CRISPR-cas9 system. The CRISPR/synergistic activation mediator (SAM) transcription activation system 
enabled the upregulation of IL-33 by utilising a D10 deactivated Cas9 nuclease fused to a VP64 
activation domain, in conjunction with a single guide RNA (MS2) and an IL-33-specific single guide RNA 
engineered to bind the MS2-p65-HSF-1 fusion protein [535]. The effectiveness of CRISPR-cas9 
overexpression was confirmed both at the gene and protein level in whole cell lysates (Fig. 5.1D, E, G). 
As IL-33 functions as a dual function cytokine, residing both within the nucleus and functioning 
extracellularly [9], there was a necessity to identify the subcellular location of IL-33 following 
overexpression. Like previous studies [136, 260, 263], constitutive nuclear expression of IL-33 was 
observed in ARPE-19 cells (Fig. 5.1F). When IL-33 was overexpressed using the activation plasmid, 
nuclear retention was still observed (Fig. 5.1F). Immunoblotting for nuclear histone 3 and cytoplasmic 
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Figure 5.1. Establishing knockdown and overexpression of IL-33 in ARPE-19 using siRNA and CRISPR-cas9: 
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene. (A) Representative immunoblot of IL-33 protein expression following 
transfection. (B) Densitometry analysis of IL-33 protein expression. (C) Quantitative RT-PCR of IL33 mRNA 
transcripts. ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid or an IL33 activation gDNA 
plasmid. (D) Representative immunoblot of IL-33 protein expression following transfection. (E) Densitometry 
analysis of IL-33 protein expression. (F) Representative immunoblot of IL-33 subcellular location following 
transfection. (G) Quantitative RT-PCR of IL33 mRNA transcripts. Data are expressed as means ± SD. (A, B, D, E, F) 
Represents data from three independent blots, (C and G) represents data from three independent experiments 
performed in triplicate. One-way ANOVA with Tukey’s multiple comparisons test; *p<0.05, **p<0.01, 
***p<0.005. 
  
5.3. Toxicity and IL-33 release in transfected ARPE-19 
Considering the observations from the previous chapter -whereby recombinant IL-33 drove metabolic 
changes to the RPE - there remained a necessity to investigate (A) whether IL-33 is released from RPE 
cells in health or stress and (b) (if the previous proved to be correct) whether altering the expression 
status with siRNA or CRISPR-cas9 would simply alter the output of IL-33 secreted, and drive metabolic 
changes to the RPE in an autocrine or paracrine manner (Fig 5.2). As IL-33 lacks a traditional signal 
sequence or a non-canonical export pathway, previous studies have suggested that its release occurs 
only through necrotic mechanisms, allowing the full-length cytokine to reach the extracellular milieu 
[530].   
 
In order to measure the release of IL-33 into cell culture supernatants, a commercial ELISA was used. 
ARPE-19 cells were first treated with increasing doses of H2O2 to induce cellular necrosis through 
oxidative stress.  Consistent with previously reported observations, increased IL-33 release from the 
ARPE-19 cells was observed with increasing cell death (Fig 5.3A-B). In the untreated group, IL-33 
release was not reliably detected within the culture supernatant (Fig 5.3A). The mean concentration 
of IL-33 was 7± 2 pg/ml and below the assay detection limit of 23.4 pg/ml and therefore unreliable to 
construe as constitutive release from the cells. To further assess, cell supernatants were analysed from 
ARPE-19 cells transfected with an IL-33 siRNA or a scrambled control siRNA for 48h. IL-33 was detected 
in the supernatants of all groups but again below the detection limits of the ELISA (control (10.1± 4 
pg/ml), scrambled siRNA (11.6± 4.6 pg/ml) and siRNA (9.12± 6 pg/ml)) (Fig. 5.3A). Transfection with 
either siRNA had no significant effect on the LDH release of the target cells (Fig. 5.3C). As there were 
no detectable differences between the groups, and IL-33 was not detected above an accurate 
threshold in supernatants, I concluded that under these culture conditions IL-33 is not constitutively 
released from ARPE-19 and the “below sensitivity” concentrations of IL-33 present may be a result of 
low levels of cell death which occur within a cell culture system.  
 
There remained a need to investigate whether IL-33 would be secreted from cells transfected with an 
IL-33 overexpression plasmid. Cell culture supernatants were taken post transfection for 48h and an 
ELISA was used to determine the release of IL-33. It was observed that in all groups, IL-33 release was 
below the detection limits of the assay. The IL-33 concentrations in the supernatants were control - 
4.7± 2 pg/ml, control plasmid - 7.6± 5.6 pg/ml and IL-33 plasmid - 17.1± 6.5 pg/ml (Fig. 5.3C). 
Transfection of cells with both plasmids significantly increased the LDH release, however it was 
observed that the IL-33 plasmid elicited increased cytotoxicity compared to the control plasmid (Fig. 
5.3D). 
 
Considering these observations, it was necessary to optimise the transfection strategy of both 
plasmids to elicit a similar amount of toxicity and (in theory) IL-33 release in the ARPE-19 system. The 
rationale behind this was: if the IL-33 plasmid is more cytotoxic that the control plasmid, any results 
observed when looking at the metabolic profiles may be skewed by both IL-33 release and damage to 
the cells. Additionally, it was essential to optimise the IL-33 plasmid to induce the greatest IL-33 
expression with the lowest cytotoxicity. In the first set of experiments, the concentration of the IL-33 
activation plasmid was titrated around a pre-optimised concentration of 1µg (1.5-0.25µg) and IL33 
expression was assessed using RT-PCR. Unsurprisingly, it was found that increasing concentrations of 
the IL-33 activation plasmid dose dependently increased the expression of IL33 (Fig. 5.3E). 
Supernatants were assessed for the release of LDH and IL-33 protein. It was found that titrating the 
activation plasmid had little effect on the LDH release between titration groups, yet there was still a 
significant cytotoxicity in the IL-33 activation plasmid groups compared to that of the scrambled 
control (Fig. 5.3F). In terms of the IL-33 release from the transfected cells, levels in supernatants were 
below the reliable detection limits of the ELISA (Fig. 5.3G). This showed although the IL-33 activation 
plasmid was more cytotoxic to the cells than the control, titrating the transfection dose had little effect 
on the cell viability. Considering this, I kept the concentration of the plasmid at 1.5 µg, whilst titrating 
out different doses of the transfection reagent around a pre-optimised volume of 10µL (15-2.5µL). 
IL33 expression was first assessed using RT-PCR. A “bell curve” distribution pattern was observed in 
terms of IL33, with the maximum expression observed at 10µL (Fig. 5.3H). Following this, supernatants 
were then assessed for the release of LDH and IL-33. A dose response was observed, leading to 
increased LDH release with increasing transfection reagent volume (Fig. 5.3I). IL-33 release into the 
cell culture supernatants was below the assay detection limits (Fig. 5.3J).  
 
These results highlighted that in order to minimise the difference of toxicity between the two 
treatment groups, an alternate dose of transfection reagent would need to be used for the control 
plasmid. The IL-33 plasmid appeared to be more cytotoxic than the control plasmid, even when its 
concentration was reduced. Altering the concentration of transfection reagent appeared to be the 
pivotal factor in reducing cytotoxicity. Considering this, it was necessary in future experiments to 
utilise 10µL of transfection reagent for the IL-33 plasmid and 15µL of transfection reagent for the 
control plasmid. These volumes elicited a similar cytotoxicity (362± 31 %LDH release (control plasmid) 
and 346± 17 %LDH release (IL-33 plasmid)) from the transfected cells. Optimising the toxicity 
conferred from plasmid transfection enabled a more reliable assessment of the cell biology in 
transfected cells and ruled out confounding factors such as IL-33 autocrine/paracrine activation of ST2 
and mitochondrial dysfunction with increasing cytotoxicity. These experiments indicate that IL-33 is 
not released from ARPE-19 cells constitutively or under genetic modulation via siRNA knockdown or 
CRISPR overexpression. Therefore, any effect observed in terms of altering the expression status is 
due to the intracellular endogenous effects of the cytokine rather than extracellular release and 
exogenous signalling through ST2. 
  
 
Figure 5.2. Would the overexpression of IL-33 drive RPE metabolic reprogramming in an autocrine/paracrine 
manner?: 
As detailed in chapter 4, IL-33 activates RPE cells through ST2 signalling and increases both glycolysis and 
mitochondrial OXPHOS. During cellular homeostasis IL-33 is observed in the nuclear of epithelial cells. Whether 
IL-33 is constitutively released from epithelial cells is currently unknown, due to a lack of a signal sequence for 
Golgi-mediated release. The consensus appears to be that full-length IL-33 is released extracellularly upon cell 
death or damage. In the context of RPE cells constitutively overexpressing IL-33, questions emerge as to (A) 
whether its nuclear expression is retained and (B) whether it is released into the extracellular milieu. If IL-33 
overexpression lead to its extracellular release, it is plausible that through autocrine (or paracrine activation), 
bioenergetic changes could be observed in the RPE which may be falsely interpreted as an intracellular effect of 
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Figure 5.3. Toxicity and IL-33 release in transfected ARPE-19:  
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene; or treated for 24h with varying doses of H2O2 (0.2-1.2mM). (A) IL-33 was 
quantified in supernatants using an ELISA. (B) LDH release was quantified in supernatants and expressed relative 
to an untreated control. ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid or an IL33 
activation gDNA plasmid. (C) IL-33 was quantified in supernatants using an ELISA. (D) LDH release was quantified 
in supernatants and expressed relative to an untreated control. ARPE-19 were transfected for 48h with varying 
concentrations of either a scrambled gDNA plasmid or an IL33 activation gDNA plasmid. (E) Quantitative RT-PCR 
of IL33 mRNA transcripts. (F) LDH release was quantified in supernatants and expressed relative to an untreated 
control. (G) IL-33 was quantified in supernatants using an ELISA. ARPE-19 were transfected for 48h with either a 
scrambled gDNA plasmid or an IL33 activation gDNA plasmid. Varying concentrations of the plasmid transfection 
reagent were utilised. (H) Quantitative RT-PCR of IL33 mRNA transcripts. (I) LDH release was quantified in 
supernatants and expressed relative to an untreated control. (J) IL-33 was quantified in supernatants using an 
ELISA. Represents data from two independent experiments run in duplicate. One-way ANOVA with Tukey’s 




5.4. Effect of IL-33 genetic modulation on ARPE-19 metabolism 
Following optimisation of transfection in the previous two sections, ARPE-19 cells were obtained 
either exhibiting IL-33 knockdown or overexpression using siRNA or CRISPR-cas9, respectively. The 
first set of experiments to assess the role of nuclear IL-33 in the metabolism of the RPE utilised the XF 
platform. Mitochondrial stress analysis identified reduced maximal respiration and spare respiratory 
capacity in the IL-33 siRNA compared to the scrambled siRNA (Fig. 5.4A-B). There were no significant 
changes observed in the basal respiration or proton leak (Fig. 5.4A-B). ATP-production post oligomycin 
was increased (Fig. 5.4A-B). Transfection of ARPE-19 cells with a control scrambled siRNA had no 
significant effect on mitochondrial fitness (Fig. 5.4A-B). Collectively the results from the mitochondrial 
stress analysis indicated that the ability of the RPE to respond metabolically under “stress” conditions 
was impaired when IL-33 expression was reduced. After identification of defects in mitochondrial 
metabolism using the mitochondrial stress test, I chose to investigate how glycolytic metabolism may 
be affected by the loss of IL-33. A glycolysis stress test identified increased glycolysis and glycolytic 
capacity following IL-33 KD, yet there was no change in non-glycolytic acidification or glycolytic reserve 
(Fig. 5.4C-D). Transfection of the cells with a control scrambled plasmid had no effect on glycolytic 
function (Fig. 5.4C-D). As the ECAR values plateaued after the initial glycose injection in the absence 
of IL-33 and failed to respond to the injection of the ATP synthase inhibitor oligomycin, this suggested 
that IL-33 KD cells relied more on aerobic lactate production rather than mitochondrial glucose 
utilisation. Indeed, the reduced OCR/ECAR ratio indicated the increased aerobic glycolysis compared 
to mitochondrial activity in the IL-33 KD cells (Fig. 5.4E).  
 
Following these sets of experiments, a similar experimental pipeline was used in the context of IL-33 
overexpression. First a mitochondrial stress test to assess the effect of constitutive IL-33 
overexpression on RPE metabolism was carried out. In comparison to the control plasmid, the IL-33 
plasmid elicited a significant increase in basal respiration, ATP-production and maximal respiration 
(Fig. 5.4F-G). There was a non-significant increase in the spare-respiratory capacity of IL-33 plasmid 
group (p=0.08) (Fig. 5.4F-G). No-significant changes were observed in the mitochondrial proton leak 
(Fig. 5.4F-G). The transfection of a control scrambled plasmid had no significant effect on any 
mitochondrial respiratory parameter, indicating the results obtained were specific to altered IL-33 
expression (Fig. 5.4F-G). Together the results from the mitochondrial stress test indicated that with IL-
33 overexpression, ARPE-19 cells had improved mitochondrial fitness and maximal respiration. 
Glucose-starved cells were subjected to a glycolysis stress test to identify changes in glycolytic 
parameters. It was observed that IL-33 overexpression significantly increased both glycolysis, 
glycolytic capacity and glycolytic reserve (Fig. 5.4H-I). Transfection with a control plasmid had no 
significant effect on glycolytic function in cells (Fig. 5.4H-I). No significant changes were observed in 
the OCR/ECAR ratio with IL-33 overexpression (Fig. 5.4J). These results indicated that glycolytic 
function was increased with IL-33 expression. The ECAR values did not plateau after the glucose 
injection and continued to increase post-inhibition of ATP synthase (Fig. 5.4H). This suggested that 
although glycolysis was increased, glucose continued to remain a substrate for mitochondrial OXPHOS.  
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Figure 5.4. Effect of IL-33 genetic modulation on ARPE-19 metabolism: 
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene. (A) Representative mitochondrial stress test measured with sequential injections 
of Oligomycin, FCCP and rotenone/antimycin A (B) Mitochondrial stress parameters (BR- basal respiration; MR- 
maximal respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from (A). 
(C) Representative glycolysis stress test measured with sequential injections of glucose, oligomycin and 2DG. (D) 
Glycolysis stress parameters (G- glycolysis; GC- glycolytic capacity; GR- glycolytic reserve; NGA- non-glycolytic 
acidification) calculated from (C). (E) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR. 
ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid or an IL33 activation gDNA plasmid. (F) 
Representative mitochondrial stress test measured with sequential injections of oligomycin, FCCP and 
rotenone/antimycin A (G) Mitochondrial stress parameters (BR- basal respiration; MR- maximal respiration; SRC- 
spare respiratory capacity; PL- proton leak; ATP- ATP-production) calculated from (F). (H) Representative 
glycolysis stress test measured with sequential injections of glucose, oligomycin and 2DG. (I) Glycolysis stress 
parameters (G- glycolysis; GC- glycolytic capacity; GR- glycolytic reserve; NGA- non-glycolytic acidification) 
calculated from (H). (J) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR. Data are expressed 
as means ± SD. Represents data from six independent experiments performed with either two or no technical 
repeats. One-way ANOVA with Tukey’s multiple comparisons test; *p<0.05, **p<0.01, ***p<0.005. 
  
5.5. Bioenergetic analysis of Il33-/- and Il1rl1-/- primary murine RPE 
To investigate the role of IL-33 further, I performed a bioenergetic analysis of primary RPE derived 
from Il33-/- mice. This was carried out to assess the metabolic effects of IL-33 loss in another system.  
 
Using a mitochondrial stress test, it was observed that in comparison to WT, Il33-/- mice had reduced 
maximal respiration and spare respiratory capacity (Fig. 5.5A-B). No significant changes were observed 
in basal respiration, ATP-production or non-mitochondrial oxygen consumption (Fig. 5.5A-B). Like IL-
33 KD ARPE-19 cells, I observed that primary Il33-/- RPE had increased glycolysis, and yet lacked 
glycolytic reserve, measured post-oligomycin (Fig. 5.5C-D).  There was no significant effect on the 
OCR/ECAR ratio (Fig. 5.5E). Together, these results mirror IL-33 inhibition caused by siRNA knock-down 
and suggest a change in the relative importance of glycolysis over OXPHOS in the absence of IL-33. 
 
The results from the previous sections suggest that altered IL-33 release and autocrine signalling does 
not contribute to the metabolic changes of transfected cells. However, it remained possible that 
autocrine IL-33 signalling could play a role and there remained a need to identify if the effects of IL-33 
loss (or overexpression) required receptor engagement. IL-33 binds and signals through its cognate 
receptor ST2 (encoded by Il1rl1) [133], and therefore targeting this signalling pathway addressed the 
question of whether ST2 is required for optimal metabolic function in the RPE. To address this, 
bioenergetic analysis was performed of primary RPE derived from Il1rl1-/- mice. A mitochondrial stress 
test was used to assess the activity and function of mitochondria in both WT and Il1rl1-/- mice. No 
significant changes were observed in mitochondrial respiration between groups (Fig. 5.5E-F). 
Following this, a glycolysis stress test was utilised to assess the key parameters of glycolytic flux within 
the isolated RPE cells. No significant changes were observed in glycolytic metabolism between Il1rl1-/- 
and WT controls (Fig. 5.5G-H). There was no significant effect on the OCR/ECAR ratio (Fig. 5.5I). 
Together these results show that a loss of ST2 expression has no effect on the metabolism of RPE. 
Furthermore, these results indicate that the effect of IL-33 loss is not dependent on ST2 signalling.  
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Figure 5.5. Bioenergetic analysis of Il33-/- and Il1rl1-/- primary murine RPE:  
Primary RPE were isolated from WT or Il33-/- mice. (A) Representative mitochondrial stress test measured with 
sequential injections of oligomycin, FCCP and rotenone/antimycin A. (B) Mitochondrial parameters (BR- basal 
respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-production) 
calculated from data shown in (A). (C) Representative glycolysis stress test measured with sequential injections 
of glucose, oligomycin and 2DG. (D) Glycolysis stress parameters (G- glycolysis; GC- glycolytic capacity; GR- 
glycolytic reserve; NGA- non-glycolytic acidification) calculated from (C). (E) Basal OCR and ECAR measurements 
expressed as the ratio OCR/ECAR. Primary RPE were isolated from WT or Il1rl1-/- mice. (F) Representative 
mitochondrial stress test measured with sequential injections of oligomycin, FCCP and rotenone/antimycin A. 
(G) Mitochondrial parameters (BR- basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; 
PL- proton leak; ATP- ATP-production) calculated from data shown in (F). (H) Representative glycolysis stress test 
measured with sequential injections of glucose, oligomycin and 2DG. (I) Glycolysis stress parameters (G- 
glycolysis; GC- glycolytic capacity; GR- glycolytic reserve; NGA- non-glycolytic acidification) calculated from (H). 
(J) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR. Data presented as means ± SD. (A, B 
and E) Represents data from three mice per group. (C-D) Represents data from two mice per group. Unpaired 
Student’s T-test; *p<0.05, **p<0.01, ***p<0.005. 
   
5.6. Glucose consumption, lactate production, ATP/ADP ratio and glycolysis/TCA gene transcription 
in ARPE-19 with IL-33 genetic modulation 
The results from the previous sections indicate that altering IL-33 expression status has an impact on 
the metabolism of RPE cells by a cell intrinsic mechanism. In the absence of IL-33, there appeared to 
be increased aerobic glycolysis, potentially at the expense of mitochondrial function. When IL-33 was 
overexpressed, both glycolysis and mitochondrial function increased. To extend these observations 
further using the XF platform, I tested alternative readouts of metabolism.  
 
Starting with the IL-33 KD cells, glucose consumption was assessed in the supernatants using a 
commercial glucose assay. No significant changes were observed in the glucose consumption between 
any group (Fig. 5.6A). Following this, I assessed the lactate output in the supernatants of IL-33 KD cells. 
Lactate output is used as a direct readout of aerobic glycolysis and therefore, one would expect the 
readout from the seahorse assay to match lactate production. The assay indicated that there was a 
significant increase in lactate production in the IL-33 siRNA group compared to that of a scrambled 
siRNA control (Fig. 5.6B). No significant changes were observed between the scrambled control and 
untreated cells, indicating the effects of the IL-33 siRNA were not a result of the transfection process 
(Fig. 5.6B). The ATP/ADP ratio gives an indication of the balance between ATP synthesis and ATP 
consumption in a cell. The ratio of ATP and ADP present was assessed, and it was found that IL-33 KD 
had no significant effect on this (Fig. 5.6C) suggesting the balance of ATP synthesis and consumption 
was not altered. To assess how metabolism relevant genes were affected by IL-33 KD, RT-PCR analysis 
of selected mRNAs encoding glycolytic and TCA cycle enzymes and nuclear transcription factors was 
performed. In the glycolysis pathway, KD of IL-33 with siRNA increased the expression of LDHA and 
GAPDH transcripts (Fig. 5.6D). PKM2 (the alternatively spliced isoform of pyruvate kinase) transcript 
levels were reduced with KD (Fig. 5.6D). In the TCA cycle, only the expression of PC (pyruvate 
carboxylase (PC)) was significantly reduced by IL-33 KD, no significant changes were observed in the 
transcription of other TCA cycle enzymes (Fig. 5.6D). Out of the five transcriptional regulators 
assessed, only the gene expression of SIRT4 was affected by IL-33 KD (Fig. 5.6D). Interestingly, SIRT4 
was a gene target upregulated with exogenous IL-33 expression in the previous chapter (see Fig. 4.15.). 
Together these results supported the earlier conclusions but indicated that the increased aerobic 
lactate production was not a result of upregulated glycolysis, as no changes were observed in glucose 
uptake by cells. The RT-PCR results pointed to transcriptional changes that occur with IL-33 KD in the 
glycolysis and TCA pathways. Up-regulation of lactate dehydrogenase-A expression may account for 
the increased lactate protection observed. However, the lack of mitochondrial capacity observed in 
the previous chapter could not attributed to reduced expression of TCA cycle enzymes, with only the 
anaplerotic enzyme pyruvate carboxylase affected in the context of IL-33 KD.  
 
Similar experiments were used to obtain a greater insight into the mechanisms governing metabolic 
changes occurring with upregulated IL-33 expression. In cells transfected with an IL-33 activation 
plasmid, there was increased glucose consumption in the supernatants compared to a control plasmid 
(Fig. 5.6E). Lactate output was also assessed to determine if aerobic glycolysis was also increased in 
cells, yet no significant changes were observed in the supernatants (Fig. 5.6F). The ATP/ADP ratio was 
measured in cells constitutively overexpressing IL-33 to identify if the metabolic changes were 
accompanied by a shift in ATP synthesis. No significant changes were observed in the ATP/ADP ratio, 
suggesting that the balance of synthesis to consumption remained unaltered (Fig. 5.6G). Pan 
glycolysis, pan TCA and transcriptional metabolic enzyme expression was assessed using RT-PCR. This 
permitted a greater understanding of how these metabolic pathways are influenced by IL-33. With 
transfection of the IL-33 plasmid, I found that there was an increased expression of multiple targets 
in glycolysis and the TCA cycle. IL-33 overexpression increased the transcript abundance of GLUT1 
(responsible for glucose import into the cell), and the glycolytic enzymes PFKP, ENO1 and both PKM 
isoforms (Fig. 5.6H). In terms of the TCA cycle enzymes, increased transcripts were observed in PDH, 
IDH1, FH, CH and SDHD (Fig. 5.6H). Nuclear located transcriptional regulators of metabolism were also 
observed to be affected by the overexpression of IL-33. MYC transcripts were significantly increased, 
yet the expression of SIRT1 was significantly reduced (Fig. 5.6H). These data strengthen those of 
section 5.4.  which show that increasing nuclear IL-33 expression via CRISPR-cas9 leads to an increase 
in both RPE glycolysis and OXPHOS. The increased glucose uptake from these cells and increased 
transcription of glycolytic enzymes support the increased glycolysis shown using the seahorse. 
Moreover, the lack of increased lactate production and increased expression of TCA cycle enzymes 
supports the hypothesis that glucose may be used as a substrate for mitochondrial OXPHOS and 
overexpression increases its flux into the TCA cycle. 
 
PDH is a key metabolic checkpoint which bridges both glycolysis and the TCA cycle. PDH is responsible 
for the conversion of pyruvate to acetyl-CoA for entry into the TCA cycle and inactivated by the PDK1-
dependent phosphorylation of a serine residue (Ser293) on the E1 subunit [469]. To identify whether 
nuclear IL-33 influenced oxidative glucose metabolism, there remained a necessity to identify if the 
activity of PDH was affected by IL-33 expression status. Cell lysates were taken from both scrambled 
siRNA/ IL-33 siRNA and control plasmid/ IL-33 plasmid transfected cells and an immunoblot was 
performed for both PDH and phosphorylated PDH (Ser293). With IL-33 KD there was no significant 
change in the activation status of PDH (Fig. 5.6I-J). When IL-33 was overexpressed, there was 
decreased phosphorylation of the Ser293 residue, and therefore increased activation compared to the 
control plasmid (Fig. 5.6I and K). This indicates, collectively that in the context of IL-33 overexpression 
there is increased flux through glycolysis and the TCA cycle. The activation of pyruvate kinase by IL-33 
overexpression suggests that there is increased entry of pyruvate into the TCA cycle. However, as IL-
33 KD had no effect of the activation status of PDH, it is unlikely that IL-33 regulates metabolic function 
in the RPE through PDH. The increased PDH activity with IL-33 is likely secondary to an alternative step 
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Figure 5.6. Glucose consumption, lactate production, ATP/ADP ratio and glycolysis/TCA gene transcription in 
ARPE-19 with IL-33 genetic modulation: 
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene. (A) Supernatants were assessed for relative glucose consumption. (B) 
Extracellular lactate measurements were taken in the media and expressed as a percentage of the mean 
untreated control. (C) ATP and ADP levels were quantified following cell lysis and expressed as the ratio 
ATP/ADP. (D) Quantitative RT-PCR of glycolytic pathway enzymes (HK2, LDHA, PFKP, GAPDH, PKM1, PKM2 and 
ENO1), GLUT1, HIF1α, PGC1α, SIRT1, SIRT4, and TCA cycle enzymes (SDHD, PDK1, IDH1, FH and CS) mRNA 
transcripts. ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid or an IL33 activation gDNA 
plasmid. (E) Supernatants were assessed for relative glucose consumption. (F) Extracellular lactate 
measurements were taken in the media and expressed as a percentage of the mean untreated control. (G) ATP 
and ADP levels were quantified following cell lysis and expressed as the ratio ATP/ADP. (H) Quantitative RT-PCR 
of glycolytic pathway enzymes (HK, LDHA, PFKP, GAPDH, PKM1, PKM2 and ENO1), GLUT1, HIF1α, PGC1α, SIRT1, 
SIRT4, and TCA cycle enzymes (SDHD, PDK1, IDH1, FH and CS) mRNA transcripts. (I-K) Western blot analysis was 
used to determine the phosphorylation of pyruvate dehydrogenase following transfection. Data are expressed 
as means ± SD. (A-C, E-G) Represents data from two independent experiments performed in duplicate. (D and 
H) Represents data from three independent experiments performed in duplicate. One-way ANOVA with Tukey’s 
multiple comparisons test; *p<0.05, **p<0.01, ***p<0.005. (I-K) Represents data from two independent blots. 
Unpaired Student’s t-test; *p<0.05. 
  
5.7. Contribution of pyruvate import and fatty oxidation to the metabolism of IL-33 knockdown or 
overexpressing ARPE-19  
The results in the previous sections have demonstrated that IL-33 expression is a critical determinant 
of ARPE-19 metabolism. When nuclear IL-33 is reduced, mitochondrial spare respiratory capacity is 
impaired at the expense of aerobic glycolysis. Although there was an increase in lactate production 
(despite no overall increase in glycolytic uptake), this was not attributable to reduced PDH activity. 
Considering this there remained a necessity to identify the extent to which pyruvate was utilised as a 
substrate for OXPHOS. When IL-33 was overexpressed, there was an increase in both glycolysis and 
OXPHOS accompanied by increased glucose uptake, broad transcriptional changes in glycolysis and 
TCA pathway genes, and increased end-point glycolysis activity into the TCA cycle via PDH. In view of 
these results, the logical next step was to consider if the increased mitochondrial function was solely 
a result of increased pyruvate import. 
 
Pyruvate is the end-point metabolite of glucose metabolism and the breakdown of many amino acids. 
It is produced within the cytosol and requires facilitated transport into the mitochondria for further 
degradation [536]. Pyruvate import is mediated through the MPC consisting of components MPC1/2 
[536]. These two inner mitochondrial membrane proteins (MPC1 and MPC2) form a 150kDa complex 
and are essential for the transport of pyruvate into the mitochondria [537]. A modified mitochondrial 
stress test with the additional injection of the MPC-specific inhibitor UK5099 [538] was used to assess 
the contribution of aerobic glucose metabolism to total OCR. In ARPE-19 cells that overexpress IL-33, 
the increased maximal respiration was largely due to increased pyruvate-dependent respiration (Fig. 
5.7A-B). UK5099 treatment reduced the maximal OCR to a similar level of the control plasmid (Fig. 
5.7A). When a similar experiment was performed on IL-33 siRNA cells it was observed that pyruvate-
dependent respiration had a significantly reduced contribution to maximal OCR (Fig. 5.7C-D).  
 
To assess if pyruvate metabolism was the only component affected by the altered expression of IL-33, 
or if other metabolic pathways feeding into the TCA cycle were involved, a similar experiment was 
conducted to assess fatty acid oxidation. Fatty acids are significant metabolic intermediates, because 
they can be used for lipid synthesis, protein modification, or degradation through β-oxidation to 
maintain ATP generation through oxidative phosphorylation [539]. The rate limiting step in the β-
oxidation process is the transfer of free fatty acids from the cytosol into the mitochondria by carnitine 
palmitoyltransferase-1 (CPT-1) [539]. A modified mitochondrial stress test with the additional 
injection of the CPT1 inhibitor etomoxir was used to assess the contribution of β-oxidation to maximal 
OCR. Etomoxir treatment post mitochondrial uncoupling significantly reduced the OCR, however 
between control plasmid and IL-33 plasmid groups this reduction was not significant (Fig. 5.7E-F). With 
IL-33 loss, we observed that β-oxidation was significantly increased (Fig. 5.7G-H), suggesting that β-
oxidation is upregulated in the absence of IL-33 to compensate for defects in pyruvate metabolism. 
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Figure 5.7. Contribution of pyruvate import and fatty oxidation to the metabolism of IL-33 knockdown or 
overexpressing ARPE-19: 
ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid/ IL33 activation gDNA plasmid or with 
either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes targeting the human IL33 gene. (A) 
Representative modified mitochondrial stress test measured with sequential injections of oligomycin, FCCP, UK-
5099 (40μM) and rotenone/antimycin A. (B) Parameter calculated from (A). (C) Representative modified 
mitochondrial stress test measured with sequential injections of oligomycin, FCCP, UK-5099 (40μM) and 
rotenone/antimycin A. (D) Parameter calculated from (C). (E) Representative modified mitochondrial stress test 
measured with sequential injections of oligomycin, FCCP, etomoxir (200μM) and rotenone/antimycin A. (F) 
Parameter calculated from (E). (G) Representative modified mitochondrial stress test measured with sequential 
injections of oligomycin, FCCP, etomoxir (200μM) and rotenone/antimycin A. (H) Parameter calculated from (G). 
Data are expressed as means ± SD. Represents data from three independent experiments performed in triplicate. 
Unpaired Student’s t-test; *p<0.05. 
   
5.8. Glucose pathway tracing in IL-33 knockdown or overexpressing ARPE-19 
To confirm that IL-33 influenced pyruvate oxidation in ARPE-19, I utilised SITA analysis to trace the flux 
of glucose through glycolysis and into the TCA cycle. SITA with [U-13C]-glucose allowed me to assess 
the uptake of isotopically labelled glucose into metabolite pools following KD or overexpression of IL-
33. Quantifying C13 labelling in different metabolite pools as cells approach steady-state equilibrium 
allows a true defect in pyruvate import into the mitochondria to be detected.  
 
To assess the effect of IL-33 KD on glucose metabolism in ARPE-19, GC-MS was used to measure the 
abundance of intracellular glycolysis and TCA cycle metabolites in samples. As cells were cultured with 
C13-isotopically labelled glucose, the C13 abundance of these metabolites could be solely attributed to 
a glucose carbon source. In the glycolysis pathway, there were no significant changes in the relative 
abundances of glyceraldehyde-3-phosphate, 3-phosphoglycerate, 2-phosphoglycerate or pyruvate 
(Fig. 5.8A-D). There was, however, a significant increase in the relative abundance of lactate in the IL-
33 siRNA compared to the scrambled siRNA control (Fig. 5.8E), matching the observed increase in 
extracellular lactate in the preceding sections. Glucose-derived pyruvate constitutes a major source 
of acetyl-coA which serves as a key carbon input into the TCA cycle [540]. Acetyl-coA enters at the 
citrate synthase step and combines with oxaloacetate to form citrate [540]. Citrate C13 enrichment 
was observed to be significantly decreased in the IL-33 siRNA compared to the scrambled siRNA 
control (Fig. 5.8F).  Relative abundances of C13-labelled succinate and malate were also reduced by IL-
33 siRNA treatment (Fig. 5.8G and I). However, no significant changes were observed in the abundance 
of C13-labelled fumarate, malate, oxaloacetate and aspartate (Fig. 5.8H, J-L). `These results support 
the earlier conclusions and suggest that there is a defect in pyruvate entry into the TCA cycle when IL-
33 is reduced. The carbon tracing data indicates that pyruvate is metabolized into lactate rather than 
entering the TCA cycle to form citrate.  
 
For each metabolite, signals were monitored at the nominal m/z (M0) and at all detectable naturally 
labelled mass isotopomers (M+X). MID patterns of a given metabolite can yield essential information 
into the flux between interacting metabolic pathways. Labelling patterns using C13-labelled glucose 
then highlight differential flux from glycolysis and pyruvate input into the TCA cycle. Glucose-derived 
pyruvate can enter the TCA cycle through either PDH or PC (Figure 5.9). The citrate M+2/pyruvate 
M+3 ratio can serve as a surrogate for PDH activity, while the citrate M+3/pyruvate M+3 ratio is used 
as a surrogate of PC activity [541]. 
 
With IL-33 siRNA there was an increased enrichment of M+3 pyruvate (Fig. 5.10A), indicating an 
increased abundance of glucose-derived pyruvate and a reduced utilization of these carbons in the 
TCA cycle [541]. KD of IL-33 significantly reduced both the citrate M+2/pyruvate M+3 (Figure 5.10B) 
and citrate M+3/pyruvate M+3 (Figure 5.10C) ratios suggesting a decrease in the activity of both PDH 
and PC complexes.  
 
After performing the experiments in the context of IL-33 loss, I assessed how glucose metabolism was 
affected by IL-33 overexpression. In a similar manner, cells were cultured with an C13-isotopically 
labelled glucose tracer permitting the identification of glucose derived metabolite abundances within 
ARPE-19 cells. In the glycolysis pathway, there were significant increases in the relative metabolite 
abundances of C13-isotopically labelled glyceraldehyde-3-phosphate, 3-phosphoglycerate and 2-
phosphoglycerate (Fig. 5.11A-C). No significant changes were observed in the relative abundances of 
the glycolysis “end-point” metabolites pyruvate or lactate (Fig. 5.11D-E). In the TCA cycle, there was a 
significant increase in C13-enrichment in all metabolites assessed (Fig. 5.11F-L), indicating that glucose-
derived TCA cycle activity was up-regulated with IL-33 overexpression.  
 
Overexpression of IL-33 lead to a decrease in the enrichment of M+3 pyruvate (Fig. 5.12A). There was 
a significant increase in the citrate M+2/pyruvate M+3 ratio (Fig. 5.12B), suggesting that PDH activity 
was augmented with IL-33 plasmid treatment. No significant changes were observed in the citrate 
M+3/pyruvate M+3 ratio with IL-33 overexpression (Fig. 5.12C), indicating that increased pyruvate 
entry into the TCA cycle was largely dependent on PDH rather PC activity. With IL-33 overexpression 
a significant increase in citrate M+6 was observed (Fig. 5.12D). This pattern will occur in citrate when 
both oxaloacetate and malate carbons are derived from glucose. Increased M+4 aspartate (Fig. 5.12E) 
and malate (Fig. 5.12F) indicate the increased TCA cycling which occurs with IL-33 overexpression. 
When TCA cycling increases, the production rate of labelled TCA metabolites may be greater than their 
consumption rate. If this is the case, C13 labelling may be increased in amino acid metabolites which 
branch off the glycolysis pathway (e.g. alanine, which is transaminated via glutamic pyruvic 
transaminase 1/2) [542]. With IL-33 overexpression, there was an observed decrease in M+3 alanine 















0 .0 0 0 0
0 .0 0 0 1
0 .0 0 0 2
0 .0 0 0 3
0 .0 0 0 4













G ly c e ra ld e h y d e



































3 -p h o s p h o



































2 -p h o s p h o
















0 .0 0 0
0 .0 0 5
0 .0 1 0
0 .0 1 5
0 .0 2 0

















































































































































































































































































































Figure 5.8. Glucose tracing in ARPE-19 with IL-33 knockdown: 
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene. Cells were incubated for 2h with media containing isotopically labelled glucose 
and GC-MS was used to quantify relative C13 (black) or C12 (white) incorporation into glyceraldehyde-3-
phosphate (A), 3-phosphoglycerate (B), 2-phosphoglycerate (C), pyruvate (D), lactate (E), citrate (F), α-
ketoglutarate (G), succinate (H), fumarate (I), malate (J), oxaloacetate (K) and aspartate (L) metabolite pools.  




Figure 5.9. Citrate labelling from C13-glucose via pyruvate dehydrogenase and pyruvate carboxylase activity in 
the first turn of the TCA cycle: 
Isotopologue distribution in citrate can be used to obtain a clearer representation of pathways feeding into the 
TCA cycle. Glucose-derived pyruvate can pass into the TCA cycle via either oxidation into acetyl-coA by the PDH 
complex or the anaplerotic generation of oxaloacetate through PC. Activation of PDH will conventionally form 
M+2 citrate, as positions C1 and C2 are labelled with the glucose-derived tracer. In contrast, activation of PC 
conventionally forms M+3 oxaloacetate, which in turn forms M+3 citrate as positions C3, C4 and C5 are labelled 
with C13. The citrate M+2/pyruvate M+3 ratio can serve as a surrogate for PDH activity, whereas the citrate 
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Figure 5.10. Differential citrate labelling from C13-glucose in ARPE-19 with IL-33 knockdown: 
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene. Cells were incubated for 2h with media containing isotopically labelled glucose 
and GC-MS was used to quantify relative C13 incorporation. (A) Mass isotopomer distribution of [U-13C]-glucose-
derived carbon into pyruvate. This data indicates the raw abundances of the indicated isotopomers in the 
pyruvate metabolite pool. (B) Citrate m+2/pyruvate m+3 ratio can be a surrogate for PDH activity. (C) Citrate 
m+3/pyruvate m+3 ratio can be a surrogate for PC activity. Data expressed as relative mean from three 
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Figure 5.11. Glucose tracing in ARPE-19 constitutively overexpressing IL-33: 
ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid/ IL33 activation gDNA plasmid. Cells 
were incubated for 2h with media containing isotopically labelled glucose and GC-MS was used to quantify 
relative C13 (black) or C12 (white) incorporation into glyceraldehyde-3-phosphate (A), 3-phosphoglycerate (B), 2-
phosphoglycerate (C), pyruvate (D), lactate (E), citrate (F), α-ketoglutarate (G), succinate (H), fumarate (I), malate 
(J), oxaloacetate (K) and aspartate (L) metabolite pools.  Data expressed as relative mean from three 
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Figure 5.12. ARPE-19 overexpressing IL-33 exhibit increased TCA cycling: 
ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid/ IL33 activation gDNA plasmid. Cells 
were incubated for 2h with media containing isotopically labelled glucose and GC-MS was used to quantify 
relative C13 incorporation. (A) Mass isotopomer distribution of [U-13C]-glucose-derived carbon into pyruvate. 
This data indicates the raw abundances of the indicated isotopomers in the pyruvate metabolite pool. (B) Citrate 
m+2/pyruvate m+3 ratio can be a surrogate for PDH activity. (C) Citrate m+3/pyruvate m+3 ratio can be a 
surrogate for PC activity. Mass isotopomer distribution of [U-13C]-glucose-derived carbon into citrate, malate, 
aspartate and alanine. The distribution of m+6 citrate (D), m+3 and m+4 aspartate (E), m+1 and m+4 malate (F), 
and m+3 alanine (G) was determined by GC-MS. This data indicates the raw abundances of the indicated 
isotopomers in their respective metabolite pools. Data expressed as relative mean from three independent 
experiments. Unpaired Student’s T-test; *p<0.05; *p<0.01. 
 
  
5.9. IL-33 regulates the expression of MPC1 and 2 in ARPE-19 cells 
Collectively the data presented so far suggest that nuclear IL-33 is a regulator of pyruvate oxidative 
metabolism in the RPE. When over expressed, there is increased glycolytic flux into the TCA cycle, 
which boosts OXPHOS likely through increased PDH activity. The absence of IL-33 reduces OXPHOS 
activity as pyruvate is “metabolically redirected” into lactate production. Whilst the data indicated a 
bona fide alteration to pyruvate metabolism when IL-33 was either lost or overexpressed, there 
remained a need to identify the molecular mechanisms.  
 
As detailed in the previous section, the use of the MPC inhibitor UK5099 indicated that MPC-
dependent pyruvate entry and mitochondrial oxidation was affected by IL-33 expression. These results 
suggested that in the absence of IL-33, defects in the entry of pyruvate into the mitochondria were 
present. When IL-33 was overexpressed, increased pyruvate entered the TCA cycle for OXPHOS. 
Considering these results, I investigated whether altering IL-33 expression would alter MPC expression 
in transfected ARPE-19. Altered MPC1/MPC2 expression results in significant metabolic disorders and 
has been previously shown to contribute to the Warburg effect in cancer cells [295].  
 
RT-PCR was used to identify the gene expression of nuclear encoded MPC1 and MPC2 genes following 
modulation of IL-33 using either siRNA or CRISPR-cas9. KD of IL-33 using siRNA significantly reduced 
the abundance of both MPC1 and MPC2 mRNA transcripts (Fig. 5.13A). Overexpression of IL-33 lead 
to increased MPC1 but had no significant effect on MPC2 mRNA expression (Fig. 5.13B). To confirm 
that the differences in gene transcription matched translation (and therefore protein expression), 
immunoblotting was performed for both MPC1 and MPC2 proteins. Transfection of ARPE-19 with IL-
33 siRNA significantly reduced the protein expression of both MPC components relative to a scrambled 
siRNA control (Fig. 5.13C-D). In contrast ARPE-19 transfected with an IL-33 overexpression plasmid 
increased MPC1 expression, yet no significant effect was observed in MPC2 expression relative to a 
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Figure 5.13. IL-33 regulates the expression of MPC1 and 2 in ARPE-19 cells: 
(A) ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene; RNA was extracted, and RT-PCR was used to determine the expression of MPC1 
and MPC2. (B) ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid or an IL33 activation 
gDNA plasmid; RNA was extracted, and RT-PCR was used to determine the expression of MPC1 and MPC2. (C-D) 
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene; protein was extracted, and western blot analysis was used to determine the 
expression of MPC1 and MPC2. (E-F) ARPE-19 were transfected for 48h with either a scrambled gDNA plasmid 
or an IL33 activation gDNA plasmid; protein was extracted, and western blot analysis was used to determine the 
expression of MPC1 and MPC2. (A-B) Represents data from three independent experiments performed in 
triplicate. (C-F) Represents data from three independent western blots. Unpaired Student’s T-test; *p<0.01.   
5.10. Recombinant IL-33 is unable to rescue metabolic defects with IL-33 loss 
Results presented in both this chapter and chapter 4 suggest differential roles of the cytokine on RPE 
metabolism through intracellular interactions ST2 dependent extracellular alarmin activity. 
Extracellular IL-33/ST2 signalling was accompanied with increased metabolic activity (particularly in 
the glycolysis pathway/TCA cycle). Similarly, increases in the nuclear expression of IL-33 lead to 
augmented glycolytic flux into the TCA cycle, whereas KD/loss of endogenous IL-33 impaired TCA 
activity. Considering these findings, I considered whether IL-33 signalling via ST2 could overcome the 
metabolic defects observed in the RPE with IL-33 loss.  
 
To address this hypothesis, primary RPE were isolated from both WT and Il33-/- mice and treated with 
rmIL-33 for 24h; following this, XF analysis was performed to identify metabolic changes. A 
mitochondrial stress test was utilised to investigate mitochondrial metabolism. As previously detailed, 
IL-33 loss impairs primary RPE spare respiratory capacity, whereas treatment with exogenous IL-33 
boosts RPE OXPHOS capacity. The addition of rmIL-33 to primary Il33-/- RPE was unable to restore 
impaired mitochondrial function (Fig. 5.14A-C). A complimentary experiment was performed in 
human ARPE-19 cells. IL-33 KD was first induced using siRNA; following KD cells were incubated for 
24h in the presence or absence of rhIL-33. The addition of rhIL-33 to the IL-33 KD cells was unable to 
alleviate impaired mitochondrial function (Fig. 5.14D-F). These data indicate that regulation of 
metabolic properties by intrinsic IL-33 is independent from IL-33 receptor dependent signalling.  
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Figure 5.14. Recombinant IL-33 fails to reverse the effects of IL-33 loss in the RPE: 
Primary RPE were isolated from WT or Il33-/- mice and treated for 24h with rmIL-33 (100ng/ml). (A) 
Representative mitochondrial stress test measured with sequential injections of oligomycin, FCCP and 
rotenone/antimycin A. (B) OXPHOS parameters calculated from data shown in (A). (C) Basal OCR and ECAR 
measurements expressed as the ratio OCR/ECAR. ARPE-19 were transfected for 48h with either scrambled siRNA 
or a pre-selected mixture of 4 siRNA duplexes targeting the human IL33 gene. Cells were treated for a further 
24h with rhIL-33. (D) Representative mitochondrial stress test measured with sequential injections of 
oligomycin, FCCP and rotenone/antimycin A. (E) OXPHOS parameters calculated from data shown in (D). (F) Basal 
OCR and ECAR measurements expressed as the ratio OCR/ECAR. (100ng/ml). Data presented as means ± SD. (A-
C) Represents data from two mice per group. (D-F) Represents data from four independent experiments run 
with no technical repeats. One-way ANOVA with Tukey’s multiple comparisons test; *p<0.05. 
  
5.11. RPE mitochondrial analysis with alternate IL-33 expression status 
Recent studies have determined a novel role for IL-33 in the maintenance of mitochondrial respiration. 
Mitochondria from Il33-/- and Il1rl1-/- beige and brown adipocytes were observed to exhibit reduced 
OXPHOS and expression of ETC components; moreover, electron microscopy demonstrated functional 
defects in mitochondrial structure [19]. Given the pronounced changes in metabolism in 
absence/overexpression of IL-33 I used transmission electron microscopy to identify visible structural 
changes in primary murine RPE mitochondria. Compared to WT mitochondria, Il33-/- mitochondria 
were smaller, elongated and more irregular in size (Fig. 5.15A-B, F). Image analysis of mitochondrial 
samples showed that mitochondrial diameter was decreased in Il33-/- cells (Fig. 5.15C). No significant 
changes were observed in mitochondrial area (Fig. 5.15D), but there was increased mitochondrial 
number/field in the Il33-/- group (Fig. 5.15E). Additionally, retinal sections from Il33-/- mice stained with 
MitoGreen™ were observed to have increased mitochondrial density (Fig. 5.15G-H). Mitochondrial 
staining was localised to the RPE, outer plexiform layer and inner plexiform layer (Fig. 5.15G). 
 
A similar experimental pipeline was used to assess mitochondrial structure in ARPE-19 cells exhibiting 
IL-33 KD (via siRNA). Electron microscopy was used to identify structural changes in the IL-33 siRNA 
group compared to a scrambled siRNA control (Fig. 5.16A-C). Image analysis identified significant 
alterations to both the mitochondrial diameter (Fig. 5.16D) and area (Fig. 5.16E) in the IL-33 siRNA 
group compared to a scrambled siRNA control. Interestingly, transfection with the scrambled siRNA 
alone elicited changes to the mitochondrial diameter (Fig. 5.16D). After transfection with the IL-33 
siRNA, it was apparent there were changes to mitochondrial morphologies. Unstimulated cells showed 
typically fragmented mitochondria (62.4%) and short tubular mitochondria (32%), long tubular 
mitochondria were observed at a lower frequency of (5.6%) (Fig. 5.16E). This was similar in the 
scrambled siRNA transfected group, with fragmented mitochondria (67.3%), short tubular 
mitochondria (13.1%) and long tubular mitochondria (19.6%). In the IL-33 siRNA group, the frequency 
of mitochondrial morphologies was altered, with almost all mitochondria observed as fragmented 
(97.4%), with very few tubular mitochondria observed (Fig. 5.16F). The increased mitochondrial size 
and elongation suggested that mitochondrial fission and fusion processes (see section 3.14) were 
affected by IL-33 KD. The transcription status of nuclear-encoded mitochondrial fission/fusion 
enzymes was assessed by RT-PCR in ARPE-19 cells transfected with either scrambled or IL-33 siRNA. 
In response to IL-33 KD there was no changes observed to the transcription of DRP1 (involved in 
mitochondrial fission), MFN2 and OPA1 (both involved in mitochondrial fusion) or PINK1 (a regulator 
of mitophagy) mRNA transcripts (Fig. 5.16G). Surprisingly, IL-33 KD significantly upregulated the 
expression of MFN1, an enzyme involved in OMM fusion (Fig. 5.16G). Collectively, the QPCR data 
suggested that the mitochondrial fission (and generation of fragmented mitochondria) was not as a 
result to IL-33-mediated transcriptional reprogramming of fission/fusion genes. As DRP1 is regulated 
by phosphorylation, it is plausible that its activation state is altered in the absence of IL-33. This, 
however, was not investigated in this body of work.  
 
As the electron microscopy analysis showed structural alterations that affected the mitochondria, this 
was followed up by an assessment of total mitochondrial number was affected. RT-PCR was used to 
estimate mitochondrial content through the amplification of cytochrome B and 16 S rRNA transcripts 
[397]. An increased mitochondrial copy number was observed in the absence of IL-33 compared to a 
scrambled siRNA control (Fig. 5.16H). Following establishing the increased mitochondrial mass in the 
IL-33 KD group, it was of interest to identify if there were alterations in the abundance of 
mitochondrial ETC complexes, as quantified by immunoblotting. It was observed that IL-33 siRNA 
treatment significantly increased the expression of complexes IV, III and II (Fig. 5.17A-B). No significant 
changes were observed to the expression of the ATP synthase complex (complex V) and complex I (Fig. 
5.17A-B).  
 
Having established that IL-33 loss - both in murine RPE sections and human cell line cultures – leads 
to changes in mitochondria architecture (albeit varied between mouse and human), mitochondrial 
density and the expression of ETC components, it was necessary to examine how IL-33 overexpression 
would influence mitochondrial structure. Again, using electron microscopy, it was determined that 
overexpression of IL-33 significantly altered the structure of ARPE-19 mitochondria (Fig. 5.18A-C). 
although, no significant changes were observed to either mitochondrial diameter (Fig. 5.18D) or 
mitochondrial area (Fig. 5.18E) when IL-33 was overexpressed, there was a significant shift in the 
percentage of tubular mitochondria, compared to a scrambled plasmid control (Fig. 5.18F). In the 
control plasmid group, fragmented mitochondria were observed at the highest frequency (45.3%), 
with long tubular and short tubular mitochondria observed at 27.2% and 27.5%, respectively (Fig. 
5.18F). In the IL-33 plasmid group, the percentage of fragmented mitochondria had shifted to 10.4%. 
Long tubular and short tubular mitochondria were observed at a higher frequency in these images, 
occurring at 52.6% and 37%, respectively (Fig. 5.18F). Like the IL-33KD experiments, mitochondrial 
morphologies were affected by IL-33 overexpression. To investigate if the alterations in mitochondrial 
morphology were attributed to nuclear-encoded mitochondrial fission/fusion enzymes, I utilized RT-
PCR to determine their gene expression. IL-33 overexpression led to increased mRNA expression of 
the pro-fusion enzyme MFN2 (Fig. 5.19G). PINK1 mRNA transcripts were found to be significantly 
decreased with IL-33 overexpression (Fig. 5.18G). No significant changes were observed to the 
expression of MFN1, OPA1 and DRP1 (Fig. 5.18G). Collectively, these data indicate that mitochondrial 
remodelling occurs with IL-33 overexpression, increasing the frequency of “fused” mitochondria. 
Although MFN2 expression status was altered by the overexpression of IL-33 its role in mitochondrial 
remodelling was not investigated further. 
 
To investigate if mitochondrial number was affected by the overexpression of IL-33, mtDNA copy 
number was quantified using RT-PCR. However, no significant changes in mitochondrial copy number 
were observed (Fig. 5.18H). Whilst mitochondria number remained unchanged, it was of interest to 
see if the changes in mitochondria structure and function were accompanied by alterations to the 
expression of ETC components. Using immunoblotting, the expression of complexes V-I were 
quantified in ARPE-19 cells transfected with either a control plasmid or an IL-33 activation plasmid. It 
was observed that overexpression of IL-33 had no significant effect on the protein expression of 
complexes V, IV and II (Fig. 5.19A-B). Interestingly, IL-33 overexpression significantly reduced the 
expression of complexes I and III (Fig. 5.19A-B). 
 
Taken together, the results from this section indicate that the previously described metabolic changes 
observed in the RPE with changes in IL-33 expression status are concurrent with alterations in 
mitochondrial structure, morphology and expression of functional components. Primary RPE from 
Il33-/- mice exhibited alterations to mitochondrial morphology and increased mitochondrial number. 
Although mitochondrial structural changes were observed in ARPE-19 cells with transient IL-33 KD, 
these were towards a higher proportionality of fragmented punctate mitochondria, rather than short 
(and to a lesser extent) long tubular, as observed in from Il33-/- mice. IL-33 KD, both transiently and 
germline KO, led to increased mitochondrial abundance. Moreover, IL-33 siRNA treated ARPE-19 cells 
exhibited increased abundance of ETC components compared to a scrambled siRNA. IL-33 
overexpression equally altered both mitochondrial structure and morphology. IL-33 overexpressing 
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Figure 5.15. Mitochondrial analysis of Il33-/- RPE: 
Representative transmission electron microscopy of RPE from (A) WT and (B) Il33-/- mice. Magnification 9300x. 
(C) Mitochondrial diameter, (B) mitochondrial area and (C) mitochondrial number were calculated using ImageJ 
from transmission electron microscopy images of RPE from WT and Il33-/- mice (as detailed in methods). (F) 
Quantification of mitochondrial morphology into either fragmented, short tubular or long tubular phenotypes. 
(G) Eyes from both WT and Il33-/- mice were collected and sections or RPE/choroid whole-mounts were 
prepared. Representative confocal images of sections show the mitochondrial content in the retina 
(MitoGreen™ was used to analyse mitochondrial density). (H) Quantitative MFI analysis from confocal images 
displayed in (G). Data are expressed as means ± SD from three independent experiments. Unpaired Student’s 
T-test; *p<0.05, ***p<0.001. 
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Figure 5.16. Mitochondrial analysis of ARPE-19 with IL-33 knockdown: 
Representative transmission electron microscopy of ARPE-19 from (A) untreated, (B) scrambled siRNA 
transfected and (C) IL-33 siRNA transfected. (D) Mitochondrial diameter and (E) area were calculated using 
ImageJ. (F) Quantification of mitochondrial morphology into either fragmented, short tubular or long tubular 
phenotypes. (G) Quantitative RT-PCR was performed to assess mitochondrial content; this was estimated from 
the amplification of CTYB and 16S rRNA relative to BGLOB mRNA transcripts. Data are presented as means ± SD 
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Figure 5.17. Expression of ETC components in ARPE-19 with IL-33 knock-down: 
(A) ARPE-19 cells were transfected with either a scrambled siRNA or an IL-33 siRNA. Western blot analysis was 
used to determine the expression of ETC complexes (ATP synthase V, Cox2 IV, UQCRC2 III, SHDB II and NDUFB8 
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Figure 5.18. Mitochondrial analysis of ARPE-19 cells with IL-33 overexpression: 
Representative transmission electron microscopy of ARPE-19 from (A) untreated, (B) control plasmid transfected 
and (C) IL-33 plasmid transfected. (D) Mitochondrial diameter and (E) area were calculated using ImageJ. (F) 
Quantification of mitochondrial morphology into either fragmented, short tubular or long tubular phenotypes. 
(G) Quantitative RT-PCR was performed to assess mitochondrial content; this was estimated from the 
amplification of CTYB and 16S rRNA relative to BGLOB mRNA transcripts. Data are presented as means ± SD from 
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Figure 5.19. Expression of ETC components in ARPE-19 with IL-33 overexpression: 
(A) ARPE-19 cells were transfected with either a control plasmid or an IL-33 activation plasmid. Western blot 
analysis was used to determine the expression of ETC complexes (ATP synthase V, Cox2 IV, UQCRC2 III, SHDB II 
and NDUFB8 I). (B) Relative densitometry was calculated from (G) using ImageJ.  
  
5.12. Discussion 
In this chapter I have addressed a central question in the biology of IL-33 focusing on the role that 
endogenous IL-33 plays regulating cellular function. These results demonstrate that endogenous IL-33 
expression status influences metabolic regulation in RPE cells. IL-33 loss in RPE cells increases aerobic 
glycolysis at the expense of oxidative glucose catabolism, as IL-33 was found to regulate pyruvate 
import into the mitochondria through the MPC complex. Cells overexpressing IL-33 display increased 
expression of MPC complex components and activity of pyruvate dehydrogenase to facilitate 
increased pyruvate flux into the TCA cycle. This may have implications for innate immune activation 
of the RPE whereby metabolic changes are accompanied by an increase in the expression of nuclear 
IL-33. 
 
The intracellular properties of IL-33 remain poorly defined to date and it is currently unknown to what 
extent nuclear localised IL-33 exerts effects on gene expression, although  within the literature it is 
reported as a difunctional cytokine, acting both as a “nuclear transcription factor” and extracellular 
ligand for ST2-dependent signalling [256]. IL-33 is constitutively expressed in mainly epithelial cells 
and fibroblasts during homeostasis [137], with expression levels augmented during inflammation 
[146, 543]. Following cellular damage or stress IL-33 is released and acts as a potent pro-inflammatory 
cytokine [243]. Emerging evidence suggests that functions of IL-33 do not extend beyond its 
extracellular ability to activate ST2-expressing cells; and its unique nuclear localisation and chromatin 
binding properties are simply evolutionary conserved mechanisms which relate to storage for cytokine 
release and bioactivity [230, 263]. These conclusions are in contrast with other recent findings, 
providing a plethora of experimental data which suggests a nuclear role for the cytokine (e.g. 
regulation of Nf-kB activity [10, 259, 260], binding to homeobox binding motifs in the promoter 
regions of IL1RL1, IL6 and CCL5 [257] or Il13 [258] and an extensive nuclear interactome converging 
on transcriptional and chromatin remodelling factors [261].  
 
My findings strongly support the conclusion that nuclear localised IL-33 plays an essential part in 
mitochondrial respiration in the RPE. These results attribute a dual-function to IL-33 in the cellular 
context of the RPE. Cells lacking IL-33 display abnormal mitochondrial respiration, with diminished 
spare respiratory capacity. This is consistent with observations in adipose tissue where isolated 
mitochondria from Il33-/-  (and Il1rl1-/-) mice exhibited profound respiratory defects, including reduced 
OXPHOS, and enzymatic activity of ETC complexes II and IV [19]. It is therefore of note that RPE from 
Il1rl1-/- deficient mice did not exhibit bioenergetic changes. The same study identified an increased 
expression of genes involved in the catabolism of fatty acids, glucose and amino acids in Il33-/- adipose 
tissue suggesting a similar compensatory mechanism as I report in the RPE in the face of reduced 
mitochondrial function [19]. This study identified a mechanism whereby IL-33 indirectly affects 
mitochondrial function through the alternative splicing of UCP1 mRNA transcripts [19]. UCP1 is 
localised to the inner mitochondrial membrane and plays a key role in the regulation of energy 
expenditure through uncoupling substrate oxidation from ATP production [544]. Until recently it was 
believed that UCP1 expression was exclusive to brown adipose tissue. Recent studies have identified 
Ucp1 in white adipose tissue, pancreatic islets, skeletal muscle, rat and mouse thymus [545-547]. UCP1 
expression has been observed in both bovine and human retina [548, 549], and the UCP1 −3826A/G 
polymorphism is associated with diabetic retinopathy [549]. It would be of interest to investigate (A) 
whether UCP1 is expressed in human RPE and (if so) (B) is IL-33 involved in its alternative splicing 
therefore contributing to defects in mitochondrial function with IL-33 loss.  
 
Multiple lines of evidence suggest that the increased aerobic glycolysis seen with IL-33 loss in the RPE 
occurs at the expense of oxidative glucose catabolism, as IL-33 impairs pyruvate import into the 
mitochondria through the MPC complex. Support for this was obtained from IL-33KD ARPE-19, where 
reduced expression of both MPC1 and MPC2 was found. These are known to be essential proteins in 
the facilitated transport of pyruvate into the mitochondria [537].  Furthermore, cells overexpressing 
IL-33 displayed reduced aerobic glycolysis as mitochondrial activity was increased. The increased 
expression of MPC complex components and activity of pyruvate dehydrogenase was accompanied 
by an increased consumption and oxidation of glucose within the TCA cycle. The increased spare 
respiratory capacity was found to be attributed to pyruvate import following the use of the MPC-
specific inhibitor UK5099 (Fig. 7E) [294]. I found that IL-33 is a key mediator of transcriptional changes 
to glycolytic and TCA cycle genes, which either drive the RPE into aerobic glycolysis or mitochondrial 
metabolism in its absence or presence, respectively. Altered MPC1/MPC2 expression results in 
significant metabolic disorders and has been previously shown to contribute to the Warburg effect in 
cancer cells [295]. An increased reliance on glycolysis may lead to RPE dysfunction and increase the 
metabolic burden placed upon the photoreceptors; although future work will be required to assess if 
retinal degeneration is accelerated in mice lacking IL-33.  
 
Carbon tracing data with C13-glucose supports the hypothesis that IL-33 loss impairs pyruvate import 
in the RPE. Indeed, loss of C13 enrichment was observed in the first three TCA cycle intermediates, 
increased lactate enrichment and reduced enzymatic activities of PDH and PC. As the C13 enrichment 
was maintained in the remainder of TCA metabolites from fumarate onwards, this suggests that 
glucose may be redirected into other metabolite pools and fed back into the TCA cycle at different 
entry points. Pyruvate supports the biosynthesis of alanine, valine, isoleucine and leucine. Glucogenic 
valine and isoleucine enter the TCA cycle via succinate-coA, whereas leucine and alanine enter via 
acetyl-coA and pyruvate respectively. One can speculate that the TCA cycle may be maintained 
through a metabolic “shunt” via fatty acid synthesis and catabolism effectively bypassing pyruvate 
entry. This, however, is purely theoretical and will require further investigation into these pathways 
in the RPE.  
 
Although alterations to MPC expression likely contributes to the bioenergetic differences observed in 
RPE cells with alternate IL-33 expression, it is unlikely that this alone regulates the altered flux of 
glucose-derived carbon into the TCA cycle. In the context of IL-33 overexpression, there was an 
increased abundance of C13 labelling in many glycolytic intermediates, indicating increased glycolytic 
flux. It is dubious that MPC1 upregulation alone is responsible for an upregulation of glycolysis, and so 
a question emerges as to which other regulatory nodes are affected by IL-33. GLUT1, MYC and multiple 
glycolytic enzyme mRNA transcripts were found to be upregulated with IL-33 overexpression 
suggesting an influence of pro-glycolytic pathways. 
 
In addition to this, future work will be required to examine the extent to which glutamine metabolism 
and fatty acid oxidation maintain the TCA cycle in the absence of pyruvate entry. Fatty acid oxidation 
was assessed in the context of IL-33 KD using a modified seahorse analysis including etomoxir 
treatment, with significant effects were observed.  However, many effects of etomoxir are regarded 
as “off target” nonspecific effects (via the disruption of coA homeostasis/ inhibition of mitochondrial 
ETC complex 1) which have led to its use as a CPT1 inhibitor to be questioned [298, 550]. As a result 
of this, further work using isotopically labelled palmitate will be required to assess how β-oxidation is 
impacted by changes in pyruvate metabolism. Glutamine metabolism can be assessed using 
isotopically labelled glutamine and may additionally provide insight into how mitochondrial 




Figure 5.20. IL-33 regulates RPE metabolic phenotype: 
In an IL-33-deficient RPE (left), glucose enters through surface GLUT1 transporters and is metabolised through 
glycolysis to produce pyruvate. As MPC1 and 2 expression is lost, pyruvate is metabolically rediverted to produce 
lactate, which is then exported. As pyruvate does not undergo oxidative catabolism, a functional TCA cycle, and 
thus ATP levels are maintained through increased fatty acid oxidation. In an IL-33-overexpressing RPE (right), 
increased levels of glucose enter the cell through the increased expression of cell surface GLUT1. Increased 
glycolysis lead to the production of pyruvate, which enters the mitochondrion through increased expression of 
MPC1 and 2. Mitochondrial pyruvate oxidation provides increased levels of OXPHOS and greatly enhances the 
RPE respiratory capacity. RPE, retinal pigment epithelium; GLUT1, glucose transporter 1; MPC, mitochondrial 
pyruvate carrier; OXPHOS, oxidative phosphorylation; KO, knock-out; OE, overexpression.  
 
  
While these experiments have uncovered a role for IL-33 in mitochondrial respiration in RPE, a key 
question that emerges from this work is how does IL-33 regulate expression of MPC1/2 in RPE to 
facilitate the transport of pyruvate. One could speculate a likely (direct or indirect) nuclear interaction 
with either MPC promoter regions, an MPC regulating transcriptional factor or splicing machinery that 
influence expression of MPC transcript variants. Future research exploiting high-throughput 
approaches (e.g CHIP-sequencing and/or proteomics of the IL-33 interactome) will provide a clearer 
understanding of the regulation of RPE metabolism by IL-33 and will benefit the understanding of 
extent, to which nuclear IL-33 exerts effects on the cellular function. Whilst this chapter has looked at 
the effects of IL-33 genetic modulation at basal state metabolism, the role of nuclear IL-33 in “stress”-
induced changes has not been examined. Inflammatory mediators mediate cellular metabolic 
adaptations and lead to the increased expression of nuclear IL-33, essential for cellular responses [223, 
229, 551]. As nuclear IL-33 is reportedly involved in the regulation of HIF1-α [442], and HIF1-α is a 
critical regulator of the Warburg effect in immune cells  [345], it would be of interest to uncover the 
role (if any) of IL-33 in the regulation of bioenergetic responses to inflammatory stress.  
 
Dynamic changes in mitochondrial morphology are suggested to regulate mitochondrial metabolism 
[472]. The elongated mitochondrial phenotype observed in the Il33-/- group was reminiscent of 
previously published data whereby reduced bioenergetic capacity and mitochondrial elongation were 
observed in LPS-stimulated monocytes [552]. It is worth considering the observation that in IL-15 
polarised T-memory cells, mitochondrial elongation and fusion promote increased mitochondrial mass 
and bioenergetic capacity [472]. The conflict between these data indicate the need to further decipher 
the role of mitochondrial dynamics in metabolic reprogramming. In the context of T-memory cells, 
increased cristae remodelling promoted a metabolic shift to increased β-oxidation and OXPHOS [472]. 
Considering that RPE in the absence of IL-33 have diminished pyruvate utilisation yet still maintain 
basal OCR, it is plausible that changes in alternate pathway engagement (e.g. fatty acid oxidation) 
support TCA cycle activity under metabolic stress. Moreover, a bioenergetic program of increased 
mitochondrial abundance, mitochondrial ATP-production (as shown by seahorse) and expression of 
ETC components in IL-33 KD cells may be established to compensate a lack of ATP derived from 
oxidative glucose catabolism. 
In conclusion, I have identified that IL-33 acts at a point that controls a key metabolic checkpoint, 
antagonising the Warburg effect to ensure the functional stability of the RPE. The identification of IL-
33 as a key regulator of mitochondrial metabolism suggests roles for the cytokine that go beyond its 
extracellular “alarmin” activities. For example, when RPE is under stress, IL-33 contributes to minimise 
the effects of oxidative damage to the RPE and bolster mitochondrial metabolism. IL-33 exerts control 
over mitochondrial respiration in RPE by facilitating pyruvate import into mitochondria via up 
regulation of MPC expression and may be systemically integrated by the capacity of RPE to maintain 
homeostasis. Therefore, as well as identifying a molecular pathway for activation of mitochondrial 
respiration in RPE, my results demonstrate that intrinsic cellular IL-33 acts as a metabolic regulator 










Chapter 6. A proteomics-based approach to 
determine the role of nuclear interleukin-33 
  
6.1. Introduction  
Cytokines are mediators of intercellular communication through the activation of surface receptors, 
upon release into the extracellular environment. Classically, cytokines contain a signal sequence which 
permits their processing through the Golgi pathway, ultimately leading to constitutive release or 
sequestration into granules for release upon activation [553]. A subset of cytokines, including multiple 
IL-1 family members and HMGB1 do not exhibit a signal sequence and instead remain localised to the 
nucleus [554]. These nuclear cytokines have been dubbed “alarmins” as a result of their potent 
cytokine activity occurring upon cell damage/necrosis and release into the extracellular milieu. In 
addition to their function extracellularly upon release, many alarmins exhibit nuclear functions [554]. 
 
IL-33 is constitutively expressed in barrier cells (e.g fibroblasts, endothelial cells and epithelium) [9]. 
When released from necrotic or damaged cells, it functions to alert immune cells expressing its 
cognate receptor ST2 (mast cells, ILC2s, Tregs and Th2 CD4 cells) of nearby tissue disruption [134]. IL-
33 has multiple cellular targets (see chapter 1) and has arose as a critical immune regulator with 
pleiotropic activities in type 1, type 2 and regulatory immune responses, and underlying key 
mechanisms in allergic, infectious and chronic inflammatory diseases [134]. IL-33 is unique as an 
alarmin, in the sense that release from necrotic cells primes the immune system for allergic responses. 
Furthermore, polymorphisms in the genes encoding IL-33 and ST2 have been identified as major 
susceptibility loci for human asthma [282]. Consequently, therapeutic targeting of the IL-33/ST2 axis 
has emerged as a novel therapeutic in allergic disorders. 
 
Despite being extensively studied in terms of its extracellular signalling, a clear nuclear function for IL-
33 remains ambiguous. A largely unanswered question in the biology of IL-33 is the functional 
significance of both nuclear localisation and chromatin binding. IL-33 binds directly to chromatin 
nucleosome acidic patch comprised of histones H2A and H2B, which is critical in the regulation of 
chromatin remodelling [256]. This chromatin binding domain has a strikingly high sequence similarity 
to that of latency-associated nuclear antigen (LANA), which is responsible for the attachment of viral 
genomes to mitotic chromosomes [256]. Additionally, IL-33 promotes chromatin compaction [254]. 
Despite these findings, no key IL-33 nuclear targets have been elucidated.  Recent work has suggested 
that IL-33 may exhibit nuclear localisation solely to regulate its potent cytokine activity, and therefore 
protecting against lethal inflammation [230]. In this model, IL-33 is sequestered to the nuclei of barrier 
cells, so that in the event of cell damage, full length IL-33 could be released and activate ST2 expressing 
cells. Whilst an interesting model, two key questions emerge. One: Why are nuclear levels of IL-33 so 
high; two: does IL-33 have nuclear functions, like other alarmins. 
 
In this chapter, I utilised a proteomics-based approach to address the functional significance of nuclear 
localisation of IL-33 in epithelial cells; focusing on the RPE as model epithelial cell with constitutively 
high levels of IL-33 expression. This approach allowed an identification of the IL-33 interacting 
networks in the nucleus of epithelial cells and indicated how alterations to IL-33 expression status 
directly influenced the RPE cell proteome. 
 
6.2. Using tandem mass-tagging to identify the IL-33 interactome in both human and murine RPE 
In order to establish a nuclear function of IL-33, nuclear localisation of IL-33 was first confirmed in the 
RPE. Previous studies had identified IL-33 expression in different parts of the retina. IL-33 was 
expressed by cells in the RPE, inner nuclear layer (INL), with expression localized to the nuclei of Müller 
glial cells and retinal endothelial cells [8]. Previously I identified nuclear IL-33 expression in the ARPE-
19 cell line (both constitutively, and when genetically engineered to overexpress IL-33 using CRISPR-
cas9 (see chapter 5) It was also important to identify the subcellular localisation in primary murine 
RPE. Cells were pooled from multiple eyes to generate the numbers required for sub cellular 
fractionation. Following fractioning lysates into nuclear and cytoplasmic proportions, immunoblotting 
was used to confirm the nuclear localisation of IL-33 in primary murine RPE cells. As a control, 
immunoblotting of IL-33 was not observed in primary RPE derived from Il33-/- mice (Fig. 6.1A).  
 
I next sought to better understand how nuclear IL-33 regulates RPE cell function. In published studies, 
IL-33 is suggested to regulate cancer cell function predominantly through the recruitment and/or 
regulation of a range of binding proteins [261]. This reflects a disease setting and may not accurately 
capture the physiological interaction repertoire of IL-33. To conduct a high-resolution, global, 
unbiased proteomic analysis of the complete IL-33 interactome of RPE cells I performed TMT-labelling 
of antibody-bead eluate prepared with two anti-IL-33 antibodies validated for their ability to “pull-
down” IL-33 in both human and mouse RPE cell lysates (Fig. 6.1B-C).  
 
To control for non-specific binding, blank beads (and no antibody [555]) were incubated with the 
lysates to validate the binding of IL-33 targets. In order to pass the target selection criteria, IL-33 
interacting proteins (present in all three samples). Binding targets were further filtered based on an 
abundance ratio of >1.5 (anti-IL-33 vs beads alone). This was repeated using two different antibodies 
(Nessy-1 and R&D anti-IL-33) to validate the interactome. This controlled quantitative approach 
validated the specificity and reproducibility of the method and enabled the application of a filtering 
criteria to the proteomics data to define the IL-33 interactome in human and mouse cells.  
 
This analysis revealed an extensive RPE IL-33 interactome in both human and mouse. Contextualised 
to the size other interactomes, the IL-33 interactome was around a similar level to that of other 
transcription factors or signalling molecules identified with TMT analysis [556-558]. Using the selected 
criteria for significance, 260 human and 159 mouse proteins interacting with IL-33 were identified. Of 
these, 80 were found in both situations. 
 
Functional analysis of the IL-33 interactome was conducted using the STRING database (version 11) 
[559].  This allowed protein-protein interaction data to be retrieved and the “functional association” 
(i.e. a specific and productive functional relationship between two proteins, likely contributing to a 
common biological pathway) to be identified. STRING interactions are derived from multiple sources: 
(1) known experimental interactions from primary databases, (2) pathway knowledge from databases, 
(3) interactions are predicted de novo by several algorithms and (4) pre-computed ortholog 
relations. Data inputs to STRING provide assessment and integration of protein–protein interactions, 
including direct (physical) and indirect (functional) associations. The IL-33 interactome showed high 
interconnectivity around two nodes using STRING analysis (Fig. 6.1E). Upon further investigation, 
these nodes were found to be significantly enriched with proteins involved in node A: translation and 
node B: RNA splicing (Fig. 6.1E). Gene ontology analysis of both biological and cellular processes 
[Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics database] 
represented within the data set identified significantly enriched terms associated with translation, 
gene expression, RNA splicing, cellular metabolic pathways, cytoskeleton, pyruvate metabolism, 
chromatin structure and regulation of RNA splicing (Fig. 6.1F). Enriched pathways exhibited a 
Benjamini-Hochberg corrected p-value of <0.01. Interestingly, translation and the regulation of 
chromatin structure were key pathways identified in the nuclear IL-33 interactome of a previous study 
[261]. 
 
Taken together, the results from this section demonstrate nuclear localisation IL-33 in both human 
(cell line) and murine (primary cells) RPE. Using proteomics analysis of the pull-down, I observed a 
large interactome of proteins with IL-33 affinity. Whilst this does not confirm a nuclear role for IL-33, 
it supports the possibility that whilst in the nucleus IL-33 plays a role (either directly or indirectly) in 
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Figure 6.1. Tandem mass-tagging identifies the IL-33 interactome in both human and murine RPE: 
(A) Cell lysates from both WT and Il33 deficient mice were separated into nuclear or cytoplasmic fractions to 
determine IL-33 subcellular location. (B) Immunoprecipitation of IL-33 in ARPE-19 with two independent 
antibodies. (C) Immunoprecipitation of IL-33 in primary RPE with two independent antibodies. (D) Venn diagram 
of proteins identified in IL-33 pull-down TMT analysis. (E) Mapped interactions of proteins identified in IL-33 
pull-down TMT analysis using STRING. Interactions include direct (physical) and indirect (functional) 
associations. (F) Pathway analysis of proteins identified in IL-33 pull-down TMT analysis using DAVID. Data are 
expressed from three independent experiments. (A) represents pooled data from three mice.   
6.3. The IL-33 interactome in primary human podocyte cells  
Having identified an interaction network of nuclear IL-33 in human and murine RPE, it was necessary 
to investigate nuclear IL-33 in the context of another IL-33 expressing epithelial cell, the podocyte 
(kindly gifted by Dr. Gavin Welsh, University of Bristol). Podocytes are specialised epithelial cells 
located on the urinary side of the glomerular filtration barrier [560]. Importantly, podocytes, similarly 
to RPE become terminally differentiated after birth, with little ability to re-enter the cell cycle and 
proliferate [561]. This allowed me to test a terminally differentiated epithelial cell from a completely 
different biological setting. To first validate the expression of IL-33, immunoblotting was performed 
on whole podocyte cell lysates (Fig. 6.2A). Having established that IL-33 is expressed in podocyte cells 
and has robust pull-down by both antibodies, proteomics was used to investigate proteins with IL-33 
affinity. A similar selection pipeline was utilised for protein identification, based on an abundance ratio 
of >1.5 (IL-33 pulldown vs beads alone) and presence in the pull down from two antibodies.  
 
This analysis revealed an extensive human podocyte IL-33 interactome of 135 proteins which passed 
the selection criteria. Functional analysis of the IL-33 interactome was conducted using the STRING 
data base. This identified the presence of three main nodes of interconnectivity based on direct and 
indirect protein-protein interactions. These corresponded to enriched pathways with proteins 
involved in translation (node A), RNA splicing (node B) and cytoskeletal regulation (node C) (Fig. 6.2B). 
This was like the RPE interactome in terms of protein enrichment in translation and splicing pathways. 
However, the podocyte interactome displayed a degree of interconnectivity around cytoskeletal 
protein enrichment which was not observed in the RPE STRING analysis. Gene ontology analysis using 
the DAVID bioinformatics database identified significant biological and cellular processes enriched 
within the dataset. These corresponded to translation, cell-cell adhesion, RNA splicing, RNA 
recognition, cytoskeleton, histone binding, chromatin assembly and glycolysis (Fig. 6.2C). Between the 
podocyte and RPE interactomes there were a total of 88 conserved proteins with IL-33 affinity (Fig. 
6.2D). 
 
The data presented in this section indicates the presence of nuclear IL-33 in another specialised 
epithelial cell and suggests a similar nuclear interactome between the two cell types. This set of 
experiments were required to identify conserved IL-33 targets and pathways between the two cell 
types, suggesting that IL-33 nuclear function is ubiquitous to other epithelial cells. 
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Figure 6.2. Tandem mass-tagging identifies the IL-33 interactome in human podocytes: 
(A) Immunoprecipitation of IL-33 in primary podocytes with two independent antibodies. (B) Mapped 
interactions of proteins identified in IL-33 pull-down TMT analysis using STRING. Interactions include direct 
(physical) and indirect (functional) associations. (C) Pathway analysis of proteins identified in IL-33 pull-down 
TMT analysis using DAVID. (D) Venn diagram of proteins identified in IL-33 pull-down TMT analysis in ARPE-19 
and primary podocytes. Data are expressed from three independent experiments.   
6.4. Immune-stimulation of ARPE-19 cells modulates IL-33 interactions 
Previous work has identified that IL-33 expression is upregulated in the RPE in response to 
inflammatory stimulus [8]. This is not restricted to the RPE, with increased IL-33 expression observed 
in multiple cell types in response to TLR and cytokine receptor stimulation [9]. There is little evidence 
of inducible release and secretion in these cells, with the increased IL-33 localised to the nucleus [9]. 
Considering the observations in the previous section, whereby a large array of proteins was found to 
display affinity for IL-33 in a basal state, I hypothesised that this interactome may be subject to 
alterations upon stimulation, with IL-33 functioning as a key node in the transcriptional response to 
danger signals. Indeed, a loss of endogenous IL-33 negatively impairs IFN-γ-induced cytokine 
production in oesophageal epithelial cells [534].  
 
RPE cells were first exposed to an array of inflammatory stimuli to identify signalling pathways which 
upregulate the expression of nuclear IL-33. I chose inflammatory mediators with known cognate 
receptor complexes expressed on the RPE and/or reported changes in RPE function upon stimulation 
[8, 63, 562-566]. As two positive controls I included TLR-3 and -4 agonists Poly (I:C) and LPS, which 
have been previously shown to up regulate IL-33 in the RPE (see chapter 3/ [8]). In addition to this, I 
chose to assess agonists for TLRs 2 and 9 (peptidoglycan (PGN) and CpG oligodeoxynucleotide for TLR-
2 and -9, respectively) as these have been reported to be expressed in RPE cells [62]. In addition to 
TLR agonists, I investigated if the cytokines IL-1β, IL-4, IL-6 IL-10, IL-17A, IL-22, TNFα and IFN-γ elicited 
an increased expression of nuclear IL-33. Doses of all agonists/cytokine were based around commonly 
used concentrations found within the literature [8, 63, 562-566]. After stimulation for 24h with each 
cytokine/TLR agonist listed above, cell lysates were split into a nuclear fraction and IL-33 expression 
was assessed using immunoblotting. All four TLR agonists upregulated the expression of IL-33, 
although this effect was greater in LPS and PGN than Poly (I:C) or CpG (Fig. 6.3A-B). Out of the panel 
of 8 cytokines assessed for their ability to increase IL-33 expression, changes were only observed with 
IL-1β, IL-6 and IFN-γ (Fig. 6.3A-B). 
 
Following this, I proceeded to investigate how the IL-33 interactome was altered under immune 
stimulation, whereby ARPE-19 cells increased their nuclear IL-33 expression. The IL-33 interactome 
was investigated in two conditions promoting IL-33 expression (LPS and Poly (I:C)) and one condition 
where IL-33 remained unaffected (TNFα). Cells were unstimulated or treated with either LPS, Poly (I:C) 
or TNFα for 24h. Following treatment immunoprecipitation against IL-33 was performed on the cell 
lysate and eluted antibody-bead complexes were analysed using TMT-labelling. In response to LPS 
treatment, 67 variant proteins were observed (FDR 5% and p<0.01). Only 42 of these were passed the 
selection criteria of p<0.01 and >50%-fold change, 23 of which were up-regulated and 19 down-
regulated (Fig. 6.4A; Table 10.6.1, page 410). There were no proteins absent in either control or LPS 
samples. Functional analysis of the LPS-stimulated IL-33 interactome was conducted using the STRING 
data base. It was observed that in the up-regulated group of proteins, there were two main nodes of 
interconnectivity, whereby their interactions were clustered around groups of biologically connected 
proteins. These areas of interaction enrichment were comprised of proteins with the following 
biological processes (GO terms), node A: RNA catabolism, translation initiation and mRNA metabolic 
processes; node B: nucleosome assembly, nucleosome organization and DNA conformational change. 
Following this, gene ontology analysis of both biological and cellular processes represented within the 
data set identified significantly enriched terms associated with negative regulation of gene expression, 
chromosome organisation, chromatin silencing, histone exchange and chromatin remodelling (Fig. 
6.4B). In the down regulated group of proteins, there was one node of interconnectivity among the 
proteins which corresponded to GO terms such as: RNA binding, ribosome and pre-mRNA binding (Fig. 
6.4C). In addition to this, gene ontology analysis was conducted on the data set to identify 
overrepresented pathways. It was found that in the down-regulated data set, significant enrichment 
was observed in translation initiation, RNA processing, gene expression and mRNA splicing (Fig. 6.4D). 
STRING analysis identified one cluster of proteins involved in translation initiation (Fig. 6.4E).  
 
A similar analysis was performed on ARPE-19 cells in response to the TLR-3 agonist, Poly (I:C). 
Following treatment 41 variant proteins were observed (FDR 5% and p<0.01). Of these, 40 proteins 
were observed to be above the selection criteria of a >50%-fold change, 27 of which were up-regulated 
and 13 down-regulated (Fig. 6.5A; Table 10.6.2, page 411). There were no proteins absent in either 
control or Poly (I:C) samples. Functional analysis of the Poly (I:C)-stimulated IL-33 interactome was 
conducted using the both STRING and DAVID data bases. It was observed that in the up-regulated set 
of proteins there were large areas of interconnectivity, with proteins forming a clustered node 
corresponding to pathogenic/E.coli infection (Fig. 6.5B). A PPI enrichment of p=1.27e-09 was observed 
indicating significant enrichment in pathways than what would be expected for a list of proteins of 
similar size, drawn randomly from the genome. Such an enrichment indicates that the proteins are at 
least partially biologically connected, as a group (http://version10.string-db.org ). Gene ontology 
analysis was subsequently conducted to identify significantly enriched biological processes within the 
altered proteins. In the data set of 27 proteins, significantly enriched terms were found associated 
with translation, microtubule, glycolysis, cell-cell adhesion and ribosome (Fig. 6.5C). It was of interest 
to note four glycolytic enzymes associated with IL-33 were increased upon Poly (I:C) stimulation (Table 
6.2). It is well known that many glycolytic enzymes “moonlight” in the nucleus where they have diverse 
roles in the regulation of transcription, translation and chromatin stability (see section 1.8.5.1.). I then 
proceeded to investigate the downregulated set of proteins present in the Poly (I:C)-stimulated 
interactome. After inputting these proteins into the STRING software, it was clear that there were two 
clusters of proteins. Cluster A corresponded to GO terms such as translational initiation and SRP-
dependent protein targeting to the membrane (Fig. 6.5E). Cluster B was observed to include GO terms 
such as the spliceosome and mRNA processing (Fig. 6.5D). Gene ontology analysis of both biological 
and cellular processes represented within the data set identified significantly enriched terms 
associated with viral transcription, translation initiation and ribosome (Fig. 6.5D).  
 
In addition to the studies performed on the Poly (I:C) or LPS-stimulated cells, it was essential to 
investigate how IL-33 interactions would change in response to a stimulus not observed to increase 
IL-33 expression in ARPE-19 cells. Out of all the inflammatory stimuli used, I chose to investigate TNFα 
for several reasons: (1) TNFα is a proinflammatory cytokine and therefore its effects on the IL-33 
interactome would be more comparable to TLR signalling; (2) Its effects are better studied in RPE cells 
(including ARPE-19 [566]) and therefore one could concur a TNFα response would be more 
representative of RPE activation than IL-17A, IL-4 and IL-22, where cognate receptor expression is 
observed but the downstream effects are unfamiliar. I performed a similar experiment to the previous 
two sections, immunoprecipticating IL-33 after exposure to TNFα. Despite no observed change in IL-
33 expression with TNFα, 10 variant proteins found between the unstimulated and stimulated 
conditions (p<0.01 and FDR 5%). Of these 10 proteins, 8 were above the selection criteria of a >50%-
fold change (Table 10.6.3, page 413). Interestingly all proteins were observed to be down regulated in 
the TNFα treated IL-33 pull down compared to an untreated control. Using STRING analysis, I observed 
that these proteins clustered around a central node of consisting of enrichment of terms including 
translation and the negative regulation of gene expression (Fig. 6.6A).  
 
Between the three treatment groups, there were small overlaps in IL-33-interacting partners. Poly (I:C) 
and LPS stimulated interactomes shared 5 conserved proteins, whereas TNFα and Poly (I:C) exhibited 
6. No conserved proteins were found in the IL-33 interactomes of LPS and TNFα-stimulated cells, and 
therefore between all groups assessed (Fig. 6.6B).  
 
Taken together, the results obtained within this section indicate a plasticity in the IL-33 interactome 
in response to immune stressors. To date, the biological significance of nuclear IL-33 upregulation 
after activation remains unsolved.  
  
 








































































Figure 6.3. Stimulated nuclear IL-33 production in ARPE-19 cells: 
(A) Cells were treated for 24h with either Poly (I:C) (10μg/ml), LPS (1μg/ml), PGN (50ng/ml), CpG (10μg/ml), rhIL-
1β (50ng/ml), rhIL-4 (10ng/ml), rhIL-6 (10ng/ml), rhIL-10 (10ng/ml), rhIL-17A (100ng/ml), rhIL-22 (100ng/ml), 
TNFα (50ng/ml) or IFN-γ (100ng/ml). Nuclear lysates were fractionated, and immunoblotting was used to assess 
IL-33 expression. (B) Densitometry analysis of (A). Represents data from two independent blots.   
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Figure 6.4. LPS stimulation alters the IL-33 interactome in ARPE-19 cells: 
Cells were either unstimulated or treated for 24h with LPS (1μg/ml). (A) Heatmap of differentially expressed 
proteins observed in IL-33 pull down. (B) Pathway analysis of proteins up-regulated in IL-33 pull-down TMT 
analysis using DAVID. (C) Mapped interactions of proteins up-regulated in IL-33 pull-down TMT analysis using 
STRING. (D) Pathway analysis of proteins down-regulated in IL-33 pull-down TMT analysis using DAVID. (E) 
Mapped interactions of proteins down-regulated in IL-33 pull-down TMT analysis using STRING. Data are 
expressed from three independent experiments.  
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Figure 6.5. Poly (I:C) stimulation alters the IL-33 interactome in ARPE-19 cells: 
Cells were either unstimulated or treated for 24h with Poly (I:C) (10μg/ml). (A) Heatmap of differentially 
expressed proteins observed in IL-33 pull down. (B) Pathway analysis of proteins up-regulated in IL-33 pull-down 
TMT analysis using DAVID. (C) Mapped interactions of proteins up-regulated in IL-33 pull-down TMT analysis 
using STRING. (D) Pathway analysis of proteins down-regulated in IL-33 pull-down TMT analysis using DAVID. (E) 
Mapped interactions of proteins down-regulated in IL-33 pull-down TMT analysis using STRING. Data are 







Figure 6.6. STRING analysis of IL-33 interactome following TNFα stimulation: 
(A) Cells were either unstimulated or treated for 24h with TNFα (50ng/ml). Mapped interactions of proteins 
down-regulated in IL-33 pull-down TMT analysis using STRING. (B) Venn diagram of differentially regulated 
proteins found in the IL-33 interactomes of LPS, Poly (I:C) or TNFα-stimulated cells. Data are expressed from 
three independent experiments.   
 6.5. A global proteomic approach to analyse endogenous IL-33 function in ARPE-19 cells 
In the previous sections I have identified a large IL-33 interaction network in epithelial cells 
corresponding to protein involved in translation, RNA splicing and other nuclear processes. In order 
to confirm that these interactions were functional it was subsequently investigated whether a loss of 
nuclear IL-33 would affect the total proteome in RPE cells. I chose to utilise proteomics as opposed to 
transcriptomics due to the significant enrichment of post-transcriptional pathways (i.e splicing/ 
translation) in the data sets.  
 
Previous studies have utilised a large-scale proteomic approach to analyse the effect of endogenous 
IL-33 cell proteome, however these studies have largely focussed on endothelial cells [230]. To identify 
IL-33 regulated proteins in RPE cells, I performed TMT-based proteomics in ARPE-19 cells exhibiting 
IL-33 silencing by siRNA. Cells transfected with a scrambled siRNA were used as a control. IL-33 
knockdown was first confirmed by immunoblotting (Fig. 6.7A). Proteomics identified a total of 8341 
proteins identified in all six experiments (three scrambled siRNA and three IL-33 siRNA). A false 
discovery rate of 5% was applied in the identification of differentially modulated proteins. Out of the 
total of 8341 proteins, 2368 were found to be significantly changed between scrambled and IL-33 
siRNA samples (p<0.01). However only 857 proteins were above the cut-off of a >25% fold change 
[567]  (368 total upregulated and 489 total down regulated) (Fig. 6.7B-C). As a positive control for 
silencing, I observed a significant decrease of IL-33 (~4-fold) (Fig. 6.7B). Gene ontology analysis (DAVID) 
of the proteomics data indicated that knock down of endogenous IL-33 induced the expression of 
proteins with significantly enriched terms associated with mitochondrion, protein transport, fatty acid 
metabolism, mRNA splicing, TCA cycle, WD40-repeat domain and amino acid metabolism (Fig. 6.7D). 
Conversely, pathway analysis of downregulated proteins represented within the data set indicated 
significant enrichment in terms such as: nucleotide binding, cell-cell adhesion, chaperone, cell cycle, 
NADP oxoreductase, mitochondrial matrix and DNA condensation (Fig. 6.7D).  
 
Taken together, the proteome-wide analysis indicated that multiple biological pathways may be 
affected by IL-33 loss in epithelial cells. Within the up-regulated data set there appeared to be a large 
focus on cellular bioenergetics, with a selection of significantly enriched GO terms highlighting 
mitochondrial metabolism and pathways such as fatty acid oxidation which feed into the TCA cycle.  
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Figure 6.7. Effect of IL-33 loss on the ARPE-19 proteome: 
ARPE-19 were transfected for 48h with either scrambled siRNA or a pre-selected mixture of 4 siRNA duplexes 
targeting the human IL33 gene. (A) Representative immunoblot of IL-33 protein expression following 
transfection. (B) Volcano plot displaying fold change (log2) of proteomic data reveals differentially expressed 
proteins in whole cell lysates following transfection. (C) Heatmap of differentially expressed proteins in whole 
cell lysates following transfection (FDR <5%, p<0.01 and >1.25-fold expression). (D) Pathway analysis of proteins 
induced with IL-33 KD. (E) Pathway analysis of proteins suppressed with IL-33 KD. Data are expressed from three 
independent experiments.   
6.6. A global proteomic approach to analyse endogenous IL-33 function in primary murine RPE 
Having established that ARPE-19 cells treated with IL-33 siRNA pools exhibited global proteomic 
changes, it was essential to investigate if a similar shift in the RPE proteome was observed in primary 
RPE from mice lacking endogenous IL-33 in comparison to WT counterparts. This experiment tested 
whether the observed protein changes were specific to a loss of IL-33 and rather than off target effects 
of gene silencing. Having isolated RPE cell lysates from both WT and Il33-/- mice, I proceeded to analyse 
respective proteomes using TMT. There was a total of 9529 proteins identified in all six samples (three 
WT and three Il-33-/-). Of these proteins, 501 were observed to be significantly changed (p<0.01) in 
the Il33-/- murine RPE proteome compared to the WT control. When a selection criteria of a fold 
change >25% was applied to the data set, only 417 proteins were taken forward. Of these 417 proteins, 
45 were down-regulated and 372 were up-regulated (Fig. 6.8B). Following identification of 
differentially regulated proteins in the RPE proteome, I used the DAVID software to perform pathway 
enrichment analysis of both data sets. In the down-regulated protein set, I observed a significant 
enrichment in clusters corresponding to nucleosome core, histone and chromatin silencing, myosin 
complex, tight junction, cell adhesion and actin filament binding, and extracellular matrix remodelling 
(Fig. 6.8C). In the up-regulated protein data set, there was significant enrichment in clusters 
corresponding to mitochondrial metabolism, fatty acid oxidation, zinc ion homeostasis, 
oxidoreductase and innate immunity (Fig. 6.8D). 
 
The data collected from the primary RPE proteome further supports a role for nuclear IL-33. Taken 
together, the data presented in this section shows that loss of IL-33 at the germline level leads to 
significant alterations in the RPE proteome, thus indicating that IL-33 acts as a key node in the control 
of protein expression. Noted was the reduced total number of significantly down-regulated proteins 
compared to that of significantly upregulated within the data set; this corresponded to a ~8-fold 
change (45 vs 372). This, however, may be attributed to the fact that these samples were taken from 
cells ex vivo compared to an in vitro cell line system.  
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Figure 6.8. Whole proteome analysis of WT and Il33-/- primary RPE: 
Primary RPE cell lysates were isolated from WT or Il33-/- mice. (A) Volcano plot displaying fold change (log2) of 
differentially expressed proteins in primary RPE cell lysates. (B) Heatmap of differentially expressed proteins in 
whole cell lysates (FDR <5%, p<0.01 and >1.25-fold expression). (D) Pathway analysis of proteins induced in Il33-
/- RPE. (E) Pathway analysis of proteins suppressed Il33-/- RPE. Data are expressed from three independent 
experiments.   
6.7. Overexpression of nuclear IL-33 alters the ARPE-19 proteome 
As previously discussed, an important question in the biology of IL-33 is the role of endogenous 
intracellular nuclear IL-33 in the regulation of cellular function. It has been long proposed that IL-33 is 
a dual function cytokine with relative roles in extracellular signalling and in the nucleus where it 
controls gene expression [10]. In the previous two sections of this chapter I have provided evidence 
of a nuclear role for IL-33 in the RPE whereby its loss, both in vitro (siRNA) and at the germline level 
(mice lacking endogenous IL-33) exhibited functional biological changes, as indicated by proteome-
wide analysis. Having established that a loss of IL-33 elicits proteomic changes in RPE cells, I further 
assessed proteomic changes in RPE cells constitutively overexpressing IL-33 by CRISPR-cas9.  
 
Prior to examining proteomic changes, up-regulation of nuclear IL-33 was confirmed by 
immunoblotting (Fig. 6.9A). Following establishment of efficient plasmid transfection and increased 
IL-33 expression, I performed proteome-wide analysis on whole cell lysates from both control plasmid 
and IL-33 plasmid transfected cells. Proteomics identified a total of 8117 proteins identified in all six 
experiments (three control plasmid and three IL-33 plasmid). A false discovery rate of 5% was applied 
in the identification of differentially modulated proteins. Out of these proteins, 1240 were observed 
to be significantly modulated (p<0.01), yet only 421 of these variant proteins passed the selection 
criteria of >25% fold change. Out of these proteins, 244 were found to be up-regulated and 177 were 
found to be down-regulated (Fig. 6.9B-C). IL-33 was not found within the total number of proteins 
observed within each group and therefore, there was no positive control for this experiment. Despite 
this, I used DAVID to identify pathways that were induced or repressed from the proteins identified in 
IL-33 overexpressing cells. While gene ontologies associated with cell-cell adhesion, nucleotide 
binding, carbon metabolism, actin binding and RNA binding were repressed in IL-33 overexpressing 
ARPE-19, gene ontologies associated with cell-cell adhesion, chaperone, glycolysis, amino acid 
biosynthesis, proteasome and NFκB signalling were all induced with IL-33 overexpression (Fig. 6.9D-
E). 
 
Collectively, these data demonstrate that the augmented presence of nuclear IL-33 alters a consistent 
proteomic shift in ARPE-19 cells under the conditions tested. Gene ontologies for glycolysis and other 
carbon metabolic pathways were highlighted in the data set, indicating that increased glycolytic flux 
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Figure 6.9. Effect of IL-33 overexpression on the ARPE-19 proteome: 
ARPE-19 were transfected for 48h with either control plasmid or an IL-33 activation plasmid. (A) Representative 
immunoblot of IL-33 protein expression following transfection. (B) Volcano plot displaying fold change (log2) of 
proteomic data reveals differentially expressed proteins in whole cell lysates following transfection. (C) Heatmap 
of differentially expressed proteins in whole cell lysates following transfection (FDR <5%, p<0.01 and >1.25-fold 
expression). (D) Pathway analysis of proteins induced with IL-33 OE. (E) Pathway analysis of proteins suppressed 
with IL-33 OE. Data are expressed from three independent experiments.   
6.8. IL-33 interacts with components of the PKM splicing complex in ARPE-19 cells, but not primary 
RPE 
Within the data sets from the previous sections, a large focus of gene ontologies associated with the 
proteomic changes appeared to focus around aspects of cellular metabolism. In IL-33 knock-down RPE 
cells, aspects of mitochondrial metabolism were significantly enriched within the data sets. 
Conversely, overexpression of IL-33 was accompanied by significant enrichment in gene ontologies 
involving the glycolysis pathway. Whilst unsurprising considering the observations made in chapter 5 
(whereby IL-33 was observed to promote glycolytic flux and oxidative mitochondrial catabolism of 
pyruvate), this indicated an opportunity to further investigate the molecular mechanisms governing 
the control of metabolism by nuclear IL-33.  
 
A major control point of glycolysis is the regulation of pyruvate kinase splicing (see section 1.8.5.2.). 
Indeed, multiple studies have identified key roles for PKM2 in metabolic reprogramming of cancer 
cells [330]. PKM1 and PKM2 are generated by exclusive alternative splicing of the PKM mRNA, a 
mechanism largely driven by the activity of MYC [331]. In the glycolytic pathway, pyruvate kinase is a 
rate limiting enzyme that catalyses the final reaction of PEP into pyruvate. PKM2 is responsible for 
augmented glycolytic activity in its tetramer form yet when dimerized, PKM2 translocates to the 
nucleus where it interacts with HIF-1α and promotes the expression of a glycolytic gene program 
[328]. Using the data generated in section 6.1, I found that IL-33 interacted with multiple factors 
involved in the regulation of PKM2 splicing, including SRSF3, hnRNPA1, hnRNPA2B1, PTB, and even 
PKM2 itself (Fig. 6.10A). In order to confirm these interactions, IL-33 was co-immunoprecipitated for 
SRSF3, hnRNPA1 and hnRNPA2B1, which were confirmed to be both present in the input (cell lysate) 
and also in the IL-33 pull-down, suggesting an interaction between these factors and IL-33 (Fig. 6.10B). 
This, however, was restricted to the human RPE cell-line, with IL-33 not observed to interact with any 
of these factors in primary murine RPE. Due to a lack of interaction in the proteomics data, 







Figure 6.10. IL-33 interacts with components of the PKM splicing complex in ARPE-19 cells: 
(A) Schematic of splicing of the PKM gene. Green stars indicate presence in the IL-33 pull-down TMT analysis. 
Yellow stars indicate a physical interaction by IL-33 I.P. and western blotting. (B) IL-33 was immunoprecipitated 
in ARPE-19 cells. Western blotting was used to confirm the presence of SRSF3, HNRNPA1 and HNRNPA2. Data 
are expressed from three independent experiments.   
6.9. Differential expression patterns of pyruvate kinase are regulated by IL-33 in human but not 
murine RPE cells 
The results from the previous section appeared to suggest an interaction between IL-33 and 
components of the PKM splicing machinery in an in vitro ARPE-19 system. This was supported by 
interactions both via TMT-labelling proteomics and immunoprecipitation experiments. Interestingly, 
this did not appear to be the case in the context of primary murine RPE cells. In order to further 
investigate the fundamental differences between the two cell types, I investigated the levels of PKM1 
and PKM2 abundances in the total proteome of both WT mice RPE and untreated ARPE-19 cell lysates. 
In the ARPE-19 cell lysates, PKM2 was the dominant isoform, with an abundance ~4-fold greater than 
PKM1 (Fig. 6.11A). Similarly, PKM2 was the predominant isoform in the primary RPE cell lysates. 
However, from the total proteomics data only the one isoform could be detected (Fig. 6.11B). In order 
to confirm, primary RPE cell lysates from WT and Il33-/- mice were probed for both PKM1 and PKM2. 
Immunoblotting indicated that PKM2 was the predominant isoform, with no PKM1 expression 
detected (Fig. 6.11C). Although PKM2 has been demonstrated as the predominant isoform in the 
retina (particularly photoreceptors) [568, 569], no study has identified which isoform is expressed by 
RPE cells. No changes were observed in the expression of PKM2 between WT and Il33-/- groups (Fig. 
6.11C). Upon further investigation of the PKM splicing factors hnRNPA1, hnRNPA2B1 and SRFS3, it was 
revealed that there were no significant changes between WT and Il33-/- groups (Fig. 6.11D). In the 
ARPE-19 cell lysates, expression of both PKM1 and PKM2 was confirmed by immunoblotting (Fig. 
6.11E). In addition to this, it was observed that modulation of the IL-33 expression status altered 
PKM1/PKM2 ratio. With IL-33 siRNA, an increase of PKM1 was observed as PKM2 levels dropped (Fig. 
6.11E). Conversely, with IL-33 overexpression, PKM1 levels dropped whilst the expression of PKM2 
increased (Fig. 6.11E). Upon further investigation of the ARPE-19 proteomics data, it was clear that 
alteration of IL-33 expression by either siRNA or CRISPR-cas9 differentially modulated the expression 
of PKM splicing components (Fig. 6.11F-G). In the context of IL-33 knock down, protein expression of 
both hnRNPA1 and hnRNPA2B1 were significantly increased, yet expression of SRSF3 was decreased 
(Fig. 6.11F). Proteomics confirmed that knockdown of IL-33 increased the PKM1/PKM2 ratio (Fig. 
6.11F). With IL-33 overexpression, protein expression of both PKM1, hnRNPA1 and hnRNPA2B1 were 
significantly decreased (Fig. 6.11G). In addition to this, SRSF3 and PKM2 were increased (Fig. 6.11G). 
 
These data indicate fundamental differences in the metabolism of pyruvate in ARPE-19 cells compared 
to primary RPE. Although both cell types express PKM2 as their predominant isoform, PKM1 is 
expressed in ARPE-19 cells. Expression of these two isoforms (albeit at differing abundances) permits 
modulation of the splicing machinery and an upregulation of the pro-glycolytic PKM2 isoform 
compared to a basal state. In ARPE-19 cells PKM splicing appears to be regulated by IL-33, with altered 
expression of PKM1/PKM2 isoforms, and components of the splicing machinery observed with 
alterations in IL-33 expression. As primary murine RPE only express one isoform of PKM, it is unlikely 
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Figure 6.11. IL-33 regulates PKM splicing in ARPE-19 cells, but not primary murine RPE: 
(A) Abundance count of PKM1 and PKM2 in ARPE-19 cell lysates using TMT labelling. (B) (A) Abundance count of 
PKM1 and PKM2 in primary RPE cell lysates using TMT labelling. (C) Immunoblot of PKM1 and PKM2 expression 
in cell lysates from WT and or Il33-/- mice. (D) Relative expression of PKM2 and splicing factors using proteome 
datasets generated in Fig. 6.8. (E) Immunoblot of PKM1 and PKM2 expression in cell lysates from ARPE-19 cells 
transfected with either scrambled siRNA/IL-33 siRNA or a control plasmid/IL-33 activation plasmid. (F) Relative 
expression of PKM2 and splicing factors using proteome datasets generated in Fig 6.9. (G) Relative expression 
of PKM2 and splicing factors using proteome datasets generated in Fig 6.7. Data are expressed as means ± SD 
from three independent experiments. Unpaired Student’s T-test; **p<0.01, ***p<0.005.  
6.10. Discussion 
The IL-1 family cytokine IL-33 has well-described extracellular roles in the initiation of innate immune 
responses and type 2 immune responses [231]. Activation of ST2 expressing cells by IL-33 has been 
well described within the literature. One aspect of IL-33 biology which remains enigmatic is that of its 
unique nuclear localisation and binding to chromatin. In this chapter I have addressed the biological 
significance of IL-33 nuclear localisation and how this affects epithelial cell function in vitro and ex 
vivo. Important observations were: that (A) IL-33 retains its nuclear localisation in vitro under multiple 
conditions of inflammatory stress; (B) whilst in the nucleus, multiple proteins display high affinity for 
IL-33; (C) upon activation of multiple innate immune signalling components, IL-33 exhibits alterations 
in the abundance of various binding partners, as identified by interactome analysis; (D) In the nucleus, 
IL-33 affects homeostatic protein expression as assessed by three independent strategies: 1. 
proteome-wide profiling of RPE cells engineered to overexpress IL-33 via CRISPR-cas9, 2. RPE cells 
transiently silenced via IL-33 siRNA pools and 3. ex vivo from RPE cell lysates of mice from WT or IL-33 
deficient backgrounds and (E) IL-33 interacts with key components of the splicing machinery in 
epithelial cells, however only functional roles for IL-33 in the regulation of an RPE cell line have been 
described. Taken together, these proteomics studies support a view of dual functionality in IL-33, 
acting as both a nuclear regulator and extracellular cytokine. 
 
RPE cells were an ideal system for this investigation on the basis of three key points: (1) they signify a 
major source of endogenously derived IL-33 within the eye (along with Müller glia) [17]; (2) although 
a specialized form in the context of RPE, all epithelial cells are known to express IL-33 at high levels, a 
phenomenon not observed in branches of the endothelial tree [134]; (3) functional changes were 
previously observed in terms of regulating the metabolism of RPE cells when endogenous IL-33 
expression was genetically manipulated (see chapter 5). Considering the previously characterised 
metabolic changes regulated by endogenous IL-33, any metabolic alterations would likely be 
downstream of endogenous functional roles.   
 
IL-33 has been linked to the regulation of transcription in previous studies [10], although precise 
mechanisms supporting these observations are unknown. I confirmed that nuclear IL-33 interacts with 
chromatin histone components, supporting a nuclear role, and TMT proteomics identified proximal 
interactions with components of the translation and splicing machinery, various factors involved in 
the modulation of chromatin dynamics and nuclear localised metabolic enzymes, including members 
of the glycolytic pathway. These results suggest that IL-33 may have diverse roles within the nucleus 
of RPE cells which differ from its traditional view as a transcriptional repressor.  
 
A recent study focusing on the role of IL-33 in cancer cells, suggests key roles for the cytokine in core 
epigenetic pathways, including transcriptional initiation and chromatin remodelling [261]. In this 
study, binding of multiple epigenetic factors (including WD Repeat Domain 82 (WDR82), SWI/SNF-
related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARC1), 
TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor (TAF9), Bromodomain-
containing protein 4 (BRD4) and HDAC4) to IL-33 was observed. IL-33 was observed to be a critical 
core component of the WDR82 chromatin complex, a key regulatory step of H3K4 trimethylation 
[261]. In addition to this, IL-33 bound to various chromatin modifiers essential for the modulation of 
NF-κB-target genes, such as Ccl5 [261]. Whilst, none of the listed above proteins were key IL-33 
interaction targets in the RPE, one cannot rule out a context where IL-33 which may be aberrantly 
modulated in the squamous cell carcinoma. I identified WD repeat and FYVE domain containing 1 
(WDFY1) to be a key IL-33 target in the interactome analysis, and as one of the most significantly up-
regulated proteins in whole proteome analyses from both mouse and human cells. As WDFY1 is a 
critical adaptor protein in the TLR-3/4 signalling pathways [570] (responsible for the recruitment of 
TRIF and subsequent NF-κB activation), it is plausible that IL-33 acts via alternate mechanisms to 
control the transcription of NF-κB-target genes in the RPE.  
 
It was interesting to note that the IL-33 interactome exhibited a degree of plasticity, with stimulation 
from immune-mediated stress signals enough to alter the abundance of different binding partners. 
Furthermore, even signals not observed to alter IL-33 expression status (i.e. TNFα) were observed to 
have effects on the interactome. This suggests that IL-33 may act as a nuclear node in multiple cytokine 
signalling pathways where previously regarded as redundant. In both TNFα and Poly (I:C) treatment 
settings, one key transcription factor was found to have a much lower protein abundance in the IL-33 
pull-down compared to other significantly altered targets (>10-15-fold). This corresponded to nuclear 
factor 1 (NF1), a key transcription factor containing an unusual DNA binding domain [571]. NF1 family 
members interact with chromatin to promote both gene repression and activation by binding to DNA 
dyad symmetric consensus site or half-site sequence TTGGC(N5)GCCAA [571]. NF1 activity (for the 
most part) correlates with increased expression of target genes and is associated with higher levels of 
active promoter methylation marks such as H3K4me3 and H3K36me3, implicating them 
predominantly as activators of transcription [571]. Future work will be required to investigate the 
interactions between IL-33 and NF1, both in basal and stimulated states, to better understand the role 
of IL-33 in the regulation of gene expression. 
 
From the proteomics datasets generated in this chapter, it was evident that proteins involved in core 
cellular metabolic pathways were significantly enriched. This was unsurprising considering my 
previous observations in chapter 5. In the IL-33 siRNA and Il33-/- data sets, many mitochondrial 
proteins were significantly up-regulated, including targets in FAO, glutaminolysis, TCA and 
mitochondrial biogenesis pathways. Interestingly, significant enrichment of mitochondrial metabolic 
pathways have been highlighted in an RNA-sequencing experiment of Il33-/- adipocytes previously 
[19]. On the other hand, IL-33 overexpressing cells had multiple glycolytic enzymes and key targets in 
amino acid/ fatty acid biosynthesis pathways significantly up-regulated. These observations suggest 
that in the context of IL-33 loss, cells appear to favour a more quiescent metabolic state, whereby 
catabolic pathways fuel the TCA cycle. With IL-33 overexpression an anabolic metabolic state appears 
to predominate, favouring glycolytic metabolism to support biosynthetic demands. This correlates to 
a degree with data obtained in the previous chapter and may explain observations made, including: 
(A) why glycolytic flux was augmented with IL-33 overexpression and (B) how basal mitochondrial 
metabolism was maintained despite the loss of IL-33 and lack of pyruvate oxidation in the TCA cycle.  
 
Whilst searching for a downstream target which could mediate the bioenergetic adaptations observed 
in RPE cells, I observed that IL-33 interacted with the splicing machinery of the PKM gene in ARPE-19 
cells. Whist the mechanisms underlying the interactions (and to what degree IL-33 influenced their 
function) were unknown, it was clear that upon modulation of IL-33 expression status, alterations in 
the abundances of various splicing factors were observed, correlating to differential expression of PKM 
isoforms PKM1 and PKM2. This, however, was not observed in primary RPE cells, indicating that 
regulation of PKM splicing by IL-33 may not be a property observed in vivo, but rather that of a cell 
line adapted to a two-dimensional culture environment. This observation highlights the need to utilise 
a combination of both primary cells and cell lines to validate and translate observations on RPE 
function from in vitro studies, to the in vivo environment. Much of the current understanding of RPE 
function originates from in vitro studies using various “RPE-esque” cell lines. Although frequently used 
in RPE research, it is unclear to what extend these cells are representative of a “true” RPE cell. Indeed, 
studies have shown that once brought into culture, primary RPE cells quickly lose their specialised 
function and expression of key markers, expressing characteristics of cells from a mesenchymal origin 
[572]. Furthermore, differential protein profiling experiments of primary vs immortalised RPE cells 
indicated that none of the commonly used cell lines (including ARPE-19) exhibited a protein expression 
signature found in native RPE [572]. Expression of the PKM1 isoform in ARPE-19 cell lines may act as 
a survival advantage in vitro. Whilst not a key regulator of PKM splicing in RPE cells, it would be of 
interest to investigate IL-33 has any role in the alternative splicing of PKM in other epithelial cells 
expressing both isoforms of PKM. 
 
It was apparent from the total proteome experiments that IL-33 exhibited a bone fide nuclear role, 
with three unique experiments (two in the context of IL-33 loss and one with IL-33 overexpression) 
displaying significant alterations to protein expression compared to either WT controls or control 
nucleotides via transfections. Whilst, the mechanism of IL-33 in the nucleus remains unclear, future 
work utilising the generated data sets from this chapter may allow the identification of key pathways 
and IL-33-target proteins. The involvement of IL-33 in the regulation of splicing machinery may be an 
interesting avenue to follow considering the observations made with PKM in ARPE-19 cells, and 
considering recent work which has suggested a role for nuclear IL-33 in the regulation of UCP1 splicing 
[19].  Additionally, as IL-33 was observed to bind to core chromatin components and affect key 
epigenetic components, it would be of interest to observe the key DNA binding sites of IL-33 and its 
effects on the epigenetic landscape.  
Despite the observations made in this chapter, it is essential to note the work of previous studies 
indicating that there no evidence for a role of nuclear IL-33 in epithelial cells and endothelial cells. The 
first of these studies utilised a cell line lacking constitutive IL-33 expression and following transfection  
(with a vector permitting doxycycline (Dox)-inducible expression of IL-33)  analysed the 
transcriptome [263]. In this study, the only transcript observed to be regulated by IL-33 overexpression 
was that of Il-33 itself. Following a subsequent series of elegant experiments, this study concluded 
that IL-33 slowly dissociates from cells as part of an IL-33-histone high-molecular weight complex 
which synergistically augments ST2 receptor activation. Thus, proposing that nuclear retention and 
chromatin binding constitute a post-translational mechanism to regulate ST2-mediated bioactivity 
[263]. One potential caveat of this study is the use of a cell line lacking constitutive IL-33 expression. 
Upon dox-mediated induction of IL-33, nuclear translocation and histone binding was observed, but 
not changes in transcription. Although one would expect induction of a foreign “nuclear factor” (as IL-
33 is dubbed within the literature) to elicit transcriptional alterations, it is plausible that IL-33 is not 
required as an epigenetic node in these cells and therefore is not constitutively expressed. Considering 
observations made in this body of work and others [19], as IL-33 interacts with key translational and 
spliceosome constituents, it may be that IL-33 acts post transcriptionally on the translatome. This, 
however, will require further investigation into the roles of protein translation/ splicing machinery 
with IL-33 affinity. 
 
Another study (of similar experimental set up to this chapter) took a proteomics-based approach and 
observed no reproducible effect of nuclear IL-33 silencing on total protein expression in primary 
human endothelial cells [230]. A well-designed study in the sense that two independent RNA silencing 
strategies were applied to endothelial cells. This allowed robust identification of the IL-33 induced 
proteome without potential off-target effects associated with siRNA transfection. Although 
endothelial cells constitute a major source of endogenous IL-33 in human tissues [217], there appear 
to be fundamental species related differences in the endothelial vasculature trees of humans and 
mice. In murine endothelial cells from blood vessels, IL-33 is not expressed constitutively, and its 
nuclear expression is exclusively observed in a chronic inflammatory state [134]. To further examine 
the role of IL-33, it will be necessary to investigate how homeostatic cell function is altered cells 
constitutively expressing IL-33. Whilst not considered in the study, it would be of interest to 
interrogate the role of nuclear IL-33 during chronic disease states, where significantly increased 
expression is observed.  
 
The lack of “clear cut” nuclear functions for the cytokine can be likely attributed to the fact that cell 
lines vary in the expression of their IL-33 splice variants [573]. This in turn, may impact functional roles 
[574]. It is therefore critical to understand what splice isoforms are expressed in RPE cells and indeed 
additional cell types before attributing endogenous faction (or in the case of previous studies, lack of).  
 
The sequestration of IL-33 to the nucleus may likely serve as a mechanism of controlling its potent 
extracellular signalling activities in a variety of tissues. Despite an observed nuclear function in RPE 
cells under the conditions tested in this body of work, it is plausible that these may be context and cell 
specific, with IL-33 selected for during evolution to act solely as a local alarmin upon cell damage 
without exhibiting nuclear transcriptional repressor properties. In a recent study, deletion of the 
chromatin-binding nuclear domain of IL-33 dramatically affects immune homeostasis in mice. When 
not actively targeted to the nucleus, there was constitutive IL-33 release into the serum, leading 
ultimately to lethal eosinophil-dominated inflammation [531]. This provides evidence that a lack of 
signal peptide and a nuclear localisation may be related to IL-33 mode of action, with sequestration 
necessary to limit the potent extracellular biological activity.  
 
In conclusion, the data presented in this chapter indicate that nuclear IL-33 regulates protein 
expression of human and murine RPE cells. These support the current view of IL-33 as a dual function 
protein including functional roles in the nucleus. As IL-33 and its nuclear interactions are enhanced or 
dampened in response to inflammatory cues indicates that IL-33 acts as a key node to maintain cellular 














Chapter 7. Final discussion and future directions  
The RPE cell layer endows functional support to the entire retina. The importance of these cells is 
evident, with RPE loss contributing to the pathogenesis of several retinal degenerative diseases, 
including AMD. To sustain its numerous functions in photoreceptor phagocytosis, nutrient transport 
and the maintenance of tissue immune homeostasis, RPE are highly metabolically active. The 
metabolism of RPE cells revolves around a functional mitochondrial TCA cycle, whereby carbon inputs 
from fatty acids, lactate and amino acids (such as proline and glutamine) support OXPHOS [6, 379]. 
Although capable of carrying out glycolysis, glucose is largely unused by the RPE as a fuel source, and 
instead traverses the monolayer to support other cells within the retina such as photoreceptors, which 
depend on a highly glycolytic program. Work from Hurley et al., has informed us on how the cells 
within the retina are co-dependent on each other both functionally and metabolically [4]. Increasing 
the dependence of RPE cells to the use of glucose as a fuel source has dire consequences for the rest 
of the retina. As glucose concentrations fall on the apical side of the RPE, photoreceptors starve and 
degrade. Indeed, a lack of mitochondrial function (naturally occurring with age and enhanced in AMD) 
forces RPE to utilise glycolysis to survive, at the expense of photoreceptors. 
 
Whilst targeting metabolism in the RPE appears to be a tractable hypothesis for the prevention of 
AMD, one cannot ignore additional confounding factors implicated in disease pathogenesis. Despite 
its multifaceted aetiology, immune dysfunction appears to be a central player. Clinical and genetic 
data support a role for the immune system in AMD pathogenesis in particular, innate immunity and 
the regulation of the complement pathway [2].  A functional immune response is critical for retinal 
homeostasis, yet evidence points towards the overactivation and dysregulation of these responses in 
AMD. Obscuring the understanding of inflammatory contributions to disease pathogenesis are the 
mechanisms underlying the “initial switch” from homeostatic to chronic low-grade inflammation. The 
balance between immune activation and regulation involves intrinsic control through soluble 
mediators at the cellular level. If homeostasis is perturbed following tissue stress in the retina, para-
inflammatory responses remain unchecked and manifest in augmented tissue damage. Tissue damage 
itself further increases endogenous sterile inflammatory signals (e.g alarmin release), and the cycle 
continues. One defining feature of AMD development is the build-up of drusen deposits, predicted to 
be of RPE origin. Drusen is comprised of many immune-stimulating components such as oxidised lipids 
and complement factors. It is unknown if drusen is the trigger for the initial inflammatory response or 
participates in the heightened sterile inflammation later in disease progression.  
 
Work from O’Neill has highlighted the “Warburg effect” in context to immune cell activation [5]. 
Extrapolating from observations made almost a century ago (whereby tumour cells preferentially use 
aerobic glycolysis for survival), it is appreciated that macrophages, dendritic cells, and many other cells 
of the innate and adaptive arms of the immune cell tree, undergo metabolic reprogramming in 
response to “stress signals”, namely that of TLR and cytokine receptor signalling. Metabolic changes 
in innate immune cells plays a predominant role in the regulation of cellular phenotype; mitochondria 
themselves play a central role in the regulation of IL-1 expression, inflammasome activation and the 
generation of ROS through reverse ETC flux [412]. These studies show the interconnectivity (and to an 
extent) co-dependency of core metabolic pathways in inflammatory responses. For example, the up 
regulation of glycolysis in LPS activated macrophages not only supports the bioenergetic demands of 
cytokine secretion and phagocytosis but also feeds the pentose phosphate, fatty acid synthesis and 
serine biosynthesis pathways which support ribose for nucleotides, amino acids for protein synthesis 
and malonyl coA, which influences translation of key inflammatory mRNAs [485].  
 
The RPE is critical to the maintenance of immune privilege within the retina. As an innate-immune 
competent cell, the RPE respond to inflammatory cues through a rich expression of PAMP and DAMP 
receptors [45]. Data presented in this thesis shows that in a similar manner to macrophages, RPE cells 
exhibit a plasticity between metabolic pathways which permits a bioenergetic switch from 
mitochondrial OXPHOS to aerobic glycolysis under conditions of innate immune stress. The initial 
metabolic switch is almost certainly a protective response, bolster flux through ATP-producing 
pathways to support cytokine production and respond to extracellular danger signals by attracting 
innate immune cells. Whilst this adaptive metabolic response permits the RPE to main homeostasis in 
health, it raises concerns for the heightened para-inflammatory environment observed in AMD.  
 
If one is to appreciate the theory of a metabolic ecosystem within the retina [4], it is easy to see how 
the interplay between innate immune and metabolic dysfunction may accelerate AMD progression. 
Under healthy conditions, glucose is passed to the photoreceptors as a fuel source, leaving 
mitochondrial metabolism to support the RPE. With age and early AMD development, it is now 
appreciated that a bioenergetic switch occurs in the RPE towards an increased reliance on glycolytic 
metabolism. With age (and implicated in AMD development) RPE exhibit increased strain on 
mitochondria function and abundance of dysfunctional mitochondria, as mitophagy/autophagy 
housekeeping pathways are impaired [575]. Cybrid RPE cells, created from AMD risk haplogroups, 
indicate that mitochondrial variants themselves determine the bioenergetic switch to aerobic 
glycolysis [18]. With a reliance on glycolysis, comes the breakdown of the symbiotic metabolic 
relationship shared between RPE and photoreceptors. Glucose is passed through the glycolysis 
pathway and exits as lactate. Although, lactate could normally be used as an RPE fuel source [4], the 
diminished mitochondrial function prevents enough ATP generation from oxidative lactate/pyruvate 
metabolism. Consequently, little glucose passes through to the photoreceptors and they begin to 
starve, and ultimately degrade. A similar mechanism likely occurs in the face of uncontrolled para-
inflammatory responses observed in the AMD RPE. Endogenous-derived signals activate innate 
immune receptors present on the RPE (such as TLR-4), permitting a switch to aerobic glycolysis. 
Chronic low-grade inflammation has the potential to constantly rewire the metabolism of RPE cells 
towards a program of increased aerobic glycolysis. This state of augmented glycolysis once again 
negatively impacts the metabolic co-dependency of RPE and photoreceptors, as glucose is effectively 
prevented from traversing the RPE without being consumed for ATP production (Figure 7.1). Whilst 
considered individually here, it is likely that the development of AMD is based on interactions between 
both innate immune and metabolic dysfunction. An RPE forced into a glycolytic state by a decline in 
mitochondrial function lacks the ability to switch between metabolic pathways under stress. This 
occurs naturally over the course of a lifetime regardless of AMD development. We see in normal aging 
mice, a complete loss of any RPE glycolytic capacity. A lack of ability to adapt metabolically likely limits 
the ability of RPE cells to adequately respond and maintain homeostasis in the retina, leading to a 
downwards spiral of uncontrolled inflammation. 
 
 
Figure 7.1. Interplay between metabolic dysfunction and low-grade inflammation in AMD pathogenesis: 
In a heathy retina (left), RPE cells take up glucose through GLUT1 transporters, yet is not used as a metabolic 
substrate. Instead, glucose from the choroidal blood flow is shuttled to the photoreceptors for use in aerobic 
glycolysis. Lactate produced in the photoreceptors is taken up by RPE monocarboxylate transporters and enters 
the mitochondrial TCA cycle as pyruvate. Photoreceptors also supply RPE cells with lipids from the degradation 
of photoreceptor outer segments. These lipids are used to generate ATP in mitochondrial β-oxidation. In AMD 
(middle), a bioenergetic switch to glycolysis occurs, as dysfunctional mitochondria limit the cell’s ability to 
generate ATP through oxidative phosphorylation. This limits the concentration of glucose transported to the 
photoreceptors, leading to starvation and death. Mitochondrial dysfunction impairs the ability of RPE cells to 
process lipids from degraded photoreceptor outer segments, leading to the accumulation in RPE. A similar 
bioenergetic switch may occur in the RPE under conditions of chronic low-grade inflammation. The constant 
interaction between tissue-derived danger associated molecular patterns (DAMPS) and DAMP receptors/ 
cytokines and cytokine receptors present on the RPE surface lead to metabolic rewiring into aerobic glycolysis 
through an up-regulation of hypoxia-inducible factor α (HIF-1α). Increased RPE glycolysis renders the RPE less 
able to support the photoreceptors and subsequently leads to their starvation and death. β-oxidation is similarly 
reduced as the RPE switches away from mitochondrial metabolism, leading to the accumulation of outer-
segment lipids. RPE, retinal pigment epithelium; AMD, age-related macular degeneration; FAS, fatty acid 
synthesis; DAMP, danger-associated molecular pattern; PRR, pattern recognition receptor; ATP, adenosine 
triphosphate; GLUT1, glucose transporter 1. Adapted from [4].  
  
Data presented in this thesis has highlighted the metabolic adaptations of the RPE to other 
immune-derived stress signals, namely the TLR-3 agonist Poly (I:C) and alarmin IL-33. Unlike 
TLR-4 activation, TLR-3 ligation was accompanied by an increase in mitochondrial OXPHOS, 
mediated by activation of AMPK. Whilst activation of this pathway was not accompanied by 
a bioenergetic switch to aerobic glycolysis, flux through the glycolysis pathway was still 
augmented. This has highlighted the differential metabolic response of the RPE to varying 
signalling pathways likely to be activated in the context of the low-grade chronic 
parainflammatory environment of AMD. Despite the differential metabolic outcomes in terms 
of aerobic glycolysis vs oxidative glucose catabolism in response to immune stimulation, it is 
evident that “activated” RPE cells increase their glucose consumption. This, as highlighted in 
previous sections, would have adverse effects for the photoreceptors. Although, endogenous 
TLR-3 agonists can elicit retinal degeneration in vivo [576], it is unknown to what extent RPE 
metabolism is altered in vivo and if this contributes to photoreceptor loss.  
 
A limitation of the work presented in this thesis is that the metabolism of RPE was assessed 
ex vivo and in vitro and therefore may not be truly representative of the in vivo metabolic 
environment whereby RPE cells scarcely use glucose as a fuel source. When primary RPE cells 
are cultured ex vivo they adopt a metabolic program of glycolysis and lactate production. The 
work conducted in this study assumed that these pathways may be redundant in vivo, using 
in vitro studies to answer the question “does metabolic reprogramming occur in the RPE in 
response to immune stressors?” and subsequently assess the underlying molecular 
mechanisms. Whilst this work has unravelled some interesting conclusions on RPE 
behaviours, future work should aim to explore some of the observations made in this study, 
with the focus on investigating if RPE cells adapt their metabolism to glycolysis in vivo 
following activation of PAMP or DAMP-mediated signalling pathways. 
 
The groundwork of this thesis was built on the overarching hypothesis that the induction of 
the Warburg effect in RPE generates an IL-33 signature that regulates cellular gene responses 
and prevents unwanted immune activation. It was originally hypothesised that changes in the 
tissue environment are signals to drive changes in RPE metabolism, resulting in a direct signal 
to activate inflammation. Whilst immune activation could be perceived as adverse, in the 
context of RPE and retina, a consequence of this is the “protective” response conferred by 
increased IL-33 production. Whilst we now appreciate a metabolic switch does indeed occur 
in response to immune stressors, it is important to note the multifaceted nature of such a 
response in terms of both the “metabolic ecosystem” and the concurrent production of IL-33. 
The initial up-regulation of IL-33 is almost certainly a protective response to cellular stress. 
During injury, RPE cells are destroyed, liberating IL-33 into the extracellular milieu. Once 
released, IL-33 signals to nearby cells to alert the immune system of tissue damage and 
dysfunction. IL-33 can also act in a paracrine/autocrine manner on RPE cells within the 
monolayer to preserve cellular function through increasing overall bioenergetic demands. 
There is much interest in the ability to protect against noxious damage to the RPE in the form 
of oxidative stress (a key early event in AMD progression [577]) and the observation of IL-33 
to protect against oxidative damage has exciting implications. One cannot, ignore the fact 
that IL-33 is a highly pro-inflammatory cytokine with many pleiotropic functions [9]. Whilst in 
the context of bolstering RPE mitochondrial function, use of therapeutic IL-33 appears 
attractive, there is however, evidence that IL-33 is released from Müller cells and contributes 
to photoreceptor loss through recruitment of mononuclear phagocytes 
(macrophage/microglia) [17]. As previously stated, the initial IL-33 release is protective, 
leading to the co-ordination of immune responses and attempt to repair tissue damage [8]. 
The increased IL-33 expression observed in areas of macular degeneration [17] supports the 
alarmin nature of the cytokine in response to RPE cell loss and lesions. However, with an 
attempt to maintain homeostasis comes the price of undesired inflammation and starvation 
of photoreceptors through rewiring of RPE glucose metabolism. Therefore, one can argue the 
context-dependent protective or damaging effects of IL-33 depend on both the location and 
degree of insult.  
 
It is of interest to assess the role of IL-33 in the context of other ST2-expressing cells in the 
retina (namely mononuclear cells, Müller glia and mast cells) in response to RPE death during 
early AMD. Data presented in chapter 4 highlighted that the metabolic effects of IL-33/ST2 
signalling appear to be specific to RPE. This, however, does not rule out that IL-33 has no 
effect on Müller glia and mast cells. The caveat with investigating Müller glia is that high levels 
of ST2 are only expressed when “active” (e.g. following exposure to phototoxic light in animal 
models). Upon ligation of ST2, IL-33 induces the expression of chemokines and cytokines [17]. 
Müller glia are important in the maintenance of laminar structure, neuronal survival, 
metabolic homeostasis and repair of the damaged retina [578];  understanding how these 
processes may be altered following activation of the IL-33/ST2 axis require further 
investigation. The main source of IL-33 is in the nucleus of Müller glia in the normal retina, 
suggesting a key role of these cells in immune-mediated repair processes [17]. Interestingly, 
the deletion of IL-33 in murine models of photoreceptor detachment leads to persistent 
Müller gliosis and augmented degeneration [579]. These results suggest that IL-33 negatively 
regulates Müller glia to protect against inflammatory photoreceptor damage. Macrophages 
and microglia are key ST2 expressing myeloid cells [580], and key contributors to immune 
homeostasis in the retina [41]. One can extrapolate from previous observations that IL-33 
signalling in retinal myeloid cells establishes a homeostatic tissue tone. The observation that 
IL-33 protects against EAU through the polarisation of M2 macrophages [16] has interesting 
implications for AMD whereby macrophage subtype shifts towards an M1 phenotype [581]. 
In the brain, IL-33 serves to protects against tissue injury through the polarization of microglia 
to an M2 phenotype with enhanced IL-10 production, critical for neuronal survival [582]. We 
now understand that a functional interface is observed between the RPE and macrophage; 
impairing RPE function through perturbation of autophagy or mitochondrial function is 
sufficient to recruit macrophages which phagocytose the damaged RPE [518]. A consequence 
of this however, is macrophage inflammasome activation and proangiogenic inflammatory 
responses [518]. As Th2 cytokines suppress these responses [583], it is likely that the IL-33 
released in the context acts to subvert noxious pro-angiogenic responses [8] without 
suppressing macrophage phagocytotic functions [15]. Mast cells are abundant in the choroid 
and play a key role in the regulation of choroidal inflammation, they exhibit high expression 
of ST2 and are an important target of release IL-33 [200, 203]. The role of mast cells in AMD 
pathogenesis is currently unknown. Studies suggest that increased mast cell degranulation 
may drive early AMD, with an increased choroidal mast cell number observed in AMD tissue 
[584]. Further research suggests that tryptase (a highly abundant mast cell secretory granule-
derived serine protease) is released during degranulation of choroidal mast cells, 
accumulating at the basement membrane in high levels in GA patients [585]. One important 
function of IL-33 is that it does not induce degranulation of mast cells, but rather “fine tunes” 
and potentiates IgE-mediated mast cell responses [203]. In addition to this, IL-33 orchestrates 
the initiation of the mast cell-mediated inflammatory response through the production of 
pro-inflammatory cytokines (IL-6 and TNFα) and Th2 cytokines (IL-5, IL-10 and IL-13) [205]. As 
mast cells are implicated in disease development, interrogating the RPE/mast cell IL-33/ST2 
axis is essential for furthering our understanding of IL-33 release in the context of early AMD 
pathology.  
 
One aspect of this thesis entailed investigating how IL-33 release regulates homeostasis through 
maintenance of RPE function. As previously discussed, IL-33 acts in an autocrine manner when 
released to increase RPE mitochondrial respiration which protects against oxidative damage. I have 
additionally discussed how IL-33 likely serves to protect retinal homeostasis through recruitment of 
mononuclear cells and mast cells. Whilst these are essential to discuss, there is a need to consider 
how IL-33 functions in conditions of cellular stress below a threshold to which RPE are damaged and 
IL-33 is not released (potentially akin to the earliest stages of AMD development). Although, chronic 
low-grade inflammation is likely to contribute to RPE death through un-controlled tissue destruction, 
the initial response of RPE to cellular stress is not that of immediate death but rather activation of 
innate immune pathways. A consequence of RPE stress is the up-regulation of intrinsic IL-33 which 
retains its localisation in the nucleus. Studies show that IL-33 release from cells is unlikely to occur 
without damage due to a lack of signal sequence and canonical processing pathway (like that of IL-1β 
and IL-18) [134]. Therefore, IL-33, exhibiting nuclear localization signals and containing a homeobox 
Helix-Turn-Helix DNA binding motif ubiquitous to many transcription factors [136], likely contributes 
to the regulation of cellular function through nuclear mechanisms in the absence of cell death. 
 
The nuclear role of IL-33 in the RPE was first assessed through probing protein interaction networks. 
The data presented in chapter 6 highlighted a robust IL-33 interaction network in RPE cells of both 
human and murine origin, converging on core histone-modifying and chromatin remodelling 
complexes (as expected considering previous observations [261]). As IL-33 was found to interact with 
components of the translation machinery, I hypothesised that IL-33 may also be involved in post-
transcriptional regulation and this led to further proteomics-based experiments exploring the effect 
of IL-33 loss (or augmented expression) on the RPE proteome. Collectively, these data indicated that 
IL-33 directly impacted protein expression in RPE cells and emphasised a bone fide intrinsic role. The 
observation that alterations of IL-33 expression status in human and murine RPE cells led to a 
proteomic signature with enrichment in targets in metabolic function was of interest considering 
observations made in chapter 5. Therefore, one can assume that a consequence of nuclear IL-33 up-
regulation in response to immune stress is for the control of the core-biosynthetic pathways. 
Upregulation of glycolysis in RPE cells through the action of nuclear IL-33, likely serves as an adaptive 
mechanism, allowing the RPE to respond bioenergetically to the demands of an innate immune 
response (Figure 7.2). 
 
While the role of endogenous IL-33 in the regulation of immune cell metabolism is multifaceted 
(discussed to a greater extent in section 1.9.3), it appears that its function converges on aspects of 
glycolytic and central carbon metabolism. In macrophages overexpressing IL-33, increased glucose 
uptake and lactate production are observed suggesting increases in glycolytic flux [444]. Cancer lines 
transfected to overexpress IL-33 exhibit a similar shift in metabolism [443]. Additionally, knockdown 
of endogenous IL-33 in synovial fibroblasts reduces HIF-1α expression [442]. These observations 
suggest that IL-33 is a key regulator of the glycolysis pathway and supports observations presented in 
this thesis, whereby overexpression of IL-33 in human RPE cells augmented glycolytic flux and 
pyruvate entry into the TCA cycle. The paradox that IL-33 appears to increase glycolytic metabolism 
when overexpressed and knocked-down in the RPE endows a level of complexity to its endogenous 
functions. Whilst data presented in chapter 5 indicates that RPE cells lacking IL-33 have increased ECAR 
(and lactate production) this does not necessarily translate to increased glycolysis. Through employing 
SITA, I found that IL-33 does not increase C13-glucose labelling in any other metabolite except for 
lactate. Upon further investigation I observed defects in the expression of key pyruvate transporters 
MPC1 and 2 with IL-33 KD. Faults in the expression of these key import proteins are likely contributors 
to the increased ECAR observed (rather than glycolytic flux) as pyruvate is reduced to lactate. One 
cannot rule out the contribution of TCA cycle acidification to ECAR under these test conditions, as 
increased flux of fatty acid metabolites appear to support the TCA cycle. The metabolic phenotype of 
IL-33 KD RPE therefore appears to be that of increased mitochondrial fatty acid oxidation rather than 
enhanced glycolysis. Supporting the view of IL-33 as a key metabolic regulator, proteomic signatures 
from three lines of investigation identified significant enrichment of metabolic pathways that 
supported the functional analysis (seahorse). Pathway analysis of IL-33 overexpressing cells showed 
that up-regulation of glycolytic proteins formed one of the highest significance functional annotation 
clusters. Vice versa, RPE cells lacking IL-33 displayed increased enrichment of clusters containing 
proteins of mitochondrial metabolism and fatty acid oxidation. It is of interest to note that similar 
gene expression ontologies were significantly enriched in Il33-/- adipocytes [19], suggesting conserved 
roles in metabolic regulation across cell types. A schematic showing the metabolic phenotypes 
observed with alterations to IL-33 expression is shown in Figure 7.2. 
 
Translating the observations made in this thesis regarding IL-33 expression and metabolic 
phenotype into the in vivo environment has interesting implications for RPE health and AMD 
pathogenesis. A previous observation that IL-33 expression status was altered in RPE cybrids 
from AMD “high-risk” haplotypes [18] highlighted contemporaneous changes in RPE 
metabolism and expression of IL-33 when mtDNA content changes. It was thus proposed that 
IL-33 acts as a signal in the RPE to adapt or maintain mitochondrial metabolism; a down-
regulation in the expression status (as observed in “high-risk” AMD groups) would therefore 
have adverse effects on RPE metabolism and accelerate disease progression. Taking 
experimental data from chapter 5 into consideration, one would anticipate that this would be 
the case considering a loss of IL-33 impairs RPE spare respiratory capacity (suggesting damage 
to mitochondrial health). A decline in RPE mitochondrial function in animal models (e.g. loss 
of antioxidant enzymes in SOD1, SOD2 and NRF2-deficient mice [586-588] and loss of OXPHOS 
in mitochondrial transcription factor A-deficient mice [383]) leads to phenotypes resembling 
the clinical features of AMD development, namely RPE degeneration, photoreceptor decline 
of function and lipofuscin accumulation. However, we find no observable ocular phenotype 
in young IL-33-deficient mice (Unpublished data, Matthew Campbell, Trinity College Dublin). 
This raises the question on how clear metabolic differences observed ex vivo and in vitro do 
not translate into a phenotype in vivo which would impair RPE function. If we return our 
attention to the observation that RPE cells are not glycolytic in vivo it becomes clear how IL-
33 loss may not be deleterious for retinal health. When RPE are cultured ex vivo they rapidly 
dedifferentiate [589] and switch to the use of glycolytic metabolism [381]. As IL-33 regulates 
the expression of MPC1 and 2, this manifests in the apparent increase in lactate production 
as RPE are forced to utilise glucose as a substrate. In vivo, glucose passes through the RPE 
monolayer and is utilised by photoreceptors [4]. An impairment in glucose-derived carbon 
input into the TCA cycle is therefore unlikely to affect RPE (unless required to adapt under 
stress) as their metabolism is supported by lactate, amino-acid and fatty acid catabolism [6, 
374, 379]. It was interesting to note that the TCA cycle, mitochondrion and fatty acid oxidation 
were all significantly enriched GO terms in proteomics experiments from primary RPE lysates 
of Il33-/- mice. As these were not from ex vivo cultures, it suggested that core mitochondrial 
pathways were up-regulated in the absence of IL-33 in vivo and were not an adaptive 
response to maintain TCA cycle activity in the absence of pyruvate import. In addition to this, 
increased mitochondrial staining of retinal sections and mitochondrial number from EM 
experiments suggest that mitochondria activity is augmented in vivo. Extrapolating from 
results in macrophages [444], upregulation IL-33 which likely serves to rewire RPE metabolism 
and enhance inflammatory responses. With defects in glucose metabolism with IL-33 loss, 
RPE cells likely exhibit an impaired ability to respond to endogenous stress signals, leaving 
chronic inflammation to persist unchecked. Future directions of this work will aim to observe 
how RPE cells with differential IL-33 expression respond to inflammatory signalling.  
 
Taken together, this does not necessarily translate to the hypothesis that increasing IL-33 
expression in RPE cells (whether that be through targeted gene therapy etc.) could be an 
attractive therapeutic adjuvant for early AMD. As previously discussed, IL-33 upregulation in 
cells serves as a switch to up-regulate glycolytic flux, providing rapid ATP synthesis for 
functional responses. The initial metabolic switch is protective from the point of view that 
RPE cells can respond and control inflammatory responses, but this likely occurs at the 
expense of photoreceptors (although there is no experimental data to show this to date). 
Depriving photoreceptors of glucose for extended periods leads to starvation and 
degeneration. Indeed, transgenic enhancement of mTOR-dependent glycolysis in mice leads 
to a progressive regional loss of photoreceptors [383]. Future work will be required to 
examine how overexpression of IL-33 affects RPE and photoreceptor health in vivo. 
Furthermore, as the regulation of IL-33 and concurrent metabolic shifts are likely a tightly 
regulated process, further work will be required to identify whether a down-regulation of IL-
33 is required to restore the RPE β-oxidation program (see Figure 7.2.)  In order to further 
understand the role played by intrinsic IL-33 during the innate response, work from this thesis 
will also need to be translated into the in vivo environment. In vivo C13 labelling will be 
essential to understand IL-33-mediated metabolic reprogramming without confounding 
factors, such as the adaptation of RPE to in vitro culture environment. As mentioned, 
transgenic models of IL-33-overexpressing RPE will likely be required to assess how enhancing 
RPE glycolysis will impact the rest of the retina. 
 
 
Figure 7.2. IL-33 regulates RPE metabolic adaptations in response to immune stressors: 
In a heathy retina, RPE cells take up glucose through GLUT1 transporters, yet is not used as a metabolic substrate. 
Instead, glucose from the choroidal blood flow is shuttled to the photoreceptors for use in aerobic glycolysis. 
RPE cells are supported through β-oxidation and amino acid catabolic pathways, which feed into the TCA cycle. 
In response to innate immune stress signals (left), RPE cells increase the expression of nuclear IL-33 which in 
turn reprograms RPE metabolism towards a program of enhanced glycolysis. Pyruvate enters the mitochondrial 
through MPC 1 and 2 and is oxidised to produce ATP. The enhanced ATP produced from glycolysis is required to 
fuel the production and release of immunomodulatory cytokines. Downregulation of IL-33 (right) elicits a 
metabolic shift towards mitochondrial β-oxidation. As pyruvate entry into the mitochondria is impaired, ATP-
production is likely supported by β-oxidation and glucose passage through the retina may be restored. IL-33, 
interleukin-33; MPC, mitochondrial pyruvate carrier; DAMP, danger-associated molecular pattern; PRR, pattern 





Data has demonstrated a key intrinsic role for the nuclear cytokine IL-33 in RPE cells. Despite gaining 
insight into how altering IL-33 expression status influences protein expression and thus basic cellular 
function (metabolism), the underlying endogenous function(s) of IL-33 remain elusive. Homology 
studies of the IL-33 protein indicated the presence of a helix-turn-helix domain [136] which when 
combined with its constitutive nuclear expression has led to the broad assumption that IL-33 binds 
directly to DNA. ChIP-RT-PCR studies have reported enrichment of IL-33 at the promoters of IL13 and 
IL1RL1 [254, 257] [258]. Despite these findings, there is insufficient evidence of IL-33 DNA binding and 
the mechanisms of its nuclear function. This likely stems to much of the research converging on its 
extracellular cytokine activity. However, this may be a result of a lack of suitable IL-33-specific ChIP-
grade antibodies or simply that IL-33 does not exhibit DNA binding. 
 
The preliminary experimental data (presented in appendices 10.5, page 405) suggests that the Nessy-
1 antibody may unsuitable for ChIP, despite functioning well for immunoprecipitation and 
immunoblotting (see chapter 6). Library preparation was successful, yet peak splitting analysis 
revealed an extremely low peak number compared to what one might expect to see from a typical 
non-histone protein (99 with Nessy-1 compared to ~5,000 [590]). Despite a low peak number attained 
from the Nessy-1 antibody, ChIP peaks were investigated further to reveal a small number of 
annotated genes with IL-33 affinity. Most of these corresponded to non-coding regions/pseudogenes 
(indicative of background signal), leaving only 15 protein coding genes; none of which corresponded 
to IL1RL1 or IL13 (genes displaying an affinity for IL-33 in previous studies [257] [258]) (Table 10.6.4, 
page 414).  
 
One may argue that that IL-33 may not exhibit extensive DNA binding in ARPE-19 cells and the small 
list of genes are in fact bona fide interactions. This, however, will require further investigation with 
additional IL-33 antibody(s). Moreover, a single biological replicate is insufficient to create conclusions 
on lack of nuclear function. Although, the data presented does not fit the hypothesis that IL-33 binds 
to DNA and exerts function on gene expression, there is uncertainty in the authenticity and reliability 
of the peaks. 
 
As discussed in the conclusion of chapter 6, it is essential to take into consideration the contexts 
whereby IL-33 may not display “dual functional” properties and is localised to the nucleus to sequester 
its potent biological activity [230, 263]. IL-33 is undeniably a potent inflammatory cytokine with the 
capacity to elicit overt inflammation when not sequestered to the nucleus [531]. Indeed, IL-33 lacking 
an N-terminal chromatin-binding domain is readily secreted from Müller glia and contributes to ST2-
dependent inflammation and retinal cell loss [17]. Whilst the data presented in this thesis and a mass 
of other experimental evidence suggests an intrinsic role for IL-33 [10, 19, 223, 260, 261, 442], the 
observations that IL-33 has no transcriptional properties in certain systems cannot be ignored. 
 
In summary, this thesis has explored the ability of the RPE to adapt metabolically to stress signals. I 
find that intrinsic IL-33 functions as a metabolic checkpoint to potentiate a bioenergetic switch to 
glycolysis, which in turn supports the bioenergetic demands of innate immune responses. Non-
canonical intrinsic IL-33 responses likely serve to maintain metabolic and immune function, 
particularly within sensitive tissues such as the retina. The benefits of keeping RPE metabolic function 
and uncontrolled inflammatory responses in check is clear, especially when we consider the 
degenerative diseases such as AMD whereby a bioenergetic crisis and chronic inflammation likely 
contribute to the underlying pathology. Debatably, further investigation into the molecular 
mechanisms governing these processes will elucidate novel approaches that serve to prevent further 
disease development and restore tissue homeostasis. 
 
The future directions of this work will be to investigate the nature of metabolic coupling within the 
retina and how this is influenced under conditions of innate immunological stress. As previously 
discussed, a caveat of this thesis is the lack of translation from in vitro studies and therefore, a lack of 
understanding to how metabolic reprogramming occurs in vivo when we consider the unique 
metabolic relationship shared between RPE cells, photoreceptors and Müller glia. The emergence of 
techniques such as in vivo C13 labelling will allow us to assess to what extent RPE glycolytic 
reprogramming occurs in animal models of innate immune stress, and how this affects export of 
metabolic intermediates into the retina. In addition to this, the translation of this work into an in vivo 
environment will allow us to dissect visual function and photoreceptor health, which one cannot 
achieve in 2D cell culture studies. This is essential for furthering our understanding of the complex 
interplay between innate immune responses and energy metabolism. It will be important to further 
assess the molecular mechanisms whereby intracellular immune-derived signals, drive metabolic 
adaptations of the RPE. Thus, we can employ alternative approaches that can target the “protective” 
aspects of innate immunity and restore metabolic health in the RPE, forestalling the insidious 
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Chapter 10. Appendices  
  
10.1. Detection of “metabolic switching” on the XF platform 
To identify potential metabolic changes to the RPE under innate immune “stress”, there was a need 
to observe if: (A) the RPE was able to rapidly alter its metabolism and (B) if the Seahorse XFp can detect 
these changes in real-time. Together the experiments were designed to observe whether a potent 
metabolic signal could induce real-time metabolic changes to the RPE. Lactate was chosen as a suitable 
signal due to its well-described ability to suppress glycolysis in cancer cells [463].  Lactate has a 
described role in suppressing RPE glycolysis and is used as an RPE fuel source [4]. In order to assess 
the changes to ARPE-19 metabolism, basal OCR and ECAR measurements were taken before and after 
an injection of lactate. It was found that lactate dose-dependently increased OCR measurements and 
suppressed ECAR measurements post injection (Fig. 10.1A-B). This data indicated that rapid changes 
in metabolism could be identified in RPE cells.    
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Figure 10.1. Metabolic switching in ARPE-19 cells: 
The ability of lactate to suppress glycolysis and increase oxidative phosphorylation in ARPE-19 cells was assessed 
on the XFp platform. Varying doses of lactate was injected into ports of XFp cartridges and OCR (A) or ECAR (B) 
measurements were taken for over 100min. Data presented as means ± SD from two independent experiments 
performed in triplicates.   
10.2. Detection of alternate bioenergetic profiles  
Extracellular bioflux analysis allows quantification of the ATP-producing respiratory processes via 
measurement of OCR for oxidative phosphorylation and ECAR for glycolysis. These are subsequently 
utilized to determine various metabolic parameters, which can be used to examine the “bioenergetic 
status” of a cell. Because bioflux is a cell-type specific process, it was important to first identify if 
alternate parameters (such as the Warburg effect) could be observed using cells with distinct known 
metabolic characteristics. I chose to utilize the ARPE-19 (as a typically OXPHOS utilizing cell [376]) and 
as a comparator, the colon cancer cell line SW1463 (highly glycolytic cells established from a grade III 
solid rectal adenocarcinoma [444]). A glycolysis stress test was utilised to measure the glycolytic 
function in these cells (as detailed in materials and methods). It was found that SW1463 were 
significantly more glycolytic than ARPE-19 yet lacked glycolytic reserve post-oligomycin injection (Fig. 
10.2A-B). The lack of glycolytic reserve indicated that the SW1463 cells relied less on mitochondrial 
ATP production compared to ARPE-19. A mitochondrial stress test was utilised to measure the 
mitochondrial function in these cells (as detailed in materials and methods). It was found that SW1463 
cells had reduced basal and maximal respiration compared to ARPE-19 cells (Fig. 10.2C-D). The 
reduced OCR/ECAR in the SW1463 cells further highlighted the increased reliance on glycolysis over 
OXPHOS (Fig. 10.2E).  
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Figure 10.2. Comparative bioflux analysis indicates SW1463 colon cancer cells exhibit increased glycolysis 
compared to ARPE-19: 
(A) Representative glycolysis stress test measured with sequential injections of glucose, oligomycin and 2DG (B) 
Glycolysis parameters (G- glycolysis; GC- glycolytic capacity; GR- glycolytic reserve; NGA- non-glycolytic 
acidification) calculated from data shown in (A). (C) Representative mitochondrial stress test measured with 
sequential injections of oligomycin, FCCP and rotenone/antimycin-A. (D) Mitochondrial parameters (BR- basal 
respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- proton leak; ATP- ATP-production) 
calculated from data shown in (C). (E) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR. (F) 
Data presented as means ± SD from two independent experiments performed in triplicates. (B-C) One-way 
ANOVA with Tukey’s multiple comparisons test, (D) Unpaired Student’s T-test; *p<0.05, **p<0.01, ***p<0.005, 
****p<0.001. 
  
10.3. Low-molecular weight Poly (I:C) has similar effects to the high-molecular weight agonist on 
ARPE-19 metabolism 
Treatment of ARPE-19 cells with LMW Poly (I:C) for 24h had no significant effect on the cytotoxicity 
(Fig. 10.3A). Having confirmed that the LMW displayed similar tolerability by ARPE-19 cells, I 
proceeded to undertake metabolic analysis.  
 
Post injection of LMW Poly (I:C) there were no changes observed in real-time ECAR or OCR 
measurements (Fig. 10.3B-C). A mitochondrial stress test was used to identify changes in OXPHOS 
parameters. It was found that treatment of ARPE-19 cells for 24h with 10µg/ml of LMW Poly (I:C) 
increased mitochondrial respiration. Basal respiration and maximal respiration were both significantly 
increased (Fig. 10.3D-E). No significant changes were observed to spare respiratory capacity or any 
deleterious mitochondrial parameter (Fig. 10.3D-E). The corresponding ECAR data was used to identify 
how basal glycolysis and glycolytic capacity were affected by LMW Poly (I:C) stimulation. It was 
observed – post oligomycin injection – that cells pre-treated with LMW poly (I:C) for 24h had increased 
glycolytic capacity (Fig. 10.3F-G). The OCR and ECAR data were expressed as the ratio OCR/ECAR to 
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Figure 10.3. Low-molecular weight Poly (I:C) has similar effects to the high-molecular weight agonist on ARPE-
19 metabolism: 
(A) ARPE-19 cells were treated for 24h with LMW Poly (I:C) (10µg/ml). Supernatants were taken and LDH levels 
were assessed using a commercial kit. LDH release was expressed as a (%) of an untreated control. (B) Real-time 
changes in ECAR following injection of LMW Poly (I:C) (10µg/ml). (C) Real-time changes in OCR following injection 
of LMW Poly (I:C) (10µg/ml). (D) Representative mitochondrial stress test measured with sequential injections 
of Oligomycin, FCCP and rotenone/antimycin A, following stimulation with LMW Poly (I:C) (24h; 10µg/ml). (E) 
Mitochondrial parameters (BR- basal respiration; MR- maximal respiration; SRC- spare respiratory capacity; PL- 
proton leak; ATP- ATP-production) calculated from data shown in (D). (F) ECAR data from (D). (G) Glycolytic 
capacity calculated from (F). (H) Basal OCR and ECAR measurements expressed as the ratio OCR/ECAR, after 24h 
LMW Poly (I:C) (10µg/ml) treatment. Data presented as means ± SD, from two independent experiments 
performed in triplicate. Unpaired Student’s T-test; *p<0.05. 
 
  
10.4. Validation of recombinant IL-33 bioactivity 
I chose to use recombinant mouse (ALX-522-101-C010) and human recombinant IL-33 (ALX-522-098 
C010) from Enzo Life Sciences Ltd (see Section 2.2.1) [8]. Prior to assessing the role of IL-33 on RPE 
metabolism, there was a necessity to validate the bioactivity of both human and murine rIL-33 in RPE 
cells. A previous study identified transcriptional changes in an IL-33-stimulated murine cell line, 
whereby increased Il33 and Mpc-1 mRNA transcripts were observed [16]. I decided to repeat this 
experiment in both human ARPE-19 and murine B6RPE-07 cell lines exposed to varying doses of rIL-
33 for 24h, using the expression changes of IL33/Il33 mRNA as a positive control for the recombinant 
proteins. Both RPE cell lines were observed to exhibit a dose-dependent increase in the expression of 
IL33 or Il33 in response to rhIL-33 or rmIL-33, respectively (Fig. 10.4A-B). Collectively, these 





































































































Figure 10.4. Validation of recombinant IL-33 bioactivity: 
(A) ARPE-19 cells were treated for 24h in the presence or absence of rhIL-33 (1-100ng/ml). RNA was isolated, 
converted to cDNA and RT-PCR was used to assess the expression of IL33. (B) B6RPE-07 cells were treated for 
24h in the presence or absence of rmIL-33 (1-100ng/ml). RNA was isolated, converted to cDNA and RT-PCR was 
used to assess the expression of Il33 or IL33. Represents data from one experiment with two biological repeats.   
  
10.5. Nessy-1 antibody test and small-scale ChIP sequencing 
To determine the role of IL-33 in DNA binding, A ChIP reaction was carried out using 30μg of human 
ARPE-19 epithelial cells chromatin and anti-IL-33 antibody (Nessy-1). In the absence of a suitable 
commercially available ChIP/ChIP-seq grade antibody for IL-33, Nessy-1 was chosen as a preliminary 
antibody for two reasons: firstly, it was observed to successfully pull-down IL-33 in the experiments 
detailed in chapter 6; secondly, Nessy-1 was used successfully to show the binding of IL-33 to the 
IL1RL1 promoter (ChIP-RT-PCR) and co-immunoprecipitation of SUV39H1 in a previous study [256]. 
The ChIP DNA was processed into a standard Illumina ChIP-Seq library and sequenced to generate >5 
million reads. Reads were aligned to the human genome (hg38), and after removal of duplicate and 
non-uniquely mapped reads, ~6.5 million alignments were obtained. A signal map capturing fragment 
densities along the genome was generated and visualized in the Integrated Genome Browser (IGB). In 
addition, MACS peak finding was performed to identify the most significant peaks. Using a default cut-
off of p-value <1e-7 (without control file), only 99 peaks were identified (after ENCODE blacklist 
filtering). Typically, antibody validations for non-histone proteins which pass this criterion exhibit a 
peak number of around 5,000 [588].  
 
Further investigation into the peaks identified from the Nessy-1 test revealed that almost two thirds 
(63/99) of these corresponded to repetitive/centromeric/near-telomeric regions with no gene 
annotation. The remaining 36 peaks with gene annotations are summarised in Table 10.4, Appendices. 
Of these, only 15 peaks corresponded to protein encoding genes, with 19 peaks corresponding to 
pseudogenes or non-coding RNA. It was essential to note that gene position varied across the genes 
with no enrichment in promoter or exon regions. Indeed, most peaks corresponded to upstream or 
downstream gene regions indicative of no clear regulatory function. 
 
Six Integrated Genome Browser 9.0.2 (IGB) screenshots are enclosed (Fig. 10.5-7), showing different 
chromosomes and regions of the genome. Each image shows the IL-33 data in the top track (blue 
colour), followed by a track with red marks indicating the location of the filtered MACS peaks. The 
bottom two data tracks of the screenshots (black colour) show a negative (“input control”) and 
positive ChIP-Seq assay (historical, unrelated data) for comparison and as illustration. These “control 
tracks” were generated from 5 million tags, and IGB y-axis scales were adjusted to make all tracks 
comparable. The bottom 2 tracks show the RefSeq gene annotations in green.  
 
Based on the background-level number of peaks identified and the essentially flat appearance of the 
signal map in the genome browser, it suggested that this antibody test was likely unsuccessful. As 
there was no positive control available for Nessy-1, the antibody validation assay did not include an 
actual positive control with the same chromatin. Instead, the reactions were carried out in batches 
with other ChIP-Seq assays using validated antibodies at Active Motif Laboratories, Carlsbad, USA. The 
latter reactions serve thus as technical controls for the present antibody validation.  
 
Taken together, the results obtained in this section suggest that Nessy-1 may not be a suitable 
antibody for ChIP of IL-33 and therefore future work should aim to investigate an alternate antibody 





Figure 10.5. Small-scale DNA sequencing reveals few Nessy-1 binding sites in chromosomes one and two:  
Integrated Genome Browser was used to determine Nessy-1 affinity DNA sites on (A) chromosome one and (B) 
chromosome two following ChIP and small-scale DNA sequencing. Nessy-1 data track (blue), followed by a track 
indicating the location of the filtered MACS peaks (red). The bottom two data tracks of the screenshots (black) 
show a negative (“input control”) and positive ChIP-Seq assay (historical, unrelated data) for comparison and as 
illustration. These “control tracks” were generated from 5 million tags, and IGB y-axis scales were adjusted to 
make all tracks comparable. The bottom 2 tracks show the RefSeq gene annotations in green.  
 
 
Figure 10.6. Small-scale DNA sequencing reveals few Nessy-1 binding sites in chromosomes three and four:  
Integrated Genome Browser was used to determine Nessy-1 affinity DNA sites on (A) chromosome three and 
(B) chromosome four following ChIP and small-scale DNA sequencing. Nessy-1 data track (blue), followed by a 
track indicating the location of the filtered MACS peaks (red). The bottom two data tracks of the screenshots 
(black) show a negative (“input control”) and positive ChIP-Seq assay (historical, unrelated data) for comparison 
and as illustration. These “control tracks” were generated from 5 million tags, and IGB y-axis scales were 
adjusted to make all tracks comparable. The bottom 2 tracks show the RefSeq gene annotations in green.  
 
 
Figure 10.7. Small-scale DNA sequencing reveals few Nessy-1 binding sites in chromosomes five and six:  
Integrated Genome Browser was used to determine Nessy-1 affinity DNA sites on (A) chromosome five and (B) 
chromosome six following ChIP and small-scale DNA sequencing. Nessy-1 data track (blue), followed by a track 
indicating the location of the filtered MACS peaks (red). The bottom two data tracks of the screenshots (black) 
show a negative (“input control”) and positive ChIP-Seq assay (historical, unrelated data) for comparison and as 
illustration. These “control tracks” were generated from 5 million tags, and IGB y-axis scales were adjusted to 
make all tracks comparable. The bottom 2 tracks show the RefSeq gene annotations in green.  
10.6. Tables 
10.6.1. Differentially expressed IL-33-interacting proteins following LPS stimulation 
 
Protein Fold change (LPS vs control) 
40S ribosomal protein S14  3.123487 
Serine/threonine-protein kinase ATR  1.913947 
General transcription factor II-I  1.869565 
Histone H3.2  1.811798 
X-ray repair cross-complementing protein 6  1.781768 
Histone H3.1  1.747967 
SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily A  1.699605 
Histone H2B type 1-J  1.641221 
Prothymosin alpha  1.578947 
60S ribosomal protein 1.575092 
Granulins  1.567436 
Heat shock 70kDa protein 8 isoform 1 variant  1.556092 
RNA-binding protein EWS  1.556092 
Histone H4  1.546763 
40S ribosomal protein S2 1.546763 
ABC transporter ATP-binding protein 1.539379 
Polyadenylate-binding protein 1  1.537545 
Heterogeneous nuclear ribonucleoprotein U  1.532067 
Acidic leucine-rich nuclear phosphoprotein 32 family member B  1.532067 
Enhancer of rudimentary homolog  1.530249 
60S acidic ribosomal protein P2  1.523022 
Polyadenylate-binding protein  1.517647 
Non-histone chromosomal protein HMG-17  0.144514 
Myosin-14  0.144811 
Heterogeneous nuclear ribonucleoprotein K 0.146297 
Myosin 0.146593 
Actinin 0.149836 
Mitochondrial import receptor subunit TOM20  0.151592 
Heterogeneous nuclear ribonucleoprotein AB  0.151592 
60S ribosomal protein L23a  0.16138 
60S ribosomal protein L10a  0.163925 
Heterogeneous nuclear ribonucleoproteins A2/B1  0.178277 
Ribosome-binding protein 1  0.1918 
40S ribosomal protein S7  0.219289 
Poly [ADP-ribose] polymerase  0.263242 
60S ribosomal protein L28  0.267032 
Fus-like protein  0.313059 
Caprin-1  0.316345 
Alternative protein CHST9  0.320679 
Heterogeneous nuclear ribonucleoprotein A1 0.456714 
Heterogeneous nuclear ribonucleoprotein A3  0.481648 
 
 
10.6.2. Differentially expressed IL-33 interacting proteins following Poly (I:C) stimulation 
 
Protein Fold change (Poly (I:C) vs control) 
L-lactate dehydrogenase A  3.361564 
Aldose reductase  3.225166 
Alpha-enolase 3.077091 
Protein transport protein sec16  2.646907 
Pyruvate kinase M2 isoform 2.632353 
Epididymis luminal secretory protein 52  2.559402 
Glyceraldehyde-3-phosphate dehydrogenase  2.534081 
Prothymosin alpha  2.409938 
Eukaryotic translation initiation factor 4A, isoform 1 2.38403 
ATP synthase subunit alpha 2.24605 
Elongation factor 1-alpha 1.93407 
Tubulin alpha chain 1.902827 
Tubulin beta-4B chain 1.824503 
Histone H4  1.79562 
Histone H2B 1.683208 
Moesin  1.681967 
mRNA cap guanine-N7 methyltransferase  1.666031 
Eukaryotic translation initiation factor 2A  1.663866 
Eukaryotic translation initiation factor 5A-1  1.636071 
Mitochondrial import receptor subunit TOM20  1.63197 
Actin, cytoplasmic 1  1.618684 
Autoantigen La  1.602317 
Liver histone H1e  1.572554 
Ribosomal protein L3  1.55 
Elongation factor 2 1.541401 
Serine/threonine-protein phosphatase  1.534639 
Heterogeneous nuclear ribonucleoprotein AB  1.527969 
60S ribosomal protein L35a  0.491538 
Chromosome-associated kinesin KIF4A variant  0.487546 
60S ribosomal protein 0.450539 
Splicing factor U2AF  0.438163 
Ras-GTPase-activating protein SH3-domain-binding protein 0.433944 
ATP-dependent RNA helicase  0.422881 
40S ribosomal protein S25  0.408405 
Bcl-2-associated transcription factor 1  0.4006 
Putative RNA-binding protein Luc7-like 2  0.377295 
60S ribosomal protein L22  0.353086 
Ribosomal protein L30 0.339869 
E3 ubiquitin-protein ligase UBR5 0.332685 
eIF4G1 variant protein  0.245236 
Nuclear factor 1  0.072939 
 
 
 10.6.3. Differentially expressed IL-33 interacting proteins following TNFα stimulation  
 
  Protein  Fold change (TNFα vs control) 
Nuclear factor 1  0.098835 
60S ribosomal protein L12  0.477248 
Ribosomal protein L30 0.351307 
ATP-dependent RNA helicase DDX3X  0.490478 
60S ribosomal protein L22  0.417284 
40S ribosomal protein S25  0.387931 
Bcl-2-associated transcription factor 1  0.480006 
eIF4G1 variant protein  0.416249 
10.6.4. Gene intervals identified from small-scale Nessy-1 ChIP-sequencing 
Gene  Protein 




Family With Sequence Similarity 
230 (RNA gene) 
 






Family With Sequence Similarity 
230 Member A (RNA gene) 
 
Upstream (-3,111) 18,730,624 
 
DUX4L21 
Double Homeobox 4 Like 21 
(Pseudogene) 
 
Downstream (9071) 133,689,440 
 
FAM230C 
Family With Sequence Similarity 
230 (RNA gene) 
 




Long Intergenic Non-Protein 
Coding RNA 234 




Long Intergenic Non-Protein 
Coding RNA 932 
Upstream (-2,255) 8,220,000 
 
TIMP2 TIMP Metallopeptidase Inhibitor 2 
 




MAFF Interacting Protein-Like 
 






Family With Sequence Similarity 27 
Member C (RNA gene) 
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Member C (RNA gene) 
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Downstream (16671) 57,210,208 
 
GLIS3 
GLIS Family Zinc Finger 3 
 







 (RNA gene) 
In gene (14609) 4,164,848 
 
SLC7A8 Solute Carrier Family 7 Member 8 





Long Intergenic Non-Protein 
Coding RNA (9211) 





Zinc Finger Protein 236 
 
Downstream (148639) 21,854,336 
 
MBP 
Myelin Basic Protein 
 
Upstream (-9278) 76,971,200 
 
FEM1A 







WD Repeat Containing Planar Cell 
Polarity Effector 





STAM Binding Protein 
 
In gene (316) 73,857,712 
 
SP100 
SP100 Nuclear Antigen 
 




Collagen Type XXIII Alpha 1 Chain 
 









Germinal Center Associated 
Signaling And Motility Like 





Double Homeobox 4 Like 22 
(Pseudogene) 




Musashi RNA Binding Protein 2 
 






















Glutamate Ionotropic Receptor 
Kainate Type Subunit 2 






Amylase Alpha 1C 
 





Family With Sequence Similarity 90 
Member A19, Pseudogene 
Upstream (-5564) 7,765,232 
 
FAM91A1 
Family With Sequence Similarity 91 
Member A1 
 
In gene ( 
34,945) 
123,803,384 
 
 
 
